<SEC-DOCUMENT>0001129928-17-000003.txt : 20170328
<SEC-HEADER>0001129928-17-000003.hdr.sgml : 20170328
<ACCEPTANCE-DATETIME>20170327185203
ACCESSION NUMBER:		0001129928-17-000003
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170328
DATE AS OF CHANGE:		20170327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		17716446

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf2016-20f.htm
<DESCRIPTION>20-F
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s63C179B5D70FB12764ABFBCAAFF1C18E"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 20-F</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:81%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For fiscal year ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from ____ to ____</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of event requiring this shell company report:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number: 000-31062</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><img src="logo1.jpg" alt="logo1.jpg" style="height:160px;width:682px;"></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of Registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Province of Alberta, Canada</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Jurisdiction of incorporation or organization)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Kirk Look</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tel: (403) 670-7377</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E-mail: info@oncolytics.ca</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act: None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act:  Common Shares, no par value</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">121,258,222</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">common shares as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">December&#160;31, 2016</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:inherit;font-size:10pt;">No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every&#160;&#160;Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.&#160;&#160;See definition of &#8220;accelerated filer and large accelerated filer&#8221; in Rule 12b-2 of the Exchange Act.&#160;&#160;(Check one)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Non-accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;US GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Financial Reporting Standards as issued&#160;&#160;by the International Accounting Standards Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Other&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 17 </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sE6C3903D17E72238B60CFBCAB033BCD5"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 20-F</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s8D0594B4ACB91ED839DBFBCAB0CA9091"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s8D0594B4ACB91ED839DBFBCAB0CA9091">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s027CC9071A31385BD81FFBCAB0EB3A3D"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s027CC9071A31385BD81FFBCAB0EB3A3D">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s266C8043EE5DEAB493B2FBCAB12CD130"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s266C8043EE5DEAB493B2FBCAB12CD130">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sB66BBE39818E0F6DF598FBCAB16484A4"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sB66BBE39818E0F6DF598FBCAB16484A4">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s025CF015DE83F92AF7F5FBCAB1E4081D"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Item 4A.    Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s025CF015DE83F92AF7F5FBCAB1E4081D">24</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sE309E373D4E861979754FBCAB1ECB8A0"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sE309E373D4E861979754FBCAB1ECB8A0">24</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s5F4D177204A079348F8CFBCAAA0CFEB2"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s5F4D177204A079348F8CFBCAAA0CFEB2">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s0B0655323335EB68B318FBCAB50F9F52"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s0B0655323335EB68B318FBCAB50F9F52">44</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;color:#000000;" href="#s4E740DA7DEC9ABADB1FEFBCAB5286D84"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;color:#000000;">&#160;Item 8.&#160;&#160; &#160;&#160;&#160; Financial Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s4E740DA7DEC9ABADB1FEFBCAB5286D84">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s45BD960553AE46017EDCFBCAB55706AD"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s45BD960553AE46017EDCFBCAB55706AD">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s3687AD30B46A9E6F3E76FBCAB5E90A23"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 10.&#160;&#160;&#160; Additional Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s3687AD30B46A9E6F3E76FBCAB5E90A23">47</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sA7A0BDA3613E361246BAFBCAB6125A34"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sA7A0BDA3613E361246BAFBCAB6125A34">57</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s92085058F73A18F67827FBCAB61A3221"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s92085058F73A18F67827FBCAB61A3221">57</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s44019429B7700FE9BC85FBCAB6298622"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s44019429B7700FE9BC85FBCAB6298622">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s0B7BD132991485A01949FBCAB6526F25"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s0B7BD132991485A01949FBCAB6526F25">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sCC3C24AA393CBECD2154FBCAB673B92A"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sCC3C24AA393CBECD2154FBCAB673B92A">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sD68616772C1C03E0EFA7FBCAB6A7C362"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Item 16.     [Reserved]</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sD68616772C1C03E0EFA7FBCAB6A7C362">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sFAD521484FD314651DEAFBCAB6C7598A"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16A. &#160;Audit Committee Financial Expert</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sFAD521484FD314651DEAFBCAB6C7598A">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sF10E77C8542DBC79489FFBCAB70834CD"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16B.&#160;&#160; Code of Ethics</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sF10E77C8542DBC79489FFBCAB70834CD">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sF7754A8F5A9C74875376FBCAB7191A22"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sF7754A8F5A9C74875376FBCAB7191A22">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s8FBC5E53B315513AB102FBCAB74D9199"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s8FBC5E53B315513AB102FBCAB74D9199">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sA6782B339E304FDA9261FBCAB76EB5A1"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sA6782B339E304FDA9261FBCAB76EB5A1">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sE661FB1AF57C47411EA4FBCAB7A0C9FD"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sE661FB1AF57C47411EA4FBCAB7A0C9FD">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sD942C78AE19248FF883CFBCAB7C07AEF"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16G.&#160; Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sD942C78AE19248FF883CFBCAB7C07AEF">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s2A872E7FFF19C66CC088FBCAB8021A8C"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Item 16H.   Mine Safety Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s2A872E7FFF19C66CC088FBCAB8021A8C">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sDFA9FD250C6F8F255B7DFBCAB846E281"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sDFA9FD250C6F8F255B7DFBCAB846E281">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s44BF6BADA6DD002615B6FBCAB868B190"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s44BF6BADA6DD002615B6FBCAB868B190">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s344B9C0538CF4BCB9223FBCAB8990943"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s344B9C0538CF4BCB9223FBCAB8990943">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sC939EE19819E1A739570FBCAB8BB51FB"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sC939EE19819E1A739570FBCAB8BB51FB">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sBCC90A21ED7267971F83FBCAB8FCF54B"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">F1 - F24</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sD6518F7C6762A5BECF5EFBCAB04FEF26"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All references in this annual report on Form 20-F to the terms &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;the Company&#8221; and &#8220;Oncolytics&#8221; refer to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221; and similar expressions, or that events or conditions &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could&#8221; or &#8220;should&#8221; occur.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The forward-looking statements in this annual report are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control, including without limitation:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to all of our products, including REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, being in the research and development stage and requiring further development and testing before they can be marketed commercially;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks inherent in pharmaceutical research and development;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to timing and possible delays in our clinical trials;  </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to some of our clinical trials being conducted in, and subject to the laws of foreign countries;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our pharmaceutical products being subject to intense regulatory approval processes in the United States and other foreign jurisdictions;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to being subject to government manufacturing and testing regulations;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to the extremely competitive biotechnology industry and our competition with larger companies with greater resources;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our reliance on patents and proprietary rights to protect our technology;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to potential products liability claims;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our limited manufacturing experience and reliance on third parties to commercially manufacture our products, if and when developed;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our new products not being accepted by the medical community or consumers;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our technologies becoming obsolete;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our dependence on third party relationships for research and clinical trials;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our lack of operating revenues and history of losses;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to other third-party arrangements; </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our ability to obtain additional financing to fund future research and development of our products and to meet ongoing capital requirements;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to potential increases in the cost of director and officer liability insurance;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our dependence on key employees and collaborators;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to Barbados law;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to the effect of changes in the law on our corporate structure;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate fluctuations;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our compliance with the Sarbanes-Oxley Act of 2002, as amended;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our status as a foreign private issuer;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;risk related to&#160;&#160;possible &#8220;passive foreign investment company&#8221; status;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to fluctuations in interest rates;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to information technology systems; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our common shares.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This list is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements.&#160;&#160;Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below.&#160;&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;&#160;Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements.&#160;&#160;We do not assume responsibility for the accuracy and completeness of these statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s73396EDA665E253A4731FBCAB076CB3D"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENCY AND EXCHANGE RATES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Canadian Dollars Per US Dollar</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the exchange rates for United States dollars (&#8220;US$&#8221;) expressed in terms of Canadian dollars (&#8220;Cdn$&#8221;) including the average exchange rates (based on the average of the exchange rates on the last day of each month in such periods) and the range of high and low exchange rates for such periods.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:137px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Canadian Dollars Per One US Dollar</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average for the period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3248</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2787</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1045</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0299</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9996</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:645px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:110px;"></td><td style="width:89px;"></td><td style="width:82px;"></td><td style="width:92px;"></td><td style="width:93px;"></td><td style="width:81px;"></td><td style="width:96px;"></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Month of</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">February<br>2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January<br>2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December<br>2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">November<br>2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">October<br>2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September<br>2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High for the period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3248</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3438</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3556</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3582</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3403</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3248</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low for the period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3004</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3030</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3120</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3337</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3104</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2843</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exchange rates are based on the Bank of Canada nominal noon exchange rates.&#160;&#160;&#160;The nominal noon exchange rate on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;as reported by the Bank of Canada for the conversion of United States dollars into Canadian dollars was US$1.00 = Cdn</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.3373</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Unless otherwise indicated, in this annual report on Form 20-F, all references herein are to Canadian Dollars.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s239C3A3E89AB6C5E1668FBCAB0975DE3"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s8D0594B4ACB91ED839DBFBCAB0CA9091"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s027CC9071A31385BD81FFBCAB0EB3A3D"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s266C8043EE5DEAB493B2FBCAB12CD130"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3. KEY INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Financial Data</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The selected financial data presented below for the five years ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;is presented in Canadian dollars and is derived from our consolidated financial statements in Canadian dollars and in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).  The information set forth below should be read in conjunction with our consolidated financial statements (including notes thereto) included under Item 18 and "Operating and Financial Review and Prospects" included under Item 5.  For exchange rate data please see the section heading &#8220;Currency and Exchange Rates&#8221; above.</font></div><div style="line-height:120%;text-align:justify;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:270px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,619,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,532,647</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,373,521</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,346,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,242,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,418,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,395,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,313,135</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.48</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,383,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,193,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,222,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,078,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,819,193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,213,366</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,786,780</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,880,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,613,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,869,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,530,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,102,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in net loss and net loss per share for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are share based payment expenses of </font><font style="font-family:inherit;font-size:10pt;">$406,078</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$429,537</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;-  </font><font style="font-family:inherit;font-size:10pt;">$980,325</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$424,384</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$730,751</font><font style="font-family:inherit;font-size:10pt;">). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,106,600</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$956,133</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">24,639,128</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$23,667,654</font><font style="font-family:inherit;font-size:10pt;">;  </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">8,708,676</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$9,044,492</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;-  </font><font style="font-family:inherit;font-size:10pt;">8,093,533</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$30,398,036</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">5,458,950</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">20,848,785</font><font style="font-family:inherit;font-size:10pt;">).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Capitalization and Indebtedness</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reasons for the Offer and Use of Proceeds</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this Annual Report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results or cash flow.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">All of our potential products, including REOLYSIN, are in the research and development stage and will require further development and testing before they can be marketed commercially.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, REOLYSIN, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early stage human clinical trials, whether REOLYSIN will prove to be safe and effective in humans. REOLYSIN will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market REOLYSIN commercially. There can be no assurance that the research and development programs we conduct will result in REOLYSIN or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favourable results. If we are unable to establish that REOLYSIN is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There are inherent risks in pharmaceutical research and development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical and non-competitive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proprietary rights of third parties or competing products or technologies may preclude commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any failure or delay in clinical trials for our products, including REOLYSIN, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome.&#160;&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidates, including the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or we may abandon projects that we expect to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of our clinical trials may be greater than we anticipate; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The supply or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The size and nature of the subject population;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proximity of subjects to clinical sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The eligibility criteria for the trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The design of the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competing clinical trials; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Condition Risks</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have no operating revenues and a history of losses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit.  As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$278.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and we incurred net losses of </font><font style="font-family:inherit;font-size:10pt;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.  We anticipate that we will continue to incur significant losses during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and in the foreseeable future.  We do not expect to reach profitability at least until after successful and profitable commercialization of one or more of our products.  Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain third-party reimbursement for the cost of our product.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government authorities and third party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the US healthcare industry and elsewhere is cost containment. Government authorities and these third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for REOLYSIN.&#160;&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively affect the price of, these products. If REOLYSIN does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-Party Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of our business, we have entered into contractual arrangements with third parties which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our contract research organizations and other parties.&#160;&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents (including short-term investments) of </font><font style="font-family:inherit;font-size:10pt;">$14.1 million</font><font style="font-family:inherit;font-size:10pt;">. Working capital was approximately </font><font style="font-family:inherit;font-size:10pt;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.&#160;&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums.   As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favourable to us or our existing shareholders.&#160;&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product.&#160;&#160;There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulatory Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory process for pharmaceuticals, which includes preclinical studies and clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States Food and Drug Administration (&#8220;FDA&#8221;) and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to approval of the facility to manufacture a specific drug, there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The products we anticipate manufacturing will have to comply with the FDA&#8217;s current Good Manufacturing Practices (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">cGMP</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to regulation by governments in many jurisdictions.&#160;&#160;If we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on patents and proprietary rights to protect our technology.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;&#160;Our success will depend, in part, on our ability to obtain, enforce and maintain patent protection for our technology in Canada, the United States and other countries. We cannot be assured that patents will issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be challenged, invalidated, infringed or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavours will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from the third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information and</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">know-how, the value of our technology and products could be adversely affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to patented technology, we rely upon unpatented proprietary technology, processes and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants and third parties as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cyber security breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Business Risks</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The biotechnology industry is extremely competitive and we must successfully compete with larger companies with substantially greater resources.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition and have substantially greater financial, technical and marketing resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies and human clinical trials of new pharmaceutical products, obtaining regulatory approvals and manufacturing and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development or commercialization expenses incurred with respect to any such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our products may fail or cause harm, subjecting us to product liability claims.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of our product during current clinical trials may entail risk of product liability.&#160;&#160;We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be named as a defendant in various legal actions or other proceedings, inlcuding class action lawsuits. Certain of these actions include and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition and results of operations, possibly materially.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited manufacturing experience and intend to rely on third parties to commercially manufacture our products, if and when developed.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have relied upon a contract manufacturer to manufacture small quantities of REOLYSIN. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of REOLYSIN on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing REOLYSIN and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New products may not be accepted by the medical community or consumers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary activity to date has been research and development and we have no experience in marketing or commercializing products. We will likely rely on third parties to market our products, assuming that they receive regulatory approvals. If we rely on third parties to market our products, the commercial success of such product will be subject to a number of risks that may be outside of our control, including:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perceived ease of use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of coverage or reimbursement by third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainties regarding marketing and distribution support; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">distribution or use restrictions imposed by regulatory authorities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, there can be no assurance that physicians, patients or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by Health Canada, the FDA and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our technologies may become obsolete.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts and third party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are highly dependent on third-party relationships for research and clinical trials.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely upon third party relationships for assistance in the conduct of research efforts, pre-clinical development and clinical trials, and manufacturing. In addition, we expect to rely on third parties to seek regulatory approvals for and to market our product. Although we believe that our collaborative partners will have an economic motivation to commercialize our product included in any collaborative agreement, the amount and timing of resources diverted to these activities generally is expected to be controlled by the third party. Furthermore, if we cannot maintain these relationships, our business may suffer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the US equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on our key employees and collaborators.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Competition for such personnel and relationships is intense. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. The loss of key employees and/or key collaborators may affect the speed and success of product development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Barbados, which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Barbados in Barbados based on the civil liabilities provisions of applicable securities laws. In addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in law could adversely affect our business and corporate structure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurances that changes will not occur in corporate, tax, property and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur some of our expenses in foreign currencies and therefore we are exposed to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the US dollar, the Euro and the British pound (&#8220;GBP&#8221;).&#160;&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We earn interest income on our excess cash reserves and are exposed to changes in interest rates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest our excess cash reserves in investment vehicles that provide a rate of return with little risk to principal. As interest rates change the amount of interest income we earn will be directly impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage and similar events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted and our business reputation could be adversely affected. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal controls over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal controls over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal controls over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal controls over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the challenges involved in implementing appropriate internal controls over financial reporting will increase and will require that the Company continue to improve its internal controls over financial reporting.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because the Company is a Canadian Company and some of its directors and officers are resident outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a Canadian company, with its principal place of business in Canada.  Some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for US investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the US Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of US courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the US federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the US federal securities laws or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As a foreign private issuer, our shareholders may have less complete and timely data.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;US Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f) and 16 of the US Exchange Act pursuant to Rule&#160;3a12-3 of the US Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company is likely a "passive foreign investment company" which may have adverse US federal income tax consequences for US shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US shareholders of the Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) for the tax year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and based on current business plans and financial expectations, the Company anticipates that it may qualify as a PFIC for its current and subsequent taxable years.&#160;&#160;If the Company is a PFIC for any year during a US shareholder&#8217;s holding period, then such US shareholder generally will be required to treat any gain realized upon a disposition of Common Shares, or any so-called &#8220;excess distribution&#8221; received on its common shares, as ordinary income, and to pay an interest charge on a portion of such gain or distributions, unless the shareholder makes a timely and effective "qualified electing fund" election (&#8220;QEF Election&#8221;) or a "mark-to-market" election with respect to the Common Shares.&#160;&#160;A US shareholder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;     However, US shareholders should be aware that there can be no assurance that the Company will satisfy the record keeping requirements that apply to a qualified electing fund, or that the Company will supply US shareholders with information that such U.S. shareholders require to report under the QEF Election rules, in the event that the Company is a PFIC and a U.S. shareholder wishes to make a QEF Election. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">Thus, US shareholders may not be able to make a QEF Election with respect to their Common Shares.  A US shareholder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the common shares over the taxpayer&#8217;s basis therein.&#160;&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;Certain United States Federal Income Tax Considerations.&#8221;&#160;&#160;Each US shareholder should consult its own tax advisor regarding the PFIC rules and the US federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our Common Shares</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have been delisted from the NASDAQ Capital Market and we have qualified for quotation on the OTCQX&#174; which may adversely affect the liquidity of the Company's common shares. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 29, 2015, the Company received notice from the Nasdaq OMX Group ("Nasdaq") stating that, in accordance with Nasdaq listing rules, the Company's shares will be delisted from the Nasdaq Capital Market, effective from the opening of trading on November 5th, 2015, for not maintaining the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 29, 2015, the Company received notification from OTC Markets Group Inc. that it qualified for quotations in the United States on the OTCQX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;International ("OTCQX") and quotations commenced on November 5, 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our share price may be highly volatile.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market prices for securities of biotechnology companies generally are volatile and the share price for our common shares has been historically volatile. This increases the risk of securities litigation. Factors such as announcements (publicly made or at scientific conferences) of technological innovations, new commercial products, patents, the development of proprietary rights, results of clinical trials, regulatory actions, publications, quarterly financial results, our financial position, public concern over the safety of biotechnology, future sales of shares by us or our current shareholders and other factors could have a significant effect on the market price and volatility of the Common Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Potential dilution of present and prospective shareholdings.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company does not intend to pay cash dividends in the foreseeable future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition and capital requirements, restrictions in financing agreements, business opportunities and conditions and other factors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Penny stock&#8221; rules may make buying or selling our securities difficult, which may make our stock less liquid and make it harder for investors to buy and sell our securities. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 5, 2015, we were delisted from the NASDAQ Capital Markets and are now only quoted on an over-the-counter market, the OTCQX International, maintained by OTC Markets, Inc. Trading in our securities is now subject to the SEC&#8217;s &#8220;penny stock&#8221; rules and it is anticipated that trading in our securities will continue to be subject to the penny stock rules for the foreseeable future. The Securities and Exchange Commission has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer who recommends our securities to persons other than prior customers and accredited investors must, prior to the sale, make a special written suitability determination for the purchaser and receive the purchaser&#8217;s written agreement to execute the transaction. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market. In addition, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities. </font></div><div><a name="sB66BBE39818E0F6DF598FBCAB16484A4"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">History and Development of the Company</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was formed under the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Corporations Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive office is located at 210, 1167 Kensington Cres. NW, Calgary, Alberta, Canada, T2N 1X7, telephone (403) 670-7377. Our agent for service in the US is CT Corporation, 111 Eighth Avenue, 13</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Floor, New York, New York 10011.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A description of our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Overview</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN, our potential cancer therapeutic.&#160;&#160;We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.&#160;&#160;We do not expect to generate significant revenues until, if and when, our cancer product becomes commercially viable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our potential product for human use, pelareorep (REOLYSIN), an unmodified reovirus, is a first in class systemically administered immune-oncology (I-O) viral agent for the treatment of solid tumors and hematological malignancies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Summary of Research and Development highlights</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical and Translational Research data to date indicate the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep has anticancer effects in models of metastatic cancers that can prolong survival in these models when using immuno-competent rodents. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The survival benefit in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors, IMiDs, rituximab, etc.) or radiotherapy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A toxic dose of reovirus T3D has not been reached/established in animal models and infection presents with minimal side-effects.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical data to date indicate the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More than 1,400 patients have been enrolled in clinical studies conducted in the US, Canada and EU. Of these, more than 1,000 patients received pelareorep, with over 930 via intravenous (IV) administration and over 90 by intratumoral injections (ITu). The remaining patients were randomized to control arms. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a mono-therapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and radiotherapy.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No Maximum Tolerated Dose (MTD) for intravenous pelareorep as mono-therapy was defined in the two Phase 1 trials (REO 004 and 005). Dose-limiting toxicities (DLTs) were seen in some of the combination trials with pelareorep and chemotherapy, which generally enrolled heavily pre-treated patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When combined with chemotherapeutic agents, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of the chemotherapeutic agents.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Scientific Background</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep&#8217;s anti-tumor activity is based on three modes of action which are complementary but not interdependent (Figure 1): </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activation of innate immunity in response to the infection which results in a cascade of chemokines/cytokines causing natural killer (NK) cells to be activated and attack cancer cells.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs, infected tumor cells and/or dendritic cells) to T cells.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 1. Proposed mechanism of action for pelareorep (REOLYSIN).</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font></div><div style="line-height:120%;"><img src="figure1a04.jpg" alt="figure1a04.jpg" style="height:408px;width:682px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Direct cell lysis - Reovirus Replication in Permissive Cancer Cells</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selective viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein PKR (dsRNA-activated protein kinase). In non-cancer cells that are infected with reovirus, PKR activates in the presence of the virus which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing for viral gene translation and eventual cell lysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It was originally established that selective lysis with reovirus</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">was mediated by tumor cells with an activated RAS-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not just restricted to cells with an active RAS pathway, oncogenic mutations and amplifications in upstream (EGFR) and downstream (BRAF) mediators of the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication, such as activation of Raf/MEK/ERK, RalGEF/p38, and JNK signalling pathways. Cells bearing dysfunctional or deleted tumor suppressor genes (p53, ATM and Rb) and or chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Induction of Innate Immunity</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical and clinical studies provide compelling lines of evidence that pelareorep functions as an immunogenic agent. Indeed, preclinical studies have demonstrated that the beneficial immunogenic functions of pelareorep can occur independent of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus in turn stimulate the innate antitumor activity of NK (natural killer) cells through the release of proinflammatory cytokines, demonstrating that dendritic cells' recognition of reovirus may trigger a beneficial innate immune response. Similar studies by Steele and colleagues demonstrated that melanoma cells infected with Pelareorep can also produce an innate immune response by the release of inflammatory cytokines. This inflammatory milieu promotes a chemotactic response</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in NK cells, dendritic cells, and cytotoxic T-cells, altering the tumour microenvironment to support bystander immune-mediated cancer cell death.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation, in humans,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak of pro-inflammatory cytokines. NK cells within reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover, NK cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;and suggest that this may contribute to the therapeutic effect of pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Induction of Adaptive Immunity</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adaptive anti-tumor immunity allows for elimination of existing cancer cells and performs constant surveillance, preventing relapse, and increasing patient overall survival. An adaptive immune response requires two signals: a signal from an antigen presenting cell (APC), as well as a co-stimulation signal in the form of cytokines. In the absence of both signals, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both signals. Following its therapeutic administration, pelareorep enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through the combined actions of these immunological events, pelareorep facilitates the display of novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APC. Simultaneously, pelareorep induces an inflammatory response promoting the expression of co-stimulatory molecules and inflammatory cytokines. Together, pelareorep mediated immunological events over-rule tumor antigen presentation impairments and initiate adaptive anti-tumor immunity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By promoting the expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by T-cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early stage cancers. In metastatic cancers, an inflamed tumor phenotype is associated with a clinical response to immunotherapies, including immune checkpoint inhibition, cancer vaccines, and adoptive T-cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 2. Pelareorep (REOLYSIN) primes an anti-cancer immune response</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="fig2.jpg" alt="fig2.jpg" style="height:313px;width:564px;"></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Development Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are directing a clinical development program with the objective of developing REOLYSIN as a human cancer therapeutic.  Our clinical development program focuses on the three components of REOLYSIN's mechanism of action and includes the following three pathways:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Direct tumour lysis</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our primary focus has been on the investigation of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various cancer indications.  In 2016, we reported preliminary clinical data from our Randomized Clinical Program which includes the clinical trial collaborations with the Canadian Cancer Trials Group (CCTG, formerly known as the National Cancer Institute of Canada) and the US National Institute of Cancer (NCI).  The clinical data reported in 2016 from the CCTG studies showed little to no difference in progression free survival (the primary endpoint) between the test and control arms.  However, preliminary survival data reported suggests a potential survival benefit in female patients with colorectal cancer and lung patients with TP53 or EGFR mutations.  As well, survival data reported from our NCI pancreatic trial suggests a long term survival benefit when comparing test and control arms at 24 months.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Activation of innate immunity</font><font style="font-family:inherit;font-size:10pt;">&#32;-  Our second pathway focuses on the potential of REOLYSIN to stimulate a patient's innate immunity and the potential for an infection to cause a cascade of chemokines/cytokines  activating natural killer (NK) cells to attack cancer cells.  In 2016, we looked to enter into research collaborations that would combine REOLSYIN with immune modulator therapies (IMiDs).  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Activation of adaptive immunity</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our third pathway focuses on the potential for REOLSYIN to cause a specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs, infected tumor cells and/or dendritic cells) to T cells.  In 2016, we commenced our first checkpoint inhibitor clinical trial that investigated the combination of REOLYSIN with pembrolizumab (Keytruda&#174;).  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patents and Trade Secrets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions and proprietary rights of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. We believe there will continue to be significant litigation in the industry regarding patent and other intellectual property rights.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, we have over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">415</font><font style="font-family:inherit;font-size:10pt;">&#32;issued patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">61</font><font style="font-family:inherit;font-size:10pt;">&#32;issued US. patents.&#160;&#160;We also have numerous patent applications filed in the US, Canada, and other jurisdictions, but we cannot be certain whether any given patent application filed by us will result in the issuance of a patent or if any given patent issued to us will later be challenged and invalidated. Nor can we be certain whether any given patent that may be issued to us will provide any significant proprietary protection to our product and business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation or other proceedings may also be necessary to enforce or defend our proprietary rights and patents. In Europe, patents can be revoked through opposition or nullity proceedings. In the United States patents may be revoked or invalidated in court actions or challenged in interference, post-grant review, derivation or re-examination proceedings in the USPTO. Such litigation or proceedings could result in substantial cost or distraction to us, or result in an adverse decision as to our or our licensors&#8217; patent applications and patents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success depends, in part, on not infringing the patents or proprietary rights of others and not breaching licenses granted that may be granted to us. Competitors may have filed patent applications and obtained patents and may in the future file patent applications and obtain patents relevant to our product and technologies.&#160;&#160;We are not aware of competing intellectual property relating to our REOLYSIN project.&#160;&#160;While we currently believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future.&#160;&#160;Litigation to defend our position could be costly and time consuming. We also cannot be certain that we will be successful. We may be required to obtain a license from a prevailing party in order to continue the portion of our business that relates to the proceeding. We may also be required to obtain licenses to other third-party technologies necessary in order to market our products. Such licenses may not be available to us on acceptable terms or on any terms and we may have to discontinue that portion of our business. Any failure to license any technologies required to commercialize our technologies or products at reasonable cost may have a material adverse effect on our business, results of operations, financial condition, cash flow and future prospects. We are not currently involved in any litigation concerning our competitors&#8217; patent applications and patents. We may be involved in such litigation in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of the employment or consulting relationship generally must be kept confidential. In the case of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business measurements to protect confidential information, these agreements may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business strategy is to develop and market REOLYSIN in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;&#160;We intend to achieve our business strategy by focusing on these key areas:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Develop REOLYSIN through our clinical development plan assessing the safety and efficacy in human subjects;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Establish collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Implement strategic alliances with selected pharmaceutical and biotechnology companies and selected laboratories, at a time and in a manner where such alliances may complement and expand our research and development efforts on the product and provide sales and marketing capabilities;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;&#160;Our new product development presently being conducted is primarily of a research and development nature.&#160;&#160;In the context of this Annual Report, statements of our "belief" are based primarily upon our results derived to date from our research and development program with animals, and early stage human trials, and upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;&#160;It is not possible to predict, based upon studies in animals, or early stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160;&#160;There are no assurances that the particular result expected by us will occur.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At this time we do not intend to become a fully integrated pharmaceutical company with substantial in-house research and development, marketing and distribution or manufacturing capabilities.&#160;&#160;We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;&#160;We intend to partner or joint venture with larger pharmaceutical companies that have existing and relevant marketing capability for our products.&#160;&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance.&#160;&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in gross proceeds from the sale of our product or products and potentially share in various market or manufacturing opportunities.&#160;&#160;The proceeds generated from partnering or joint venturing projects are expected to be distributed on the basis of relative risk taken and resources contributed by each party to the partnership or joint venture.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;&#160;The drug approval process in Canada is regulated by Health Canada.&#160;&#160;The primary regulatory body in the United States is the FDA and in the UK is the Medicines and Healthcare Products Regulatory Agency (the &#8220;MHRA&#8221;).&#160;&#160;Similar processes are conducted in other countries by equivalent regulatory bodies.&#160;&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;&#160;Companies must establish the safety and efficacy of their products, comply with current Good Manufacturing Practices and submit marketing materials before being allowed to market pharmaceutical products.&#160;&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market our pharmaceutical product in Canada, the United States, Europe and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the Appropriate Regulatory Authority will generally include the following stages as part of the regulatory process:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pre-Pharmacological Studies</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;disease model and has any adverse toxicology in a disease model.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investigational New Drug Application</font><font style="font-family:inherit;font-size:10pt;">&#32;- An Investigational New Drug ("IND") Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmacological Studies&#160;</font><font style="font-family:inherit;font-size:10pt;">(or Phase 1 Clinical Trials)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Therapeutic Studies</font><font style="font-family:inherit;font-size:10pt;">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy.  Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Drug Submission </font><font style="font-family:inherit;font-size:10pt;">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;&#160;Once marketing approval is granted, the product is approved for commercial sales.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketing Approvals</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all, or if granted may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions or contraindications with respect to conditions of use.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or targeted disease. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early stage clinical trials or with prior versions of products does not assure success in later stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Post-Marketing Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use contract toll manufacturers to produce REOLYSIN.&#160;&#160;Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising and Promotion Regulations</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies, and foreign, state and federal civil and criminal investigations and prosecutions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Government Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market and Competition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to estimates for 2016 from the American Cancer Society, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.69 million</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Americans are expected to be diagnosed with cancer in the year, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">595,690</font><font style="font-family:inherit;font-size:10pt;">&#32;Americans are forecast to die of cancer.&#160;&#160;In the United States cancer accounts for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of all deaths, second only to heart disease.&#160;&#160;In the United States, the relative lifetime risk of a male developing cancer is 1 in  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2</font><font style="font-family:inherit;font-size:10pt;">, while for women, this risk is 1 in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;(Source: American Cancer Society's Cancer Facts &amp; Figures 2015).  The World Health Organization estimates the number of deaths in the "More Developed Regions" will increase to 3.28 million patients in 2020 from 2.8 million patients in 2012. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Source: Incidence/mortality data - Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 18/03/2015).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The costs of this disease state are also significant.&#160;&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2016 that the Agency for Healthcare Research and Quality estimated the 2011 direct medical costs for cancer treatment was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$88.7 billion</font><font style="font-family:inherit;font-size:10pt;">.  (Source: American Cancer Society's Cancer Facts &amp; Figures 2016).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face substantial competition in the development of products for cancer and other diseases. This competition from other manufacturers of the same types of products and from manufacturers of different types of products designed for the same uses is expected to continue in both US and international markets.&#160;&#160;Oncolytic virus therapies, our primary focus area, are rapidly evolving areas in the biotechnology industry and are expected to undergo many changes in the coming years as a result of technological advances. We are currently aware of a number of groups that are developing oncolytic virus therapies including early-stage and established biotechnology companies, pharmaceutical companies, academic institutions, government agencies and research institutions. We face competition from all of these groups in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. It is possible that our competitors could achieve earlier market commercialization, could have superior patent protection, or could have safer, more effective or more cost-effective products. These factors could render our potential products less competitive, which could adversely affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Marketing Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;&#160;Our management and consultants have relevant experience with the partnering process.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Seasonality of Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations have not been materially impacted by seasonality.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organizational Structure</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;&#160;In addition, Oncolytics Biotech (US) Inc., a Delaware corporation, is a material wholly owned subsidiary  of OBB.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plants and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently lease our head office in Calgary, Alberta, Canada as well as our office space in Barbados.&#160;&#160;We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s025CF015DE83F92AF7F5FBCAB1E4081D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sE309E373D4E861979754FBCAB1ECB8A0"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Management Discussion and Analysis (&#8220;MD&amp;A&#8221;) contains forward-looking statements, including our belief as to the potential of REOLYSIN, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.&#160;&#160;See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within our MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of REOLYSIN and future expense levels being within our current expectations.&#160;&#160;Investors are cautioned against placing undue reliance on forward-looking statements.&#160;&#160;We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Results</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development, Patents, and Licenses, etc.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see the disclosure in "Item 4.&#160;&#160;Information on the Company B. Business Overview" for information on the Company&#8217;s research and development policies.&#160;&#160;Our research and development expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9,770,007</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,601,864</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$13,824,252</font><font style="font-family:inherit;font-size:10pt;">&#32;for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trend Information</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures.&#160;&#160;The amount and timing of expenditures and availability of capital resources vary substantially from period to period, depending on the level of research and development activity being undertaken at any one time and the availability of funding from investors and prospective commercial partners.  See our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1 for our comparative discussion on our expenditures between </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and our expectations for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as disclosed elsewhere in our annual report, we know of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had not entered into any off-balance sheet arrangements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tabular Disclosure of Contractual Obligations</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have the following contractual obligations as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:580px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:172px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:94px;"></td><td style="width:4px;"></td><td style="width:70px;"></td><td style="width:4px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than 1 year</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2 -3 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 - 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">After 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,026</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,643</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,551,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,197,597</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Our operating leases are comprised of our office leases and exclude our portion of operating costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to fund our capital expenditure requirements and commitments with existing working capital.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safe Harbor</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek safe harbor for our forward-looking statements contained in Items 5.E and F.&#160;&#160;See &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cautionary Note Regarding Forward-Looking Statements&#8221;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5F4D177204A079348F8CFBCAAA0CFEB2"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors and Senior Management</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the names and places of residence of all our directors and officers as at December 31, 2016, as well as the positions and offices held by such persons and their principal occupations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:706px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:265px;"></td><td style="width:138px;"></td><td style="width:209px;"></td><td style="width:93px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew C. Coffey, Ph.D.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim Chief Executive Officer and Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim Chief Executive Officer  of the Company since November 2016. Chief Operating Officer of the Company from 2008 to November 2016. From April 1999 to December 2008, Dr. Coffey held other senior management positions with the Company and is a co-founder of Oncolytics.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 11, 2011</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:706px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:265px;"></td><td style="width:138px;"></td><td style="width:209px;"></td><td style="width:93px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">George M. Gill, M.D.<br>Maryland, USA<br>&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Regulatory Affairs &amp; Chief Safety Officer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to taking on the role of Senior Vice President, Regulatory Affairs &amp; Chief Safety Officer, Dr. Gill held senior positions in clinical research and regulatory affairs in the pharmaceutical and biotechnology industries. From 1992-2000 he was VP of Clinical Research with Ligand Pharmaceuticals after serving as head of US Clinical Research with ICI (now AstraZeneca) Prior to that he was VP and Head of World-wide Regulatory Affairs for Bristol-Myers Squibb. He previously was head of Oncology Clinical Research at Hoffmann-La Roche. Dr. Gill holds a B.Sc. in chemistry from Dickinson College in Pennsylvania and an M.D. from the School of Medicine of the University of Pennsylvania in Philadelphia. He began his career as an academic pediatric oncologist at Childrens Hospital of Philadelphia and Boston Childrens Hospital.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andres A. Gutierrez, M.D., Ph.D.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to taking on the role of Chief Medical Officer, Dr. Gutierrez held progressively senior clinical development positions designing and implementing both early and later-stage oncology clinical studies at a range of U.S. and European companies including Sellas Life Sciences Group, Bristol-Myers Squibb, Sunesis Pharmaceuticals Inc., Biomarin Pharmaceutical Inc., Proteolix and Oculus Innovative Sciences. Prior to that, he held a series of academic and consulting positions. He received his MD and a PhD in Biomedical Sciences from the National Autonomous University of Mexico.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham, FCPA, FCMA, ICD.D</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After 8 years as the Vice President Finance and Chief Financial Officer of The Hospital for Sick Children (SickKids) in Toronto, Ms. Holtham now holds a number of Board and Audit Committee governance positions in both the public and private sectors in Canada including IBI Group Inc.,  the Ontario Financing Authority and Plexxus (Hospital Administrative Services).  </font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to her position at SickKids, Angela held a number of senior positions in both the for-profit and not-for-profit sectors, including 20 years with Nabisco Canada, the last 5 as Senior Vice President and Chief Financial Officer.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 18, 2014</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:706px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:265px;"></td><td style="width:138px;"></td><td style="width:209px;"></td><td style="width:93px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. Mark Lievonen, CM, FCPA, FCA, LLD</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(4)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former president of Sanofi Pasteur Limited, a vaccine development, manufacturing and marketing company. Mr. Lievonen has served on a number of industry and not-for-profit boards including Rx&amp;D, BIOTECanada, the Public Policy Forum, the Ontario Institute for Cancer Research, York University and Markham Stouffville Hospital, and is a past Chair of Rx&amp;D, BIOTECanada, the Ontario Genomics Institute, and the Markham Stouffville Hospital Foundation.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 5, 2004</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, CA</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer of the Company since November 2012.  From 2003 to November 2012, Mr. Look held the position of Controller with the Company.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano, MBA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)(6)</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;New Jersey, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chair of the Board</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. Mr. Pisano is the former president and Chief Executive Officer of Sanofi Pasteur, one of the largest vaccine companies in the world. After retiring from Sanofi Pasteur in 2011, he served as the president and Chief Executive Officer of VaxInnate a privately held biotech company until November 2016. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor&#8217;s degree in biology from St. John Fisher College, Rochester NY and an MBA from the University of Dayton, Ohio.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 9, 2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William G. Rice, Ph.D.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)(5)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013; from 2003 to present, Chairman, President and Chief Executive Officer of Cylene Pharmaceuticals Inc.; former Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center; former faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine. </font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:706px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:265px;"></td><td style="width:138px;"></td><td style="width:209px;"></td><td style="width:93px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd R. Seizinger, M.D., Ph.D.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)(5)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA and Munich, Germany</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman of Oxford BioTherapeutics Limited since 2016; Chairman of Aprea Therapeutics AB since 2015; Executive Chairman of CrytpoMedix Inc. since 2015; Chairman of Opsona from 2009-2016; President and CEO of GPC Biotech from 1998-2009; former VP of Oncology Drug Discovery and VP of Corporate and Academic Alliances at Bristol-Myers Squibb; Senior Faculty Member of Harvard Medical School and Massachusetts General Hospital.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alan J Tuchman, M.D., MBA (FAAN),</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, USA</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Neuro Oncology Research Officer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Tuchman is Clinical Professor of Neurology at New York Medical College and the author of over thirty scientific papers and book chapters. He is currently in the private practice of Neurology in Manhattan and consults to a number of biotechnology and investment firms. He has served as a partner of Xmark Opportunity Partners and as Executive Chairman of Neurophysics, Inc. He was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Coffey was appointed President and Chief Executive Officer on January 19, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Member of the Compensation Committee.&#160;Mr. Pisano is Chair of this Committee. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Member of the Governance Committee.&#160;Mr. Lievonen is Chair of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Member of the Science and Technology Committee. Dr.'s Rice and Seizinger serve as Co-Chairs of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Governance and Science and Technology Committees.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">, the directors and senior officers as a group beneficially owned, directly or indirectly, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">430,350</font><font style="font-family:inherit;font-size:10pt;">&#32;of our common shares, representing </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.35%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the issued and outstanding common shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;&#160;In accordance with the</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">ABCA, directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of our directors have been a director or officer of a company that went bankrupt in the last 10 years.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of our directors or officers are related by blood, marriage or adoption to any other director or officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Compensation</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information concerning the total compensation paid in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to each director.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:129px;"></td><td style="width:81px;"></td><td style="width:77px;"></td><td style="width:78px;"></td><td style="width:92px;"></td><td style="width:66px;"></td><td style="width:90px;"></td><td style="width:62px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fees Earned</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Based Awards</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Based Awards</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Equity Incentive Plan Compensation</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pension Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other Compensation</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jim Dinning</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,457</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,720</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Lievonen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,922</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,263</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,185</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,422</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,691</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,113</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,672</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,263</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,935</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bob Schultz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,955</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,337</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,169</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,506</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors are paid fees in US Dollars.&#160;&#160;These amounts are presented in Canadian dollars and have been converted at a US/CDN exchange rate of $1.3427.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of share based and option based awards are based on the grant date assumptions as disclosed in note 8 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments" </font><font style="font-family:inherit;font-size:10pt;">in our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Dinning resigned as a director on March 10, 2016. Amounts reflect compensation received by Mr. Dinning prior to his resignation.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Schultz did not stand for re-election to the Board at the annual general meeting of the Company held on May 5, 2016. Amounts reflect compensation received by Mr. Schultz prior to this date.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Officers</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information concerning the total compensation paid to our officers in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:708px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:140px;"></td><td style="width:38px;"></td><td style="width:48px;"></td><td style="width:57px;"></td><td style="width:66px;"></td><td style="width:53px;"></td><td style="width:81px;"></td><td style="width:54px;"></td><td style="width:81px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Name and principal position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Salary<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Share-<br>based awards<br>$</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Option-<br>based </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">awards </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Bonus</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-equity incentive<br>plan compensation<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pension value<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">All other compensation<br>  $</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total<br>compensation </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Matthew C. Coffey</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">406,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">693,466</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interim Chief Executive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">380,107</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">173,307</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,822</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,039</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">690,275</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Officer and Chief Operating Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">370,475</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54,950</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">425,425</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Bradley G.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">519,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,402,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,921,788</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thompson</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">551,937</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">287,113</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">154,542</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">71,215</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,064,807</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Former Chief Executive Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">537,950</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">606,979</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Kirk J. Look</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">325,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">81,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">539,761</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">319,200</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,556</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">547,802</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,466</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">332,666</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Andres A.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">68,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176,323</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gutierrez</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. George Gill</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">455,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">497,118</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Senior Vice President,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">438,371</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">81,695</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,371</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,549</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">621,986</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Regulatory Affairs &amp; Chief Safety Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">367,452</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">401,442</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Alan J. Tuchman</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">210,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">230,214</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Neuro Oncology </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">202,990</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,906</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,418</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,777</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">288,091</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">165,825</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,339</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">181,164</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of share and option based awards are based on the grant date assumptions as disclosed in note 8 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments" </font><font style="font-family:inherit;font-size:10pt;">in our </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The dollar amounts set forth under this column are related to contributions to the officer's respective retirement savings plan and amounts provided for health care benefits by the Company. With regards to Dr. Thompson, the amount also includes a retirement allowance of $1,330,828, which will be paid over twelve months beginning December 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 2, 2016, Dr. Thompson resigned as President and Chief Executive Officer and Dr. Coffey was appointed Interim President and Chief Executive Officer. Dr. Coffey was appointed President and Chief Executive Officer on January 19, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of the compensation paid to Dr. Thompson and Dr. Coffey related to their roles as directors of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Gutierrez was appointed Chief Medical Officer of the Company on October 31, 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US Employees are paid salaries, bonuses and other compensation in US Dollars.&#160;&#160;These amounts are presented in Canadian dollars and have been converted at a US/CDN exchange rate of $1.3427, 1.3840 and $1.1601 for the years 2016, 2015 and 2014, respectively.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Tuchman was formerly the Senior VP, Medical and Clinical Affairs of the Company. Dr. Tuchman became the Chief Neuro Oncology Research Officer of the Company on October 31, 2016.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Narrative Discussion</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into employment agreements with each of the following Executive Officers (each an "Employment Agreement").&#160;&#160;Pursuant to the terms of the Employment Agreements,</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:398px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:261px;"></td><td style="width:64px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and principal position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Salary</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew C. Coffey</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, C.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Andres A. Gutierrez</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. George Gill, MD </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338,890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Regulatory Affairs and Chief Safety Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Alan J Tuchman, MD, MBA (FAAN) </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Neuro Oncology Research Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 1:</font><font style="font-family:inherit;font-size:10pt;">&#160;US Employees are paid in US Dollars and salaries above for those US employees are presented in US dollars.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, each Executive Officer is entitled to additional benefits and performance-based bonuses.&#160;&#160;As well, the Employment Agreements provide that each Executive Officer is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company.&#160;&#160;Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not provide pension plan benefits to its Executive Officers and employees. The Company does not currently have a stock appreciation rights plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Termination of Employment or Change of Control</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects amounts payable to the Executive Officers (other than Dr. Thompson who resigned as President and Chief Executive Officer of the Company on November 2, 2016) based on each Executive Officer's employment agreement assuming that their employment was terminated on December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;without cause or due to a change of control of the Company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:509px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:242px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Termination without Cause Severance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change of Control Severance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Matthew C. Coffey<br>Chief Executive Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">984,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, C.A.<br>Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">800,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Andres A. Gutierrez</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)<br></sup></font><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. George Gill, MD</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) </sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Clinical and Regulatory Affairs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Alan J Tuchman, MD, MBA (FAAN) </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Neuro Oncology Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, all options granted to Officers had fully vested except for the options granted on December 1, 2015 and November 10, 2016.  As a result, all Officers shall be entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such Officer is terminated unless otherwise approved by the Board of Directors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a change of control of the Company, the Officers shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such Officer is terminated.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US Employees are paid in US Dollars and are presented in US dollars.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Board Practices</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;&#160;The officers are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:37%;"></td><td style="width:20%;"></td><td style="width:18%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Corporation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Corporation Since</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Expiration of Current Term of Office</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew C. Coffey Ph.D</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 11, 2011</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2017 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></font><font style="font-family:inherit;font-size:10pt;">FCPA, FCMA, ICD.D</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 18, 2014</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2017 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. Mark Lievonen, CM, FCPA, FCA, LLD</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 5, 2004</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2017 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano, MBA</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chair and Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 9, 2013</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2017 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William G. Rice, Ph.D.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2017 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd R. Seizinger, M.D., Ph.D.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA and Munich Germany</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2017 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors&#8217; Contracts</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director who is not a salaried employee of the Company is entitled to the following fees:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual Retainer (USD):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Board chair annual retainer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$80,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit Committee chair retainer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$60,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Governance &amp; Compensation Committee chair retainers&#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;$50,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other directors&#8217; retainer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   &#160;&#160;&#160;&#160;$40,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Retainer for Non-Chair Directors Serving on the Following Board Committees (USD):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$10,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Governance&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$5,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$5,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Science &amp; Technology&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$15,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors, annually, may opt to take up to 100% of their respective annual retainer in restricted share awards. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Share Units </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the combined retainer, the Corporation will grant annually $20,000 of restricted share awards that will vest over a three year period.  The annual restricted share unit award will be granted on October 1 of each year.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also grant to directors, from time to time, stock options in accordance with the Option Plan and the reimbursement of any reasonable expenses incurred by them while acting in their directors' capacity.&#160;&#160;During the year ended December 31, 2016, total compensation of </font><font style="font-family:inherit;font-size:10pt;">$561,414</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid to the independent directors which consisted of fee payments of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$391,765</font><font style="font-family:inherit;font-size:10pt;">, share based awards of </font><font style="font-family:inherit;font-size:10pt;">$169,649</font><font style="font-family:inherit;font-size:10pt;">&#32;and option based awards of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Committee</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation has formed a compensation committee (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Compensation Committee</font><font style="font-family:inherit;font-size:10pt;">&#8221;) which consists of two outside, independent directors, Dr. Seizinger and Ms. Holtham, and Mr. Pisano, the Chair of the Board. Mr. Pisano is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee officer of the Company or any of its affiliates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The objectives of the Corporation&#8217;s compensation arrangements are: (i)&#160;to attract and retain key personnel; (ii)&#160;to encourage commitment to the Corporation and its goals; (iii)&#160;to align executive interests with those of its shareholders; and (iv)&#160;to reward executives for performance in relation to overall corporate progress goals.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The key elements of the compensation program are the base salary, health benefits, and payments allocated to employees to be directed by them to their personal retirement accounts. Bonuses and the granting of Options (as defined herein) and Share Awards (as defined herein) are also part of the Corporation&#8217;s compensation program and are based on corporate performance. Part of corporate performance includes goals and objectives that are determined based on the strategic planning and budgeting process, which is conducted at least annually. The elements of the compensation plan are intended to reward performance, and the various elements are intended to provide a blend of short-term and long-term incentives to align the interests of management and the shareholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In arriving at its recommendations for compensation, the Compensation Committee considers the long-term interests of the Corporation as well as its current stage of development and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging. Based on these factors, the Compensation Committee recognized the need to strike a balance between compensation to retain employees and resources expended to maintain operations. In the past, the Compensation Committee has engaged specialist consultants to assist in benchmarking its compensation practices and provide recommendations to the committee with respect to compensation for directors and officers, however, no such consultant was engaged in 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following a review of the risks in the Corporation&#8217;s compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to have a material adverse effect on the Corporation. The Compensation Committee&#8217;s role of approving the compensation policies and practices includes considering whether the compensation policies and practices could encourage an officer of the Company to take inappropriate or excessive risks.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Corporation&#8217;s corporate trading policy, insiders (including officers and directors) are not permitted to hedge their position in Common Shares, Options, Share Awards, deferred share units, performance share units, debentures or other debt instruments by use of any financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit the holder from a change in the market value of the Common Shares of the Corporation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the following guidelines were employed by the Board in granting bonuses, Options and Share Awards to the Corporation&#8217;s executive and senior officers. For </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, similar guidelines are expected to be applied.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annual Bonus, Option Grants and Share Award Grants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the Chief Executive Officer and Chief Financial Officer of the Corporation is eligible for a cash bonus of up to 40% of his base salary, the Chief Medical Officer is eligible for a cash bonus of up to 35% of his base salary and the other senior officers are eligible for a cash bonus of up to 15 to 20% of their respective base salaries.  In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation Committee and approved by the Board. The overall performance of the Corporation is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Committee Mandate</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Policy Statement</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain a Compensation Committee (the "Committee"), composed entirely of independent directors, to assist the Board of Directors of the Corporation (the "Board") in carrying out its responsibility for the Corporation&#8217;s human resources and compensation policies and processes.  The Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board, including </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">administrative support.  If determined necessary by the Committee, it will have the discretion to investigate and conduct reviews of any human resource or compensation matter including the standing authority to retain experts and special counsel.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Composition of Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall consist of a minimum of three (3) directors.  The Board shall appoint the members (&#8220;Members&#8221;) of the Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Committee to be the Chair of the Committee, or delegate such authority to appoint the Chair of the Committee to the Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Committee shall be responsible for the leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director appointed to the Committee by the Board shall be an outside director who is unrelated.  An outside, unrelated director is a director who meets the requirements of NASDAQ Rule 5605 and National Instrument 58-101 who is independent of management and is free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to be independent of management and to act with a view to the best interests of the Corporation, including, but not limited to the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the Corporation to such director and whether such director is affiliated with the Corporation, a subsidiary of the Corporation or an affiliate of a subsidiary of the Corporation other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the then current legislation, rules, policies and instruments of applicable regulatory authorities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Board shall be an ex officio Member of the committee. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Meetings of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall meet a minimum of once per year at such time and place as may be designated by the Chair of the Committee and whenever a meeting is requested by the Board, a Member of the Committee, or the Chief Executive Officer of the Corporation (the "CEO"). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of each meeting of the Committee shall be given to each Member of the Committee.  The CEO shall attend each meeting of the Committee whenever requested to do so by a Member of the Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of a meeting of the Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be in writing, including by electronic communication facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state the nature of the business to be transacted at the meeting in reasonable detail;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Committee may permit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A quorum for the transaction of business at a meeting of the Committee shall consist of a majority of the Members of the Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Member or Members of the Committee may participate in a meeting of the Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the absence of the Chair of the Committee, the Members of the Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary shall be the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Minutes shall be kept of all meetings of the Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Committee shall be distributed to members of the Committee, to other members of the Board and, with the exception of &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in camera</font><font style="font-family:inherit;font-size:10pt;">&#8221; items, to the Chief Executive Officer and Chief Financial Officer.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Duties and Responsibilities of the Committee</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee&#8217;s primary duties and responsibilities are to review and make recommendations to the Board in respect of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">human resource policies, practices and structures (to monitor consistency with the Corporation&#8217;s goals and near and long-term strategies, support of operational effectiveness and efficiency, and maximization of human resources potential);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compensation policies and guidelines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">management incentive and perquisite plans and any non-standard remuneration plans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">senior management, executive and officer appointments and their compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">management succession plans, management training and development plans, termination policies and termination arrangements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Board compensation matters.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In carrying out its duties and responsibilities, the Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually assess and make a recommendation to the Board with regard to the competitiveness and appropriateness of the compensation package of the CEO, all other officers of the Corporation and such other key employees of the Corporation or any subsidiary of the Corporation as may be identified by the CEO and approved by the Committee (collectively, the "Designated Employees");</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually review the performance goals and criteria for the CEO and evaluate the performance of the CEO against such goals and criteria and recommend to the Board the amount of regular and incentive compensation to be paid to the CEO;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, review and make a recommendation to the Board regarding the CEO&#8217;s performance evaluation of Designated Employees and the CEO&#8217;s recommendations with respect to the amount of regular and incentive compensation to be paid to such Designated Employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and make a recommendation to the Board regarding any employment contracts or arrangements with each of the Designated Employees, including any retiring allowance arrangements or any similar arrangements to take effect in the event of a termination of employment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">periodically, review the compensation philosophy statement of the Corporation and make recommendations for change to the Board as considered necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">from time to time, review and make recommendations to the Board in respect of the design, benefit provisions, investment options and text of applicable pension, retirement and savings plans or related matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, in conjunction with the Corporation&#8217;s general and administrative budget, review and make recommendations to the Board regarding compensation guidelines for the forthcoming budget period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">when requested by the CEO, review and make recommendations to the Board regarding short term incentive or reward plans and, to the extent delegated by the Board, approve awards to eligible participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and make recommendations to the Board regarding incentive stock option plans or any other long term incentive plans and to the extent delegated by the Board, approve grants to participants and the magnitude and terms of their participation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as required, fulfill the obligations assigned to the Committee pursuant to any other employee benefit plans approved by the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, prepare or review the report on executive compensation required to be disclosed in the Corporation&#8217;s information circular or any other human resource or compensation matter required to be publicly disclosed by the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, review and make a recommendation to the Board regarding the compensation of the Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xiii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as determined in the sole discretion of the Committee, retain independent advice in respect of human resources and compensation matters from a compensation consultant, legal counsel or other advisor (the &#8220;Advisor&#8221;) and, if deemed necessary by the Committee, meet separately with the Advisor; the Committee shall be directly responsible for the appointment, compensation and oversight of the work of the Advisor retained by the Committee; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xiv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">select, or receive advice from, an Advisor to the Committee, other than in-house legal counsel, after taking into consideration the following factors:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the provision of other services to the Corporation by the entity that employs the Advisor ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount of fees received from the Corporation by the entity that employs the Advisor, as a percentage of the total revenue of the entity that employs the Advisor;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the policies and procedures of the entity that employs the Advisor that are designed to prevent conflicts of interest;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any business or personal relationship of the Advisor with a member of the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any stock of the Corporation owned by the Advisor; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any business or personal relationship of the Advisor or the entity employing the Advisor with an executive officer of the Corporation;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provided however, none of the above factors shall prevent the Committee from retaining any Advisor as the Committee deems appropriate, in its sole discretion, after consideration of the above factors. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and consider the implications of the risks associated with the Corporation&#8217;s compensation policies and practices, specifically, situations that could potentially encourage an insider to expose the Corporation to inappropriate or excessive risks; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xvi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the foregoing, the Committee shall undertake on behalf of the Board such other initiatives as may be necessary or desirable to assist the Board in discharging its responsibility for the Corporation&#8217;s human resources development, performance evaluation, compensation and succession planning programs are in place and operating effectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">External Advisors</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If, in order to properly discharge its function, duties and responsibilities, it is necessary, in the opinion of the Committee that the Committee obtains the advice and counsel of external advisors, the Chair shall, at the request of the Committee, engage the necessary experts. The Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Committee&#8217;s regular reports to the Board.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Mandate</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Mandate was last reviewed, amended and approved by the Board on March 9, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Audit Committee</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of three independent directors pursuant to the Rule 5605(a)(2) of the NASDAQ Capital Market and Rule 10A-3 of the Exchange Act: Ms. Angela Holtham, Mr. Lievonen and Mr. Pisano, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;&#160;Each Audit Committee member is financially literate.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Audit Committee Mandate</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Policy Statement</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain an Audit Committee, composed entirely of independent directors, to assist the Board of Directors (the "Board") in carrying out their oversight responsibility for the Corporation&#8217;s internal controls, financial reporting and financial risk management processes.  The Audit Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board including administrative support.  If determined necessary by the Audit Committee, it will have the discretion to institute investigations of improprieties, or suspected improprieties within the scope of its responsibilities, including the standing authority to retain special counsel or experts.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Composition of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall consist of a minimum of three (3) directors.   The Board shall appoint the members (&#8220;Members&#8221;) of the Audit Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Audit Committee to be the Chair </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">of the Audit Committee, or delegate such authority to appoint the Chair of the Audit Committee to the Audit Committee.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Committee shall be responsible for leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director appointed to the Audit Committee by the Board shall be an outside director who is unrelated and independent.  An outside, unrelated and independent director is a director who meets the requirements of NASDAQ Rule 5605(a)(2) and National Instrument 52-110. A director appointed to the audit committee shall also meet the requirements of NASDAQ Rule 5605(c)(2) and Rule 10A-3(b)(1) of the United States Securities Exchange Act of 1934, as amended. Such director shall be independent of management and free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to act with a view to the best interests of the Corporation, other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the abovementioned rules and any applicable revisions thereto, and any additional relevant and then current legislation, rules, policies and instruments of applicable regulatory authorities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member of the Audit Committee shall be financially literate.  In order to be financially literate, a director must be, at a minimum, able to read and understand financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation's financial statements. At least one Member shall have accounting or related financial management expertise, meaning the ability to analyze and interpret a full set of financial statements, including the notes attached thereto, in accordance with generally accepted accounting principles and shall be a &#8220;financial expert&#8221; as defined in Item 407 of Regulation S-K promulgated by the U.S. Securities and Exchange Commission and &#8220;financially sophisticated&#8221; as defined in NASDAQ Rule 5605(c)(2).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining whether a Member of the Audit Committee is financially literate or has accounting or related financial expertise, reference shall be made to the then current legislation, rules, policies and instruments of applicable regulatory authorities. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member of the Audit Committee shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Audit Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Board shall be an ex officio Member of the committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Meetings of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall convene a minimum of four times each year at such times and places as may be designated by the Chair of the Audit Committee and whenever a meeting is requested by the Board, a Member of the Audit Committee, the auditors, or senior management of the Corporation.  Scheduled meetings of the Audit Committee shall correspond with the review of the year-end and quarterly financial statements and management discussion and analysis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of each meeting of the Audit Committee shall be given to each Member of the Audit Committee and to the auditors, who shall be entitled to attend each meeting of the Audit Committee and shall attend whenever requested to do so by a Member of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of a meeting of the Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be in writing, including by electronic communication facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state the nature of the business to be transacted at the meeting in reasonable detail;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Audit Committee may permit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A quorum for the transaction of business at a meeting of the Audit Committee shall consist of a majority of the Members of the Audit Committee.  However, it shall be the practice of the Audit Committee to require review, and, if necessary, approval of certain important matters by all Members of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Member or Members of the Audit Committee may participate in a meeting of the Audit Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the absence of the Chair of the Audit Committee, the Members of the Audit Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary shall be the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A member of the Board, senior management of the Corporation and other parties may attend meetings of the Audit Committee; however the Audit Committee (i) shall, at each meeting, meet with the external auditors independent of other individuals other than the Audit Committee and (ii) may meet separately with management.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chief Executive Officer and the Chief Financial Officer shall each attend meetings of the Audit Committee when requested to do so by a Member of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Minutes shall be kept of all meetings of the Audit Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Audit Committee shall be distributed to Members of the Audit Committee, to other members of the Board and, with the exception of &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in camera</font><font style="font-family:inherit;font-size:10pt;">&#8221; items, to the Chief Executive Officer and Chief Financial Officer.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Duties and Responsibilities of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee&#8217;s primary duties and responsibilities are to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">identify and monitor the management of the principal risks that could impact the financial reporting of the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the integrity of the Corporation&#8217;s financial reporting process and system of internal controls regarding financial reporting and accounting compliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the independence and performance of the Corporation&#8217;s external auditors. This will include receipt, review and evaluation, at least annually, of a formal written statement from the independent auditors confirming their independence, and qualifications, including their compliance with the requirements of the relevant oversight boards and actively engage in a dialogue with the auditors with respect to any disclosed relationships or services that may impact objectivity and independence of the auditors and take, or recommend that the full board take, appropriate action to oversee the independence of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deal directly with the external auditors to pre-approve external audit plans, other services (if any) and fees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">directly oversee the external audit process and results (in addition to items described in Section 4(d) below);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide an avenue of communication among the external auditors, management and the Board; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">carry out a review designed to ensure that an effective "whistle blowing" procedure exists to permit stakeholders to express any concerns to an appropriately independent individual;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-approve any related party transactions to be entered into by the Company, and ensure appropriate disclosure thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ensure financial disclosure incorporates inclusion of any material correcting adjustments required by the external auditors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require and ensure that the external auditors are directly responsible to the Audit Committee, to whom they report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall have the authority to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inspect any and all of the books and records of the Corporation and its affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discuss with the management of the Corporation and its affiliates, any affected party and the external auditors, such accounts, records and other matters as any Member of the Audit Committee considers necessary and appropriate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engage independent counsel and other advisors as it determines necessary to carry out its duties.  The Audit Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Audit Committee&#8217;s regular reports to the Board; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">communicate directly with the external auditors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">set and pay the compensation for (A) any external auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review, or attest services for the Corporation, (b) any advisors employed by the Audit Committee, and (C) ordinary administrative expenses of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review the audit plan with the Corporation&#8217;s external auditors and with management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with the independent auditors the matters required to be discussed relating to the conduct of the audit, including (a) the proposed scope of their examination, with emphasis on accounting and financial areas where the Committee, the independent auditors or management believes special attention should </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">be directed; (b) the results of their audit, including their audit findings report and resulting letter, if any, of recommendations for management; (c) their evaluation of the adequacy and effectiveness of the Company&#8217;s internal controls over financial reporting; (d) significant areas of disagreement, if any, with management; (e) co-operation received from management in the conduct of the audit; (f) significant accounting, reporting, regulatory or industry developments affecting the Company; and (g) review any proposed changes in major accounting policies or principles proposed or contemplated by the independent auditors or management, the presentation and impact of material risks and uncertainties and key estimates and judgements of management that may be material to financial reporting;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with management and with the external auditors material financial reporting issues arising during the most recent fiscal period and the resolution or proposed resolution of such issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review any problems experienced or concerns expressed by the external auditors in performing an audit, including any restrictions imposed by management or material accounting issues on which there was a disagreement with management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with senior management the process of identifying, monitoring and reporting the principal risks affecting financial reporting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review audited annual financial statements (including management discussion and analysis) and related documents in conjunction with the report of the external auditors and obtain an explanation from management of all material variances between comparative reporting periods. Without restricting the generality of the foregoing, the committee will discuss with management and the independent auditors to the extent required, any issues and disclosure requirements regarding (a) the use of &#8220;pro forma&#8221; or &#8220;adjusted&#8221; non-GAAP information, as well as financial information and earnings guidance provided to analysts and rating agencies, (b) any off balance sheet arrangements, and (c) any going concern qualification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consider and review with management, the internal control memorandum or management letter containing the recommendations of the external auditors and management&#8217;s response, if any, including an evaluation of the adequacy and effectiveness of the internal financial controls of the Corporation and subsequent follow-up to any identified weaknesses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with financial management and the external auditors the quarterly unaudited financial statements, management discussion and analysis, letter to shareholders and press release (all to be considered the &#8220;Quarterly Financial Reports&#8221;) and recommend the Quarterly Financial Reports to the Board for approval by the Board before release to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">before release, review and if appropriate, recommend for approval by the Board, all public disclosure documents containing audited or unaudited financial information, including any prospectuses, financial statements, including the notes thereto, annual reports, annual information forms, management discussion and analysis and press releases; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">oversee, any of the financial affairs of the Corporation or its affiliates, and, if deemed appropriate, make recommendations to the Board, external auditors or management.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluate the independence and performance of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recommend the nomination of the external auditors to the Board for appointment by the shareholders at the Corporation&#8217;s annual general meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;recommend the discharge of the external auditor when circumstances warrant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the rotation of the audit partner of the external auditors as required by applicable law or regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consider the recommendations of management in respect of the appointment of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-approve all non-audit services to be provided to the Corporation or its subsidiary entities by its external auditors, or the external auditors of affiliates of the Corporation subject to the over-riding principle that the external auditors not being permitted to be retained by the Corporation to perform specifically listed categories of non-audit services as set forth by the Securities and Exchange Commission as well as internal audit outsourcing services, financial information systems work and expert services.  Notwithstanding, the foregoing the pre-approval of non-audit services may be delegated to a Member of the Audit Committee, with any decisions of the Member with the delegated authority reporting to the Audit Committee at the next scheduled meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approve the engagement letter for non-audit services to be provided by the external auditors or affiliates, together with estimated fees, and considering the potential impact of such services on the independence of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">when there is to be a change of external auditors, review all issues and provide documentation related to the change, including the information to be included in the Notice of Change of Auditors and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">documentation required pursuant to the then current legislation, rules, policies and instruments of applicable regulatory authorities and the planned steps for an orderly transition period; and</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review all reportable events, including disagreements, unresolved issues and consultations, as defined by applicable securities policies, on a routine basis, whether or not there is to be a change of external auditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall enquire into and determine the appropriate resolution of any conflict of interest in respect of audit or financial matters, which are directed to the Audit Committee by any member of the Board, a shareholder of the Corporation, the external auditors, or senior management.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review the Corporation&#8217;s accounting and reporting of revenues, costs, liabilities and contingencies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall establish and maintain procedures for:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal controls, or auditing matters; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the confidential, anonymous submission by employees of the Corporation or concerns regarding questionable accounting or auditing matters.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review and approve the Corporation's hiring policies regarding partners and employees and former partners and employees of the present and former external auditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review with the Corporation's legal counsel, on no less than an annual basis, any legal matter that could have a material impact on the Corporation's financial statements, and any enquiries received from regulators, or government agencies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review with management and the Corporation&#8217;s external auditors, on no less than an annual basis, any taxation matters that could have a material impact on the Corporation&#8217;s financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee, through the Chair, shall receive notice from management of any instance of non-trivial fraud or other failure or weakness of the control system promptly upon management becoming aware of such.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(m)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review and approve the signing authority for the Corporation at least annually or when a change is required. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(n)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Audit Committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Mandate</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Mandate was last reviewed and approved by the Board on March 9, 2017.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:512px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:349px;"></td><td style="width:58px;"></td><td style="width:52px;"></td><td style="width:52px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Activity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:462px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:310px;"></td><td style="width:52px;"></td><td style="width:46px;"></td><td style="width:52px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic location</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Ownership</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the share ownership and options held of our directors and officers as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:633px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="width:101px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:85px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td><td style="width:132px;"></td><td style="width:86px;"></td><td style="width:11px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of&#160;&#160;<br>Ownership</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">&#160;<br>Options</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise<br>Price</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry Date</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Outstanding</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Officers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Bradley G. Thompson</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">608,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,880,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew C. Coffey</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;12, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;8, 2019</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July&#160;27, 2021</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">734,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January&#160;16, 2027</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,820,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;12, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;8, 2019</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;13, 2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January&#160;16, 2027</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,243,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.97</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Andres A. Gutierrez</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;10, 2026</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. George Gill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;12, 2017</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;8, 2019</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:633px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="width:101px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:85px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td><td style="width:132px;"></td><td style="width:86px;"></td><td style="width:11px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Alan J. Tuchman</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;11, 2020</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;1, 2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;18, 2024</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Lievonen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;12, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;8, 2019</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;9, 2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;8, 2025</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;8, 2025</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TOTAL:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,321,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">** Less than 1% ownership</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">121,258,222</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares issued and outstanding on </font><font style="font-family:inherit;font-size:10pt;">March&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable to acquire common shares.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ownership percentage assumes aggregate beneficial ownership of common shares, common shares acquirable upon exercise of options and fully diluted shares outstanding of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">132,262,378</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Thompson resigned as President and Chief Executive Officer on November 2, 2016.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Share Units</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the restricted share units held by our directors as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:383px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:133px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:81px;"></td><td style="width:71px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Granted</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Vested</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Lievonen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,322,829</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,322,829</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Share Units</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the performance share units held by our officers as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:408px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:133px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:96px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Granted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Vested</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andres Gutierrez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0B0655323335EB68B318FBCAB50F9F52"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Major Shareholders</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not directly or indirectly owned or controlled by another corporation(s) or by any foreign government. To the knowledge of our directors and senior officers, as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">, we are not aware of any shareholder who beneficially owns, directly or indirectly, or exercises control or direction over, our common shares carrying more than 5% of the voting rights.   </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shares Held in the United States</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table indicates, as of </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with US&#160;addresses, the portion of the outstanding common shares held by US&#160;holders of record, and the percentage of common shares held by US&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:44%;"></td><td style="width:14%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Number of Holders of Record</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Number of Common Shares Issued and Outstanding</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of US&#160;Holders of Record</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Common Shares Held by US&#160;Holders of Record&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of Common Shares Held by US&#160;Holders of Record&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,730,085</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.36</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change of Control</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Control by Others</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation, any foreign government, or any other natural or legal person, severally or jointly.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into employment contracts with each of our officers (see Item 6).&#160;&#160;Since the beginning of the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interests of Experts and Council</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4E740DA7DEC9ABADB1FEFBCAB5286D84"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8. FINANCIAL INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements and Other Financial Statements</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements filed as part of this annual report are filed under Item 18.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The directors and the management of the Company do not know of any material, active or pending, legal proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not paid any dividends on its common shares.&#160;&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Changes</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no significant changes to our annual financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s45BD960553AE46017EDCFBCAB55706AD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9. THE OFFER AND LISTING</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Offering and Listing Details</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Shares are traded on the TSX under the symbol ONC.  As well, effective November 5, 2015, our Common Shares commenced quotations on the OTCQX International ("OTCQX") under the symbol ONCYF.  Prior to November 5, 2015 our Common Shares traded on the NASDAQ Capital Market under the symbol ONCY.  On November 5, 2015, our Common Shares were delisted from the NASDAQ.  The last reported sales price of our common shares on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;on the TSX was Cdn</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.60</font><font style="font-family:inherit;font-size:10pt;">&#32;and on the OTCQX was US</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.45</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The following table sets forth the high and low per share sales prices for our common shares on the OTCQX, the NASDAQ and TSX for the periods indicated.  In relation to the OTCQX, the following quotations reflect inter-dealer prices without retail mark-up, mark-down or commission and may not represent actual transactions.&#160;&#160;The following table sets forth the range of high and low bid prices during the periods indicated on the OTCQX.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:98px;"></td></tr><tr><td colspan="7" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTCQX</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NASDAQ</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TSX</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.58</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.59</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.70</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.93</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.94</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.54</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.99</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.45</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.16</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.35</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.16</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.53</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.80</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.50</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.05</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.60</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.70</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.45</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.94</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.46</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.60</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.35</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.36</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.34</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.44</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.49</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.34</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.34</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March (1 &#8211; 24)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.48</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.36</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Price Volatility of Common Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market prices for the securities of biotechnology companies, including our securities, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors, such as fluctuations in our operating results, the aftermath of our public announcements, and general market conditions, can have an adverse effect on the market price of our common shares and other securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Plan of Distribution</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Markets</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Shares, no par value, are traded/quoted on the OTCQX and the TSX under the symbol &#8220;ONCYF" and &#8220;ONC&#8221;, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selling Shareholders</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dilution</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses of the Issue</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3687AD30B46A9E6F3E76FBCAB5E90A23"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.&#160; ADDITIONAL INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Memorandum and Articles of Association</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Articles of Continuance</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Directors</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rights, Preferences and Dividends Attaching to Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a distribution of assets on a winding-up, dissolution or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">pro&#160;rata</font><font style="font-family:inherit;font-size:10pt;">&#32;share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other classes of shares are currently permitted to be issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Action Necessary to Change the Rights of Shareholders</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Annual and Special Meetings of Shareholders</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the US&#160;&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Limitations on the Rights to Own Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Share Ownership</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 10&#160;days from the day on which the change takes place.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rules in the US governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Provisions of Articles and By-laws</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no provisions in the Articles or By-laws:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requiring disclosure of share ownership; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material Contracts</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have employment contracts with each of our officers as summarized in Item 6B.&#160;&#160;Other than these employment contracts, we have not entered into any other contract other than in the ordinary course of business over the last two years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exchange Controls</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities, except as discussed below in Section&#160;E,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restrictions on Share Ownership by Non-Canadians</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no limitations under the laws of Canada or in our organizational documents on the right of foreigners to hold or vote securities of our company, except that the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Canada Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "Investment Canada Act") may require review and approval by the Minister of Industry (Canada) of certain acquisitions of "control" of our Company by a "non-Canadian."</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Canada Act</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Investment Canada Act, transactions exceeding certain financial thresholds, and which involve the acquisition of control of a Canadian business by a non-Canadian, are subject to review and cannot be implemented unless the Minister of Industry and/or, in the case of a Canadian business engaged in cultural activities, the Minister of Canadian Heritage, are satisfied that the transaction is likely to be of "net benefit to Canada". If a transaction is subject to review (a&#160;"Reviewable Transaction"), an application for review must be filed with the Investment Review Division of Industry Canada and/or the Department of Canadian Heritage prior to the implementation of the Reviewable Transaction. The responsible Minister is then required to determine whether the Reviewable Transaction is likely to be of net benefit to Canada taking into account, among other things, certain factors specified in the Investment Canada Act and any written undertakings that may have been given by the applicant. The Investment Canada Act contemplates an initial review period of up to 45&#160;days after filing; however, if the responsible Minister has not completed the review by that date, the Minister may unilaterally extend the review period by up to 30&#160;days (or&#160;such longer period as may be agreed to by the applicant and the Minister) to permit completion of the review. Direct acquisitions of control of most Canadian businesses by or from World Trade Organization ("WTO") investors are reviewable under the Investment Canada Act only if, in the case of an acquisition of voting securities, the value of the worldwide assets of the Canadian business or, in the case of an acquisition of substantially all the assets of a Canadian business, the value of those assets exceed C$295 million for the year 2008 (this figure is adjusted annually to reflect inflation). Indirect acquisitions (e.g., an acquisition of a US corporation with a Canadian subsidiary) of control of such businesses by or from WTO investors are not subject to review, regardless of the value of the Canadian businesses' assets. Significantly lower review thresholds apply where neither the investor nor the Canadian business is WTO investor controlled or where the Canadian business is engaged in uranium mining, certain cultural businesses, financial services or transportation services.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if the transaction is not reviewable because it does not meet or exceed the applicable financial threshold, the non-Canadian investor must still give notice to Industry Canada and, in the case of a Canadian business engaged in cultural activities, Canadian Heritage, of its acquisition of control of a Canadian business within 30&#160;days of its implementation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Competition Act</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Competition Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(Canada) (the&#160;"Competition Act") requires that a pre-merger notification filing be submitted to the Commissioner of Competition (the&#160;"Commissioner") in respect of proposed transactions that exceed certain financial and other thresholds. If a proposed transaction is subject to pre-merger notification, a pre-merger notification filing must be submitted to the Commissioner and a waiting period must expire or be waived by the Commissioner before the transaction may be completed. The parties to a proposed transaction may choose to submit either a short-form filing (in&#160;respect of which there is a 14-day statutory waiting period) or a long-form filing (in&#160;respect of which there is a 42-day statutory waiting period). However, where the parties choose to submit a short-form filing, the Commissioner may, within 14&#160;days, require that the parties submit a long-form filing, in which case the proposed transaction generally may not be completed until 42&#160;days after the long-form filing is submitted by the&#160;parties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Commissioner may, upon request, issue an advance ruling certificate ("ARC") in respect of a proposed transaction where she is satisfied that she would not have sufficient grounds on which to apply to the Competition Tribunal for an order under the merger provisions of the Competition Act. If the Commissioner issues an ARC in respect of a proposed transaction, the transaction is exempt from the pre-merger notification provisions. In addition, if the transaction to which the ARC relates is substantially completed within one year after the ARC is issued, the Commissioner cannot seek an order of the Competition Tribunal under the merger provisions of the Competition Act in respect of the transaction solely on the basis of information that is the same or substantially the same as the information on the basis of which the ARC was&#160;issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Commissioner is unwilling to issue an ARC, she may nevertheless issue a "no action" letter waiving notification and confirming that she is of the view that grounds do not then exist to initiate proceedings before the Competition Tribunal under the merger provisions of the Competition Act with respect to the proposed transaction, while preserving, during the three years following completion of the proposed transaction, her authority to initiate proceedings should circumstances change.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regardless of whether pre-merger notification is required, the Commissioner may apply to the Competition Tribunal (a special purpose tribunal) for an order under the merger provisions of the Competition Act. If the Competition Tribunal finds that the transaction is or is likely to prevent or lessen competition substantially, it may order that the parties not proceed with the transaction or part of it or, in the event that the transaction has already been completed, order its dissolution or the disposition of some of the assets or shares involved. In addition, the Competition Tribunal may, with the consent of the person against whom the order is directed and the Commissioner, order that person to take any other action as is deemed necessary to remedy any substantial lessening or prevention of competition that the Competition Tribunal determines would or would likely result from the transaction.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Taxation</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares.  In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty.  Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder.  This summary does not address the U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares.  In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements.  Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.  This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary.  In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scope of this Summary</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Authorities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &#8220;Canada-U.S. Tax Convention&#8221;), and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document.  Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively.  This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Holders</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of this summary, the term "U.S. Holder" means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an individual who is a citizen or resident of the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that:  (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); or (h) own, have owned or will own  (directly, indirectly, or by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">attribution) 10% or more of the total combined voting power of the outstanding shares of the Company.  This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are:  (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Income Tax Act (Canada) (the &#8220;Tax Act&#8221;); (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold Common Shares in connection with carrying on a business in Canada; (d) persons whose Common Shares constitute &#8220;taxable Canadian property&#8221; under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention.  U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants).  This summary does not address the tax consequences to any such partner (or owner or participants).  Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Passive Foreign Investment Company Rules</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">PFIC Status of the Company</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules may affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares.  The Company believes that it was classified as a PFIC for the tax year ended December 31, 2014, and based on current business plans and financial expectations, the Company anticipates that it may be a PFIC for its current tax year and subsequent tax years.  The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations.  In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document.  Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Company (or any subsidiary of the Company) concerning its PFIC status.  Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Company and each subsidiary of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require.  In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax.  U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Company is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Company&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;).  &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation.  In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under certain attribution rules, if the Company is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Company&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC.  In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares.  Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Default PFIC Rules Under Section 1291 of the Code</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Company and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;).  A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares.  A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares.  The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates).  The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year.  A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years.  A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Company was a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">QEF Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares.  A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Company, which will be taxed as ordinary income to such U.S. Holder.  Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain.  A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company.  However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election.  If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge.  If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a timely and effective QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Company that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election.  In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely.  A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Company was a PFIC.  A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year.  If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective.  If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares.   If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election.  If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company is not a PFIC.  Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Holders should be aware that there can be no assurances that the Company will satisfy the record keeping requirements that apply to a QEF, or that the Company will supply U.S. Holders with information that such U.S. Holders are required to report under the QEF rules, in the event that the Company is a PFIC.  Thus, U.S. Holders may not be able to make a QEF Election with respect to their Common Shares.  Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a QEF Election.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return.  However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Mark-to-Market Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock.  The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks.  If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter.  Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock.  However, each U.S. Holder should consult its own tax advisor in this regard.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares.  However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Company is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section&#160;1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares.  A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election.  In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years).  Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder makes a Mark-to-Market  Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return.  A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election.  Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable.  Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other PFIC Rules</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations).  However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain additional adverse rules may apply with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election.  For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC.  Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit.  The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General Rules Applicable to the Ownership and Disposition of Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Distributions on Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Company, as computed for U.S. federal income tax purposes.  A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Company is a PFIC for the tax year of such distribution or the preceding tax year.  To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder's tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below).  However, the Company may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Company with respect to the Common Shares will constitute ordinary dividend income.  Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221;  Subject to applicable limitations and provided the Company is eligible for the benefits of the Canada-U.S. Tax Convention, dividends paid by the Company to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year.  The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sale or Other Taxable Disposition of Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder's tax basis in such Common Shares sold or otherwise disposed of.  A U.S. Holder&#8217;s tax basis in Common Shares generally will be such holder&#8217;s U.S. dollar cost for such Common Shares.  Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust.  There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation.  Deductions for capital losses are subject to significant limitations under the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Considerations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Additional Tax on Passive Income</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Holders that are individuals, estates or trusts (other than trusts that are exempt from tax) will be subject to a 3.8% tax on all or a portion of their &#8220;net investment income,&#8221; which includes dividends on the Common Shares and net gains from the disposition of the Common Shares.  Further, excess distributions treated as dividends, gains treated as excess distributions under the PFIC rules discussed above, and mark-to-market inclusions and deductions are all included in the calculation of net investment income.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury Regulations provide, subject to the election described in the following paragraph, that solely for purposes of this additional tax, that distributions of previously taxed income will be treated as dividends and included in net investment income subject to the additional 3.8% tax.  Additionally, to determine the amount of any capital gain from the sale or other taxable disposition of Common Shares that will be subject to the additional tax on net investment income, a U.S. Holder who has made a QEF Election will be required to recalculate its basis in the Common Shares excluding QEF basis adjustments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alternatively, a U.S. Holder may make an election which will be effective with respect to all interests in controlled foreign corporations and QEFs held in that year or acquired in future years.  Under this election, a U.S. Holder pays the additional 3.8% tax on QEF income inclusions and on gains calculated after giving effect to related tax basis adjustments.  U.S. Holders that are individuals, estates or trusts should consult their own tax advisors regarding the applicability of this tax to any of their income or gains in respect of the Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Receipt of Foreign Currency</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time).  A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt.  Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes.  Different rules apply to U.S. Holders who use the accrual method.  Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Tax Credit</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax.  Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax.  This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Complex limitations apply to the foreign tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. Holder&#8217;s U.S. federal income tax liability that such U.S. Holder&#8217;s &#8220;foreign source&#8221; taxable income bears to such U.S. Holder&#8217;s worldwide taxable income.  In applying this limitation, a U.S. Holder&#8217;s various items of income and deduction must be classified, under complex rules, as either &#8220;foreign source&#8221; or &#8220;U.S. source.&#8221;  Generally, dividends paid by a foreign corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income tax treaty, and if an election is properly made under the Code.  However, the amount of a distribution with respect to the Common Shares that is treated as a &#8220;dividend&#8221; may be lower for U.S. federal income tax purposes than it is for Canadian federal income tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder.  In addition, this limitation is calculated separately with respect to specific categories of income.  The foreign tax credit rules are complex, and each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Backup Withholding and Information Reporting</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation.  For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds.  The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity.  U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions.  Penalties for failure to file certain of these information returns are substantial.  U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax, at the rate of 28%, if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax.  However, certain exempt persons generally are excluded from these information reporting and backup withholding rules.  Backup withholding is not an additional tax.  Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder.  A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement.  Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES.  U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends and Paying Agents</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statements by Experts</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">H.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Documents on Display</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. You may read and copy any of our reports and other information at, and obtain copies upon payment of prescribed fees from, the Public Reference Room maintained by the SEC at 100&#160;F&#160;Street, N.E., Washington,&#160;D.C. 20549. In addition, the SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at http://www.sec.gov. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR") (http://www.sedar.com), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look.&#160;&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolytics.ca.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiary Information</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA7A0BDA3613E361246BAFBCAB6125A34"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate primarily in Canada, the US, the U.K. and Europe.&#160;&#160;Therefore, we are exposed to foreign currency risk associated with our expenses outside of Canada.&#160;&#160;We do not use financial derivative instruments to manage this market risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary objective of our policy for the investment of temporary cash surpluses is the protection of principal, and, accordingly, we generally invest in investment-grade debt securities with varying maturities.&#160;&#160;As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;&#160;We do not currently engage in hedging transactions.&#160;&#160;See &#8220;Currency and Exchange Rates&#8221; and Item 4 &#8211; &#8220;Information on the Company&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s92085058F73A18F67827FBCAB61A3221"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants and Rights</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">American Depository Shares</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Common Shares are not represented by American Depository Receipts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sFF38CF3E77DB5AC7E77DFBCAB6215E48"></a></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s44019429B7700FE9BC85FBCAB6298622"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0B7BD132991485A01949FBCAB6526F25"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification of Instruments Defining Rights of Security Holders</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification or Issuance of Other Class of Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Withdrawal or Substitution of Security</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change of Trustee or Paying Agent</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Proceeds</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been no change to the information provided in our first annual report on Form 20-F.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCC3C24AA393CBECD2154FBCAB673B92A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosures and Procedures</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Annual Report on Internal Control Over Financial Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management and other personnel, to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with  IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework,  (COSO) in Internal Control-Integrated Framework.&#160;&#160;Based on this assessment, management believes that, as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Attestation Report of the Registered Public Accounting Firms</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with Securities and Exchange Commission&#8217;s rules, this Annual Report does not include an attestation report of the Company's independent registered public accounting firm regarding the Company's internal control over financial reporting. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Controls over Financial Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD68616772C1C03E0EFA7FBCAB6A7C362"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16 .&#160; [RESERVED]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFAD521484FD314651DEAFBCAB6C7598A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, and Mark Lievonen, is a financial expert and each is independent pursuant to the Rule 5605(d)(2) of the NASDAQ Capital Market and Rule 10A-3 of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF10E77C8542DBC79489FFBCAB70834CD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16B.&#160; CODE OF ETHICS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Board of Directors has adopted a Code of Ethics for our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer and Controller.&#160;&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at http://www.oncolyticsbiotech.com.&#160;&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look &#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no amendments to our Code of Ethics during the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.  We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF7754A8F5A9C74875376FBCAB7191A22"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Audit Fees and Services</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the financial years ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, Ernst &amp; Young LLP received the following fees:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:301px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:133px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1),(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other fees</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes review of interim financial statements, accounting consultations and subscription to on-line accounting services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprised of tax return preparation, scientific research and development return and other tax consultation fees.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes fees associated with matters relating to the provision of a consent letter for various filings.  </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Audit Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees were for professional services rendered by Ernst &amp; Young, LLP for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Audit-Related Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;&#160;These services consisted of accounting consultations, assistance with prospectus filings and assistance with preparations for compliance with section 404 of the Sarbanes-Oxley Act of 2002.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Tax Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees were for tax compliance and professional tax consultations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">All Other Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8FBC5E53B315513AB102FBCAB74D9199"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA6782B339E304FDA9261FBCAB76EB5A1"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE661FB1AF57C47411EA4FBCAB7A0C9FD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD942C78AE19248FF883CFBCAB7C07AEF"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16G. CORPORATE GOVERNANCE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2A872E7FFF19C66CC088FBCAB8021A8C"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFC8ABA3523461B096025FBCAB813E251"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDFA9FD250C6F8F255B7DFBCAB846E281"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 17. FINANCIAL STATEMENTS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s44BF6BADA6DD002615B6FBCAB868B190"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 18 FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements appear on pages F-1 through F-24.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><a name="s344B9C0538CF4BCB9223FBCAB8990943"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 19. EXHIBITS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following exhibits are filed as part of this annual report:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">EXHIBIT</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;text-decoration:underline;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Constating Documents</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Articles of Incorporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By-laws</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material Contracts</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services Agreement, dated October 16, 2002, between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement No. 1, dated January 6, 2005, to the Services Agreement between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill, dated October 16, 2001</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated January 12, 2007, between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated May 29, 2007, between the Company and its Chief Scientific Officer, Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated May 29, 2007, between the Company and its Chief Medical Officer, Dr. Karl Mettinger</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated May 30, 2007, between the Company and its Chief Financial Officer, Douglas Ball</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated June 6, 2007, between the Company and its Chief Executive Officer, Bradley Thompson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement No. 1, dated December 3, 2007, to the Employment Agreement between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty, dated January 12, 2007</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 7, 2008, to the Executive Employment Agreement between the Company and its Chief Financial Officer, Douglas Ball, dated May 30, 2007</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No.1, dated March 7, 2008, between the Company and its Chief Scientific Officer, Matthew Coffey, dated May 29, 2007</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.11</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 7, 2008, to the Executive Employment Agreement between the Company and its Chief Executive Officer, Bradley Thompson, dated June 6, 2007</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 20, 2008, to the Employment Agreement between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty, dated January 12, 2007</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.13</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 28, 2008, to the Executive Employment Agreement between the Company and its Chief Medical Officer, Dr. Karl Mettinger, dated May 29, 2007</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 2, dated March 31, 2008, to the Services Agreement between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill, dated October 16, 2001</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.15</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated January 26, 2009, between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Dr. Karl Mettinger</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.16</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated January 22, 2009 between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.17</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 2, dated January 1, 2011, to the Executive Employment Agreement between the Company and its Chief Executive Officer, Bradley Thompson, dated June 6, 2007</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">4.18</font><font style="font-family:inherit;font-size:10pt;text-align:center;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated January 1, 2011 between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">4.19</font><font style="font-family:inherit;font-size:10pt;text-align:center;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated November 10, 2011 between the Company and its Senior Vice President of Clinical Development and Chief Medical Officer, Gerard T. Kennealey.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated March 22. 2013, between the Company and its Chief Operating Officer, Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated September 27, 2012, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.22</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated March 22, 2013, between the Company and its Chief Financial Officer, Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.23</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated March 22, 2013, between the Company and its Chief Executive Officer, Bradley Thompson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.24</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2014, between the Company and its Chief Executive Officer, Bradley Thompson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2014, between the Company and its Chief Financial Officer, Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.26</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2014, between the Company and its Chief Operating Officer, Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.27</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.28</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between Oncolytics Biotech (U.S.) Inc. and its Vice President, Intellectual Property, Mary Ann Dillahunty.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.29</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between the Company and its Chief Executive Officer, Bradley Thompson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.30</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Clinical and Regulatory Affairs, George Gill.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between the Company and its Chief Financial Officer, Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between the Company and its Chief Operating Officer, Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.33</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between the Company and its Chief Executive Officer, Bradley Thompson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.34</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between the Company and its Chief Financial Officer, Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.35</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between the Company and its Chief Operating Officer, Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.36</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated November 10, 2015, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.37</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Clinical and Regulatory Affairs, George Gill.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated October 27, 2016, between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Dr. Andres Gutierrez.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated February 23, 2017, between the Company and its Chief Executive Officer, Matthew Coffey.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated February 23, 2017, between the Company and its Chief Financial Officer, Kirk Look.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.42</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement Agreement and Release, dated December 5, 2016 between the Company and its former Chief Executive Officer, Brad Thompson.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiaries</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">List of subsidiaries</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certifications</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Exhibits</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent of Ernst &amp; Young LLP</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;Previously filed with the SEC on Form 20-F dated June 14, 2002</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Previously filed with the SEC on Form 20-F dated June 27, 2003</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;Previously filed with the SEC on Form 20-F dated March 23, 2008</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Previously filed with the SEC on Form 20-F dated March 6, 2009.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e) Previously filed with the SEC on Form 20-F dated March 24, 2011.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f) Previously filed with the SEC on Form 20-F dated March 23, 2012.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(g) Previously filed with the SEC on Form 20-F dated March 22, 2013.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(h) Previously filed with the SEC on Form 20-F dated March 19, 2014.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)  Previously filed with the SEC on Form 20-F dated March 19, 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(j)  Previously filed with the SEC on Form 20-F dated March 24, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="sC939EE19819E1A739570FBCAB8BB51FB"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey, Ph.D&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="sBCC90A21ED7267971F83FBCAB8FCF54B"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consolidated Financial Statements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">2015</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sABC2BC153C750ED55401FBCAB90D8098"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;) and all other information in the Annual Report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The MD&amp;A has been prepared in accordance with the requirements of securities regulators as applicable to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements and information in the MD&amp;A generally include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until future periods.&#160;&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements and MD&amp;A.&#160;&#160;The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources and risks and uncertainty.&#160;&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for financial purposes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We, as the Chief Executive Officer and Chief Financial Officer, will certify to our annual filings with the CSA and the SEC as required in Canada by National Instrument 52-109 (Certification of Disclosure in Issuers&#8217; Annual Interim Filings) and in the United States by the Sarbanes-Oxley Act.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The external auditors conducted an independent examination of corporate and accounting records in accordance with generally accepted auditing standards to express their opinion on the consolidated financial statements.&#160;&#160;Their examination included such tests and procedures as they considered necessary to provide reasonable assurance that the consolidated financial statements are presented fairly.&#160;&#160;The external auditors have full and free access to our Board of Directors and its Committees to discuss audit, financial reporting and related matters.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;&#160;The Board exercises this responsibility through the Audit Committee of the Board.&#160;&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Matt Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;/s/ Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matt Coffey, Ph.D&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="s799338BE21B695FCA313FBCAB93F68F8"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEPENDENT AUDITORS' REPORT OF REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated financial statements of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc.</font><font style="font-family:inherit;font-size:10pt;">, which comprise the consolidated statements of financial position as at December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, and a summary of significant accounting policies and other explanatory information.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's responsibility for the consolidated financial statements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Auditors' responsibility</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our responsibility is to express an opinion on these consolidated financial statements based on our audits.  We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements.  The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances.  An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Oncolytics Biotech Inc. as at December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, and its financial performance and cash flows for each of the years in the three-year period ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:48%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Calgary, Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="image3a01.jpg" alt="image3a01.jpg" style="height:45px;width:242px;"></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chartered Professional Accountants</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="sC6309A60B8986C5EB0F7FBCAA97BBB9B"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:536px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:304px;"></td><td style="width:40px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,016,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">54,406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">260,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,438,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,923,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,758,284</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,383,798</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities And Shareholders&#8217; Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,068,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,709,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,068,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,709,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10, 11 and 16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share capital<br>&#160;&#160;Authorized: unlimited<br>&#160;&#160;Issued:<br>  December 31, 2016 &#8211; 121,258,222<br>  December 31, 2015 &#8211; 118,151,622</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">262,321,825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contributed surplus</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26,643,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,277,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">554,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(278,829,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,689,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,758,284</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,383,798</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:65.234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:47%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On behalf of the Board:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Angela Holtham</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Director&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Director&#160;&#160;&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="s3196EDDBA6F392921B83FBCAAC627FA2"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:657px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:314px;"></td><td style="width:65px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ending December 31,</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8, 18, 19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,770,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,601,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,824,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8, 18, 19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,524,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,315,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,998,694</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,294,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,917,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,822,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">163,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,859</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,130,605</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,719,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,612,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax recovery (expense)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,153</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,139,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,619,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other comprehensive income items that may be<br>  reclassified to net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(206,918</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,346,897</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,242,060</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,418,990</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.13</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">119,880,200</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,613,845</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,869,149</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="sE38B7CF9A596772FAB75FBCAA970EF3F"></a></div><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:854px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:260px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:99px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:108px;"></td><td style="width:4px;"></td><td style="width:110px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contributed Surplus</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Deficit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,612,564</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,892</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,491,212</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,698</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(231,347,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,213,366</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,345</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,619,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,418,990</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, pursuant to Share Purchase Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,861,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,861,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468,668</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468,668</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(376,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,285,828</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,285,828</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,657,056</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,848,429</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,043</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(249,966,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,819,193</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,935</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,242,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, pursuant to Share Purchase Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,277,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,689,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(206,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,346,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">262,321,825</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26,643,044</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">554,060</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(278,829,309</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="s5B53B47479919CCC8176FBCAA9847E61"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:313px;"></td><td style="width:66px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ending December 31,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,139,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,619,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization - property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">162,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8, 18, 19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">406,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429,537</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(139,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(816,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash working capital</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,233,865</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,105,464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,443,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash used in operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(12,477,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,034,830</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,676,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(23,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redemption (purchase) of short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(27,823</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,292</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,041</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash used in investing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(51,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(182,791</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from Share Purchase Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,305,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,830,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from "At the Market" equity distribution  agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">956,133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,362,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,214,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash provided by financing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">956,133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,667,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,044,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease) increase in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(11,572,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,495,246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,815,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,016,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,152,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,220,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign exchange on cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(409,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,368,204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(252,249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,034,282</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,016,275</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,152,825</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="sD9F579C73CC061420DB1FBCABA5A8C41"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8264C95D010341BC06EAFBCABA624D9C"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 1: Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;9, 2017</font><font style="font-family:inherit;font-size:10pt;">.  We are a limited company incorporated and domiciled in Canada.  Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.  Our lead product, REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies.  Our clinical development program for REOLYSIN emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA8A4C5DF859E1AEF55D2FBCABA6B572F"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 2: Basis of Financial Statement Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (US) Inc., and Oncolytics Biotech (UK) Inc. and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries.  Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern.  Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB777DA7AB1FF2A7AAE6DFBCABA8D9200"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 3: Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Property and equipment </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost.  Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49%;"></td><td style="width:51%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Foreign currency translation</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements for each of our subsidiaries are prepared using their functional currency.  Our presentation currency is the Canadian dollar which is also Oncolytics Biotech Inc.'s functional currency.  Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions.  Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity.  The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period.  Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used.  Exchange differences on translation into Canadian dollars are recognized as a separate component of equity.  On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research costs are expensed as incurred, net of recoveries.  Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investment tax credits</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits ("ITCs") relating to qualifying scientific research and experimental development expenditures that are refundable are accounted for as a reduction in research and development expenditures.  ITCs that are non-refundable, but are recoverable against future taxes payable, are accrued only when there is reasonable assurance that the credits will be realized.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITCs are subject to technical and financial review by the Canadian tax authorities on a project-by-project basis.  Therefore,  amounts ultimately received may vary significantly from the amounts recorded. Any such differences are recorded as an adjustment to the recognized amount in the year the review by the Canadian tax authority is completed and the results are made known to us.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loss per common share</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive.  The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Share based payments</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock option plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have one stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees, consultants and suppliers with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;).  Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines.  Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant.  Exercised stock options are settled with common shares issued from treasury. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black Scholes Option Pricing Model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.      Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments to non-employees are measured at the date we obtain the goods or the date the counterparty renders the service. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incentive share award plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees.  Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board.  Performance share units  ("PSUs") are an award to eligible employees to which common shares shall be issued based upon achieving the applicable performance criteria.  Restricted share units ("RSUs") are an award to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Financial instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are comprised of cash and cash equivalents, accounts receivable, and short-term investments.  Financial assets are initially recorded at fair market value and are classified as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents consist of cash on hand and interest bearing deposits with our bank and have been designated as held for trading.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts receivable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable have been classified as loans and receivables.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine the appropriate classification of our short-term investments at the time of purchase and re-evaluate such classification as of each reporting date.  We classify our short-term investments as held-to-maturity as we have the positive intent and ability to hold the securities to maturity.  Held-to-maturity securities are stated at original cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method.  Such amortization and interest on securities classified as held-to-maturity are included in interest income. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We assess at each reporting date whether there is any objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition of the asset (an incurred loss event) and that loss event has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable are non interest-bearing and recorded at fair market value.  They are classified as other financial liabilities and are subsequently measured at amortized cost using the effective interest rate method.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transaction Costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction costs are expensed as incurred for financial instruments designated as held for trading.  Transaction costs for other financial instruments are recognized as part of the financial instrument's carrying value.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 9 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Recognition and Measurement</font><font style="font-family:inherit;font-size:10pt;">, the IASB issued the final version of IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments. </font><font style="font-family:inherit;font-size:10pt;">IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January 1, 2018 with early application permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the IASB issued IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IFRS 16&#8221;), which replaces IAS 17 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IAS 17&#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA76E07D99D379027B6CBFBCABAAF581D"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 4:  Significant Judgments, Estimates and Assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Judgments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Estimates and assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods.  Actual results could differ from those estimates and such differences could be significant.  Significant estimates made by management affecting our consolidated financial statements include:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share based payments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Part of our share based payment expense is measured by reference to the fair value of our stock options at the date at which they are granted.  Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant.  This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them.  The value of the share based payment expense for the year along with the assumptions and model used for estimating fair value for share based compensation transactions are disclosed in Note 8.    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income.  Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset.  Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date we have determined that none of our deferred tax assets should be recognized.  Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits.  These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries.  As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3900E2BAB669F6219925FBCABAF05D74"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 5: Cash Equivalents and Short Term Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10,679,992</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,742,300</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.96%</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.76%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments which consist of guaranteed investment certificates are liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.&#160;&#160;The objectives for holding short-term investments are to invest our excess cash resources in investment vehicles that provide a better rate of return compared to our interest bearing bank account with limited risk to the principal invested.&#160;&#160;We intend to match the maturities of these short-term investments with the cash requirements of the Company&#8217;s activities and treat these as held-to-maturity short-term investments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:20%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Face</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Original Cost</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Accrued Interest</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Carrying</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Fair</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Effective</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Interest Rate</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.41%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060,977</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060,977</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060,977</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060,977</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.35%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is determined by using published market prices provided by our investment advisor.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s29D6ABFA1F012BBB4558FBCABB02BD97"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 6: Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:164px;"></td><td style="width:80px;"></td><td style="width:4px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,669</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">197,870</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">705,375</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">214,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89,466</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">466,635</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,673,431</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,635</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,640</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,927</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,010,832</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,191,243</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">144,969</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">554,174</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">137,624</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">64,167</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">452,542</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,353,476</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">52,901</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">151,201</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">76,461</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25,299</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,393</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,032</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,702</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,205</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,486</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,818</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF341BF7D1684BFF846EFFBCAAB3FE844"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 7: Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:595px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:222px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Amount<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,803,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,612,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Share Purchase<br>   Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,037,216</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,861,652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" sales agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,671,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expiry of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,945</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(376,892</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,285,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,512,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,657,056</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Issued pursuant to Share Purchase<br>   Agreement</font><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"><sup style="vertical-align:top;line-height:120%;background-color:#cceeff; font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" sales agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,860,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,151,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,006,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">121,258,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">262,321,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we entered into a share purchase agreement (the "Share Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to US$26,000,000 of common stock.  Subject to the terms and conditions of the Share Purchase Agreement and at our sole discretion, we may sell up to US$26.0 million worth of common shares to LPC over the 30-month term. The purchase price of the common shares was based on prevailing market prices of our  common shares immediately preceding the notice of a sale without any fixed discount. Subject to the Share Purchase Agreement, we controlled the timing and amount of each investment and LPC was obligated to make such purchases, if and when elected.  The Share Purchase Agreement did not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities, but required that we maintained our NASDAQ listing.  Under the Share Purchase Agreement, we issued an initial  commitment fee of 292,793 common shares to LPC valued at fair value of US$455,000.  An additional 292,793 common shares was to be issued on a pro rata basis under the terms of the Share Purchase Agreement as an additional commitment fee.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 20, 2014, we reached an agreement to amend the Share Purchase Agreement.  The specific amendments included allowing the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing the number of shares that may have been sold to LPC at certain price levels and changed the way the number of Commitment Shares issuable was to be calculated. In consideration of the amendments to the Agreement, the Company issued 146,397 shares of Common Stock to LPC. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, under the terms of the amended Share Purchase Agreement, we issued </font><font style="font-family:inherit;font-size:10pt;">5,778,674</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares (2014 - </font><font style="font-family:inherit;font-size:10pt;">7,037,216</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares) for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 - </font><font style="font-family:inherit;font-size:10pt;">US$7.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million).  As part of the shares issued, we issued </font><font style="font-family:inherit;font-size:10pt;">78,674</font><font style="font-family:inherit;font-size:10pt;">&#32;commitment shares (2014 - </font><font style="font-family:inherit;font-size:10pt;">536,254</font><font style="font-family:inherit;font-size:10pt;">&#32;commitment shares consisting of 292,793  initial commitment fee common shares, 146,397 commitment shares in consideration for the October 2014 amendments, and  </font><font style="font-family:inherit;font-size:10pt;">97,064</font><font style="font-family:inherit;font-size:10pt;">&#32;additional commitment </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fee common shares).  The commitment shares have been valued at fair value of </font><font style="font-family:inherit;font-size:10pt;">US$50,024</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 - </font><font style="font-family:inherit;font-size:10pt;">US$654,267</font><font style="font-family:inherit;font-size:10pt;">) and have been recorded as additional share issue costs.  On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under the Share Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2014, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. Under the terms of the distribution agreement, we were able to, from time to time, sell shares of our common stock having an aggregate offering value of up to US$20 million through Canaccord Genuity Inc. directly to investors in the US through our NASDAQ listing.  We were able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.  During 2015, we issued </font><font style="font-family:inherit;font-size:10pt;">18,860,454</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares (2014 - </font><font style="font-family:inherit;font-size:10pt;">1,671,460</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares) for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$15.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 - US$1.1 million).  On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under our existing ATM.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into a new ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2016, we sold </font><font style="font-family:inherit;font-size:10pt;">3,006,600</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">1,456,296</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs which included costs to establish our Canadian ATM facility of $</font><font style="font-family:inherit;font-size:10pt;">500,163</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s686DD920EEB4128F98A2FBCAA9A5BDEB"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 8: Share Based Payments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:158px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:80px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,561,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,446,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,918,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,572,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,280,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(737,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(721,667</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(972,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.56</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,674,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,446,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,729,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,476,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,841,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:182px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:100px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.26-$0.41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,972,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">809,416</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.42-$0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,172,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,390,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.58-$1.87</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,622,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.56</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,622,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.56</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.88-$3.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,592,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,592,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.04</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.96-$6.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,315,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,315,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.33</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,674,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,729,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.27</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest either annually over periods ranging from one to three years or after the completion of certain performance criteria.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the year was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:245px;"></td><td style="width:74px;"></td><td style="width:72px;"></td><td style="width:72px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.82%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.05%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;2.7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94.84%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72.55%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.54</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada marketable bond rate in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units to non-employee directors through our incentive share award plan. Grants of restricted share units to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. The following restricted share units are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:269px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">368,831</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,053,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(100,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,322,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the restricted share units granted was </font><font style="font-family:inherit;font-size:8pt;">$0.31</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2016 (2015 - $0.40).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units to certain officers of the Company. Grants of performance share units require completion of certain performance criteria and cliff vest after three years or vest over a three year period, depending on the grant. Grants will vest immediately upon a change of control of the Company. If the officer ceases employment with the Company, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following performance share units are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:274px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(660,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) &#160;&#160;&#160;&#160;The weighted average fair value of the performance share units granted was $</font><font style="font-family:inherit;font-size:8pt;">0.36</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2016.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">11,312,394</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for issuance relating to our outstanding equity compensation plans.  Compensation expense related to stock options granted to employees, directors and consultants, restricted share units to independent directors and performance share units to certain officers for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$406,078</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(</font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$429,537</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$980,325</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7E6E09D778025C38C08EFBCABBA2C042"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 9: Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">119,880,200</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">112,613,845</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">87,869,149</font><font style="font-family:inherit;font-size:10pt;">).  The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5DC62DC088F602F6C440FBCABBAC8805"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 10: Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,033,619</font><font style="font-family:inherit;font-size:10pt;">&#32;during </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our  clinical trial, manufacturing  and collaboration programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of these leases are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:59%;"></td><td style="width:40%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,513</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517,647</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4F228EB2A1F16515ACA4FBCABBEA1772"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 11: Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumption Agreement</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;to the public or the approval of a new drug application for REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the milestone payment, payments may become due and payable in accordance with the Agreement upon realization of sales of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders 11.75% of the royalty payments and other payments received.&#160;&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of 2.35%  of Net Sales received for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BRI &#8220;Work in Kind&#8221; Contribution</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;&#160;The terms of this Agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of 0.5% of Sales Revenue or $20,000 per year.&#160;&#160;The total royalty under this Agreement is equal to two times the &#8220;work in kind&#8221; contribution.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we estimate that the accumulated work in kind totals approximately </font><font style="font-family:inherit;font-size:10pt;">$301,000</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6F76E66B57EA018BD035FBCAAB603B0C"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 12: Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:316px;"></td><td style="width:76px;"></td><td style="width:13px;"></td><td style="width:78px;"></td><td style="width:11px;"></td><td style="width:78px;"></td><td style="width:11px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,130,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,719,842</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,612,556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Canadian corporate tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated tax recovery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,085,263</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,567,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,653,139</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign jurisdiction tax rate difference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,184,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,659,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,319,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">109,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,081</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,336,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to opening tax pools</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(39,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,339,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(316,193</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax benefits deemed not probable to <br>  be recovered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,739,557</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,455,622</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,462,572</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax recovery</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,687</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,439</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment in respect to prior periods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,374</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,153</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,779</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-capital losses for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:62%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,809,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,009,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,774,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,343,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,472,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,457,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">52,489,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:97px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,007</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,466,627</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,300,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized.  The components of our unrecognized deferred tax asset are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:345px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses carried forward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17,821,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,950,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,130,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and experimental development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,394,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,278,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,424,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,990,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987,214</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,083,046</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,908,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,839,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">432,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619,066</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">655,787</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net capital losses carried forward</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">31,555,913</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,681,313</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,020,433</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s250D939BAB8C10CB2713FBCABC389B01"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 13: Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position.  We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;&#160;We include shareholders&#8217; equity, cash and cash equivalents and short-term investments in the definition of capital.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,016,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board .&#160;&#160;The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities.&#160;&#160;The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2016, we renewed our short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;) in Canada. Under our Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf expires on March 16, 2018 and allowed us to enter into our Canadian ATM equity distribution agreement (see Note 7). We use this equity arrangement to assist us in achieving our capital objective.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8F79FBCCAB72D552D2EDFBCAAC915C16"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 14: Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, short-term investments,&#160;&#160;accounts receivable, and accounts payable.&#160;&#160;As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;&#160;We are exposed to credit risk on our cash and cash equivalents and short-term investments in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and short-term investments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.&#160;&#160;Currently, 100% of our short-term investments are in guaranteed investment certificates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;&#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&#160;&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;&#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from financing activities. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,913</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10,499</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,010</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:197px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,629,766</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,295</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,565</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(134,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,495,707</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,565</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 13.&#160;&#160;Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7A97D80BC0301EF94A7BFBCABC82B866"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 15: Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:392px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">285,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">245,828</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(215,116</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,190</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,359,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,634,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">343,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,233,865</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,105,464</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,443,988</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:342px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">163,902</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,859</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,390</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4A4B755D3C9EE98698C9FBCABCE4EA16"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 16: Indemnification of Officers and Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;&#160;The by-laws provide no limit to the amount of the indemnification.&#160;&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8B139801CFB584963642FBCABCF67206"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 </font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 17: Economic Dependence</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are economically dependent on our toll manufacturers.&#160;&#160;We primarily use one toll manufacturer in the US to produce the clinical grade REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;required for our clinical trial program.&#160;&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;at a smaller scale.&#160;&#160;We have attempted to mitigate this risk by producing sufficient REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;in advance of patient enrollment in a particular clinical trial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB23FB3FCBE2807DA058CFBCABD28978E"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 18:  Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:420px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">104,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">67,109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(816,319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,542</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">233,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">162,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,501</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">172,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">148,600</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,601</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,888</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s30AA86FACE752B81C386FBCABD4A2095"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 19:  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole.  We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:301px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,753,553</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,941,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,535,167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,330,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">372,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,419</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,456,389</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,294,761</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,306,605</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.39
<SEQUENCE>2
<FILENAME>ex439guttierrez.htm
<DESCRIPTION>EXHIBIT 4.39 GUTTIERREZ
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sec690985f3354cc2be2e5e6c1b349de7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">THIS AGREEMENT </font><font style="font-family:inherit;font-size:11pt;">made the 27th day of October, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">-and-</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andres Gutierrez</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">OBUS and its Affiliates are engaged in the business of developing pharmaceutical products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">OBUS has made an offer of employment to the Employee, subject to the terms and conditions contained herein, and subject to the termination of the Services Agreement concurrent with the commencement of employment under this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee is prepared to accept the offer of employment;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW THEREFORE the parties agree as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 1 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Definitions and Interpretation</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:11pt;">In this Agreement the following defined terms shall have the meanings indicated:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8221;Affiliate&#8221; means any entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with a party.  For the purposes of this definition, control shall mean: (i) the direct or indirect ownership of fifty percent (50%) or more of the voting stock of a corporation; or (ii) the direct or indirect ownership of fifty (50%) or more of the ownership interest of any other entity; or (iii) the ability to elect a majority of the directors of the entity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Business" means the business currently carried on by OBUS and its Affiliates, which is the development, testing, marketing and sale of pharmaceutical products together with such additional business as OBUS or its Affiliates may decide to undertake from time to time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Commencement Date" means October 31, 2016;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Good Reason&#8221; means any one of the following events occurring on or after the Commencement Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reduction in the Employee&#8217;s then existing annual base compensation and benefits, unless comparable reductions are made for all other executive employees of Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any material diminution of the Employee&#8217;s duties, responsibilities, authority or reporting structure, excluding for this purpose an isolated or inadvertent action not taken in bad faith which is remedied by Oncolytics immediately after notice thereof is given by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any request that the Employee relocate to a work site that would increase the Employee&#8217;s one-way commute distance by more than eighty (80) kilometers from the Employee&#8217;s then principal residence, unless the Employee accepts such relocation opportunity; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any material breach by Oncolytics of its obligations under this agreement that is not remedied within thirty (30) days of written notice of such breach from the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Confidential Information" means all confidential information of OBUS and its Affiliates, and includes:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any data or information directly or indirectly related to the Business or arising directly or indirectly in the course of, or derived from the Employee's employment with OBUS whether </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">related to products, equipment, inventions, ideas, designs, methods, systems, improvements, processes, research or otherwise;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any technical or scientific know-how;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">financial and sales information, customer lists, pricing policies, lists of suppliers, proprietary computer programs in any format whatsoever, programming techniques, the manner of plans or methods of operation and the like relating to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">patent applications, drawings, blueprints, manuals, letters, notebooks, reports and all other materials (written or otherwise) related to the Business or to the agents, joint venturers or contractors of OBUS or its Affiliates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any information provided to or received by OBUS or its Affiliates on a confidential basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Intellectual Property" means all information, data, designs, processes, software, algorithms and inventions, including those that may be the subject of patent, copyright, industrial design, trademarks, trade secret or other forms of legal protection, made, conceived or developed by the Employee during the term of employment with OBUS, whether alone or jointly with others and whether during or after regular working hours, that relates to or in any way pertains to or connects with any matter developed, or under investigation or development by OBUS or its Affiliates, or related to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Termination Event" means:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">breach by the Employee of any material provision of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">material violation by the Employee of any statutory or common law duty of loyalty to OBUS and its Affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the commission of a criminal offence by the Employee against OBUS or its Affiliates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">personal or professional conduct of the Employee which in the reasonable and good faith judgment of OBUS may significantly injure OBUS' Business or interfere with the Employee's job performance.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:11pt;">This Agreement shall be governed by and construed in accordance with the laws of California.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:11pt;">The following schedules are attached to and form part of this Agreement:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schedule "A" - Job Description</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schedule "B" - Benefits</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 2 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Employment</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:11pt;">OBUS agrees to employ the Employee in the position of Chief Medical Officer and the Employee accepts the employment, starting on the Commencement Date.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:11pt;">The Employee shall perform the duties and responsibilities associated with the position of Chief Medical Officer including those set out on the Job Description attached as Schedule "A".  The Employee may, from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a Chief Medical Office and the Employee's duties and responsibilities may be modified or expanded from time to time.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(3)</font><font style="font-family:inherit;font-size:11pt;">The Employee shall perform the duties and responsibilities set out in Section 2(2):</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">diligently, faithfully and to the best of the Employee's ability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">in the best interests of OBUS.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:11pt;">The Employee shall comply with the terms, conditions and requirements of OBUS' Policy Manual and benefit plans, as the same may be amended, revised or added to from time to time.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 3 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Remuneration</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:11pt;">OBUS shall pay to the Employee a salary of Three Hundred Thousand ($300,000.00) United States dollars per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of Twelve Thousand Five Hundred ($12,500.00) United States Dollars on the fifteenth (15) and last day of each month.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:11pt;">OBUS shall, on or before the anniversary date of this Agreement in each year, evaluate and set the Employee's salary for the next ensuing year.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(3)</font><font style="font-family:inherit;font-size:11pt;">OBUS shall reimburse the Employee for all reasonable out-of-pocket expenses incurred by the Employee in the performance of the Employee's obligations under this Agreement, subject to OBUS' policies then in force.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:11pt;">OBUS shall be entitled to withhold from any payments made to the Employee any amounts that OBUS is required to withhold pursuant to any Act in force that relates to income tax, social security, medicare or pension in any jurisdiction under which such payments are required to be made by or on behalf of the Employee.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 4 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Benefits and Equity Compensation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be entitled to participate in benefit plans described in Schedule "B" and in other benefit plans instituted or as amended by OBUS from time to time.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Restricted Share Units</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be granted 300,000 restricted share units (&#8220;RSU&#8217;s&#8221;) on the Commencement Date under Oncolytics Biotech Inc.&#8217;s Incentive Award Plan.  The RSU&#8217;s will vest one third after two years from the Commencement Date with the remaining two thirds vesting three years after the Commencement Date.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be granted 150,000 stock options on the Commencement Date under Oncolytics Biotech Inc.&#8217;s Stock Option Plan.  These options will be priced on the Commencement Date and 50,000 stock options will vest immediately followed by 50,000 vesting after 12 months from the Commencement Date with the final 50,000 vesting after 18 months from the Commencement Date.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 5 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Vacations</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall, in addition to all statutory holidays, be entitled to twenty (20) Business Days paid vacation during each twelve (12) month period of employment under this Agreement.  The Employee's vacation time shall be governed by applicable policies of OBUS.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 6 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Place of Employment</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be based within the greater</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:11pt;">metropolitan area of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[to be determined]</font><font style="font-family:inherit;font-size:11pt;">, and shall perform the majority of his employment obligations within that area.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee will make provision in his homes for an office space in which he can conduct OBUS&#8217; business. The Employee will provide furnishings and equipment for these offices, including computers with internet capability, fax machines with dedicated business phone lines and such other items as are required to properly perform his duties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;The Employee shall be available to travel within the United States and outside the United States as required to fulfill his duties and responsibilities.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 7 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that the Confidential Information is the sole and exclusive property of OBUS or its Affiliates and is held by the Employee in trust for the benefit of OBUS and its Affiliates.  The Employee shall use the Employee's best efforts and exercise utmost diligence to protect and safeguard the Confidential Information.  Neither during the period of employment by OBUS nor thereafter for a period of three years shall the Employee, directly or indirectly, use or disclose to any other person any Confidential Information, whether or not acquired, learned or obtained </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">or developed by the Employee alone or in conjunction with others, except as such disclosure or use may be required in connection with the employment with OBUS or as may be agreed to in writing by OBUS.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:11pt;">Subsection 7(1) shall not apply to Confidential Information that:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">is in the public domain at the time of its disclosure, or which, after disclosure, becomes part of the public domain other than by disclosure by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the Employee can show was in the Employee's possession at the time of disclosure and was not acquired from OBUS or its Affiliates; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">was received by the Employee from a third party without a covenant of confidentiality, provided such third party is under no obligation of confidentiality with respect to the Confidential Information.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(3)</font><font style="font-family:inherit;font-size:11pt;">The Employee shall keep informed of OBUS' policies and procedures for safeguarding OBUS' property including, without limitation, the Confidential Information and the confidentiality thereof, and will strictly comply therewith at all times.  The Employee shall not, except as required in the course of the employment with OBUS, remove from OBUS' premises any OBUS property including, without limitation, Confidential Information.  The Employee shall, immediately upon termination of employment with OBUS, return to OBUS all of OBUS' property in the Employee's possession, including, without limitation, all tangible parts of or relating to the Confidential Information as is in the Employee's possession or under the Employee's control without retaining any copies or record thereof or any other mechanical means that, alone or in combination with other means, would permit the Employee to reproduce or make available the Confidential Information.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:11pt;">The Employee shall advise any future employer, associate or affiliate that the Employee has signed this Agreement and is bound by its terms and conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 8 - </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that any and all Intellectual Property shall be the sole and exclusive property of OBUS or its Affiliates and shall be assigned by the Employee to OBUS, or its nominee.  The Employee agrees to disclose promptly to OBUS or its nominee any and all Intellectual Property and to execute written assignments of the Employee's right, title and interest in and to the Intellectual Property to OBUS or its nominee.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:11pt;">With respect to any Intellectual Property, the Employee also agrees:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to assist OBUS or its nominee in preparing any necessary copyright and patent applications, including Canadian and foreign applications, covering the Intellectual Property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to sign and deliver all such applications and their assignment to OBUS or its nominee; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">generally to give all information and testimony, to co-operate with OBUS and its solicitors, to sign all lawful papers, and to do all lawful things that may be needed or requested by OBUS to obtain, extend, reissue, maintain or enforce copyrights or patents covering the Intellectual Property.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(3)</font><font style="font-family:inherit;font-size:11pt;">OBUS shall bear all expenses that are incurred in obtaining, extending, reissuing, maintaining and enforcing any and all copyrights or patents in respect of the Intellectual Property assigned to OBUS or its nominee by the Employee, and in the vesting and perfecting of title thereto in OBUS or its nominee and shall pay the Employee reasonable compensation for any time that OBUS may require the Employee to expend in order to accomplish the above subsequent to the termination of employment with OBUS.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:11pt;">The Employee hereby waives in favour of OBUS and its Affiliates, all moral rights in any and all copyright works authored or co-authored by the Employee during the term of this Agreement that directly relate to the Business of OBUS or its Affiliates.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 9 - </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Term and Termination</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:11pt;">The Employee's employment under this Agreement shall commence on the Commencement Date and shall continue until terminated in accordance with this Section 9.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:11pt;">Subject to Sections 9(3) and (4), and notwithstanding any other provision contained herein to the contrary, the employment relationship between the Employee and OBUS arising out of this Agreement shall terminate upon forty-five (45) days notice being given to OBUS by the Employee or immediately upon notice being given to the Employee by OBUS.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(3)</font><font style="font-family:inherit;font-size:11pt;">If OBUS is entitled to terminate this Agreement for cause, or as the result of a Termination Event, OBUS shall not be required to compensate the Employee in respect of such termination or provide any period of notice in lieu of compensation with respect to such termination.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:11pt;">Subject to Section 9(5), if this Agreement is terminated by OBUS at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to twelve (12) months salary. The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">(5)</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding Section 9(4), if there is a change of control of OBUS, as defined herein, and if this Agreement is terminated by OBUS at any time within one (1) year following the change of control other than pursuant to Section 9(3), the Employee shall be entitled to severance payment equal to twice that determined pursuant to Section 9(4). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For the purposes of this section 9(5), &#8220;change of control&#8221; means any amalgamation, merger or other corporation reorganization which results in any change in the present effective voting control of OBUS, or will result in a change of the person or persons who own or control sufficient voting shares in OBUS to elect a majority of the directors of OBUS, or will result in a person acquiring sufficient voting shares in OBUS to elect a majority of the directors of OBUS, or any sale, lease, exchange, partnership, or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets of OBUS or a plan of liquidation of OBUS and/or an agreement for the sale or liquidation of OBUS is approved and completed, or the Board of Directors determines in its sole discretion the a change of control has occurred, whether or not any event described has occurred or is contemplated.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(6)</font><font style="font-family:inherit;font-size:11pt;">The Employee acknowledges and agrees that notice or payment in lieu thereof, in accordance with Section 9(4) shall be and is conclusively deemed to be reasonable compensation for termination of this Agreement and hereby waives any claim or potential claim that the Employee now has or may hereafter have, against OBUS for further compensation or notice other than that provided by the terms of this Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(7)</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any breach of this Agreement or unauthorized disclosure of Confidential Information may result in irreparable harm to the Business of OBUS or its Affiliates and considerable monetary damages to OBUS and its Affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the damages suffered by OBUS may be difficult to establish; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">interim and permanent injunctions may be the only suitable remedy for OBUS;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">but nothing herein shall in any way limit or restrict any other remedies available to OBUS at law or in equity including an action for damages.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(8)</font><font style="font-family:inherit;font-size:11pt;">Termination of the Employee's employment with OBUS for any reason whatsoever shall not terminate the Employee's obligations under Sections 7, 8 and 10 of this Agreement.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 10 - </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:11pt;">The Employee shall not, during the term of this Agreement, engage, hold an interest in or have any involvement, either directly or indirectly, in any business entity, venture or undertaking if such would materially interfere with or conflict with the Employee's duties and obligations to OBUS as provided for under this Agreement, provided that the acquisition of a non-control position in publicly traded companies will not contravene this Section.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:11pt;">The Employee shall not, during the term of this Agreement, and for a period of one (1) year following the termination or expiration of this Agreement, either individually or in partnership or jointly or in conjunction with any </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">person, firm or corporation as principal, employee, partner, director or as a shareholder or investor (if actually involved in the management of a business which is competitive with the Business of OBUS or its Affiliates) carry on or be engaged in any business which is directly competitive with the Business of OBUS or its Affiliates. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(3)</font><font style="font-family:inherit;font-size:11pt;">The parties agree that all of the restrictions contained in Subsection 10(2) hereof are reasonable and valid, and that all defences to the strict enforcement thereof by OBUS are hereby waived by the Employee.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:11pt;">The Employee agrees that the remedy at law for any breach by the Employee of the provisions of this Section 10 may be inadequate and that in the event of such breach, OBUS may make an application to a court of competent jurisdiction for an order granting OBUS temporary, permanent or both kinds of injunctive relief against the Employee, without the necessity of proving actual damage to OBUS.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(5)</font><font style="font-family:inherit;font-size:11pt;">The Employee agrees that any waiver by OBUS of a breach of this Agreement by the Employee shall only be a waiver with respect to the particular breach giving rise to the waiver.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 11 - </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Notices</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All notices, reports, invoices, payments and formal communications (collectively referred to as "Notices") required or permitted to be given hereunder shall be in writing and shall be delivered personally or sent by prepaid registered mail or facsimile transmission to the following address or such other address as the relevant party may notify from time to time:</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TO:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: President</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WITH COPY TO:</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Suite 210, 1167 Kensington Crescent N.W.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Calgary, Alberta</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">T2N 1X7</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: President</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TO:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Employee</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andres Gutierrez</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">7 Lombard Ave</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Lawrence Township NJ 08648</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">U.S.A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notices sent by prepaid registered mail shall be deemed to be received by the addressee on the seventh day (excluding Saturdays, Sundays, Statutory Holidays and any period of postal disruption) following the mailing thereof.  Notices personally served shall be deemed to be received when actually delivered, provided such delivery shall be during normal business hours.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 12 - </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Enurement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall enure to the benefit of and be binding upon the parties hereto and:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">in the case of OBUS, its successors and permitted assigns; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">in the case of the Employee, his heirs, executors, administrators or other personal representatives.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:53.90625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:57%;"></td><td style="width:43%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#160;/s/ Alan Tuchman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Alan Tuchman</font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Gilles Gosselin </font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CFO</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/s/ Floriane Riouall</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/s/ Andres Gutierrez</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Witness</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Andres Gutierrez</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHEDULE "A"</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insert job description </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHEDULE "B"</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BENEFITS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Deferred Compensation:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee shall, if qualified to do so, be entitled to allocate a portion of his salary to a 401(K) Plan established for the Employee, up to the prescribed maximum, and in accordance with the requirements thereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Benefit Plan Alternatives:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 1:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee can elect to receive an additional amount of 9.25% of base salary. Such amount shall be the employee&#8217;s full Health Benefit Allocation, and shall be taxable in accordance with the relevant regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 2:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee can elect to direct (the lesser of the maximum available or allowable by the employee under the Flexible Spending Plan), a portion of the Health Benefit Allocation (9.25% of base salary) to a Flexible Spending Account, and receive the remainder (9.25% of base salary less the amount directed to the Flexible Spending Account) of the Health Benefit Allocation as a taxable amount in accordance with the relevant regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 3:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Whether or not the Employee elects to participate in Alternative 2, the Employee can also elect to participate in an individual Health Insurance Program utilizing any amount still remaining from the Health Benefit Allocation. Any additional amounts required to be paid for this Program would be drawn from Employee&#8217;s net pay.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.40
<SEQUENCE>3
<FILENAME>ex440coffey.htm
<DESCRIPTION>EXHIBIT 4.40 COFFEY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3d576056e73746bdafa131eb22106109"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AMENDING AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:10pt;">&#32;made effective as of the 23</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">rd</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;day of February, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ONCOYLYTICS BIOTECH INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">("ONCOLYTICS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">MATTHEW C. COFFEY,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Employment Agreement Section 2 - Employment is amended as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Oncolytics confirms the employment of the Employee in the position of President and Chief Executive Officer and the Employee accepts the employment, effective January 1</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">st</sup></font><font style="font-family:Arial;font-size:10pt;">, 2017;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:Arial;font-size:10pt;">The Employee shall perform the duties and responsibilities associated with the position of President and Chief Executive Officer. The Employee may from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a President and Chief Executive Officer, and the Employee&#8217;s duties and responsibilities may be modified or expanded from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Employment Agreement Section 3 - Remuneration is amended as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commencing January 1, 2017, Oncolytics shall pay to the Employee a salary of FOUR HUNDRED THIRTY THOUSAND ($430,000.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SEVENTEEN THOUSAND NINE HUNDRED SIXTEEN DOLLARS and SIXTY-SEVEN CENTS ($17,916.67) on the 15</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;and last day of each month.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:7%;"></td><td style="width:42%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Kirk Look</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/S/ Floriane Riouall</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">/S/ Matthew Coffey</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">___________________________</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Witness</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">MATTHEW COFFEY</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SCHEDULE "A"</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Employee shall perform the duties and responsibilities associated with the position of President and Chief Executive Officer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.41
<SEQUENCE>4
<FILENAME>ex441look.htm
<DESCRIPTION>EXHIBIT 4.41 LOOK
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sd9a0aafe8f68447ab16946dee70fdf8b"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AMENDING AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:10pt;">&#32;made effective as of the 23</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">rd</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;day of February, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ONCOYLYTICS BIOTECH INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">("ONCOLYTICS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">KIRK LOOK,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Employment Agreement Section 3 - Remuneration is amended as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commencing January 1, 2017, Oncolytics shall pay to the Employee a salary of THREE HUNDRED FORTY-FIVE THOUSAND ($345,000.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of FOURTEEN THOUSAND THREE HUNDRED SEVENTY-FIVE DOLLARS ($14,375.00) on the 15</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;and last day of each month.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:7%;"></td><td style="width:42%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/S/ Floriane Riouall</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">/S/ Kirk Look</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">___________________________</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Witness</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">KIRK LOOK</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.42
<SEQUENCE>5
<FILENAME>ex442thompson.htm
<DESCRIPTION>EXHIBIT 4.42 THOMPSON
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s880f88e33b7c408689e1867983f929ff"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Settlement Agreement </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">THIS AGREEMENT is made this 5th day of December, 2016</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">B E T W E E N:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">BRADLEY GEORGE THOMPSON</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Employee</font><font style="font-family:Arial;font-size:12pt;">&#8221;)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Employer&#8221;</font><font style="font-family:Arial;font-size:12pt;">)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Background:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Employee&#8217;s employment was terminated by Employer; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Employee and Employer have agreed to terms and conditions providing for payments and other valuable consideration to Employee by Employer in exchange for Employee executing this agreement and its schedules (&#8220;collectively the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Agreement</font><font style="font-family:Arial;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THE PARTIES THEREFORE AGREE AS FOLLOWS:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee confirms that upon receipt of the first payment under Paragraph 2 below, he will have received from Employer all of his statutory entitlements including but not limited to vacation pay.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employer will pay Employee a total severance payment of CAD $1,330,828 (minus required deductions). This amount will be paid in 12 monthly installments of $110,902 (minus required deductions</font><font style="font-family:Arial;font-size:12pt;color:#0000ff;">)</font><font style="font-family:Arial;font-size:12pt;">. At Employee&#8217;s request, the installments will be taxed at the usual taxation rate (rather than the 30% retiring allowance rate) without CPP and EI deductions. Employee agrees to indemnify and save Employer harmless from and against any and all actions, causes of action, claims, proceedings, applications, complaints and demands whatsoever arising from or related to such taxation. The first payment will be made upon this Agreement being fully executed, and will made via cheque to Employee.  All remaining payments will be made via direct deposit to Employee&#8217;s bank account on or before the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;of the month, commencing on January 15, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee will immediately resign from Employer Board of Directors and will execute all documentation to effect such resignation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notwithstanding the terms of Employer&#8217;s Stock Option Plan, Employer will extend the term of 1,880,160 of Employee&#8217;s outstanding stock options to the earlier of: (i) the date of the expiration of the applicable option period; and (ii) 5:00 p.m. (Calgary time) on the date of the last payment outlined in paragraph 2 above. An aggregate of 608,000 of Employee&#8217;s options which are not scheduled to vest until December 1, 2017 (as to 304,000 options) and December 1, 2018 (as to the remaining 304,000 options) will not be extended and will terminate in accordance with their terms.  The option schedule is set out in Schedule &#8220;B&#8221;.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">All share awards granted to Employee under Employer&#8217;s Incentive Share Award Plan and the resolution of the Board of Directors of Employer dated September 9, 2016, shall have immediately terminated effective as of November 2, 2016.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee confirms that he will adhere to the terms of his employment agreement, including but not limited to the confidentiality and non-competition covenants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee can keep the electronics in his possession that were supplied to him as part of his employment. Employee will ensure that no Employer confidential information is retained on such devices.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The mosaic which is Employee&#8217;s property can be removed from Employer&#8217;s office by Employee.  Employee is responsible for all associated costs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employer will issue a press release in the following form:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">Oncolytics Biotech</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">&#32;Inc. Announces Change to Board of Directors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">CALGARY, AB, November xx, 2016 --- Oncolytics Biotech</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">&#32;Inc. (&#8220;Oncolytics&#8221; or the &#8220;Company&#8221;) (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced that Dr. Brad Thompson has resigned from Oncolytics board of directors effective immediately. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee will execute the release agreement attached as Schedule &#8220;A&#8221; (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Release</font><font style="font-family:Arial;font-size:12pt;">&#8221;) and return an originally executed copy to Employer. Nothing in this Agreement or the Release is intended to prevent Employee from communicating in good faith with the any securities regulatory authority regarding violations of securities laws by the Employer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee acknowledges that he has received independent legal advice from McLennan Ross LLP with respect to the terms and conditions of this Agreement and that he fully understands them. Employee voluntarily accepts the terms and conditions of this Agreement for the purpose of making full and final compromise, adjustment and settlement of all claims as aforesaid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee will not disclose this Agreement or the terms of settlement contained in this Agreement to any person or corporation except to the extent that such disclosure is required by law or to the extent necessary to permit him to obtain legal and/or financial advice in connection with this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement will enure to the benefit of and be binding upon the heirs, executors, administrators and legal personal representative of Employee and the successors and permitted assigns of Employer respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement will be governed by and construed in accordance with the laws of the Province of Alberta and the laws of Canada applicable in Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee acknowledges receipt of a copy of this Agreement duly signed by Employer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement may be executed in counterparts and by facsimile and electronic (pdf) transmission.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Arial;font-size:12pt;">&#32;the parties have executed this Agreement.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:42%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNED, AND DELIVERED</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the presence of:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Aasen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Brad Thompson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(s)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Witness</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BRADLEY GEORGE THOMPSON</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Wayne Pisano</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE &#8220;A&#8221; </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">WHEREAS: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the employment of </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">BRADLEY GEORGE THOMPSON</font><font style="font-family:Arial;font-size:12pt;">&#32;(the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Employee</font><font style="font-family:Arial;font-size:12pt;">&#8221;) with </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC. </font><font style="font-family:Arial;font-size:12pt;">(the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Employer</font><font style="font-family:Arial;font-size:12pt;">&#8221;) has ceased; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the Employee has agreed to accept for good consideration the terms of settlement outlined in the settlement agreement to which this Release and Indemnity is attached as Schedule &#8220;A&#8221; (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Settlement Terms</font><font style="font-family:Arial;font-size:12pt;">&#8221;) in full settlement of all Claims (as defined below);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">NOW THEREFORE THIS RELEASE AND INDEMNITY WITNESSES </font><font style="font-family:Arial;font-size:12pt;">that, in consideration of the Settlement Terms and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Employee agrees as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Release and Indemnity</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Subject to Paragraph 9 below, the Employee hereby: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">releases and forever discharges:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the Employer, its directors, officers, trustees, insurers, shareholders, employees, contractors and agents;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">all corporations associated or affiliated with the Employer, their directors, officers, trustees, insurers, shareholders, employees, contractors and agents; and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the respective heirs, executors, administrators, other legal representatives, predecessors, successors and assigns of the aforesaid corporations, individuals and other entities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(individually, a &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Releasee</font><font style="font-family:Arial;font-size:12pt;">&#8221; and, collectively, the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Releasees</font><font style="font-family:Arial;font-size:12pt;">&#8221;) from any and all actions, causes of action, claims, proceedings, applications, complaints and demands whatsoever, whether known or unknown, that have arisen or that may arise at any time in the future (individually, a &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Claim</font><font style="font-family:Arial;font-size:12pt;">&#8221; and, collectively, the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Claims</font><font style="font-family:Arial;font-size:12pt;">&#8221;) and, without limiting the generality of the foregoing, all Claims arising from the employment of the Employee with the Employer or the termination, resignation, or cessation of such employment, including all Claims, contractual, statutory or otherwise, under any benefit plan in which the Employee participated or may have been entitled to participate during his employment and all Claims for salary, wages, commissions, incentive compensation, bonuses, discrimination, mental distress, stock options, share awards, RSUs, shares or other securities, benefits, overtime pay, vacation pay, holiday pay, any other form of remuneration, perquisites, termination pay, severance pay, compensation in lieu of notice, damages for wrongful dismissal, payments, rights, or benefits under the </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Workers&#8217; Compensation Act</font><font style="font-family:Arial;font-size:12pt;">&#32;(Alberta) any other forms of damages and reinstatement in employment, and including any express or implied right under any contract of employment, the common law, or any applicable statute or regulation, including without limitation the </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Employment Standards Code</font><font style="font-family:Arial;font-size:12pt;">&#32;(Alberta), the </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Labour Relations Code</font><font style="font-family:Arial;font-size:12pt;">&#32;(Alberta), the </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Alberta Human Rights Act</font><font style="font-family:Arial;font-size:12pt;">, and the </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Workers&#8217; Compensation Act</font><font style="font-family:Arial;font-size:12pt;">&#32;(Alberta); </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">agrees he is aware of his rights under human rights legislation, and confirms he is not and does not intend to assert such rights or advance a Claim under human rights legislation </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">relating to his employment with the Employer or the resignation, termination or cessation of such employment, and hereby releases and forever discharges the Releasees from any such Claims;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">agrees, for the benefit of the Releasees, not to make any Claim or take any proceeding with respect to any matter released and discharged herein that may result in any Claim arising against any Releasee for contribution or indemnity or other relief;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">agrees to indemnify and save harmless the Releasees from and against any and all Claims under the </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Income Tax Act</font><font style="font-family:Arial;font-size:12pt;">&#32;(Canada), any applicable provincial income tax statutes, including any regulations made thereunder, and any other statutes or regulations, for or in respect of any failure on the part of the Releasees to withhold income tax from all or any part of the said consideration and any Losses arising from any such Claims;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">agrees to keep the terms of this Release and Indemnity and the Settlement Terms and the discussions leading up to them completely confidential, and not to disclose the terms of this Release and Indemnity, the Settlement Terms and the discussions leading up to them except to the extent disclosure is required by law or to the extent necessary to permit him to obtain legal and/or financial advice in connection with the Settlement Terms;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">acknowledges and agrees that the Releasees other than the Employer are intended to be third party beneficiaries of this Release and Indemnity and, as such, each of such Releasees are entitled to enjoy the benefits of this Release and Indemnity and have the right to independently enforce the terms of this Release and Indemnity directly against the Employee; and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">to the extent necessary to entitle the Releasees to enjoy the benefits of this Release and Indemnity, appoints the Employer as the trustee for such Releasees of the provisions of this Release and Indemnity that are for their benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Independent Legal Advice</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee declares he has received independent legal advice with respect to the Settlement Terms as well as this Release and Indemnity and fully understands them. The Employee hereby voluntarily accepts the Settlement Terms for the purpose of making full and final compromise, adjustment and settlement of all Claims referred to above.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Compliance with the Settlement Terms</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Release and Indemnity will not apply to any Claims the Employee may have relating to the failure or the refusal of the Employer to comply with the Settlement Terms.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">No Admission of Liability</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee understands and agrees that neither the Settlement Terms nor anything contained herein nor the payment of the said consideration will be construed as an admission of liability by the Releasees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Release and Indemnity is governed by and will be construed in accordance with the laws of the Province of Alberta and the laws of Canada applicable therein.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Benefit</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Release and Indemnity will enure to the benefit of and be binding upon the Employee and the Releasees and their respective heirs, executors, administrators, other legal representatives, successors and assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Return of Property</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee agrees that all written and electronic documents, drawings, manuals, letters, notebooks, reports, files, records and similar collections of confidential or proprietary information of the Employer (collectively the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Documents</font><font style="font-family:Arial;font-size:12pt;">&#8221;) are the property of the Employer and confirms that he has returned and delivered all such Documents to the Employer without making or retaining copies of same. The Employee also confirms that he has returned all Employer property he had in his possession. The Employee further agrees and acknowledges that the Employer has returned all of the Employee&#8217;s personal property to Employee. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Non-Disparagement </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee agrees not to do or say anything that a reasonable person would expect to diminish, impugn, or constrain the Employer&#8217;s good will or good reputation or that of any employee, officer or director of the Employer. The Employee agrees not to disparage or seek to injure the Employer&#8217;s reputation or the reputation of any employee, officer or director of the Employer. The Employee agrees to refrain from making negative statements regarding the Employer&#8217;s methods of doing business, the quality, wisdom or effectiveness of the Employer&#8217;s business policies and practices, or the quality of the Employer&#8217;s employees, officers, agents, products or services.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">9</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Exclusions </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Release does not apply to (a) the Employee&#8217;s rights as a shareholder of the Employer, or (b) any rights that the Employee may already have under the Employer&#8217;s D&amp;O insurance policies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Entire Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Release and Indemnity along with the Settlement Terms constitute the entire agreement between the Employer and the Employee with respect to the subject matter hereof. The Settlement Terms are contractual and not a mere recital.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">BRADLEY GEORGE THOMPSON</font><font style="font-family:Arial;font-size:12pt;">&#32;has executed this Release and Indemnity at Calgary, Alberta on December 5, 2016.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:41%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">SIGNED</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:12pt;">AND DELIVERED</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the presence of:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Michael Aasen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Brad Thompson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Witness</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BRADLEY GEORGE THOMPSON</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE &#8220;B&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><img src="optiontable.jpg" alt="optiontable.jpg" style="height:247px;width:682px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>6
<FILENAME>ex80subsidiaries.htm
<DESCRIPTION>EXHIBIT 8.0 SUBSIDIARIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0c3eefe5e56341aab3b7113789c673fe"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LIST OF SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:73%;"></td><td style="width:27%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jurisdiction</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech (Barbados) Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Barbados</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div style="line-height:144%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>7
<FILENAME>ex121ceocertfication2016.htm
<DESCRIPTION>EXHIBIT 12.1 CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sc24f0cf89574455db29c6ef1df9b0b88"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12.1</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Matthew Coffey, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:7%;"></td><td style="width:41%;"></td><td style="width:7%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;27, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey, PhD</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>8
<FILENAME>ex122cfocertification2016.htm
<DESCRIPTION>EXHIBIT 12.2 CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s39994db98d47455ea5bc045cb200fbdb"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12.2</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Kirk Look, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:9px;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:6%;"></td><td style="width:41%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;27, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Accounting and Financial Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>9
<FILENAME>ex131ceocertification2016.htm
<DESCRIPTION>EXHIBIT 13.1 CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sb576537547d3487fab69bbf57cd62ace"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 13.1</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. &#167;1350,</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Matthew Coffey</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey, PhD</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>10
<FILENAME>ex132cfocertification2016.htm
<DESCRIPTION>EXHIBIT 13.2 CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s476b2ee5336c4c49b9ee844578f09c2a"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 13.2</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. &#167;1350,</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Kirk Look</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Accounting and Financial Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;27, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>11
<FILENAME>ex151-2016mda.htm
<DESCRIPTION>EXHIBIT 15.1 MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1DF4F6C07310B4ED9435FBCAC7A20EFC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="logo1.jpg" alt="logo1.jpg" style="height:160px;width:682px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sD5C73E0EA9B8D94A9E45FBCAC7B7C05B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:14pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.3046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:81%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s15A0AD0EABF80AE8AB5EFBCAC7E6BBDB"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Basis of Presentation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s15A0AD0EABF80AE8AB5EFBCAC7E6BBDB">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s71293ECE5A3842B025A3FBCAC8071622">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REOLYSIN</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s09B95CB4B3829BAB0B0FFBCAC954486D"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">&#160;Development For 201</font></a><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s0A9F393CBE9BC168DF35FBCAC8397D94">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s53C8E78B7FA90EAA7E15FBCAC85C2F97"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Clinical Trial Program</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s53C8E78B7FA90EAA7E15FBCAC85C2F97">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#sAC59BC8C8BA89B397BBFFBCAC88CC787"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Manufacturing </font></a><font style="font-family:inherit;font-size:11pt;font-style:italic;">and Process Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sAC59BC8C8BA89B397BBFFBCAC88CC787">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s4348820104EDE28FB08AFBCAC8AE0DB6"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Intellectual Property</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s4348820104EDE28FB08AFBCAC8AE0DB6">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s73E428F8DD8C5BE6E35AFBCAC8DFA200"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Financing Activity</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s73E428F8DD8C5BE6E35AFBCAC8DFA200">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s815A80F3A903A7ED09CAFBCAC90119D9"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Financial Impact</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s815A80F3A903A7ED09CAFBCAC90119D9">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s4D913A91DFE58B1A275FFBCAC933969B"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Cash Resources</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s4D913A91DFE58B1A275FFBCAC933969B">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REOLYSIN</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Development For 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s09B95CB4B3829BAB0B0FFBCAC954486D">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s91DC9856670FBADB0A88FBCAC9951380"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Accounting Policies</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s91DC9856670FBADB0A88FBCAC9951380">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#sDFCB30704CDADA804768FBCAC9A8D765"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Critical Accounting Policies</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sDFCB30704CDADA804768FBCAC9A8D765">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s1578F82272618A626A9EFBCAC9D9D8B1"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Future Accounting Changes</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s1578F82272618A626A9EFBCAC9D9D8B1">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s2E2D30330CF7BE73BCF4FBCAC9FBD9D9"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Significant Estimates</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s2E2D30330CF7BE73BCF4FBCAC9FBD9D9">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sEF2D2BAA21BA99E51FA7FBCAAB2989B5"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Selected Annual Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sEF2D2BAA21BA99E51FA7FBCAAB2989B5">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s2C66CB780FF87C3958D9FBCACA4EE804"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s2C66CB780FF87C3958D9FBCACA4EE804">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s2BA44D702D2E2B469515FBCACAAF021A"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Summary of Quarterly Results</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s2BA44D702D2E2B469515FBCACAAF021A">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s9E60698F253BDA1C80D0FBCAAD5AAF47"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Fourth Quarter</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s9E60698F253BDA1C80D0FBCAAD5AAF47">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#sF3792C36FB413834AD94FBCACAE5694F"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Fourth Quarter - Review of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sF3792C36FB413834AD94FBCACAE5694F">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s25D2B4271686BAAA151EFBCACB1A14E3"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Liquidity and Capital Resources</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s25D2B4271686BAAA151EFBCACB1A14E3">14</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sE7D4477FAA57B37B5D73FBCACBEFE2F7"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Off-Balance Sheet Arrangements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sE7D4477FAA57B37B5D73FBCACBEFE2F7">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s7F302D390D8A34569749FBCACC22FFC7"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Transactions with Related Parties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s7F302D390D8A34569749FBCACC22FFC7">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s85C91ACF54E1782A92EAFBCAABA50769"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Financial Instruments and Other Instruments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s85C91ACF54E1782A92EAFBCAABA50769">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sDBCB585A745695EFFE40FBCACC8399BF"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Risk Factors Affecting Future Performance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sDBCB585A745695EFFE40FBCACC8399BF">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s100803D3F60EBB77F807FBCACC966FE2"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Other MD&amp;A Requirements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s100803D3F60EBB77F807FBCACC966FE2">21</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="s15A0AD0EABF80AE8AB5EFBCAC7E6BBDB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">March&#160;9, 2017</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BASIS OF PRESENTATION </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Management Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) should be read in conjunction with our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements and notes thereto, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). This MD&amp;A along with our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;9, 2017</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s71293ECE5A3842B025A3FBCAC8071622"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation.  Forward-looking statements, including our belief as to the potential of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize REOLYSIN, uncertainties related to the research, development and manufacturing of REOLYSIN, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within this MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of REOLYSIN and future expense levels being within our current expectations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.  Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate.  Investors are cautioned against placing undue reliance on forward-looking statements.  We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div><a name="s0A9F393CBE9BC168DF35FBCAC8397D94"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN Development Update For </font><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN, our potential cancer therapeutic.  We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.  We do not expect to generate significant revenues until, and unless, our cancer product becomes commercially viable.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal each year is to advance REOLYSIN through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">supply, and our intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s53C8E78B7FA90EAA7E15FBCAC85C2F97"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We began 2016 with an overall clinical program mainly comprised of six randomized Phase 2 clinical trials (our "Randomized Studies") and a program investigating the use of immuno-therapies.  Towards the end of 2016, we adopted an evolving understanding of REOLYSIN and a new clinical development plan based on our growing library of clinical data and our understanding of how REOLYSIN acts as an immuno-oncology viral agent.  The plan is made up of three paths, with each clearly based on a target element of REOLYSIN&#8217;s mechanism of action: direct tumour lysis; innate immune response; and adaptive immune response.  These mechanisms, working in concert, result in the lysis of cells and the release of chemical signals that attract immune cells to the tumour and results in an inflamed tumor phenotype.  The result is the long-term education of the patient&#8217;s immune system to identify and attack cancer cells.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We understand that REOLYSIN behaves like many other immuno-oncology agents, where patients may derive little or no benefit in terms of progression-free survival (PFS) or response rate (RR), but may see a meaningful improvement in overall survival (OS). In 2016, we reported data from a series of sponsored randomized studies that supported our thinking around REOLYSIN&#8217;s mechanism of action. While these were initially designed by the sponsors several years ago, and all used PFS as the primary endpoint, they served to provide us with valuable data. In a U.S. based National Cancer Institute (NCI) randomized Phase 2 study of patients with pancreatic cancer (NCI-8601), we saw a higher percentage of patients surviving two years in the test arm versus the control arm. As well, we saw a higher percentage of two year survival in patients that started in the control arm and crossed-over to the test arm compared to those who did not cross over. In a randomized Phase 2 study sponsored by the Canadian Cancer Trials Group (CCTG, formerly the National Cancer Institute of Canada Clinical Trials Group) in advanced or metastatic colorectal cancer (IND 210), we also saw a trend to improvement in OS for female patients in the test arm versus the control arm based on an interim analysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Path #1 - Direct Tumour Lysis</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first clinical development path focuses on direct tumour lysis and is based on the clinical data from our randomized chemotherapy combination trials.  We have demonstrated a strong trend showing a two-year survival benefit in patients with pancreatic cancer in two clinical studies and are planning to take advantage of this survival data and existing orphan drug designations to seek regulatory advice in the U.S. and Europe to establish a clear path to registration in pancreatic cancer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Path #2 - Innate Immune Response</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The second path involves the combination of immune modulatory drugs (IMiDs) with REOLYSIN to enhance the innate immune response against the tumor.  We expect to be able to announce collaborations in this path in the second quarter of 2017 that combine REOLYSIN with IMiDS and investigate whether the addition of REOLYSIN can enhance the benefit of this class of agents. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Path #3 - Adaptive Immune Response</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third clinical development path focuses on the adaptive immune response, a long-term, durable and learned response.  This creates a vaccination-like response that, through lysis of the tumor by the virus, educates the body&#8217;s immune cells to target and attack unique cancer antigens. We believe that REOLYSIN in combination with checkpoint inhibitors - immunological agents that enhance the adaptive immune response - will act synergistically to provide enhanced overall survival to patients. Early in 2016, we announced that the first patients had been treated in our Phase 1b study of pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN and chemotherapy in patients with advanced pancreatic adenocarcinoma.  This study is enrolling patients 18 years or older with histologically confirmed advanced or metastatic pancreatic adenocarcinoma who have failed, or did not tolerate, first line treatment. It is an open-label Phase 1b trial designed to determine the safety and dose-limiting toxicities of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and chemotherapy (gemcitabine or irinotecan or fluorouracil, at the treating physician's preference) in combination with pembrolizumab. Secondary endpoints include overall response rate and progression free survival by immune-related response criteria; overall survival; and effects of REOLYSIN and pembrolizumab when administered in combination as determined by analysis of pre- and post-treatment treatment biopsies and blood-based immune markers. Following an initial six to nine patient safety run-in, up to an additional 15 patients may be enrolled for further evaluation of safety and efficacy.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our focus will be to work towards product registration via the first path of the clinical development plan.  The objectives of paths two and three are to enhance the exposure of REOLYSIN to leading pharmaceutical companies working in immuno-oncology and enhance the market opportunities for our agent; that process is underway.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Path #1 - Direct Tumour Lysis - Clinical Trial Results</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Randomized Colorectal Cancer Study </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we announced preliminary data from our CCTG randomized Phase 2 clinical trial of  REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">in combination with FOLFOX-6 and bevacizumab (Avastin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in patients with advanced or metastatic colorectal cancer. This preliminary analysis was presented at the June 2016 American Society of Clinical Oncology ("ASCO") Annual Meeting held in Chicago, IL.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:19%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:15%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Objective Response</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Rate</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(%)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Progression Free </font></div><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Survival </font></div><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(months)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Median Overall</font></div><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Survival </font></div><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(months)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Test</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Control</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Test</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Control</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Test</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Control</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Female Patients</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.2 (n=19)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.8 (n=21)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.43 (n=19)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.08 (n=21)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.3 (n=19)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.5 (n=21)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Male Patients</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.9 (n=32)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.9 (n=31)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.33 (n=32)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.26 (n=31)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.4 (n=32)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.7 (n=31)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overall</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.9 (n=51)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.6 (n=52)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.33 (n=51)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.13 (n=52)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.57 (n=51)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.21(n=52)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:8pt;">Note: 1. This was an interim analysis, as 62 (60.2%) patients out of a total of 103 patients were alive at the time of data cut-off.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The abstract authored by CCTG,  reported that the overall test arm had an objective response rate of 52.9% (n=51) versus 34.6% (n=52) in the control arm (p=0.06) and reported on a pre-planned analysis, as specified in the protocol, of patient responses by gender.  The female patients in the test arm had an objective response rate of 63.2% (n=19) versus 23.8% (n=21) in the control arm (p=0.0054).  The male patients in the test arm had an objective response rate of 46.9% (n=32) versus 41.9% (n=31) in the control arm (p=0.6747).    The abstract also noted that, of grade 3 or higher adverse events, there was less abdominal pain (3.5% versus 17.3%, p=0.02), more hypertension (26.3% versus 3.8%, p=0.001) and more proteinuria (22.8% versus 1.9%, p=0.001) in the test arm than the control arm.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Randomized Lung Cancer Study </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we announced that the CCTG presented preliminary data from our randomized CCTG Phase 2 lung cancer study of REOLYSIN.  Patients with non-squamous cell histology were treated with REOLYSIN given in combination with pemetrexed (Arm A) versus pemetrexed alone (Arm B). Patients with squamous cell histology were treated with REOLYSIN given in combination with docetaxel (Arm C) versus docetaxel alone (Arm D). This preliminary analysis was presented at the June 2016 Annual ASCO meeting held in Chicago, IL.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.6796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:11%;"></td><td style="width:15%;"></td><td style="width:15%;"></td><td style="width:14%;"></td><td style="width:16%;"></td><td style="width:15%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Median Progression Free Survival</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;(months)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Median Overall Survival </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(months)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Test Arms</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Arm A+C) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(95% CI)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Control Arms </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Arm B+D) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(95% CI)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hazard</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ratio </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(95% CI)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Test Arms</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Arm A+C) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(95% CI)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Control Arms </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Arm B+D) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(95% CI)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hazard</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ratio</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(95% CI)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EGFR</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.16 (0.76-8.71) </font></div><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.63 (1.51-7.03)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=5)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.54 (0.13-2.22)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.66 (1.38-26.84)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.49 (4.63-16.79) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=5)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37 (0.08-1.71)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TP53</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.07 (2.63-6.21) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=24)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.40 (1.28-2.99)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=21)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.58 (0.31-1.08)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.74 (6.83-13.93)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=23)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.14 (3.02-8.18)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=21)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.55 (0.28-1.07)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Female </font></div><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patients</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.98 (2.66-5.39) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=41)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.84 (1.51-4.34)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=34)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.59 (0.36-0.98)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.38 (5.36-10.38)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=41)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.59 (5.59-10.45)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=34)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85 (0.49-1.46)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Male </font></div><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patients</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.56 (1.45-3.94) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=36)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.69 (2.46-4.24)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=41)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.34 (0.83-2.14)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.66 (4.37-10.94)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=36)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26 (4.86-10.78)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=41)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0 (0.60-1.68)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overall</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.96 (2.56-4.17) </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=77)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.83 (2.50-3.98)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=75)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.93 (0.66-1.31)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.12 (5.85-9.40)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=77)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.39 (5.72-9.43)</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(n=75)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.94 (0.64-1.37)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Note: 1. Mutated.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investigators concluded that REOLYSIN was reasonably well tolerated at the dose and schedule administered with pemetrexed or docetaxel and that no new safety signals were seen. They also noted it was of interest that female patients in the REOLYSIN-containing arms did better than in the standard treatment arms and that in a subgroup analysis that EGFR mutation and p53 mutation status was associated with a trend to improved progression free survival.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Randomized Pancreatic Cancer Study</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we further analyzed the overall survival data from our randomized Phase 2 clinical trial in combination with carboplatin and paclitaxel in patients with pancreatic cancer (NCI-8601). The study was sponsored by the NCI.  Our updated analysis is based on data collected up to August 2, 2016.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We performed an intent-to-treat analysis of overall survival on patients with confirmed treatment regimes, as assessed by the percentage of patients surviving for two and three years. The analysis showed a higher percentage of patients surviving two and three years for patients randomized to the test arm or for those patients that crossed over to the test arm  compared to those patients that stayed on the control arm. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:18%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arm</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Median OS</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(months)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1-year OS</font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2-year OS </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3-year OS </font></div><div style="text-align:center;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(%)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stayed on Control (n = 20)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Randomized to Test (n = 36)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.9</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Crossed over to Test (n = 17)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.8</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Randomized Ovarian Cancer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we announced an update to our randomized Phase 2 clinical trial investigating REOLYSIN in combination with paclitaxel in patients with ovarian cancer (GOG-0186H). The study is sponsored by the NCI and the update included data from a Gynecologic Oncology Group ("GOG") study summary report and followed a presentation made by the principal investigator regarding the study at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer which ran from March 19-22, 2016 in San Diego, CA.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A PFS analysis, stratified by measurable disease and platinum-free interval (test arm: n = 54, 43 events (progressions), and control arm: n = 54, 48 events), was performed and demonstrated a median PFS of 4.4 months for the test arm, and 4.3 months for the control arm.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An interim OS analysis (test arm: n = 54, 32 events (deaths), and control arm: n = 54, 32 events (deaths)) was performed and demonstrated a median OS of 12.9 months for the test arm, and 15.0 months for the control arm. The OS was an interim analysis, as 44 (41%) patients out of a total of 108 patients were alive at the time of analysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This study is a randomized Phase 2 clinical trial of paclitaxel versus paclitaxel plus REOLYSIN in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer. Patients received paclitaxel on days 1, 8 and 15 of each 28-day treatment cycle, with either REOLYSIN (test arm) or placebo (control arm) administered on days 1 through 5. One hundred and eight patients were randomized (1:1, 54 patients in the control arm, 54 patients in the test arm). The NCI study did not stratify on entry according to PD-L1 levels or infiltrating CD8+ T lymphocyte levels, nor were either of those levels measured post-treatment. However, pre-treatment tumour biopsies were taken from the majority of patients. The primary objectives are PFS and toxicity. The secondary objectives are median OS by treatment group, median PFS by treatment group, and tumour response as measured by RECIST criteria and CA-125 antigen levels. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAC59BC8C8BA89B397BBFFBCAC88CC787"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Manufacturing and Process Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Throughout 2016, we supplied our clinical trial program with previously filled and labeled product from our existing supply of REOLYSIN.  As well, we continued our validation activities designed to demonstrate that our manufacturing process for the commercial production of REOLYSIN is robust and reproducible as part of a process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including the FDA, for product approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s4348820104EDE28FB08AFBCAC8AE0DB6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">415</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">61</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents as well as issuances in other jurisdictions.  We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028.  Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s73E428F8DD8C5BE6E35AFBCAC8DFA200"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financing Activity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "At the Market" Equity Distribution Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 26, 2016, we entered into an "at-the-market" equity distribution agreement with Canaccord Genuity Inc. acting as sole agent in Canada (our "Canadian ATM"). Under the terms of the distribution agreement, we may, from time to time, sell shares of our common stock having an aggregate offering value of up to $4.6 million through Canaccord Genuity Inc.  Sales of  common shares, if any, pursuant to the Canadian ATM, will be made in transactions that are deemed to be "at-the-market distributions", through the facilities of the Toronto Stock Exchange or other "marketplace" (as defined in National Instrument 21-101 Marketplace Operation) in Canada.  We will determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.   During the year ending December 31, 2016, we sold </font><font style="font-family:inherit;font-size:10pt;">3,006,600</font><font style="font-family:inherit;font-size:10pt;">&#32;commons shares for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1,456,296</font><font style="font-family:inherit;font-size:10pt;">.  We incurred share issue costs which included costs to establish our Canadian ATM facility of </font><font style="font-family:inherit;font-size:10pt;">$500,163</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s815A80F3A903A7ED09CAFBCAC90119D9"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Impact</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated that our cash requirements for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to fund our operations would be approximately between $14.0 - $15.0 million.  Our cash usage for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12,477,613</font><font style="font-family:inherit;font-size:10pt;">&#32;for operating activities and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$23,527</font><font style="font-family:inherit;font-size:10pt;">&#32;for the acquisition of property and equipment.  Our net loss for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,139,979</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4D913A91DFE58B1A275FFBCAC933969B"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Resources </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We exited </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;with cash, cash equivalents  and short-term investments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14,123,082</font><font style="font-family:inherit;font-size:10pt;">&#32;(see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s09B95CB4B3829BAB0B0FFBCAC954486D"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Expected REOLYSIN Development For 2017</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our planned 2017 development activity for REOLYSIN focuses on our clinical development plan and is made up of our three clinical paths, manufacturing, and intellectual property programs.  Our primary objective in 2017 is to work towards product registration using chemo-therapy combinations while investigating synergies with immuno-therapies including checkpoint inhibitors and immune modulators.  We expect any expansion with immunotherapies to be done through research collaborations requiring us to mainly provide product.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2017 manufacturing program includes continued production of 100-litre cGMP production runs along with the related fill, labeling, packaging and shipping of REOLYSIN to our various clinical sites.  We also plan to continue progressing through our process validation master plan and related conformity testing in 2017.  Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently estimate the cash requirements to fund our operations for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;will be approximately $12 million, but will depend on our ultimate clinical program.  (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s91DC9856670FBADB0A88FBCAC9951380"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Our Accounting Policies </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing our financial statements we use IFRS as issued by the International Accounting Standards Board.  IFRS requires that we make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available in selecting our  accounting policies.  Our selection of accounting policies, along with our estimates and assumptions affect the reported amounts of our assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sDFCB30704CDADA804768FBCAC9A8D765"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing our financial statements, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available.  These estimates and assumptions affect the reported amounts of assets at the date of the financial statements and the reported amounts of expenses during the periods presented.  Significant estimates are used for, but not limited to, the treatment of our research and development expenditures, the assessment of realizable value of long-lived assets and the calculation of stock based compensation (see Note 4 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">" Significant Judgments, Estimates and Assumptions</font><font style="font-family:inherit;font-size:10pt;">") of our audited consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research costs are expensed as incurred.  Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all of our activities have been expensed. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for our research and development activity in conjunction with the IAS 38 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Intangible Assets"</font><font style="font-family:inherit;font-size:10pt;">&#32;of IFRS.   IAS 38 makes a distinction between the research phase of a project and the development phase of an internal project and requires that all costs incurred during the research phase are to be expensed.  However, an intangible asset arising from the development phase of an internal project shall be recognized if, and only if, we can demonstrate all of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The technical feasibility of completing the intangible asset so that it will be available for use or sale.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intention to complete the intangible asset and use or sell it.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to use or sell the intangible asset.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">How the intangible asset will generate probable future economic benefits.  Among other things, that we can demonstrate the existence of a market for our product that results from the use of the intangible asset or of the intangible asset itself.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ability to measure reliably the expenditure attributable to the intangible asset during its development.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that we do not meet all of the above criteria and for this reason, our research and development costs are expensed and not capitalized.  We will monitor our progress against these criteria and will capitalize our development costs once we can conclude we meet the above criteria.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1578F82272618A626A9EFBCAC9D9D8B1"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Future Accounting Changes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 9 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Recognition and Measurement</font><font style="font-family:inherit;font-size:10pt;">, the IASB issued the final version of IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments. </font><font style="font-family:inherit;font-size:10pt;">IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1, 2018 with early application permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the IASB issued IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IFRS 16&#8221;), which replaces IAS 17 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IAS 17&#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2E2D30330CF7BE73BCF4FBCAC9FBD9D9"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Significant Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As required by IFRS, share based payments are to be recorded at their fair value at the date of grant.  We have chosen to use the Black Scholes Option Pricing Model (&#8220;Black Scholes&#8221; or the &#8220;Model&#8221;) to calculate the fair value of our stock options and warrants.  Though there are other models available to calculate the option values (for example, the binomial model), Black Scholes is currently widely used and accepted by other publicly traded companies.  Therefore, we have concluded that Black Scholes is the appropriate option pricing model to use for our stock options at this time.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Black Scholes uses inputs in its calculation of fair value that require us to make certain estimates and assumptions.  For </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, we used the following weighted average assumptions for the calculation of the fair value of the stock options granted during the year:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:378px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:245px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.82%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94.84%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.17</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in these estimates and assumptions will impact the value calculated by the model.  For instance, the volatility in the price of our shares is based on the quoted trading price.  We assume that weekly trading prices best reflect our trading price volatility.  However, an entity can choose between daily, weekly, or monthly trading prices in the volatility calculation.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Model also uses an expected hold period to exercise in its calculation of fair value.  When we are estimating the expected hold period to exercise we take into consideration past history, the current trading price, the volatility of our common shares and the progress in our clinical program.  Our conclusions resulted in an expected hold period for the stock options issued in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to be </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.0 years</font><font style="font-family:inherit;font-size:10pt;">&#32;and we believe this is an appropriate estimate.  However, our options have a 10-year life and given the fluctuations in our stock price the expected hold period could be different.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded non-cash share based payment expense for the year of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$406,078</font><font style="font-family:inherit;font-size:10pt;">.  However, given the above discussion, this expense could have been different and still be in accordance with IFRS.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sEF2D2BAA21BA99E51FA7FBCAAB2989B5"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Selected Annual Information</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:586px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:318px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,139,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,619,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1), (2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,758,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,383,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,193,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="7" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Notes:</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)  Included in consolidated net loss and loss per common share for 2016, 2015, and 2014 are share based payment expenses of $406,078, $429,537 and $980,325, respectively.</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2)  We issued 3,106,600 common shares for net cash proceeds of $1.0 million in 2016 (2015 - 24,639,128 common shares for net cash proceeds of $23.7 million; 2014 - 8,708,676 common shares for net cash proceeds of  $9.0 million).  </font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3)  We have not declared or paid any dividends since incorporation.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2C66CB780FF87C3958D9FBCACA4EE804"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,139,979</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$13,722,995</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18,619,335</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,620,114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,610</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,983,644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,725,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,306,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,705,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenditures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,096,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,077,552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">369,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">698,909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,553,816</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,098,180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,703,798</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and development refund</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">171,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,051,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,130</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">233,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588,658</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,770,007</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,601,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,824,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses include those costs associated with our Clinical Development Plan which primarily included our randomized phase 2 studies investigating cancer cell lysis (Path #1) and adaptive immune response (Path #3). Included in clinical trial expenses are direct patient enrollment costs, contract research organization (&#8220;CRO&#8221;) expenses, clinical trial site selection and initiation costs, data management expenses and other costs associated with our clinical trial program.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:602px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:376px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,620,114</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,610</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,983,644</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,620,114</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,323,610</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,983,644</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.  In 2016, our clinical activities mainly related to the patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN along with costs </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">associated with the completion of enrollment in our randomized Phase 2 studies. As well, during the three year period 2014 - 2016 we benefited from the use of Third Party Trials which has allowed us to operate a broad clinical program at a lower overall cost.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, our clinical trial program activities declined compared to 2014 as we completed enrollment in our Randomized Studies and closed out fully enrolled clinical trials.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our clinical trial expenses to increase in 2017 compared to 2016. In 2017, we expect to finalize our registration path and complete the regulatory filings necessary to support and commence enrollment in a registration study as part of Path #1 of our Clinical Development Plan.  As well, we expect to expand Path #2 and Path #3 of our Clinical Development Plan to include both checkpoint inhibitors and immune modulators (IMiDs).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">M&amp;P expenses include product manufacturing and process development activities. Product manufacturing expenses include third party direct manufacturing costs, quality control testing, fill, label and packaging costs and are net of any recoveries that are received from any R&amp;D collaborators. Process development expenses include costs associated with studies that examine components of our manufacturing process looking for improvements and costs associated with the creation of our process validation master plan and related conformity testing. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.6484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,162,446</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,618,165</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,713,649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">563,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">687,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">991,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,725,835</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,306,024</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,705,296</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,725,835</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,306,024</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,705,296</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. During 2016, our production manufacturing activities have mainly related to supplying our clinical program with sufficient product including related shipping and storage activities. These costs have been partially offset by recoveries from a development collaboration.  During 2015, our production manufacturing activities remained relatively consistent compared to 2014 and mainly related to supplying our Clinical Programs with sufficient REOLYSIN.  These activities also included the fill, labeling and lot release testing of product and the shipping and storage of our bulk and vialed product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$563,389</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$687,859</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$991,647</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.  During the years ending 2016,  2015, and 2014 our process development activities focused on our validation master plan.  In 2016, these activities included stability, scale up and process optimization studies. In 2015 and 2014, our process development activities also included assay development and validation studies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our M&amp;P expenses for 2017 to increase compared to 2016.  In 2017, we expect to fill, label and store sufficient product in preparation for a registration study.  We also expect to continue to perform conformity testing related to our process validation master plan. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.1796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:64%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,096,097</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032,227</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,077,552</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,096,097</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,032,227</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,077,552</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.   The change in intellectual property expenditures reflects the timing of filing costs associated with our expanded patent base.  At the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">415</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">61</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.  We expect that our intellectual property expenses will remain consistent in 2017 compared to 2016.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations are intended to expand our intellectual property related to REOLYSIN and identify potential licensing opportunities arising from our technology base.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.5234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">369,469</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">698,909</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621,936</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, our research collaboration expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$369,469</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$698,909</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$621,936</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.  In 2016, our research collaborations included biomarker studies along with studies investigating the interaction of the immune system and REOLYSIN. In  2015 and 2014, our research collaborations also included the use of the reovirus as a co-therapy with existing chemotherapeutics and radiation.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that our research collaborations in 2017 will remain consistent with 2016.  We expect to complete our ongoing collaborative program carried over from 2016 and will continue to be selective in the types of new collaborations we enter into in 2017.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses include compensation expenses for employees (excluding stock based compensation), consultant fees, travel and other miscellaneous R&amp;D expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D consulting fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">186,221</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,427</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,685</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,138,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,388,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,989,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">229,360</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,553,816</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,098,180</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,703,798</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, our Other Research and Development expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$4,553,816</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$4,098,180</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$3,703,798</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the years ending 2016, 2015 and 2014, our Other Research and Development activities focused on supporting our Clinical Program which includes our Randomized Program, our Checkpoint Inhibitor Program along with other Third Party trials and clinical trials sponsored by Oncolytics. R&amp;D salaries and benefits in 2016 included a retirement allowance of $1,330,828 paid to the previous Chief Executive Officer in November 2016. Normalizing for the allowance, our R&amp;D salaries and benefits declined compared to 2015 as a result of a drop in head count that occurred during the second half of 2015. With the completion of enrollment in our CCTG trials in 2015 and the close out of completed Company sponsored studies, our Other R&amp;D expenses continued to decline. As well, in 2014, cash bonuses were not paid to officers or employees but were paid in 2015 and 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Normalizing for the retirement allowance, we expect that our Other R&amp;D expenses in 2017 will remain consistent with 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scientific Research and Development Refund</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.15625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:66%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and development refund</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,203</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,144</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,762</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, we received Alberta and Quebec scientific research and development refunds totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,203</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$62,144</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$84,762</font><font style="font-family:inherit;font-size:10pt;">,  respectively. During the three year period 2014-2016, our qualified expenditures for scientific research and development refunds in Canada have declined.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange (Gain) Loss</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">171,960</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,051,958</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,130</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, our foreign exchange (gain) loss was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$171,960</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$(1,051,958)</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$228,130</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The foreign exchange losses incurred in 2016 and 2014 were primarily a result of the fluctuations in the US dollar, Euro and Pound Sterling exchange rates. In 2015, our foreign exchange gain was primarily a result of the strengthening of the US dollar and that the proceeds from our financing activities were in US dollars.     </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">233,919</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588,658</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payments for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$233,919</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$257,016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$588,658</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the years ending  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.   We incurred stock based compensation associated with the grant of stock options and performance share units to employees associated with our research and development activities.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2015<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2014<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,172,676</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,932,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,761,374</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,017,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,030,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,682,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">162,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,501</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">172,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,521</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,524,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,315,837</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,998,694</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses include costs associated with investor relations and business development activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings.   In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, we incurred public company related expenses of </font><font style="font-family:inherit;font-size:10pt;">$3,172,676</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$2,932,436</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2,761,374</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.  In 2016, our public company related expenses increased due to investor relations activities compared to 2015. In 2015, the costs associated with our public company listing fees, our investor relations activities, associated professional fees and the cost of our Annual General Meeting increased compared to 2014. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent, and other office related costs.  In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, we incurred office expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2,017,432</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2,030,469</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,682,152</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.  In 2016 and 2015, our office expenses remained relatively consistent. In 2015, our office expenses increased compared to 2014 mainly due to the cash bonuses paid to officers and employees. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;">$172,159</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$172,521</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$391,667</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. In </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, 2015 and 2014, we incurred stock based compensation associated with stock option grants to officers and employees, grants of restricted share units to the board of directors, grants of performance share units to certain officers and the vesting of previously granted stock options.       </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our operating expenses in 2017 to decrease compared to 2016.    </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="s2BA44D702D2E2B469515FBCACAAF021A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Quarterly Results</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:588px;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:189px;"></td><td style="width:9px;"></td><td style="width:35px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:38px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:35px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:38px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:38px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,190</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1), (3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Included in total cash are cash and cash equivalents plus short-term investments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Included in net loss and loss per common share between December 2016 and January 2015 are quarterly share based payment expenses</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(recovery) of  </font><font style="font-family:inherit;font-size:8pt;">$106,443</font><font style="font-family:inherit;font-size:8pt;">, $98,369, $119,626, $81,640, $248,101, $10,791, $55,675, and $114,970, respectively.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We issued </font><font style="font-family:inherit;font-size:8pt;">3,106,600</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:8pt;">$1.0 million</font><font style="font-family:inherit;font-size:8pt;">&#32;in </font><font style="font-family:inherit;font-size:8pt;">2016</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2015</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">24,639,128</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:8pt;">$23.7 million</font><font style="font-family:inherit;font-size:8pt;">).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="s9E60698F253BDA1C80D0FBCAAD5AAF47"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Fourth Quarter</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statement of loss for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:486px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:316px;"></td><td style="width:83px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month periods ending December 31,</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,411,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,999,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,816,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,535,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,227,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,535,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,200,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,490,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,707</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,210,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,496,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive gain (loss) - translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">61,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,148,599</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,393,047</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">121,145,249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,121,424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF3792C36FB413834AD94FBCACAE5694F"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Fourth Quarter Review of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;our net loss was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,210,022</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$3,496,922</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">184,755</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,214</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">450,149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">269,025</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">177,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,346,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,291,464</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and development refund</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(60,097</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(262,150</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">43,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,411,185</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,999,987</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.8828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">184,755</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,214</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$184,755</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$202,214</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.  In the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial program activities related primarily to the patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN. As well, we incurred costs associated with the completion of enrollment in our other Company sponsored clinical trials.  In the fourth quarter of 2015, our clinical trial program activities related to completing enrollment in our Randomized Studies and closing out fully enrolled clinical trials while implementing our Clinical Development Plan.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development Expenses (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.90625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">353,605</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">96,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">450,149</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,104</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, our M&amp;P expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$450,149</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$185,104</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.  During the fourth quarter of 2016, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product. During the fourth quarter of 2015, our product manufacturing costs also related to the fill, labeling and lot release testing of product to be used in our clinical trial program.  In 2015, these costs were partially offset by recoveries from a development collaboration. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development activity for the fourth quarter of 2016 related to stability studies compared to assay development, optimization, validation and stability studies in the fourth quarter of 2015. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">269,025</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,097</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$269,025</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$217,097</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.  The change in intellectual property expenditures reflects the timing of filing costs associated with our expanded patent base.  At the end of the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">415</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">61</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration Expenses </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">177,794</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,118</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$177,794</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$199,118</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.  During the fourth quarter of 2016, our research collaborations were primarily focused on biomarker studies. During the fourth quarter of 2015, our research collaborations included biomarker studies along with studies investigating the interaction of the immune system and REOLYSIN and the use of REOLYSIN as a co-therapy with existing chemotherapeutics and radiation. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D consulting fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45,190</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,203</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,225,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,138,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75,782</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,346,052</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,291,464</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our other research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$2,346,052</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,291,464</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.  In the fourth quarter of 2016, our salaries and benefits costs included a retirement allowance of $1,330,828 paid to the previous chief executive officer. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">43,507</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,796</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarters of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we incurred share based payment expense associated with the grant of stock options to officers and employees associated with our research and development activities.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:377px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:72px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">911,811</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">737,889</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">813,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">670,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,668</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">62,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,816,183</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,535,025</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1,816,183</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,535,025</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. During the fourth quarter of 2016 our public company related expenses were $</font><font style="font-family:inherit;font-size:10pt;">911,811</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">737,889</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of 2015. The increase was due to an increase in professional fees in the fourth quarter of 2016 compared to the fourth quarter of 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent, and other office related costs.  During the fourth quarter of 2016, our office expenses were $</font><font style="font-family:inherit;font-size:10pt;">813,834</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">670,163</font><font style="font-family:inherit;font-size:10pt;">&#32;for the third quarter of 2015. During the fourth quarter of 2016, compensation costs increased as a result of severance payments to an employee.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s25D2B4271686BAAA151EFBCACB1A14E3"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><a name="sA16F8C60A72504A234DEFBCACB279CFD"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "At the Market" Equity Distribution Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;">3,006,600</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net proceeds of $</font><font style="font-family:inherit;font-size:10pt;">956,133</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s93206879987AD993BBD6FBCACB4981D2"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2015 Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">US Share Purchase Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2015, under the terms of the Share Purchase Agreement, we issued 5,778,674 common shares for net proceeds of approximately US$3.5 million.  As well, we issued 78,674 commitment shares with a fair value of US$50,024 which has been recorded as additional share issue costs. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">"At the Market" Equity Distribution Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2015, we issued 18,860,454 common shares for net proceeds of approximately US$15.5 million.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NASDAQ Listing</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October, 2015, we received notice from the NASDAQ OMX Group (&#8220;NASDAQ&#8221;) stating that, in accordance with NASDAQ listing rules, our common shares would be delisted from the NASDAQ Capital Market, effective from the opening of trading on November 5, 2015 for not maintaining the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2).  As a result, effective November 5, 2015, we were no longer able to use our Share Purchase Agreement or our ATM which were both conditional on maintaining a NASDAQ listing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDA517BBDD4BAD9D60506FBCACB8E2C51"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents, short-term investments and working capital positions as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:67%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,034,282</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,016,275</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital position</font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,369,665</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,214,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in our cash and cash equivalent and short term investment positions reflects the cash usage from our operating activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;along with the cash provided by our financing activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We desire to maintain adequate cash and short-term investment reserves to support our planned activities which include our clinical trial program, product manufacturing, administrative costs, and our intellectual property expansion and protection.  To date, we have funded our operations mainly through the issue of additional capital via public and private offerings and through the exercise of warrants and stock options. In February 2016, we were able to raise funds through our Canadian ATM (our "Financing Arrangement"). During 2015, we were able to raise funds through our Share Purchase Agreement with LPC and our "at the market" equity distribution agreement with Canaccord Genuity Inc. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements.  In an effort to be able to evaluate all types of financing arrangements, we maintain a current short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;). We renewed our Base Shelf on February 16, 2016 which allows us to sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement. Our Base Shelf expires on March 16, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maintaining our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. </font><font style="font-family:inherit;font-size:10pt;color:#ee2724;">&#32;</font><font style="font-family:inherit;font-size:10pt;">By utilizing our Base Shelf, we were able to enter into our Financing Arrangement. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Financing Arrangement provides us with access to, subject to the respective terms and conditions, $4.6 million of which we have raised gross proceeds of approximately $1.5 million. We expect to continue to access our Financing Arrangement to help support our current clinical trial, manufacturing, intellectual property and collaboration programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that the expected cash usage from our operations in 2017 will be approximately $12 million.  We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources.  Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources and access to additional cash resources through our Financing Arrangements to fund our presently planned operations into 2017.  Factors that will affect our anticipated cash usage in 2017, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&amp;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s64179C2631BC96397DACFBCACBAB52EE"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have the following contractual obligations as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.14634146341464%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:30%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than 1 year</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2 -3 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 - 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">More than </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,026</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,643</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,551,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,197,597</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Note:</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1. Our operating leases are comprised of our office leases and exclude our portion of operating costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to fund our capital expenditure requirements and commitments with existing working capital.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8A942796AB5E35C750D9FBCACBCCDA43"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investing Activities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our Investment Policy, we are permitted to invest in short-term instruments with a rating no less than R-1 (DBRS) with terms less than two years.  Our portfolio consists of guarantee investment certificates.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;invested under this policy, currently earning interest at an effective rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">1.41%</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE7D4477FAA57B37B5D73FBCACBEFE2F7"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had not entered into any off-balance sheet arrangements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7F302D390D8A34569749FBCACC22FFC7"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Transactions with Related Parties</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, we did not enter into any related party transactions other than compensation paid to Key Management Personnel disclosed in Note 19 of our audited consolidated financial statements.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s85C91ACF54E1782A92EAFBCAABA50769"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments and Other Instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable and accounts payable.  As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.  These financial instruments expose us to the following risks:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counter-party to a financial instrument fails to meet its contractual obligations.  We are exposed to credit risk on our cash and cash equivalents and short-term investments in the event of non-performance by counterparties, but we do not anticipate such non-performance.  Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and short-term investments.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.  For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.  Currently, 100% of our short-term investments are in guaranteed investment certificates.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.  We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.  We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.  We are exposed to currency risk from the purchase of goods and services primarily in the US, the U.K and the European Union and to the extent cash is held in foreign currencies.  The impact of a $0.01 increase in the value of the US dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,913</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$10,499</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,010</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk through the purchase of foreign currencies in sufficient amounts to settle our foreign accounts payable.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:63%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">dollars <br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,629,766</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,295</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,565</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(134,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,495,707</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,565</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.  We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDBCB585A745695EFFE40FBCACC8399BF"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Risk Factors Affecting Future Performance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General Risk Factors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative.  It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful.  There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations.  Many factors (e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and other third party relationships, including the ability to obtain appropriate product liability insurance.  There can be no assurance that this reliance and these relationships will continue as required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our product REOLYSIN is in the research and development stage and will require further development and testing before it can be marketed commercially.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, REOLYSIN, for human application, the riskiest stage for a company in the biotechnology industry.  It is not possible to predict, based upon studies in animals, or early studies in humans, whether REOLYSIN will prove to be safe and effective in humans.  REOLYSIN will require additional research and development, including extensive clinical testing, before we will be able to obtain the approval of the United States Food and Drug Administration (the &#8220;FDA&#8221;) or from similar regulatory authorities in other countries to market REOLYSIN commercially.  There can be no assurance that the research and development programs conducted by us will result in REOLYSIN or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To achieve profitable operations, we, alone or with others, must successfully develop, introduce and market our products.  To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy.  Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested.  No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results.  If we are unable to establish that REOLYSIN is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">There are inherent risks in pharmaceutical research and development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk.  The marketability of any product developed by us will be affected by numerous factors beyond our control, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger controlled clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing costs or other factors may make manufacturing of products impractical and non-competitive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proprietary rights of third parties or competing products or technologies may preclude commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product under development has never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable.  Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges, or others that may arise in the course of development.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory process for pharmaceuticals, which includes preclinical studies and clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources.  Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed.  Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.  Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products.  In addition, a marketed drug and its manufacturer are subject to continual review.  Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA in the United States and other relevant regulatory authorities may deny approval of a new drug application (&#8220;NDA&#8221;) or its equivalent in the relevant jurisdiction if required regulatory criteria are not satisfied, or may require additional testing.  Product approvals may be withdrawn if compliance with regulatory standards are not maintained or if problems occur after the product reaches the market.  The FDA may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized.  Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in or with  our customers' other drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and other jurisdictions, as the case may be. Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming.  We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to approval of the facility to manufacture a specific drug, there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical regulatory regime in Europe and other countries is, by and large, generally similar to that of Canada and the United States.  We could face similar risks in these other jurisdictions, as the risks described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing.  Approval to market products may be for limited applications or may not be received at all.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The products anticipated to be manufactured by us will have to comply with the FDA's cGMP  and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines.  Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production, and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended.  We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to regulation by governments in many jurisdictions and, if we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including requirements regarding occupational health, safety, laboratory practices, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our products may fail or cause harm, subjecting us to product liability claims, which are uninsured.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sale and use of our products entail risk of product liability.  We currently do not have any product liability insurance.  There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products.  An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us.  The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our technologies may become obsolete.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products.  The introduction of new products embodying new technologies, including new manufacturing processes, and the emergence of new industry standards may render our products obsolete, less competitive or less marketable.  The process of developing our products is extremely complex and requires significant continuing development efforts and third party commitments.  Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete.  Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks.  We may not be successful in using our new technologies or exploiting the respective niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have no operating revenues and a history of losses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$278.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;and we incurred net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.  We anticipate that we will continue to incur significant losses during </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and in the foreseeable future.  We do not expect to reach profitability at least until after successful and profitable commercialization of one or more of our products.  Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we may need additional financing in the future to fund research and development and to meet our ongoing capital requirements.  The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.  In order to meet such capital requirements, we will consider contract fees, collaborative research and development </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.  There can be no assurance that additional funding will be available or, if available, that it will be available on acceptable terms.  If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product.  There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The cost of director and officer liability insurance may continue to increase substantially or may not be available to us and may affect our ability to retain quality directors and officers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the US equity markets, director and officer liability insurance had until recently become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage will limit our ability to attract and maintain directors and officers as required to conduct our business. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We incur some of our expenses in foreign currencies and therefore are exposed to foreign currency exchange rate fluctuations.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the US dollar, the Pound Sterling and the Euro.  We are therefore exposed to foreign currency rate fluctuations.  Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We earn interest income on our excess cash reserves and are exposed to changes in interest rates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest our excess cash reserves in investment vehicles that provide a rate of return with little risk to principle.  As interest rates change the amount of interest income we earn will be directly impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s100803D3F60EBB77F807FBCACC966FE2"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other MD&amp;A Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">121,258,222</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2017</font><font style="font-family:inherit;font-size:10pt;">.  If all of our options, restricted share units and performance share units (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">11,004,156</font><font style="font-family:inherit;font-size:10pt;">) were exercised we would have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">132,262,378</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;Annual Information Form on Form 20-F will be available on www.sedar.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4CD17D386E00D3F7F6A4FBCACCC740D5"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures.  Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing them with timely material information relating to the Company.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all error and all fraud.  A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.  These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.  Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.  The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions.  Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management has evaluated the design and operation of our internal control over financial reporting as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and has concluded that such internal control over financial reporting is effective as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. There are no material weaknesses that have been identified by management in this regard.  This assessment was based on criteria for effective internal </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in Internal Controls over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting that occurred during the last fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>12
<FILENAME>ex152eyconsentletter2016.htm
<DESCRIPTION>EXHIBIT 15.2 AUDITOR CONSENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4dcc277baa9c4c03a22c70e3a1d1fc39"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We consent the use of our report dated March 9, 2017 with respect to the consolidated financial statements of Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) as at December 31, 2016 and 2015 and for each of the years in the three year period ended December 31, 2016, included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2016, as filed with the United States Securities Exchange Commission (&#8220;SEC&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We also consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-171625 and 333-205708) of our report dated March 9, 2017 with respect to the consolidated financial statements of Oncolytics as at December 31, 2016 and 2015 and for each of the years in the three year period ended December 31, 2016, included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2016, as filed with the SEC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Calgary, Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:4px;"><img src="eysig1.jpg" alt="eysig1.jpg" style="height:38px;width:208px;"></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 27, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chartered Accountants</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>eysig1.jpg
<TEXT>
begin 644 eysig1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  24DJ  @    $ !H!!0 !
M    /@   !L!!0 !    1@   "@! P !     @   #$! @ 0    3@
M  !@     0   &     !    4&%I;G0N3D54('8U+C P /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( "@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MI4VNMK_Q \=^&[JY\&?#KP?X=A$]SXR\32W,\UK;1B5K5DMIUM/SO_X(>?\
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M^-&OCQ5^T!\0_#FBL1*5\$^'O#C?!_X@NT<*6[)"4D4D"+ _X.>_BIH?@/\
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4+^NE%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>fig2.jpg
<TEXT>
begin 644 fig2.jpg
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M%C8IR8Q<9]=N-Q8IN;BU$@40?_7,D.Y&MD^C(+-S ;D3-J!WEV%79@!_P$1
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M:29WJV)O#S4-!L#G-L0G_\SU8" L*_:"MDH;_.J/:N=8H\1F$DSW80-XF6W
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MKFDDX"WE&<KLF%[%[L=ZA.!?RAK*-6ZO0(%_*/%!HAL?\CQVS69E3V5WMY>
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M##1I!EG;?^(9 W(!MM94!.Q36&@NL2P9R$QP,<"4 F)VHKC@8O:![15<+)3
M %?F/@+QY[00VQ4V&V8^L.81]V*N<J;X-5C\[1%<9'9?</$L:*A^'(2"KW$Q
M4-?L:9D)+K10!+.E$Q=<A#0??;L<"TEP[Q^5""YL6@@'$U"D23/+!!>P_WB#
MDFM,"UL>A>"W*.0Z:^K9<Q@R:RI2Z9V5V$QJU@]$85SCXKW,<WL)< \6Y?C!
M[25@W]J +93FK3TO&J%IXLQ^P=0]Y#D$%]\5+=?,%R NN-!2>7_3.."!9^%[
MQ 47,V70_,94X-ME P(" I*("\SLAI\^%6U 0$# 3F-KO9#9 9KP=&:PLE)
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MJ^'3-84H)#84YHDHC LNG%>!.1,B=+8FN!C"@B8#S!DQ+KA\+<0/+1.G$TH
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M!(Y2OJSDF@5*)J(V[*/DN"T- MHH.7:[V\L(SMERVO64O ?NR7\HK.3Z@("
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M O(!!BA')S93P'Q-NWH2S+.5U1*;60(^$/A%((1P3#TVVLXM.%+YG\1F0$!
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M626.V$P7PC6=E3Z**DF?<P\K*RI]<#^>D_=\M))XZ92N9Y2<,UK^O4KIER>
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M*-,M^X6B3'P:?_'YQLC#N*B,55JC*9W2Q;TIVTP>2UKCE0"9%%]:Z7HE#7S
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MC2VZ%FE$T$6(BPL-(N+LJ-*%)8QG>$Q)8X8&$%W[^,$9B!N4KH" @(" @("
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MBP;)'4\]*UL^^C3M=\V,?._;'W]2RN^_OWUWTJ4,\-US8R,D("!?PV]-T>7
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MK^0CR>I-@R$$*E<:M:Y*-P9AE+C*C%B,L![ACL.B1(ZK0_/FR37Q[/ E+[C
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MJU-7ZO2;+#T6/N7*$AU0&-^VX9!YTG70=3'K'6(^R?6Q;ZY/R8>ON1D-AA\
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MGC]U#[_)2._!=;RE9!M$/<O]\0T&@X(*A$2.9914.KS<# /BD9GH8FRM9,L
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M(P2W'ROHN'%U;/('8;,RW#G@>(%@_LFQR03(GT7GB#,9F058_U 0_#\H-ID
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M5"+TPF-*L=P/"P%(Z>"%(T(+\V@0",;ML<D$L"3Z<S 8# :#X:= .*;+<)*
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MQN?Z)#9I,!@,!H/A; -6'X:;,9Q8X)_'<AB,'3,8# :#P6 P& P&@\%@2(#
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M!(;=.1U14TF/1B^ YRF# W ;# :#P6 X#;!3Z=V&L)+R3 37=CH#D?6IDNM
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ML4$>WD69F> *-V)W*(/Q5;ZB^*&""[ <M[ '[C;F^0X13)]J@BL9J-RY-LH
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M)WJ/?WS19>X8Q&=Y"],KEUTA;<8OD'83I\C>&LW=O#\K/U(64U*/.5&H==J
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M)G:NO\?B9_0+\%47[.K$5MQ25[W3<"=0@V,JALG W7I__ZCT[IR?VKI I39
MB; ^5>'+(Y4P\6[T[*0SQ^-**5NDB$M2RK0GHH/\5TSWK%0I(2Q>3YWH\L11
M_GJH(&H[9J/\>G2J$S%O#1DB[<N5DW:3LS?Z &."7I@_OQ-#N/=&IRZ33E-C
M;B0L7@/2UKACOJK+.8_YPZ=+2CQ)+^PVLX-<D[8Z<6Z()X078NK7M][JXLZ(
ML8((0L08/1(19D%+%9:KW=V[.W=I[/K/D8HMK]'KN%^ZZ(= J[%WNSBN7^KV
M;!ME$4.0QN]=9L'S)P*XTSDNR51Q'9]H4-ZQ)I-_3+8^_U*DP H3P47<%@,R
ME]<ZBFT1)CJ1@=.ZW.KR_?GG'"3EHI?6:[_29_2.KGN/4F^T&Z8'0<+VB!#$
M"**EO#*J["4CL5-L]XY^"/@P#D]^]R\>ZZ&+%>N%,M6DS;@%B>7M)LR0[5>E
MN.U)D/J@LLBE%;4^BPU^[>F"^P.\[.J.LD37)?@>L87@PUJ&Z//DFK"^<>Q%
M2M)3!%V*GLV4N@Z>E)-5'QH,/RDHX+@1J93TW<LAD_KW=R(&B](?'W[86;)Z
M+'[:67.ZJ>!@G3?6I[<>(81N7Q!SY05?>D^&!6H_]BX7(T70_9?;M\O;&S>Z
MV*_#\^?+OMMOEWVWW2;[]?\C"Q:X7H/T_/N%BC-BK)*YZ>#T:Z]UYU2V01<I
M6JB0/*S[@;MFS9*9@P=+VT:-,@BLRRZ[3'JW;BV+M)&[<^I\%P/$EV';\3-E
MR:S%SG5*Y=-ISGX568]*CX5/2:^E+[@8BH30XFLP+K9@K>ZC7>XN[U:,.E?N
MK9ZKUCLNT>3)B.,B/L^?PZW,.$7!??$? 5@G$*G.@D6Z"-QN.[IVE=N:-I5B
M^6)C=<(15UZ9$!7/ID[)X-YFFKQ<"!S<><1'L5VP$4O&<\XYU[GZ2#Z*8",V
M;&[:0FVX9DNWM'4)8>,%%W%D^V^=I,OG2-<9/:1/VMH,XH??B"EO\0HR.)P0
M_[E650^):X55VERG@G*SI$Q[2,76(\X-1(J!"RZK[CH*)(OCPM4:WT=OY4]M
M72 !)L>F#+[,C!,(K'?D%GM/&2FNHN@#Y4EZNOYPK,Z#Q$7I1 8N4\';*13;
MA\#N/V2>$R0(#@0-^T!P!84' H5U"&0_OW25R+*7C(4N+B^/J9!J.69-NG(.
M8V5]E12\L+1LO+RVEI-%&=:AH\EB/???Z[&)N]JDI)Q'C8* $"M4O+2DZCKT
M<B2_EX\-"PLIB&N1ZV6?R0070B]^;X<ISP;WMN$L!I4L7Q4D-G1)3Q$["!LL
M-%AJKFW31KK>?MB)BWZK7I?N\QYW&;Q9MW.#!AF$Q;J5#TC[B1/3O=2X47I,
MNDN^B5NH"%AGW\Y5>>^]3GB]NF:-(_%:""U<F/08))@],['5.QZO<VFM%M)^
MV@YI..1.J:E?[\2)D2D>X?;DXL5.U"' "/)G_;LG3'"YN&;,6J,B\6C7?<BP
M0--FK);\14M(G^4ON9@&AHFA$HH)+159?/V%*J32==LY=RF],9,)KB-Z'AQ?
M239NQ,1/V=!Y<-R7E)P'@QO3*_!4 Q4OKJ#*2JVK<\@#W;JY5 X(GL-]^TKC
M2R]UP>4T8"R_LWGSA*#8D3I'A<ZT=,_5D^2H*6EKY-,1-SMKU0.,C*"-#*(E
M_$RA&TB]4#$WMN(K#$X=BH_:GS8SG9!"#'(^GF4KU))^UT]/+$]&]O$[W2\#
M:8^]NKXT+E4J8,6*,5>>?')YDU[2\(8[I<WX>V*])F\[X#X(7"SAVK?=NTIG
M@%F-&SLK&6(NZGCQ?3*D%^[;'^-6G*JD-_.Q<+<2RP;GH)HCQWCEB0#U&]:3
MOY72>B%*7$613.J'/_]"=K_]GJP]>%AJZ//0?3CJ#F6%4G^DXXXZ[25E8LRB
M21J:B=U&.\O/-\J%2K;%;8?P"&Z'X$*XT&NP0K,^D64P&6OWG:0?B7,RE'%/
M!%:;<7=(6Q7]4<LAKN_;VUSO>D5BA3NDO$I9\()+I.05C>62&DU=\FD"W1]0
M$A3/N6J#D<%-&.0<)=?,^N$8KB +*W4]O57N8Y"/?Q-=AC,.-/0T:(RC]E\&
MB2;1)Z( UYT?AJ=0B7+NQ7:":_4;6K$_+2DS=DFIVFUX21Q)%>&'\($;5R&Z
M)KB7F:^\WI/O3A?3A'A"D)"='FL0.:\8T)K >-R'Q'EA!6,YPB\LMCC6W>/'
MN^[^')\1\MM/?= %<_9>_J(4+EE>GEZR1#[?MLT)M_<W;Y9'%RY,G"^BA]Z2
M4^?>+1VFW)2A H+T1*O>8:B*K=<3EBQGS8H06IX$^)/V(C/!1:;]^'D0$$[G
MA.,1/T,L3N+Z?B!?5Q*L?BJ LHGUS[F!<I][KDN)\-M1L70/0VK4D&+E:TJG
M.?L2>8-F-6F2$!+/I4V55F.2]Q*$/><T<,'%[P^[25[2\LOP/FW*EI4\^0I*
M-7WN#0;?(=4[W^RRT-.K#Q<>/0JQBGD1$[96>5X1[\T[1\^IWL47N^SS_/;D
M-U8Y2*_$X#*8,W=>:3YRN=3N,]&Y3]OI>174]Y.Q(NFRWW[*#NDT:X^+?T1H
MX>HDV)DT [Z,(A*;E2[M@NU)DQ%UKI5B'5^^4/J&[H?BU\H,UW&,_%K)<$+'
M$S3<N,[)A"^#4M,BQ568/EC^X$>?2ON^_9P5L<MM!UTOO2;#ETC!"R]UYZPO
MKA->Q"SI#,?]-9JIP%DHLSL,<P(#L35;R?K!WHV(+#^-A0BW'CFR*C3O&UFW
M)"/U<(=;EF<8YLJ3H/T6J>NEZXQND<MACUDMI.,M*^5/Y^9THNM#)4'T]#(D
M[@R2KXOT$62L)VZ+S/I8Y8+7$22BC6O6"L[%A^&.32:X<'>RKM)WXC@9'Z$&
MPPD!E1 %FHJ(D?"=4 B* F_=6J.-2KV!,]R+345.$&7OY2^KL'G4?5FW&K-)
M"EQ0TK\L,E(;)2\TMJY]4"N>>2JV-J?;MR<B"G(L+%ZX&HD7XS^_PT(+D84
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M;!D+9O:\I'I3_4J;ZWI@T9CPI4F/P9Y+GHO'6,7%EIXGE20BZZ&9,]VVI(S
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MN3'C^HCAPNK\.^JW57OWIQ,W0;&UZ^WW)'>\(\'/E#H12007HH%<4H\I6;^
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MX8R";P3Y$O3B"\L77Q@()UR/""E/?C,?*P4]@&@X$1A4[-"+MW>4,O.ZZYS
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M/"DA,+;H74AP^Y:;;IJY9[+&/H87(FX*KR>Q57VO?5+Z7/&(;%JW?D@N2J]
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M\WL,UT-3)4,%8=BQOL6 L8V)P'RU2L,VB..]<?X"N>U7OY:'WLHV)R927C
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MPZ;^E&9LM1MZTT]UMFM!94O%RS94PG34P,#"D,-CBY%%?!DO"_P>][7=OX7
MNGCG,-YD^M(5JU1@25')46%2<>Z\3V$&%_$Y%]T\HU"#:WT9%HOSH\Q):ZXV
MCWR<BY#\<,0*,A+'B2H\8>1-FZ9Z5$7O;+5Q5C:Z=,=R@XH@><8NS&5LF3"2
M_ERKKG09?KWT&'NJ3.AR8HCWHMD0;Q;-C7S':T5F>9HEV5?2V$*#51P#X]%>
M,OL6N?WI9V3!V[_)]*C,&NYDCQ\\^CP9<$/^4180J4;(848:C%P&U^$G#@Z_
MJ>*96Q=3C#B.XS@)J% Q@/ @69,C!A)-'33]T92T3[V=]N[2=L34'_M-^&5\
MQ?9#9_U0NU$+@MC)F$TSN,408KQA8.$9,4]L28TLPXX/K]@[JE4JKS3%'JYA
MEUTA/2Y^*+5RC+5EHZ8RY[$G0J\TMDTSN!KOLBN5)$F,U\=Q2#E7_L/P(JCB
M?^4:8(1QWY@1AA<,PYWF8XQPFB QPOJICE21D_ 4U5#56-5D54@,75.U6&5Q
M5AA$:7JM88N5DI?VO. XN:C'$/E&EV%@\8E'"T,KS:OUBJJGBM]$N^R[KUQW
M[P,RY_$G5QZ:1^\C#*_Y>D^0(J)9VX&I]XZ)^+%JM38+J23FO_YFYCY*,;CV
M.C@SO);*/5R.XSCK&7%EBO%%18KGRRK2^M6V:;13F^$S?NP[H8VT.V>6UFEA
MOL4/8JR9<65-W&9@K8Y1PK8<#T:<U*FWQ2J55YHLALL&5*ZU>;U0&:95DJ2+
M:+AWQY!!_*YG7PC9PHOII8B79EV.X2H4^V_YG\TK3W,UUX7[P3QA7"N,<3QA
M&&)XP_"BXK'$&*.'-H88S9%%S9#GJS"\],M*>J)Y)E>6&5NF/A?UEI./N7BE
M\0]-&%XT6>H;0-AWT(8;JJ&UGUQUU]TR9>'BD&L+ ST>F@>%SA=OOQL"Z?%,
M=3KWUISW$6-%WG#_?+GSF>>*[J,TP[W:+TFI\1#RW+C!Y3B.LYZ1K$0QGJA$
M,7JJ[[#789NW.WO6GYL>V!WO%?.I9-.:N5%9P#XQXJBT9?"8\U:IO-)D%265
M'D84>95JUMU">DY8M%(EV?_Z9Z3.MHWE_$E30BH O!L6NY.V7XY!];8*3P['
M55;GN:X0__]V_W#O8(3AR2F*3U7%'C$;FY:X/X9$^T05KG=3U4@5*1UN/["G
M=!\S<A5CRW38Q8?*D2==(=?JNFK)A?@P/1#[WXI4OU$CN7K>/3+YH44RZY''
MPSWRX)MOR](/LL96UBO%?<2]@!%&\_3,%8_*D6>>)=ONUEH&9+/<DR;BP&,G
MR%;;[RA7W';G*EZRY#V$LL=AGE*NC1M<CN,XSDJ5:*PU 141%?5N*KED[JVI
M%5B:+/Z&BO36IWXM4Q8LDN-'G!N:!;?89IN0"ZG_R:?*C0\\&"I=8FX6O_=!
M3J\$XAA4="K XX8AL::NP[H U\H,<_.(89#AX<$;1E,V3=.DHJ"I&N_77-6?
M5;+!AAM)RU.OE<,O[I9J;*'^$P^2#L,GRZ9U@R>27K+D3&-8,YHN>ZN(+9/=
M#CA &-=QWO,OR@.OOR6+WGT_W"NA&3'QW_.=9D52C,Q[[D6Y>?G#<MU]#\C1
M9P^5]KW[2(^CCI8),V>'87_F//9D,,PLEULQ]]$BE1ONCN,X3H6 BIGF*9JB
MY/P;IZ168&DJ\DY\D!E0F28A!E3&\)HT/S,NWLU+5X0<4/=J)4E&^GS#L3#H
M,L>@(L6%#<GBK#X8&_S/&+#$@^'YHJDMV8%CD.JV T^XXK^'7=0CQ=@Z4-H.
MGT[O6N+%Z&V+MXQM">8GG@PQ"L//&-T/O?6;8!AA3,5>K32Q#(,,H^N>EUZ1
M6Y[\5>C->-/B93)]R7*9]?!C8<!NFB2+,[9NU_7T&-!@%88[GF(WN!S'<9RU
MBAE<-#O)#LV;IU9BN42E1^5',^&"M]^5^UYY+0RH?->SS^OG"\'0"A7O^YEQ
M_JA8<U64Y(_B&%08 C2)X:%QR@XSO.*T)=:!@XX9>+XPP X^Y-3KGNU]X1&1
ML760=!AQL]3982]Z2=(\2>H*$DICN-$<S7[P)C'_G8TWKOJ+1RO/?VXRXYVX
M0 PJ\G+1FY7[!]&$2)P7]YG=1VG[0?1@U&- -*'2N83[R TNQW$<9ZU"\Q--
M3L2Z,#"W#+WL\M2*+)>LLJ0B7&E 9?WD>Y&'(T^ER[)-JE6CDOQ(12)0/#$>
M=U,^8'QP;3%$:&[#^*+)$:\BAA,YT!JU/F/:0STO&"Q]Q[>7UF?/^&JS)KO2
M'$DB:(P8UH][R=I^,+Y"LR+-RAA-:?]WFK@'$/<*QAK&%?=/D'XW[VB^^PAE
M ^891Q2#D'@VOX\<QW&<M0Z5+QX/*E)ZM]%#4#;<:".Y\LYY(9@YK5)+4Z@P
MJ1!519Z- BI(1- ]OZLZ2^4]%-<<9GSA^8H#\#&D-FU]YK1I;8?.^IM.8U"Q
MS#IR(+9C>Q/;XS4CW<DYJI]5LFGMVB&.#\]5VG^?)C.^XGNHD/MHW$W3[3XB
M2:P%S/M]Y#B.XU0(J&SQ*-$\1)/2)2JKN&3S+;>4EEV[RK1%2U(KN3056D&B
MNU]XV7Z+<00)WL>#XG$W:QXSG#"D?M%^^V%()8VK-%@' Z>^BL2\!.634+KH
M7JI5IXXTWW,O&3=M>NJ]L#J:JO<G+PKZ.Y^K:/8D5HW[R'$<QW$J!%2@5$PT
M$Q'/PP#<C.EWM.H^%8-)%U6:J-GN>X2<2>?=.%D-L:6A"3&M$LPG@NI;=^MN
M^\38(IL^1A\Q91B!3N6"^XC_C:9%C"X\70>HVJF.5]VIHE?C2O<28W?N?4@K
MZ7O28!EV^95R_7T/R/VO%-\425,U1M9Q0X=+77TIR.Z/>]7O(V?]HGGSYE_O
MO//.KV:_.HY3L3&CB[@<>G;% RK3\XQ>;/U5=ZC^J&+XG=!DE$L;;KBAU-^^
MD;38:Z^@.O7JI:W'/A@7D#0%).YT[U;E!R,'3Q?-BP32$_O%O83QA2'?245/
MU/&J%U08223Z3;L_"M5_5->I6JKX/1(&%WL?:1TEC1LW)B._XU1>U.#ZHFG3
MIB0P=!RG<D"3$)6EI0\@B)H*D^%1K!<;E2;&$5X$4@,PSB-C^HU1W:UZ5_5/
M55JE:").#,.-[6AVHAF32A)CBU@ACL.IO&#D\!\2YX7AA1'/?\N]% ]IQ9B@
M]"0DM03W$_="7Q5#$YVAND(U1[5,A6%&AXJ75,^IN-<FJDY0]52Q#SRSW*L8
M6]S#Q=U'FV!P:5W%,$B.4WEIT:+%IVIP?9#]ZCA.Y<&:AHC=P0"*AY&ATFRD
MP@.&$4:L#A4=1A/>,(PQ*C^\8C0E49&:^(Z'@W58%P,.KQ9!\GA#"JDDG<I%
M\EZBN9&>@QA@>%+I$4GSG]U/Q/!Q7V",V3V%48;GBOL&,6VYOUB75!086NS/
M1F@HUD.ZU59;U<+@TKJ*7I6.4WG1F_C7*IH>',>IO,3>"JLT\5I@A*TT%J0*
M8XR>852@5(#D]J(B-?$=#P<&&^NR'?M@?];KS5EW2=Y+<8](NY\PO/&L8CS9
M/851AKBW$-,8Z2SG'N)E $.._6'<%6ML@1I;6V!P-6G2A)<!QZF\-&_>_+:F
M39L2Y^$XSKJ!59B(B@W%E:<98U2@5(!4HC1-FOC.?,O=Q'9F:!5423KK#/S?
M^>XGO%1V3]E]%8MYK(/B>ZC@^ZA1HT:-,;AVW'%'7A <I_+2K%FSH=S,.LE#
MXSC.NHM5=":K1//)UG6<-.+[J3B5BJ9-FYZ4K:,<IW*STTX[;</-W+QY\WOT
M\U:7RU5ZZ7-T2^/&C>NT:-&B0]IRE\M5,NDS]6\UNOZ7K;(<IW*C-_1\O;'%
MY7*MOIHU:_;7M/DNEZMTTI<8AO]Q',=QG QJ;(VR2B([RW$<QW$<QRECJF!L
M-6W:]*OL=\=Q',=Q'*>,V0B#JT6+%F]EOSN.XSB.XSAES(887,V:-7LR^]UQ
M',=Q',<I:S"XFC=OOCC[U7$<QW$<QREKLC%<]V:_.H[C.([C.&4-(S<T;]Z<
M 7T=QW$<QW$<QW$<QW$<QW$<QW$<QW$<QW$<QW$<QW$<QW'6.*>I.JCZJ(YD
MAN,XCN,XCE.V7*SZD^H]U;7,2.$6U6&9R5*QM^KQS&2%8+[J\,QDP9RG>DG5
M3;63ZF&5<:.*Y>5-+=4+JDW#MXH/USB^3N5%%=5SJFKAV_H-]\8SF<G ]2I>
MJDI")]5CF<E*Q]6J4S.3:X2G590'CN.4@AU4#+0;Z_]4=53&FZKD.G]5&?54
M?(^7?Z_JJC+8'_.W"=\R,/P)%4?,R2K6@\:J_ZGB_6ZG,FP]P#"P=9+$\RB@
M,+B>5UW#C!0^5TW/3):* :J*-)8>_^?EF<F"F*#BFI':8(ZJI^IKE?&J:F%F
M,H"GL$5F<K4X/_MI;*_Z654_?*OX7*3Z(3-9IB2O"X;6CZJMP[?2PWZ2^RX+
M[#E,TZZJLF0W%?LUWE?=EIDL&*Y!O(_*Q >J7V4FRYSA*NJ'&*[3 9E)QW%*
MBAE<FX1O&;Y1+<A,!C"X[LE,KD)5%=L_&+[] A4\\^N&;^D&%V]*S&,?L*&*
M[QA=P/1]F<D A763S&2 Y08&UQ>JGU2VO1&OUT_5176TJA4SRH&*9G"5%*X7
MAFDND@87AO.(S.1J$?]/E9'R,KC*Z[ILH2KO:U[>^U_?#:[RA&O2*S-9!//<
MX'*<4I)F<-$$%1= ^0RN&U3_SDRNPI<J<_>G&5Q  ?EN9G*#8U5XQC8*WS+K
M]\A,IA(?HWFXSE1A=,7$ZQ7"':H3,I,!SA]&J3C6[N';RN#69]DQJJ3!1=-<
MTKBS<S:X+GC=<-GOQXP(FC=?5Z4-%]-6Q3*:,+=B1@KL%P,3,&KMM^U\^H9O
M&?C.]?I[=KJF:C,51I81&UQ<FV]5?U&Q_E 5/*+"0SE,Q?E;\Q<%N!VO>6@P
MHNUW^40U5!CBOU$EFQ0GJ5CGJO#M%[AN2S.3&\Q5\;M;AF^Y.4+%OM@N]I[R
M?SR;F0S-5!QSFA=OO(KMVZB*,[AH:GY"Q;Y8/PE-6V^K'E#9<;/O^+H SX=-
M'ZSB/&/XOUAN+S)X(-GO(I7M]R 5WI'DOHV)*N9Q?DGLG&E:MF<U%R5Y]FJK
MN&]>47$M8FBNY3=Y >/>,(HSN&B6Q@/$/1M[W&-B@XL71ZZ572?NO>2U >;A
MV4^CL^H-U?VJS9F1!8\MY\>R9!,_]T2SS&2 <IEY!LW(-ZGXW=@KR8O1!9G)
MP#LJRG(KCXY2)>&Y85FL),SCFOP^.\TY ?,PN%JJF$^(1A*>HR4JEG//.XZ3
M)6EP48#BX;HY?,N0S^"B8KXS,[D*5.A6D.4RN'96T6S$<HP4*F@#0X%MVH=O
MJV+[!C.XX+^J*9G)0+Q>(7RFNBXS&6![CHW"GLJ>[\>IC-=4&)<79J?Y_=C@
M8OV!F<DBXF,Z4<7WJ2I^EV94XU$5!BV5W%TJC$F[AL2JL-VEJADJ"KDTN+Y6
M*)M'\G>J>2H,9KZ?JP+.@>^_SDY381V8G6?$!A>%/\;6,A7KMU/!/U547!@#
M5,P8 7]3$9/%>E1L[)-*B,K-?I=/Q'$RGWGF)<4C0U,:E=8X%7%X&.AFS)VD
MXMJS#O%Y&*CV&VE\I.(>BX^GN@HP9/@?>!:HZ*C$64Y%8] TS3FQ/=>3<\YE
M<'$-J+PN4_$_\S_R@F'P^S3;4H%A+/);D+PNP+-JR_E_F#8# 3#\^$^ 8WQ*
MQ?7B_F#=C54\]^:%CO<-_U+QHL0\_FON;2I\^(,*HX9E&!2YC'S#CK,XN-ZL
MRW6^1,6UM\H:PY?SX3=O5[%>0Q7D,[@P^%G&]<;(L!>G)&9P<=_0C([!R_==
M5+R@<(_%SR_/ _^S79,8VY;_F5A0GCW ZTZ9P'R,)-:AR<[@>VR$,\T\@VGN
M$:X!SZ89NIQ3_-RS'B$1*U2<LYV3\6<5SPW[X9ZE_&8Z"?/8%R^?3-O+!O-X
M6>(YIMSA.].&A83PDL(SR'6:H'(<1S&#*Q9>A1@>ZN0Z!M.G9R9787^5K9O+
MX(+_J#!F8D,#*.S,Z*(RVE,5$Q]';'#1;!@OBZ<+(<W@(H[)P BB^1*HH%G.
M^1G35"4QN#COV- TN%;)8R>VC#=D(/Z-RJ0XT@PN/($&QFD<D\?RN$DQG\$%
M:4V*&!\4[/D@MNRLS&0@>:Y)@XMI*OF8/ZI>SDP&@PM#!B/$X+X9FYDL%H[9
M[F4S &*O%I6^O5SPHI \7HS+0IL4\73% ?;L"V]B&LG?B0TNX+^[,C,9X-[,
MU:F![<Q[E-:DB)& H1S#.MP#P+09.X60W'\N6"_VU!A<?Y9A)!H8'M8I)9_!
MA5<7@[@XS."*[QNN <\Y\%_%QAKC9'+/)['_)?; Y8+G+SYNIHLSN-(,O#2#
M*RY+>+8I7XUXGU9VQ=<VAF5I38I<#P.CV/9)>4U91B]P(_G_.,YZC1E<3544
MQ$PG>UKQ4.?R<+%^+H,+(\,>MGP&%VY[EN6J&/&.4*FRSB!F9+%]0VQP 0;/
MBYG)E>870IK!%1=*-./9/O'H)/>?;%)D>3Z#B^FTIAF:=:C >1,U49G:ME8H
MX\'(1YK!%=-?]8_,9(#E96%PI?46XQ[CO^1<>/LNJ<&U1V:R" P-\^9@<"6;
MMSF.?.,:TLQ$Y<KQX,E(&EPQ>!AIE@,,+YKD8HIK4MQ1A>>!W\(39\_9OJKD
M;\4DER4-+GZ7_1G)]6F2QIO'[[(LG\'%.;$OUC6QCO7HI7+G'//%^,4D]P^_
M5=F^>:$"UMLV,[D29ZM8%A\/'C@,;<AG<-%$R3*\.G'L9Y*X2='@OL*;!W8?
M&ACU>,^2=%0E]Q/#?8RQQCE@",;K,IW/X,++B.'$RV1,FL$5>W1C@PCB:<(<
M^(ZAE ;+BHOAXIQLGW@[F8[_*\2\-&/1<=8[DDV*&%Y\C^-9\AE<GZJLT$Q"
MX4*3#.0SN'C@61;',*1!?%.NBB5I<%'08&A8(5 2BC.XXL*0"CNY_](87&E@
M*& P\,8:*VZ*(@Z*GH3L@^:6-(HSN"C$UX3!1?,%\VFBX#RH1$IJ<.V>F2R"
MY@KSSI74X**Y#6,-0Y_C83J?P47SBAE<-!U]F)DL(I_!12<4]D?/6'X+[Z09
M7+$G.(WDLJ3!!?:=9I[80XVQP7GQ__"[K)?/X,(PHSF1=6,U4AF'J/#F87@D
MO<Y)DON'<U2VW\',4%@OS>"BV8UE\;$@,SR*B^'BN>7>QYC&T$LCS>#B.IK!
M!7ANN)^MHT\:]L*:!O<\SR$>:8Y_IBI>E^E\!A=0AO!?XK7-UZ08&UQ[J>+]
M$&_)=U.^E!(L+XG!91[YY'_%_^TXCI(TN !C@:8%(Y_!1>P/E0P5>0S-(^R7
MMSXH"X,+#P/-4 ;;&$F#"ZAL*8R2\XNC) :7Q=#$RPD<3QI<<7-)LJ)C.JUS
MP*&J>+U\$&^2:]TU87 1(Q239G"Q#[P.!MZZDAI<%FMF$#-GGLR2&%Q46,G?
M^UA5J,&5;+:&6:I<!A?KQ@'$&,=F<-D]E,L+D/R=-(.+%Y_)*HS/N,-'<CV^
M)PVN^'<QMI[,3!8+L6W)_2<I;KG!>DGO#9@W.9<7ICB#*X;UT@+=S>"*?P,O
M+"]X!K%UO#!@*.>*6;68L;@L-9@?ORCA58Z/&R,J?BFC(TN\/(:76&L-*(G!
M1>]L>U8*@>TXSACFY3*X:**DK.$_<1PGA32#BV8[>X@@G\%EQA*%@/4"PGC@
MC9!*P"BIP47N);Q95@@3C,D;=1RL'A]CFL&%$<2\Y/SB*(G!!126%M/!&RQO
MD;'!A?'"^G@/Z<7(><3;T\Q$14W:"SQR5/P&Z^&EL/B24U1G9";#-G9]B&F)
M]QE3W@87\7??J;A&&"J0R^#"* $"W_F>-+@(ML6;PG$F#2X,*K[S5LX]8\:T
M&0PE,;CLGJ/R9)I 9+X7:G !RY=G)L-_R#V?S^ BF!FHO/E/XJ9[CAN/&]>0
M'H3F&0:VY?^PBC3-X.+<\>(PG_,Q^&[7W.(AS>"R:T"S'3%I@$'"/(P6KBM&
M&=?/<J%QG_"<\ASSGR=[BB9A7X6 YX]U>4$C!HKX/\H1CI%KBG?* O0Q*&EN
MAWP&%UXD.I.P#^Y_UDLSALS@PECEGL,;R'>:>@TS+'AV[5JEP3H\^Y1W/#=6
M#F# 44Y@E'#/LQXRZ-''_<,+B7G#;#G7A.6\)-A]:7%T)3&XK#SDI97_D7C(
M.#8U">MB9'+-[)R9E\O@ KRKG ?W,!#/Q;/N.(Y"P4DL36Q0 (6W]<BB8N"A
MBA57;!1HHU7$5;",0B\Y; X5*+^3W(]!H4J,2PQ&%@'BK(<GP[HF&_'V/.!Q
M<Z-![ GG4A+XK=ACP^_$7@ *'.)(#"H"*C,*8P+F:8Z-KP_;6A,"@;@66Q)#
M[R7F$=M!<X:!IQ!O(^> R(B--POHO6G7AQYY<=!O#$UWUN3'L21_N[<J#BZF
M0(Z;"#'*J5P-WOSCYDLJ:2H$]FMOQ!@/EHK"H/ G1HA]\;_0&R\VRE@?8Q6#
ME_N%<Z?B(8;/H)L[O?WX+:Y%W-1%Y4$%$<-QT-27!O\C36C<E\3L<$ST& 6"
MM9/&$__AW9G) )4]A@''POU"!9LT^ S.@?0$K$MS)"DLXHJ2.$9>:KB'V&?L
M#3%O&O$P8!5GC!G2R<H-#]$G*I;1TQ6O5)RBA.!M_@^N@\%YF0'*]:0WJ_7>
MQ,/(O<^SAK$5&W=I)(\S'Y0A7#\,$UYXK/<IG]8[$5$>65,F]V;\?/,<8K0#
M391FV/-,QX9"#"\P#ZEXT21.BF:[9%,:<%S%G0_7B?^1]7@FCE<!]S(]>9F/
MD8Y1Q+UN\/_Q$L-R#'OV8^?%,TMG&>Y3[F=KA@7V>6MF,L#V<:)@#"4S^FB.
M9SE-?+RXT4N58X@-_QCN60Q=C'_SSG*OQ,W(]B(=0^]T7A*9SW7/%>/K.([C
M.(ZS"A@0<2J'R@8&8&R< 2DX2OI"ZCB.XSB.4RY89Z+8VUK9P&O'.>"EPK-%
MTQ_?\_7@=!S'<1S'66/0-$?3>V6'YG]BXVB:)S;,FHH=QW$<QW$<QW$<QW$<
MQW$<QW$<QW$<QW$<QW$<QW$<QW$<QW$<I_)"M^3*!L-[D(0P3G[J;+!!<Q6)
M.TM*6E;WDD!B3!*D-@C?RI]DYOUU$1*;6@+1\N1P57GE@2+!)ZD/*CN4-8Q"
MD08I'BQ9K^,X3EXJ6\5%/AXJ=\9-0VFLZY5Q+I+#K!0*P\<P)%)I82@8?M>&
M.REKDN=$U_K5.=[* .?,J EE"2,DQ$,6 :,TQ,-(E1;NH>2^&8*($00J$F2*
M;YV9+!C^BSTRDZM MO@U]:+A.$XEIS05]-J$PA*#*Q^5[9S*BM(:7*O+FC:X
MU@<XY[(VN!@>!H],>8#A5AG^)P9L9]S7DL!YY3*X',=93Z%@H%F)+,:,WV<P
MOID-[/LD,R*2A>0P%0.K,I_!?FW 6F L/L:38QGCFMVLBF$D?(PAFBCF,R,+
M8ZHQ/A_-7325,)Q%/ACKC+=E?H??8WM@6 SFF9(C[S,N9;P< 6-$VK3!>'K/
M9B8#+">+-6_ 3#.>'F.HW:7BNC'&7#M5#&^W#,[,^HR%>)C*8*PT!LQE[#RN
MR615$L;D8ZPS*D&N#>,<QK!?!O/]0W::,0SC,27!QNEC_#D&JF4Z#>;'_R7P
M/S$>9-)08_R^\U2OJSAV]LNU>4?%M4 ,%LY@OE"<P<5XC0Q,S#HT S-&IS%!
MQ?DQKB/_.?>I#<C,>(IL$POPU-BT8=<AN2XPGA[C4S*/>SH>_Y'[D82:C+-(
MTQ'_<UPA,_Z=C4O'L<<#*L<<H;+U& ^0ZV<PL#7CZ>%)XKGD^B6?'>X7?IMC
M>%#%?G(97(Q?R!A[K,.]P_HQW.]V'_-?\DSSS/$]%I!0U)JAEZJXCC&,*6GK
M,G!]VO_(_Q7OU\8.9%S/>&Q+SIMGE &?68]RAGO/X#YBX/AX7XBQ3Y,P]B'W
M(\=.6<3XHL#ZC)L8P^\R+FURO^;I8G!HCHGG@?TQ%JV-(PFL:P87]Q[_D0U0
MS;0-%,VUY/[MHN*Z\^PPF'0,WME/5?P.UXE!PPW&\_Q0Q3+*<,H7QW$J*!0,
M/*A4?%04P(#63ZDHM"CL*- 6J0RV,?JJ*)R(D<$8L%'\#0H#JXRL -LI?,L,
M^,QO46A@),1Q#:PW5A6/ML]OI(&!14'* + 4P Q$2Z%F@_26QL-%TV-R'@/5
MQ@8;R]GO_BH*4[Y3F3%P,#!X;QSK@J% 06^#RIZM8AN,4F#,-[XS"#%8 1V#
M <D@U9PGYXM1$!MF;$\!3H&.P4.%3D5J4#!CU%'!8!1QO&R3!L9<;&Q3.=BZ
M''.\'?< WS$0N.[<.S-4G!,5'4TH++=!J8LSN%Y1V8"[0U3Q;]'DQ'<J>^X=
MC!^^Q]<K7A^H_.)Y5.H, $S%R?_!,JND,2BMPH6A*KZS+K N8F!I[L\IV>\&
MQM.%F<EPG7(U8V.@FS'&(.#LPRI^!F?F.T8! YRWR7[GY0C,L,1HX[CLQ2*7
MP87A;8.4F['<*7S[91#MBU48YSPOW%>0YN&RZP5I R%S_CR[@)%M]S<&(L^+
MG6.:AXOK$ ]HSW*$ 4[YLB+[W6#_SV0FP[5,[B\&XYQU^7T,3%X.@/*# >J-
MY'&E>;A8OD#%?[.U"H.+]0R6<\_1;,KT0)7!]T,RDT7W)88D1C''Q?6>J#(H
M0R@K>:YX)EC?##8&P']!Q7_(MD>J',>IH/#P8E095D!8Y0));T8\34&! 1##
M&SF55AIXK:Q0(*:&M^ZD!X; 60R%F!M55,))K'"L&[[] O/:9B;+U>"*>4Q%
MQ183K\-T<J@1*K;[,Y-%!E=)P!O&[QIL3P5@\#_8/C%NF-X\?,N0KTGQ&!7&
MN($7T8S!-(,+HS<?5ZCPG$)Q!E>2^+<PN.)*&? :)@WVF*3!A>&)Y\' V]@]
M,QD&#,:(BF%;\U@PC7<M)MXW%>3@S&2)8!_V+)K!%8-7;UQF,A@(26\MZQ?:
MI$@E;=Z0"U2Y.I,49W !!KZ5 1A%+,, 2(-E& 90J,&%H183;\,T+P(&W\T8
MB<&885G2DP5XE^)]XK'#2VTD#:Z>*N[W).S#SIMI#';6Z\.,")8E#:ZXO,4H
MM!<=MN7ZQHQ2V?&R+K*72\=Q*C#VX!J\03,O3?90,VTDUS'1) (4KE04>)QL
MF1E<%,X49LRCT##PIMFZ225A$->T^<RC(H$U:7 EC<)XG>3Z<)^*"AX*,;@P
M3M]06?,I2AI<,7'EF-:S,)_!A?>&9=N%;RM/IQE<=V8FBZ#RP<.)T<:ZJ%"#
M"V,/(XC_S;8U,+CPHL3@*2V)P84109,0QS%(Q3)K$K+F\:0X)F :XS&&>8;U
MB&0_9S(C!QAXO%A@_-EOY#.X\,B8P46STVV9R2)8/Y?!A?>.EQV,0?LM,[CN
M4.4RE@LQN/!DLF^@631^Z<!@X'^,S[&D!E?<[ [Q-C2OOYV9#-X^EEFS=8QY
MU]/@F:)\VB]\RQPKYV@D#2X\GACX2=B_>?.8YKE,^TWF)0VN&#S69G#-5+$\
M3<#+$\=+>9!\_AS'J6#8@VOD,F!BXN5,FR<I"148A0&&CU5FL8?+H."E(K88
M,CP^%*2%D,_@LC?CBF1PX4&,H=)_+C-9D,&%\8)Q:A5SFH<K)JX<DQ4EY#.X
M (/I7E4K%<VA1B$&%Q45U\L\;H5ZN*R9"D^"$?]661A<5.H8N\SC'*UY#3 0
MJ%1SP3;Y#"[C4!458=);!AA ;--/908"WPLUN%Y5/929+(+UTPPN# H,K4DJ
MFL @]G!A<"5C 8U"#"[SBC.H,K%&=NWL&>(ZQ.=8E@87QITUI^(MY[?2,(,K
MS1@#F@1YO@]0)8\IS>!*WG_ =A;KQS3-?WBPS2MLL*Q0@XM[AVM:'*2@(/0C
MCL-U'*>"D7S8S4B**Z D\3:/JZCLTB#8DW7Q9 $>#PI3,[AP\QO6% %4[DS'
M;O9<4,AC3 T(WS)8/)6Y]TMC<!%3QCQBCX!]\5:[.@87 :]/9"8#G#/-!68H
M%&)PL3QN,J$P+]3@HCF%ZT \D($QE>\W+2Z&R@@9A1A<++?_&.\H0>:%&%Q)
M3YS]%\;J&ES$MC%M,5M)^(_P(N:";?,97+%1C4&<;/J#Y/7#4\'W0@TN N@M
MT!QL^S2#B_^=91BR@ &&H6(&%T8*R^.F?6NFX_ZA/(B;K-(,=^YC\G/%\WNH
MXO\)PYOE96EP,9WK?XRA7&-=BPN$N.G=#&#B N]F1@0&%_&6AKVDQ!TI>JFX
M3@;+N>< 8]?^-V!9H0:7-87RO*1!RAMC'U5\#([C5#"2#SO0',A\@JWQ2/'&
M'S<YQ-M8Y84QPKI4?+S5&U0*%* LHU*F\#*#"T^-;<=Z!, :>'U8GX!6Q'JY
MXF*L-Q7'2T5"H1,WMQ1J<!''$AN/G#<5";_/L>!16!V#BP*1[UP#SAG/05PA
M%6)P8;!P?FS/\>*=*=3@ @IRMK=KBD&0[S>I:&ENX?J9EQ(*,;B6J>Q8.4^"
MQ MM4F09O=OL_XQ_JU"#B_.S#@/)BNT6%=\1]RO7TN+K,*Z93V ]QTZ3.)X#
M7B" 9?D,+J;C>S'VU,6P'O<"ZUF3>Z$&ES7WXD'AOV1[/%BYFA2Y%CQCG _W
M-#WBXAYM' >& <MI"K78/8PP?H?_@EZMD&9PG:KB7*UY#^)MX__1#"Y>EOA.
MLRJ_"R4UN(BEXSNR_Q&O81K$@;(>QT+/TV29P//(<GM!-'BIX9IQC-:1@GN9
M\^'>L'W%+WWLQPPN7B!9SHL#L*Q0@POHW,'_R__,,?"?VWW MEQ?^U\)Y'<<
MIX*2#'@W2*M (<IR8DWH#68DMZ%2Y@V/^4>IXK<NH!#E#9$"A[?IN-<6W]FN
M8_BV,E3J=$\G#H:"+G[+3D+%?9:*?5F!;O FG3SF)+S]LP[Q/#'T[&*_-,70
MBS,NS)/[Q'.4K!R2ZV"TD'* ^59X&UQS>N05!]>*[>D=B6<C_LWD[^%M23M.
MYEFOU'S-9T /*PR &#P"\7[Q;B138  !R:Q')<TUM.N'P8"!F>O-G?.B9QK&
M/Q5S[&&@DHK31 #?X_N*[?E=ZQW&;]OQ$H=&167GSW_/?Q)7?!@+&&!LP[(X
M,)M[A/.)B:\%O\UQ,R^700D<$\W>B&GN,[L>>#:2\5\\6W;,P+W$2PC/*=<(
M[TU:P+C!O4R'%#PSA $D>_WBD>*8DSWRN"]Y#JVY#L\S^XGA6/@_K0>RP7EQ
M[W ].#?VSSR#Z\H\\ZCS6_&]QC5)]M:-KS7_F1DVO/QA=&/<Y/*.<XW8GOLB
M:5C1M(KAF0;I+7A.N,X&+U#LB^O/;\=P?<RC",3_65RKE85 N<IUB\% 2P;:
M<X[\!^PW]E!S#O04YS@H#QS'<1RGPF#-I-9<C+% 19:,57(J/OR/UI&#_Q%C
M#4]=:< [%C?].8[C.(ZS&N I_4A%91TKCBET*@?D*2N+_]$Z:N3SHCN.XSB.
MXSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.
MXSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.
MXSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.XSB.
MXSB.XSB.XSB.XVRPP?6J#S.3!?$?E:B^4K'MSZJM5&N+?ZHX!L=Q',=QG(+8
M0H4Q@QYB1I935,S;/'PK6^SW"F&BBG6O4F%L3<E^WUJUMOBOJKCCWU=EYYG4
MMBK'<1S'<=8CME-A!/P]^[FQ"LK3X"H)*U0<AU%9#*Z87ZE.SDPZCN,XCK,^
M8@;72=E/C -(&EQU5%^K:$I#WZIJJV"LBG7/4/VH8OD+JES\H#*#I9.*Z6-5
M-O\+%3RLXKMIJBII<'$</ZF8Q_9FV&ROXCA.4/U/Q?+O5/6SGWRGJ3+&SH_]
M_9X96>JJ;!N:$VG:9+I0W.!R',=QG/4<,[@P3/ F86QLJDH:7-^K^'Z.ZI+L
M]#<J&*?B.^N<KOIK]GNNIC.6(>BLLN\C5)]DIX]4':1Z*_L=@ZRQ*FEP?:8:
MK6+Y_ZE8!HU43*.K58\FOC^9G;Y,!<24<>X<@YT?!AZ8@76^:GYV&A6*&UR.
MXSB.LYX3&UQ;9J?O4\4&5\OL]+DJX[<J,SK,X-HS?-M@@_U5?#]-U4#5-Q*P
MS+8U@ZMG^):![W=F)HMM4N38\*8QSX2A9P;7))7!]R<RDP&^TY0*3/]-9<?)
M=P1\FM<-RJ)),7E-',=Q',=9AXD-+L#8XGML<'7-3F,<&=;<!V9P-0G?,H87
MWS&X3LQ.FR">-H.+ID6#[X487+MEIY.*#:[+50;?\709?(\-KC0!GT]E)@-E
M87 E?\-Q',=QG'68I,%52\7WI[.?&%S-LM//J0R+BX)\!E<:++-M5\?@NB [
MC1<-Z&7)]](:7'_*3*X"RSA?J*Z*S[T0O$G1<1S'<=9SD@87F)<+60S7'U4V
MSV3-=6O+X-HK.YU4:0RN!U6VO>D:%;ROBN?_+OMI?*EJGIE,Q0TNQW$<QUG/
MJ:8B*+Q]^/8+!*]CC%0)WS(0,$]@^J>J'9F1I8.*?5B0/#T!^=XF?%N5Q2J6
M \V"3.\1OF7@^[#,Y 87JVQ=&**B=R&])F%O%3T':?+#R&)=>D]NIL(0.E-E
ML-X-F<D Z]Z>F0QP'G]6,7^&:A.5<9.*^6U5';/3!L97P\QD*O>K!F8F'<=Q
M',=QG)*RJ^J9S*3C.([C.(Y3'I#["V^:XSB.XSB.XSB.XSCE"*F52C+.KR74
M1N=E/]<FUEDN'X09$4.=IHU49<%A*CN.750D5'<<QW$<QPE@)##Z22$,5['^
MA:J1JLIB<+50L4Z:R&A0%KC!Y3B.XSA.3C 2"C6X+!N 45D,KAB&]2,G9UGC
M!I?C.([C.#F)#2Z&IN/[,=E/4U75],0\TA4E#2[&]HW7P1@R^$[6@'AY,DU2
M3170!,A(*3:?WOL< S!.<+S-2]G/0BG4X"+-D_T&0P):]H-XJ#P2BMMQY3.X
M_J"R;4@;Y3B.XSC.>@9&0-+@0N2YG)6=9JS>;50V6@MY*[=0)0TN$G$S1C#+
MGU6QC.V :72%RA* (_)4TD3)-/D?X=<JO@]0=<].,]XQ?*SB^QDJRZ>)"J40
M@ZN;BF3AQ+<1X\6UH*,9XRXS%C)C-V. C5?]0P6Y#*[=5:1DPC CI97E_ESG
MX6(<DIG<X#'5[,SD:L-^N?DJ C:(->)-P'$<QW%R05V1-+@P+,!&<2$/)137
MI-A.];**>::=5<#T.YG)#396\9WQC0V^?YB9#-,86.2T1$S3NQY8]J_,9* L
MFA3M=Q!>MKM5C *3A'/#PV7KDB/3?CN7P86AQOR+5)SW>@,G7=D-+GZ+AR(7
MN&$/S4Q67/Z]:%'3+Q]\<.L_W'=?C>PLQW$<9\U#G9(TN/!2 <8'WPLQN/#>
M,/V]ZFT5WBZ^QP877B^#[XR(8O ]-KB2B@TN\RK!ZAI<&ZK>BE1/M41%\V<2
M$JC_7A6OCR!?DR+>,,[])Y49L^L\7(QUW>"BK3O?\@K!-RM6B.G+I4M_^&;I
MTG^K_OS5\N4??KUTZ2U?+5MVTK<K5L0C SB.XZSS: '?Z&<U>+1FGJ,6QOM:
M:W^N\_ZMTV9PE#74*65A<)G!T3)\VV"#B2J^E];@*F2<8+ T%8522),B0P#2
M=)D$0^S6S.0JY#.X#.83YU;I:*KB!N0$T>,J.$"%%6GS:0LV^)YF<-G8B*:T
MIK@X]PB:K#+X'H_ER%!"%DAGUK?)6*:*YW,,!M\_R'ZB.2KXB\KFH23Q,HX!
MF+XT^\E;!SRIBM>=IC+LNRWC 6!L1_O.F(RK36QP%2H,LZ]6K/CPZV7+'OYF
M^?)I^CGLV^7+NWZS>#'#(SF.XU18U(C:7M5=:^&A6D%-4ZW0Z0]5_]."50I1
M=E=E#?LM"X.+.H_II$IC<)%RPK8WX4P &YO8]%KVTV XO'S#TA5B<#'4'_LD
MP)VZGOJ?,9H;JYB_4,6XQ0R!Q^]!+H/K))6M_Z:*&+!*!R<6#Z[\0/:3^?$8
M@5C"!V8FP[(T@XOYN<903(.+:1<6F+X^,QE@T.QK5=9.G60?%6,K&GARDOLC
M6!!V4"67Y?-@$9P7+V=]<WF"W136EHRK$P-U^_ MLRSN1<'WWV0F WRWP<%+
M39I!55;Z<OGRG]08>_.KY<NG?KEBQ5'_6KQX7[QE_UJP8+6/VW$<)T8+Q+IJ
MK>RD%<V^:E =HX7I35K3OO&#EJNZ+-5P*JVR/UG6$*M$CT,@ >KSJE;A6Z:>
MP&DQ(GS;8(/^*I8;^ZGB[Q@J?+]'1; \TR07!:8QT P"Y"_+3 8X!L;_-0@N
MIUYGNPDJQALV,&*8WT-%8#O3!CT*&6,X%X-4Q#H71W45UP;CC$X !@'S,U7\
M)L=O#AK&2'XD,QF.Z9G,9%@?(Y'U,20K)=Q\G$@,?RSS\029,";,6F=9FL%U
ME IOV>#P+3=<+/9IW54-IN,FQ2M5SV4F0WLO 7\-PK<,O"U@K<?'F=Q?3')9
M20TN>DD8+ZKHV1'SALH&WF;]G3*3@;1CV2XS67K2#*4UI2^7+OV6)LRO5ZSX
M0O7X5\N67?#-XL7F!G<<QRE""[R-U)!JI17)!#6D?JWZ0O4?U7>Z+-4P*B]E
M#\G)#0Z*V)GAE!'<?,F(?_,4T5TTEC4YL2Q7#!>9:!>I]#D*UFD2/&58J.S/
MNK :3,<&%U:O6;?03T60G[4)XU;%$DX>IQ'O&Y*_M3H&%^[7$S.31=#S@@S"
MP/K%&5RQ![%4)(V@"JJ_J%[\:OGR>[]>NO2*+Q<O/OK+1Q[976;.M.9BQW$J
M*5J055=#:G\M\(]78^I:U7R=?D7?O+_09:D&S]I6]M"=W!#WY>,$EP/<?/MF
M)@/FH6!^K@O.LN*"YFD^(^=&$K:U,9<L69O!=*?,9.!=%4%W,6QKVYRBLIPB
M:<3[AO@[!F&^YL_B#"Z\;R1K,^BA@7>O>?B66=\-KA+HO\N6_?ZKI4L?^&;Y
M\E%?+EW:X7_+ENWQ]X4+&[AAYCAK'C6B:J@:JO91=5>-4V-J\?<5V) J5-E3
M=)PUSIDJ;D",!]IL[68D0%R?L=!DQS(\4\1< >ND&5P8,:R/6,<2M<4PG]^Q
M=>SW@&D"YS!V[%@P9##\"+9+'B-Q4P0IVC*VXQB,>-\0?[]+A8'$<:11G,%%
MUUVN#[_/;[.O9,R6&UQEI"]7K/A1]9T:9%_IYR??K5AQT]=+EQ[V\_//>SH,
MQRDE6H!MJSI>C:B[M.#\I^IKU?^T,"OSN*F*I.SI.\Y:85?5\:JV*@P<@V [
MXK:(S8J-#=:U #>"_0A>!]8_6G6D*E=Z!YHOZ?E T"#3[,NP:?)?$9 7>S;P
M1K&<S+7)4<D[JEC6517WC.188N+?8A\T41+\G@:_7R<S&3A"1?*Z)&3O9;\$
M^L5PS6)C@"$>8EA.,.%JD6:<K,_Z>MFR_WZ]?/E[JD>_7+KT%C7*AGZS?'F[
MGQ]^F)PPCK->H$84GJF>:CQ=^-,&&\S3SZ=5OU5#:HW'2U5$92^3XSA.X:09
M':[B]?6*%?]5X^RI;U>LN.%_#S\\2(VRUO]9MJSYSPL7QCUX'*="H4;45O_;
M8(,]U'#JI--GJC$U6PVIU_7[CTFCPI5;V<OI.(Y3.&G&A&OU].72I3\'+5_^
MTY=+EGS[]=*ER]0X._U?BQ;%3<2.4RZH(760&E*7J"'UJNJGK'Y&2</!53IE
M+[7C.$[AI!D,KC6C_RY9\H/JC]\L7_Z*?E^L1MF5:J@-_';I4I+Z.4X16L.3
M$N% -9I.5V-JINIQG7Y']7<WI-:\LG^+4SSE>:U(J_2WS&290"QWG/C<<<J6
MI!'@JGC"6Z9&V=M?+UUZEWX?^?7RY;UU>K^OEBXEN6$<,^E4,M2(HB=?D^\W
MV*"M&DY'J2%UA6K%#QML\.>X@G=5+&7_OLH,YV!)MLN3LKQ6[,OBO8&XYPLR
MDV7"=!4)9QVG?$A6[J[*K:^7+'E=#;++OUVZM ,#DO_F_OLWD?OOIS>NLP;1
MFF%#U<9J3%53;:,Z60VIN]60^J?.3ZW$795'V;^Y.*S3TR8JIN.7(WJIT_&*
M97'G)SJ"L2[S8]B6^6D=I9B7W#_[0?Q&<G]\YQR:9:?3H,-9VN^Q'W['CI//
M)&QCV^6Z5NR#:Y \-H-Y\?Z99E^DG6(:*-?L=VQ>3#S/CC?MMPR6VS5DOUP[
MV\[+4&?U2:NT7>NHEBW[!X.2?[5TZ3-?/_SPK=\N6W;6U\N6[2\BR5Z[3@&H
M$45/OL/4D+I2M?S'#39X3?5'U;=4RJYU5]E;H#A8[XGL)_I>Q9B(P'=2"]E\
ML$3>IJ4JP$BP=$9HN0HP6/ZMLOFL8Y#TFY%+2,=DR_NHP+XCEB=A.+QXG7^I
M#,8!YKCUE@_+^+2$YI0CC!ULVY$'D\\T/E79>NANE4$R\G@9AB'IGN)Y,$1E
MTWS&::1N5-DP@PS_$V][BRH-4CG9\(-_5R7'.EX3'L%U%L9XBE-5K&T8"H$4
M$6N4U(K9M7YK^?(_?;UBQ7(UQJ[]S^+%)^$M^\^2)<U^7KZ< GZ=1XVHK;4&
M//"'#388H-.CM48A+0)C\GE//E=0]E8I#M8;G9D,D&^1L0B!91A+,7J+%8%G
MA75(4]1:];DJR1(5AH7!^(B_S4P&@XO]V;BU)/F.CYOI0@V(>#L,+HP12[GT
MN@H##!A3.<Y+R;B/\;:Y(.6.K4?'(GW<BB"UDAE2K!,W*<8&%T8BH[<8&((D
M1F=;]F=E%]>5ZY)6EB4-+AN1!C"^S- M<W"?Q?FHUD6PHF=D)LL5;HA<.<5B
M&#G]U<SDFB.UPG6Y"M'2I7_^=OGRV[]:L>(XXLG^>?_]=6C&K*@>,WT0-U'5
M4B.JGJJ3ELB7:DG\JLY+K51=KES*WE+%P7IQDQQC +^9F0S+QF0F [U4S$O*
MO$=XHOZ@BKTX!'DGUS=C!8,K'LN0^ISE!M/Y#"YR63(,GNW7P."RX>< KQGC
M @,>K>3H,/&V,7CM+E?9_FT]CMO&/T[".KD,+AM.$#@OFQZ@8CJIM(Y)28/K
MK,QDX%Q5/$Q@F<*?ST#.ZS)KRN BHW[<MIX+-[A<ZXR^7+'B:SQE.OTV262_
M7KKT\J^6+3OT7PL6V!MWF:.E:!4UI/97#?M^@PWNUN^D1?A$Y7%3KC)5]I8K
M#M9+&EQFG+ L-KA(E,TP<ZT2,D\2+S$DV<;(>H@9"OL@(7:\OHUNLCH&U[TJ
MFA%[JMAGO%T^@POO5J$&%^LREK$=MZW'<3^>F5P%ULEE< '7AB3F>!'O9X9"
M\G*,5?L=D\6&Q:P5@XL!HQEJAS\+ER#9XX'I.',[%[9I9C)8PS3/D2F>/\.R
MIO.'LMW^X=O*D*6=93;V(F"8#%/A86/(H-U42;93,>@SV\9#YVRJLF,<K&*=
MY$7EMS@^CC.7P84WBBSN<*HJ.< TL#V_Q4,2&U.GJ7!5'J>R#/2L9\?!'\B#
M<["*^0S4;9C!A0N593U42=JK6,8-$V,W!I_\)YRCQ0H UV1H9G)EDA6ER[4F
M]>62)5^I8?;BU\N6W?K5TJ7G?_WPP_V)*XLS^VN)RN#&NZBZJ_%TUD\;;#!5
M]:A.>T\^UUI1]M8L#M;#PV)0\5._ <MB@XN$R87LEWJ6>"; 8)F2F5R%X@PN
MFMRHQ]+ DV9C$E-WQ-OE,[@N5L6.&NK17.<4S]]99=\9>29N6B5@W;QZQ+K%
M=5_2X+I(Q5"!S+-ZF;&)\?K%MDLNUHK!A1' 1>.D"6S#$ !.(AZJYG<JVFSA
M+17;<,#,9UVZ:Q+$9]\QY !#@.]?J-@_%Y&+!/;G$GC'=MPT21A[D!OB,Q4W
MC1D2&!ILB]B68XG;D^]4<</SF^P#I1E<Y.&@'5S+]_ ;6/KLT\#@P9)F/YQ#
MO(P;_'T5(Z5;?A"6VY ^3-/.S#*.D=^P&XCKS'S;-S?)-)5! "3'PK*O5;';
ME?UR;ASO^2J6\S9E\"#\*C.Y,FF5H,NU1K1DB7PS?[Y\,V^>?#MCAGQWUEGR
M0^O6\E.=.JF5G,M5490M/HN#]:@7^424[5;Q\STVN&"!RM9%U \8''ALXOGS
M5$!:&.K/>-E\%11G<%''V39);E;9,L1Q&_D,+KQYV VVW4?9SS3PYMEZU,7Q
M>G]4V3)$+!;<I[)YD#2X@._4RS'OJ6P[4QH5JDF1@\QG<,4!9O2NX*0MEN,V
ME?6XH(< !I-!6R[[)O^%&5R,OU@(>('LXIG!96VS>,EL&=/<O+3S L?%S9#+
MX,)0- \1VV+8F2N3_<1C(G+CFC>*&WQ.9K((CB$VN.+Q&.,W @PNEENW53QD
M!%D"5GI\S2R@T@+_F.8MP<##&#\D_%=T$EB%U(K0Y2HKJ3'UW047R/=]^\I/
M39O*3]MN*S^K0?7SQANG5F0N5V50MO@L#M;#"*'\3G;08EY:;&\#%>4WXQ-;
M'#5U$#WUF,_R&.J"750LH^.5@8,C;D%A'WMF)@/4@7NH<B59IJYDGYNI^&V#
MH/;8#J!NBT?0H YGO^8]8Q]I\/L<-^MR;&94 =XIZG.VM6L S*?5R^HZCH/K
M%,-RBWN+H66,_?&;N<(:.!:K4UDO_FVN9[DEI"Z-P14;&O08P-UIX!6RFY3/
MY 7Y1,7 T69PY8.>?'A[6,\$9G#%V'=NBN2R7$V*&%P$"\;@;6*P;!X2^\U8
MHU2 P46/DAB6QP97? V!>9 6PV7+DMUT3;8OIKEI8VPY-RG3J:16DBY7<;KK
M+OGVFFODN^'#Y?LCCI ?6K:4'W?807ZN6C6U@G*YUB5EB\_B8+TXALMQ4LEE
M<,467VD-+ER@Q"+%T 1'L%MQ!A<N5+Q-Q'\!QI&M7]X&%UXL+'VF<U%2@PMK
MVHXKG\%UM8I\+KE@O:3!Q?GA&J;)U?*1K$)J9>I:/[5\N7SSX(,98VK.'/GN
MXHOE^W[]Y,>==TZM=%RN]579XK,XWE&E!6<[SDH0,!>W_P(W6;?,9'!K8GB4
MQN"Z245;J4% ',MP,19G<&&H$=]ED(K?UL]G<)F7Q_)<80#1Y);+X,*H,_<K
MYTHS(NY?VP_NQC0*,;A^DYD,$+-%;!GD,[@LET@N6"]I<.&-XSJS+.EV+2*U
MXG6MT_KVQAOE^\&#Y8<##I"?ZM?/-/%5KRYZDZ=6+BZ7:V5EBT_'*3.XJ1#Q
M5T"//9M'C!,Y-TIC<!&C%.?WP)@Q0ZB0)D4+L$.O9#\AG\$%!,#9=NR#X\UE
M<!$[%6?PO4IE<*PVWV0= @HQN)(!D/1.@7P&%R2SY<99A?F>-+B ^?D,-3>X
MUA4M62+?3I\NWXT=*]\??[S\T*F3_+C;;O)SO7JI%8;+Y2J]LL6GXSBK25J3
M8EG!@YJ,X2I/%JMNS4RFDUIYNRJ.%B^6;^Z^6[Z=/5N^O>XZ^?[44^6'5JWD
MI[IU4RL"E\M5_LH6GX[CK";KDL%5;,&06LF[UJSNNR_CF3KTT$POOMJU,TU\
M5:JD%O8NEVOM*EM\.HZSFI!P,9DMMZP@,2K-IFL"FEA)S)J75 / 538B)<(5
M5\CW0X;(#VI,_;C__O)3PX;R\R:;I!;B+I>K<BA;?*ZO3%59^B+'<0HEU5!P
MY18]^>Z_/_3B^_:&&^2[,6/D^SY]Y,<6+5(+9I?+M>XI6WR6%_NJ&F8F*QSD
M$R.QMD%R<3IH.8Y3'*E&A4N^G3I5_G?BB?+CGGO*SS5J!*\437S>D\_E<F6+
MS_*"#FE79B8K' ^KXF'GN!:Y>NT[CA.39FRLLZ(GW[1I\K]1HS+YI0X^.)/]
MW /072Y7"90M/LL#TB8QA!M#Z-#AB9A?LKY?IS((2V'$%H.QC\F>SD#-S+?$
MX@-5["/.0 \L)T<C0\?%6>1)?<3ODY6=7ORY>K['\-T,KC8J\FF2AHC?/5P%
MMC\;7Q@89_E"%2.Z<!PVC Z)8AD?\ISP+0/SDIV_9F4_8;R*Z\3^6<^&YS%(
MY\0XBURG<LL6[SC%DFJ85#8M6B3?W'Z[?#MYLGPW<6)(B_#C(8?(3UMNF5I8
MNEPNU^HH6WR6!W>K2$O$T'.+5"0;)]40R<$-AMN)CX%DXJ0D(DW2,RJ6+5,Q
M(@OIF>)U3U*1*HC$V(^K6,9XB,"P.'RGR9"A^&R8&R-.U&WPW0PNTB?]7D5^
M2;8GG^6]*E(L<2[\K@W;UU-%<R3;+U&1JNEE%6,QLBWG-%<%&%-IOVOPFXR_
M^+K*SLDZIY&RB=13OU8M5[&,CG&5'ER-L;6\KL*@E@=G)M<*#/I99CT=4PV8
MBJ@%"^3;\\Z3[[MT"8,;_[SAAAGI Z1/D,OE<JTQ98O/\B+9I%B(P44>1^.?
MJGLRDP$,J ,RD\'XB(?6PRME^S*#RW)#)NFBBH\#6#\VN.+C8C#N.-X++YT-
M=(W!%:]+?DN.C7,##"5;7HC!A:%J8%C9^3/0]\C,9  O'K]3Z8DOP.TJAJ-9
M%^$\+5'KFH WA'AX"$:8-\M_M4DU;M:DZ,EWR27R/?%2;=K(3[ONFLE^[CWY
M7"Y7!56V^"PO2F-PQ</E,9I)'&?%_L[,3*YR[/&P=V9PY:*OJCB#*TYX3K)T
MO%7&V:H/,Y/!X,)Y8- ,^;_,9" VL@HQN([(3 ;.5^$  CQFK)M4I88V6#*A
M&UB;UV<FUSGXL]:DP<7O6:9ZH\QNF%0CJ"QTWWWR[4TWR7>77BK_.^LL^:%;
M-_FQ>7/Y>>.-4PLPE\OEJBS*%I_E19K!%8]M7)8&%VF0;%YQ!E<K53RT'K!^
M13:X\/:US$RN._Q9%9]4;'#Q)[ZF8N!I$HK2E@NT37/!:6LFJ W([<&%))".
MH$%N%(P-YK^IXL^* _E8-\YKQ<U@XSU>HSI&1?LTZ\5!A\!^[E*Q+'8Y)N'8
M\#*Q7MOL9VQP$9#('\Y0.XQY:# VY'P5%O:YS,C"? ((V0]!@P;'0]L] 9*T
M?7,3LXZ)&\? 34L@XFJ3:BSET[)E(?B<N*EOITR1[X\[+GBE] !=+I=KO5"V
M^"PO&"HO'G:. '-^<U,5]=$-V>]&20PNZI9+,Y-A7P^H+-%W<087))?SO;P-
M+NI_F@$MX)TXL/@X\AE<!-03'T:]"S9F<Z6%$^#DXT1HL<'55<4-P3J]51A%
M7Z@P4'!18F2\I )N*-9# U0860S 3+#=\:JG5;'AP7KQQ>-/Z9>9W.!1%=N^
MH.+/Q4B9I#+X$^@-@?'TL2J^46(P)KE)6.\3%;]I!I>U0V/8G:[B.,WPY!P9
MF)ISMGUSK!A@]+#HI2+0S]JT6<:^Z*'"P])$Q>\PC^O$@.+&DZI+,I.K1ZI!
M==--\K]SSI$?NG>7'_?80W[:?GOY>;/-/%[*Y7*Y5-GBL[QHI^(WD,5;$?1M
M\VA-BHV3DAA<U"NV'X2Q975H136X@%Z5?$=/J'ZG,O(97(3CT '!MD4X6BHM
M2?<F) TNC!OS8A&\Q_IT]80:*MO>#"XNML'WV'/$=[M!XFE(&EQFS  #;7/A
M 8\3 7TQ["N.E8*T<^.[&5Q,QQT%Z,I*CPN@9P;&5@S'9L=@V/[-X$IK/DS.
MNT-%CP['<1S'65-0OXW(3#IK _)_F-%@) TN>O89&"CQ^AA>]MT,KIBT[S0Y
M M/Y#"Z:[HP]5)]E)D/W4;:-Q;88?S&'JNCB&L.ZL<&5%%XY8&@=#$T\6F3G
M!=Y,TK8!,[B2,,\-+L=Q'&=ML[.*>LU92\0>*F--&EQQKI!"#2X,EF0BM31P
ML<9N3N W8X.KN"$8]E;1;D[[,ZY.\H2D45*#*W;5.H[C.,Z:@%02%A/EK 5H
M0Z9MV%A3!A?&$ &$0/LPRPHQN @X9]U#PK=,SH^C,I.KP'JG9"9#<#W?S> B
MEHKVY*W"MTQ;]CXJ N )WB>N;6O5=RJ6[:1B>WJ=P+:JP9G)O 97"U6<+1@/
M7:[C=1S'<1QG'>6W*H+&#9*-79N9#*G^XV8YFMIBPR+.7IOF+4O[CF$&&'D$
MP^-!(EZ+'H\VG  >H#A5!=XJ@MX-##2V97\81*^JTNB@(L"?W\# (A@/(]*@
M-R7-AGC7R/;;7X6A10P7^V;9"I5QHLHR[+)?KAT0/Y8\5WA,9?LVTM9S',=Q
M'&<=AQZ%'E.T9L!C1D]&QW$<QW'60VA6=,H?QLNBNZWC.([C.([C.([C.,XJ
MD B=V.G2@M.!T"7'<1S'<1PG!XP^0R+STD(O21*-QR//.([C.([C.&4,(\18
MI@''<1S'<9QRA51+]-"G!SP]VFFN@\XJ>LLSG)ZE(@*2E=/[G=[NEKZ)U$88
M,(S;R&@H=,QJKHH9KJ)G/</KQ:.H#%5-4PU2D:J)# &QY^D$%;WU/U#94$7W
MJ&9G)E?I=3]:1>]_:*#"$\8Z%S,C8J#J\\RDXSB.XSA.^<+XO1@T[ZG(,;F%
MBK$3;923+BH,%AOQA/EC5*15>I 9"CDBF8_!1@JE<2JVJ:<"QEQD;.(]58S
MPC(,(R 7)LU[I%W"H/J+RD9<8<Q$MMM1A8&$<0:D5WHH,QF,M/TRDP&^VY!Y
MI&,Z2<5Y?:J*LR&0]3YIK#F.XSB.XY0+&%Q)PX/O\2@L),K&JP4L(U]DC"7E
MMC&/@2%\\$[55F&(6<)Q.%)E"<TQN!@PVR 3/9XUX'>^4"4ST\<&%\'OEJLR
MSLLY7\6@U0;Y+3'L#+Q?R?-V',=Q',<I%W(97$E9DFV:#?^D8EXO9BAF<,60
M&/P2%4V+&%Q);'T,KE]E)@-XN>)$W7>I\%0Q*@LCRT!L<-55V;ZN4=V?F0S-
MBLR/A<%%DG!P@\MQ',=QG#5&+H.K.&AZ9#W2,^0RN(Y5,5YPTN#:7V5>K.(,
M+L##A2?+8K-B@POX;;9C5!J+'7M6=5UF,A4WN!S'<1S'66.D&5RWJPA2QYL%
M].;;-S,9@NOQ$IF1A>%ETT^I:#ID]!B^XWT"IA]0T>3'V+X$XE^D@GP&UW$J
MU@>"Y-_*3*YB<)VO(O8K/@]BR1AVC^$!@;@N/&X&<5_Q^H[C.([C..7&/BH,
MDR2,_4L .D8) >U[JX"F13Q6C.D[F1F*&5P8-.R+GHCA8V'L  #_]$E$051F
MZ!@$PK,.RVCZ,R:J+#X,"'"WX>?&JEB?[0CJ9[QD6*2Z.S,9(#B?=9(]$<]0
M$2O&,KQ?<;+36:H;,Y..XSB.XS@5G[0FQ8H.Q[M99M)Q',=Q'*?B4]D,KKU4
MO\],.H[C.([C.([C.([C.([C.([C.([C.([C.([C.([C.([C.([C.([C.([C
M.([C.([C.([C.([C.([C.([C.([C.([C.([C.([C.([C.(ZS'K+?:3.KMADZ
M^X1VPV?_OOWP60M:#9W9*+O(<1S'<1S'<1S'<1S'<2HV[<;?6KWM.3,'MSUG
M^E?=QHR5_A-;2I^+^DFGD==+^Z&SWC[DK!G[ZVH;9M9V',=Q',=Q',=Q',=Q
MG I$TW,F5VL[;,X-;8;/_J[[>6<'Y]: 2PY828=?W%DZC[KD9UWOK^U&S.Z>
MW=1Q',=Q',=Q',=Q',=QUBYMSIZU4_OAL^[O,&*Z]!Q[@O2?>/ JSJVD^H[O
M(-U&C_VY_?#I?VPW;,ZINAN/['(<QW$<QW$<QW$<QW'6-.,W:GO&[%W:#9WY
M4L>1-TCO<?U2G5G%J=^$5M)MS'G2=NCTK]H.FWGA?J>-WS3[ X[C.([C.([C
M.([C.(Y3_K0[;>:6'8;/?K7#B*G2>]R 5"=6<>HWH;5T'7WAS^V'S_JR[= Y
MPS8X;6;5[.X=QW$<QW$<QW$<QW$<9\W1[IQ9#=L,FWE+AQ%3?^XQ]E3I-V'5
M7%Q)'3Z^DW09??'/[8??_&F[D7,&ZFZ\NZ+C.([C.([C.([C.(ZS]NE^SO)J
M[8?.NJ+]L-E?'GK^.=)O0IM5G%N'7=13.I][^<_MAL[^L-VPV>VSFSJ.XSB.
MXSB.XSB.XSA.16/\1JV'SCRR[3DSONHZ^B+I?\F!TF?<0.DX8IJT'S[WG=;#
MIS?.KN@XCN,XCN,XCN,XCN,X%9O]3IM9M?70N;W:#9OY>?OA<^X\>,C-VV47
M.8[C.([C.([C.([C.(Y3R=E&U4G53]5#U5SE.([C.([C.([C.([C.)6"@U7?
MJTY3_5?UH^I9U3ZJ%U5GJ!S'<1S'<1S'<1S'<1RGPM)"]9BJNHH(KC=4L$)U
MNJJ*:I[J )7C.([C.([C.([C.,X:00K4MZJYJEU5&ZERD;9M/GVF:J3*Q4ZJ
MBU6_5Z5M'^L[U?VJSJJJJEQP_%>HV(9HI'-4N2!BZ7\J^XTC5<714_65BO4Y
MOZ2SA_.]3?6-RO:;U,^J%U1[JI+01? 5%>MQ7793I3%-%>_S!]7UJFJJXOA"
M9=MMQHP(G%Q/J&JHS,E56\7Q'J["R76/:G^5XSB.XSB.XSB.XSC.&B%V@B1I
MJ,*)\9:*[FBVWCA5+O+MKR3LH'I)9?O"0?,G%0XI'%\&HQL>K_JU"H<5SB'6
M_U)UH"J-DCBY8 \57?)8_U^JPU2Y:*F*CQFG8,R5JI]4]ML+51RG.>7V5EVN
MXOC9?I0J26F<7/R63=^GVE"5CWQ.+NBN^K,*AQ=.+>"Z;JUZ5]6'&8[C.([C
M.([C.([C.&L*<V2@?)!4W-;#^9*+0O>7#YP^1([9?G"J;:HJ#IPM U7Q,5R@
M2E)2)Q<<JC+'S[]5.+.2$,7T'Q7KX'R*G7& ,^HC%<MQ$+55E8;2.+F.4TV.
MOC^EVE*5B^*<7,:V*JX%T7-\\MUQ',=Q',=Q',=Q'&>-8XX,E ^ZS=EZ.(9R
M4>C^<D$$%Q%;]CLXETK*$2ISDGVH(A(KIC1.+FBCHDNDG1_?#2*P_J!B_A]5
MAZB2T$WQ>17K$!EWE:JXB*HT2NOD(H?6%)5%Y2U6T<TPC4*=7([C.([C.([C
M.([C.!4"<V2@)$1&$4'52_6IBG6(XAJARD6\/YPQ^513E>1DU=<JML<)4TM5
M4AJH&.G/CH,NES&E=7(!SBPBN=@69Q;?Z:)GW1G)W[6+*A?M5?^GLF-#CZK8
M#TZH0N#:E<;)9>#HLODXYC91)7$GE^,XCN,XCN,XCN,XE0IS9!2G?ZAP;FVE
MRD?:MKETHRH)^:AL^4VJ0I*D)]E8]8#*]I/LLK@Z3BX@NHSKP?9$BIG3ZG>J
M)JI"(*'](RK+SV4BY]>+JHZJ7*RNDPM.4=DRSB&9.\R=7([C.([C.([C.([C
M5"K,D8&NB41R<B*5+)'[.ZJTD?Z2Q/LK#;&3:X:J-$ZN>JK'5+:?I(-G=9U<
MT%H5=UW\7)66IZL0<"+U5=VE^IO*]LD(C1-52<K"R464WADJBYHC5UB<0\R=
M7([C.([C.([C.([C5"K,D8'28/2\OZA8CL-K@BI?'JGB]E<<QZIP[K#]RRH<
M5B6%'%Q$)[$/''4'J6+*PLD%-ZCL7'$HE17[JLSYA&Y6Q92%D\L8I*(+JJW7
M7 7NY'(<QW$<QW$<QW$<IU)AC@R4"YPN'ZM8YTL5HPCFHI#]Y:..ZC.5[8,1
M 4O*DRK;_DX544LQ%=W)!41VV;Z_849$63JY@*BT>%1(1K=T)Y?C.([C.([C
M.([C.&N%NBH2K,]1D4S<NAGBQ-E1E0MS9*!\'*6R]7!T;:]*H]#]Y6-;E8U4
MB$AZS[DEG54QG/]H%<=FV]'ELJHJR=IR<EVB>DEUHBI7;C/.L;<J3D[/:)$Q
M9>WD@DXJ2ZA/;C&NBVU;G).+W&JV+B,WOJ8:KR*9ON,XCN,XCN,XCN,X3DX8
MA8\$Y\-5.#G,P8!(9/YWU:]51ZJ*&[$OWK8X1JIL74813'/4Q/LK1'0G3!N-
MD%Q<.$K,\5(2/:/*-\)A[.0J1)SK,%62DCJYSE7%>;SR"2<E$6TXGY*4AY,+
MZJN2(S^B0B*Y:JO('_:>ZEM5O#W=3V]7[:?:7.4XCN,XCN,XCN,XSGH*#A\<
M5J^J&'TO.2+?GU1$(S54;:(J"9^HV,=OPK?BN4Z%TX=C('(J"9%D\;$5)R*V
MR/N5#_)RX>R9I&+D0>M:ASY0D;"=Z"@<?XRL6 A<SS2'3IIP3 U5)3E+90Z=
M4YE1 /R7_$_'J!@!\I\J^YVW5'3/Y%SIMIDK]QG78Y&*;8B:RA6IAQ.4=;AG
M^C"C -CW]2K^8[9=H2I-\G^.GVZ0RU5$=]DYXKPCWQC=7W$<UE(YCN,XCN,X
MCN,XCK,.@I.JHXHN8.^JS#E@#@(BGZ:K>JGHHN<XE0&<CX>H+E.]KXKO:QRF
M."NGJ#JH2NJH=1S'<1S'<1S'<1QG+4.D#E$X="5[7A6_^./0(LJ';FET$W2'
MEK.N0==%HN&XQXDVLSQRIF4JG+ETHW0<QW$<QW$<QW$<IX+!2(5+56G=#G%J
M7:MJH"I-%S''J<R0/XZNJ[>IDGF]2(3_N8I<:N[P=1S'<1S'<1S'<9PUS)XJ
M1M1[095,.(Z3ZQ[5(!5.+:?B0O?0OZIPOCAK#@8((*G^"!7/T ^J^!FBZ^Z=
MJKXJ[^+H.([C.([C.([C.&4 +^/;J7JH2"9.8NWX99RHE-=55ZJV5SF5B_B_
M=-8N/&L#54M4.![C_P8G&-U^CU8U5A4Z"('C.([C.([C.([CK-<0?35;Q4A_
M\>AQB._S541R554YE9OXOW4J%E54Y.RZ6O6E*OZO> Z_4=VARC4"I>,XCN,X
MCN,XCN.L5Q!]-5KUI"J9()L7Z4=5)ZO()T0R>6?=(G:<.!4?'%K'JE:HDGGO
M_J$B)]ZIJGHJQW$<QW$<QW$<QUEGV5+52763BD3P\0LRR:_?51'!U4I%%(FS
M[A/? T[E@VC*+JJ[59^JDI&7OU6=JR+RTI]IQW$<QW$<QW$<I]*RN>I\%=T.
MXQ=?TYNJCBIR 3GK)_']X*P[#%/]317_OXC<7D2![:)R',=Q',=Q',=QG I)
M3=5)JK2DU41WX- :JB*BH[K*<2"^3YQUDZU5#!S!:(U?J>+_G%Q?SZK.4VVC
M<AS'<1S'<1S'<9PU"DZJ0U27J#Y1Q2^M.+3HMD3WI<-5[M!R\A'?.\[ZP[ZJ
M&U7OJ.+<7N3D^YV*T5+IMHSSW'$<QW$<QW$<QW'*!)*]5U,-4/U&%3LE>"$E
ME]9'JE-4CE-2XOO)67\AM]=1JL]4E"GQ !3H#16YORB+',=Q',=Q',=Q'*=@
M#E7=I^*%DQPZ\<OF'U27JO97U58YSNH0WUN.8]11M501[<6HJ_%]\IT*A_LU
MJF8JQW$<QW$<QW$<QPG1$WNK1JB>5_U/%;],_EVU0#58Y0XMISR([S?'R041
MI<U5XU6455^KXGOG_U2S5+U47E8YCN,XCN,XCN.LXS""82T5>6X>5R6'^B<Z
M@BBMRU1;J1QG31#?@XY34MJK?J7ZKRK.[87>4QVI(BJLBLIQ',=Q',=Q',>I
MI!#Y0)367-7'JF]5\0L@3BTB']JJME YSMH@OB<=9W5@D(O=5&-5..SC>XL\
M7W2_OEVUC\IQ',=Q',=Q',>IH.#0:JHZ3;54]8TJ?L%CV/Y'571+9#W'J2C$
M]ZGCE#7U558N)KLX_D?U@.HX50.5XSB.XSB.XSB.LQ8@YPQ#\!.E1416_.)&
M7JV_JNY4$=7@.!69^-YUG#7!?JJ%JB]4R8$U2'(_6M5(M8G*<1S'<1S'<1S'
M*6.(1F!$P_=5R6@$NN$L4S&\_M8JSSWC5";B>]EQUC0,OK&]ZD05.;SB^_%G
MU=]4RU5=543,.H[C.([C.([C."6 _%A'J^:I_J&*7[J(TGI1=;%J?]7&*L>I
MS,3WM^-4!.JJCE#=I2(J-KY'B9Q]2C5,Y5V_'<=Q',=Q',=Q(C95M5!=J/JS
M*GZ98O3#OZC()=-1Y3CK(O$][S@5E6U5TU2?J(B>C>];&B.N4U&6UU0YCN,X
MCN,XCN.L%VRD(@GRZRJ&O*<[3/RR](;J*-4V*H_2<M8'XOO?<2H#=%LDXK:/
MZ@55? __I"*A_6LJRG+/Z^4XCN,XCN,XSCH!+?H]5+-4'ZN(S(I?ACY07:LB
M2LM?A)SUE?B9<)S*2G45>;NFJ/ZHBN]K(K]P>I%7D0%#/&^BXSB.XSB.XS@5
MFFHJ\K.<HOJ-*AFA]7?5TRJ2&WMW%L?YA?@Y<9QU";HXDC_Q7=57JKA>8%3'
MVU3M5.0 <QS'<1S'<1S'66O0E;"[BJXJ=$U)1FG]6\4P] U5C-[E.$XZ\7/C
M..LJ='&D@>- %:/AXN2*[_UO51^ISE;54#F.XSB.XSB.XY0+.+1:JFY0D3,K
M^7+"$/,S5;U56ZD<QRF<^%ERG/4)&D!P>HU7O:,BGY<]"TQ_J+I9U4&%D\QQ
M',=Q',=QG/48\IXPVM7!JLV940"\2.RH.E+UB"I^ :>KR;]4KZC&JAJH',=9
M/>)GS''6=QAQ]W05W=N)"(Z?C^]42U0]5=0_[OAR',=Q',=QG/4$$KD_H\(Q
MA2:I<K&+ZC[5EZJX)1U]K;I)M9W*NQTZ3MD3/V^.XZP,D<3-5+>J_J>R9X5Z
MC:ABZJTK5/54CN,XCN,XCN.L8VRD.DME.;+(<T)4ED%R^'&J9U7?J.R% ?U7
M]8#J"%4CE;>2.T[Y$S^#CN/DASIN9]49*G)"QL\/CJ\_J>Y5]5<QXJ/C.([C
M.([C.)646BJZ<IBQ_[;J--7M*KH9QB\#.+]>5UVK(I++<9SR9VL5@S'$Q,]E
M#"/3(7<V.TY^Z.(X0+58];DJ&9&,,^QD%1%ACN,XCN,XCN-4 DY4X=B*#?M8
M=.M8JMI=Y2_-CK/FV5-ES^BG*LN3%S^GP O[RRJ^L_ZA*L=Q2@8C-%ZI(D(Y
M?L9XINB&?XMJ2Y7C.([C.([C.!4(NFX\I++NB4EAS),H_G$5ZS%2U4C5]BK'
M<=8<UI7X*Q7/YOLJN@_'SRN17N;@(LGVQ2IR$CF.LWI0YPU4T=C#LQ4_=_]0
M/:HB\IF(:,=Q',=Q',=QUA+-59U4QZE&JR:K[E&M4#VG8ECVWZO^HXJ[</ B
M[3C.FJ>/RA)H)_/B\9SRB=/Z))7C..4#$<T=5'-5'ZOBYY"ZDKKS7-7>JFJJ
M0ME'U20SZ3B.XSB.XSB.XSCK/N3:^H,J?K$V_5/E>?(<9\U#5^&AJK^JZ.*?
M3 'PL&I?5:[HRA$JVX;<8'54CN,XCN,XCN,XCK/.LX.*P2'BE^@_JO90.8ZS
M]ME*U47%X"T,UA(_JU^J7E*=I\)I;3":\;]5K(/#FM&*'<=Q',=Q',=Q'&>=
MIXJ*$>%X(7Y11;)LQW$J)CRO^ZFN5[VILF[')IS4UZ@8R9'!)6P^HQYOIG(<
MQW$<QW$<QW&<=1JZ/NVOJAF^.8Y3V2"A_1LJ<NPENSB:<("U43F.XSB.XSB.
MXSB.XSA.A6(+U8FJ\:HY*D9NI MR<D )$P-*,,(Q2>\=QW$<QW$<QW$<QW$<
M9ZW30/6T*NG(^E[UA8H1&U]3/:%Z0,4HCC>H+E1U5]'UT7$<QW$<9YUD(U5=
MU?8J$A%OI[)N*W1C(:$I\VLQPUD)C,1&655GAN,XCN,XCN,XCN,X3BX8Z>EK
ME;52/:[:294+G#9WJEB7' 25E<U5%G)^"C/*@6-4\;4UD=L!!\XAJC]GYXU5
M.2M# EB[9@.8X3B.XSB.XSB.XSB.DXN#5>9((/2:3\*PZZO2P#ESGXKU_L.,
M2@K157;>9S*CC"%"ZRD5^R><?1-5$G=RY6=UG%PC5&SWE@K'K..DT5#U?RJ[
MSV)1OKV@FJYJK:KHW4\ZJ^A&P[$SHE\=55GQO(K]4J8E(0<-RSY4T6A2WFRI
MXG_A-Z]E1CG03$4C#K\1ZSL5<)Z<+_-F,,-9B8-4=LVZ,<-Q',=Q',=QUA2Q
MDZNCZM[H.\N2E,3)1;<\NNGMK-I-M6OV>[ZN>6S#>DW"MTP"3Z*N&JO8QRZJ
M;52K^\)9G),+)Q6_QV]Q##A*ME:U4#&?ER#VD81AI#G^3BHBMMC_<RJVL>VL
MZUTA3BY^EWWNJ.+<V0?7D^-+<YP91.-Q'-8ULIJ*:\_VS*<+(/-B."[FLPZ_
M14Z*JJKB8!V<HIR;;5MH%T/.C^2N355LVUS%=69^:9Q<G#?[N5K%=A^H>"%E
MGBF^=^Q_MOLM#9P%G!/7/7E.W)MLC[.$^P1Q/G:?<%ZL$\.Y;:6RYX)[N[:J
M$/A]NKS:MHAKS3V2*]DMV[ >UX9SY_?Y;[D/."^.-]>VZSJM5':/,1W#_8<#
MPR(^_Z9*_I=KBEM5',,CX=N:IR(YN7AFS<$TBQEE#&4F":;9_[,JGI4D[N3*
MS^HXN:@+V>[5\,UQ',=Q',=Q2DC2R;6I"D<7PR3_0]5!%5.(D^LH%=$1/ZEL
MWTG]576\*OER?:K*UAFJ^J\J;<AFN@&>H2HMQ3FY7E&QC(@(NG#2@F_KQ_J3
M*C;B!ZG2NBB:?JO:5P7%.;GX[7S[(@$JQY;F3+)UV._[JA^B>2:VOT:%H^,C
M5=HZWZI&J]+@Y8](J;3M$",-$16(HR>-42K^W[1MOU1Q;O:]4"=76J+86-R3
M%J7(O6Q.W7P.V^$JUOFGJATS(NP%GY=_]O55]GM2[ZKXOV]7Y?I/>:'.Y6P[
M0O5W5;YGBG,8J4K"<\;R3U0X_U@OWFZ%:FTY;]8V^9Q<!@Y$[G/6^0,SU@+N
MY/J%\G9RU5,]IF+_1.'B!$[B3J[\N)/+J2S0^(>MP?-,'5T>$'WZNNI?*NPB
M;%ILRODJZ*'"WL8V8#1'9V4.5&'[H%SUM.,XCN.L1-+)!43F3%$Q[W^JKBHC
MGY.+EP'KHO>>:G]5$I*MGZRRW\3)$A,[N7"0\-M)1QA.%UL'AUII*-3)A9:I
MDGG*>/&U+C,X#XC,B<%PLA?#7"^F^9Q<1&F=I2(ZBLB;)$2*_46%P701,Q+8
ML:,;5<D7-1R(\3I7J)*.CC$J6TYWK1B,,IP^_#Z.E614&?\9QMJ_51ANAZD,
MG'*,1L1^<1+&]Q=POOS>FRK[_?+HKEB63BZ$$9N,?L1I95W($/<5$4(Q1'U9
MM- =JN3]3G<YEN&4[*-*G@_K'Z["<8SQ?(^*^],P)Q?":7F"BN?0*<S)Q;V]
M4,4Z_)<&$3\,*Y_+L8D^4_56)?]3C'9;9["*KN))9_[>JM\EYB6U7&51@$3K
MX=!F?IKSIY^*Y;D<I;QTS52E=7,LJ9.+:$,B6)G_C(J(V#18CWN2]7# %D)Q
M3BX:$EB&0_EZ%<YAOB>%4QD'O\&SS3.6MB[B?Z;<A>*<7!>K*-N2^S!1WHQ3
MI3V'5J]P/:Y3I76GI4R]3,4]2%U-.9M<A^UR=<4GBI=Z(]>UH>'B215E4QH#
M5=1[:=M2]W/<]KT0)Q?/Q\NJ>#])4?Y:5!TVRF05\RGWB'1.XU@5#29<;QH*
M8F@D8WN.%SO"(J^3XMG<4T79^TYV7BR>6^IX!I!)@W*%9R#?O45=9_=63!S-
M3#WYZ^@[HO'$!ZU9/2AG[7H>QXPRALAT>Z8I1ZW,P6:T1BWL(QQ@V '8Q\[*
M8"O;?]2&&27@7!7;T7#A.([CK$>D.;F,<U0XN7@IHJ+ *9#/R<7+-"\LO PD
M#<HDEZOL=^EZ9<1.KEQ1 1@&.!189P(SLF#P8[#P IFFV!%3J).+EORD \O
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MEZF6?O"Q//#:FV$:,3\>B"(XM MT:N?2Q3?/C,^9G&5-5-;PZV6 XSB.L\;
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MG3\>9'BS0=9Q/D;TZ?FQ/^]O,.MO=WT<!! 6-15D&V2QQ[/>"\9'/B=Y!]M
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MV[=/WB2\<MLV>7'+%GENTR9Y=N-& _^'"'M)/T<!1ACF^_OWFT$\RBW(%[(
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MI4J9)QE^5:C&4$"%B)E,8@A2YC>I:;(^=:W$:MTFIVV1SU-GWG"^@!!"US:
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M8D#V+M*8Z.$[P5L*FQ2TJ%W;R",_<L#!$4$0/1 -$ [X425W[FP/ YN4AS_
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M7C&+SMG;LT;Q$XS$2=4).=D-.S=N?$.XGP/^7J6+%;.,A)!W/5JTD'Y=N\J
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M!Z1G[9:2*T\^Z3YM[_6YEW=.ED- ND.VDU41<@N%%.HG[2#RGD(G]_*T@O#
M?@IW/@[:R40?G/*\@FNI']X3T#=<_X"0 O03""I(+\@JB"^(*T#HH -_\QU]
MBFWY#629VX\CMV[5=SEWLH'JHB@\-%Q_9FN3R0K60\P;$ A@GT&(,.2R>W'
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M @P2%O47BT:(,$<^ 4@I!_<9WS/Y]GH0\GN(-";C[---R#E..+QAECK/OYZ
MHURA0I:YSTO@./76CU.F6(CBU^/'2TJ=.E*X=&4+1_0;8XS,\8Q_CO@R-2L>
MAIGDEQFO;\O(/HC1.HN>1KW'F=?5TDZ=Y*4A0\S[ZQ4%WF//#!PHDUJVE#R>
MD$3&>LS5G1<5_ES>[),.U!^XO_G>;>M^>S?$%_OI6K5JJ%[5V\5)\L87,Q9X
MCNB"!(3L\FLS!6&+9%CLGK9?Q[\-DK@XVI?$NATR0KD'2X^TAV5:ZA9Y;<SU
M%Q(*2"[(5?H4?84%VYV^ . W.450?MZ%:^A>+#+&,/;0ER#447=!O+ND')!>
MJ%3?5/#B,41Z 1W,C*1 L05Y QQ!0^@=A,QSBFH*MN=EV:['KOD21'>+$&'U
MW0_FDP6>_.9[>>+K[^3Q6X!M -OS6\-=D%Z1R2FA]HE1D$T2<@JR"G6;([IT
M@YO"$5ZN3?V(+]K7D5YD2(2H<L<%>I&ENP)5E]OO[7!6H0\8_6\&\A<M;=G&
M'<EEOJWZ#,CB.WB+9T$*V6C7/2=):Y]1/&TJL,353YK/+:K@BHTZ26,]#B06
MQ!4J-#RW(.M>*UE1?M!_:3](/,A2?+X@^% '$E9)MDX= $/U5:" 1OW/,Y6^
M[<@L]QQW<\A@' M*4((2E*#<T\*#A8<,#QT6BBSJ)BKT^97QD"I5M*@<FS?/
MR*%P,L0/?B37MR=.F E\S8H5+3.-WV+DEG +/*=J,'(K0\U MD6431AO8MS>
M0!=TW:9NE]CY8R1NP5")G+E=4I<?E5]?O"S_=OFR$4!S!PV2@D5+9:2$]CO>
M'8"0HKH]!DNN7+G,8PO""B\RPB&=YY=?>X4#T_RRF:;&U<J5DX.S9LE3Z];)
M"YLWF[?8F[MVR;M[]YIR[--#A^2K8\<L;/)WY\Z9[YF78 M7D_WZTF.R8/4)
MZ3_OL+QQXA'YV[6L=4)U-SXNSI1OF==?YW/WZ9S8LG$RV4:]XE1<3,J#B4E0
M_KN*FQB[,<P!<L$1]HX$8V+M (GOX/V<[1SX'?W;O54.!Y^S'?N X(+\/:X(
M^6WUK%Y=WA@QX@;/*@B?D((KT_ ><WM^TZ+?;-^QQ1=>TBMS7+2Q$>++ /GU
M04;V01TK*S?K(2W+ES=5%N;ZJ+I0:>&YY>K<I4H5>7[(D!"AY4@LRZ88%65A
MCXW*E)'RA0M+D7SYC(@GRR AD;5+E) (/>?Y[=O+.WK>A%_R6R.^/&173@DO
MB++HZQE>[45&RH:7;.R'W'-$E[6'IWWP*&S>=X9EWZU=LJ1LZ-%##@R?(/VG
M;I.>,S=*0GJR+YGEA[CYHR1B^@Y9D+91/D^=9?5Z8?!U8VO%%PI'<D%VTI_H
M)^'CXZWZK.MOKM^ZOGLSN&V\_=3MSWN<H/P\BK=/<%V=:A7""Q(>HL#Y$[I,
MM+R()+21$.O#BM\IO/W2?)7TP2U1BEF*TPJ40GH0^[Y;7+Q<_N0S7W+H3N'(
M+2^I=>W+;^3P\R])O_$/29TF3:5"S?JFSJS7<[@TBATOM;OVE\J-.TNEFK6E
M9><N,G?+-GGDDT_E\:^^E2>\A%?FOOV.>S,0MGB_)_SZD@+5%:04)%5V2"X'
M1W0YD@N"RYG4XW&&,DMO3MTT Y44&,2CZO+N)R?@&#L4;K^$H;?0L8U,Y'C4
MFE?AWNO/@)L^"W2\M!<B*,!VOB,#@,Y;'2#$N!;:\<Q[C)!,2*SS#3M)TD.;
M==Q<)U%3]\@:O6;_FJ^ U0O0AI"%J 4!8:'N_!5[%"Z4&Y*+L8OQ*AB;@A*4
MH 0E*/>\N,D4DV(>."@1F)S/5F 2:0^GEK5K&['B)4&R R_)98;S%RZ8D@M2
MAK ^_*UZSCB494%R4WC(+1[6%JZC#VC>3'4>OTF*EJMN=<U7N(0TB!DCW5.W
M2]R"T=)W6=O0 H7_QR\8IL?<)A.7')8A"?TD7Y$2TG/6$?]CWB5:#9HO98H7
MEXM+EQKI].^7+V<071ZRR>'[2X_)PC4G9.C"P_+RL4="GZ?V[1N:)! :^E:F
M4@M"B[8D[-*16A!3D'>0D,X<WQTK_'A>L WD(R&)29TZ61BJ.Z;B_U:0\09C
M;\*XZBD(4X0$I;\P":</!24H/_7B%OO9A5]QW]'GF:!#8K  )7SW187=-Y ^
M#S9I(I^-&W<#60,<R0/Q0S@>)O-D4QS>J)']GG \OS$E1PB-F9_(X'W7E5Z=
MQF\TPWDR+U8L7#ATKY?(GU_FMF]O(9-.J05!]<F8,9:I$F^NT@\TEM:#Y^NX
M^ZK_,3.!@J#;E)U2N6DWRVC61Y\A*,<@\T)*KSM0=WVN;=2I<N7,.M\OQ2K6
MDMK=!DCC^(F6@;'E@#G2)'Z"U&B?8*06Q%O#TJ5E0O/F%HKYU( !IJ9[>\0(
M.Z]7)J;*Z-1M$CESHR2F)V1Y7EQ_;K23V/GCI>?T73(O=:-\D3HS5)_?ZWDD
MU:D3:D,%GF^$LZ(*A.2"_&2,Y!GK""S^YGE+W^%[R O"80E)2U:,5ZQ0D(WS
M!<7KBO<4A+P"LCCBBP@@,R#6R&Q\3L'QQRCPD"/4S2DFW(+2$6"WZN-!^>D4
M=YVX;O0;KB7/752"D 7T,T@OR'5(+\*R"0MS23FB%80XGE2\KR#,\3\5WCXK
M^0L6E/G;=O@20W<"(Z R55N06Q!;9]YZ5X:G39=2E6M(\[[3;?[F-W9XP=@5
M->>8E*_75AJW;2M[KCTA5[_XVLBRD,(KAT179$J_+.?NH TL#R@B%804;E:<
M49"1$!"R!WEU47%$L5NQ2D%8'KY:/1006=Y]5E>P#>HN_>"> 5\PE&#N..7J
MM9$^*QXSPM^K; T1_IG/ GL>. 5PV$L1+P;N>E_J1XVR\_DT=Q[9US)*>D_:
M+M&SYTO2D@@;%U.6MI?>\\=)C^E[9%6OT?*[HJ6,]'-*-T"F19THNGJ293A-
M 2'+.H/G)N,?XQ)CDAN7@A*4H 0E*$&YX\*#Q+M(8R),> Z9H9"]&P$5H0L#
MB!,_8B0[<.0**B(41<Z3Z_,C1^2=O7ME4/?N)KG&^^J&#(L.[J&L#UX>W -U
MD<8;*SP'FB9-E5QY\]L#E PR+0?.LP=N_,*A-RQ4PI&PJ)^%[/68<5@P,;[I
M\>\255M%2Y0N)C%NA^1#T>8EG_[TZ#5)6WY,Z[W/LADF+^FI"ZXU$C/S@#QY
MZ*+\^=(C<G^FPD(OFF6+_/KX<?GMN7/RIT<>"7E_T<; 2VH![_5 1>:\T?#N
MBFK5RDT^O$"Q]3\5SRK(%(>Y-IX@3* Q!B64B\4;;Y>9>+M)>%""\DLO;B+.
MN,GDG(4FBTDF[W;_%,Z;UY1"**"\Y$PX('90)D'X6)CB0P_)QZ-'2]]Z]6P_
M>/WYC2?9@EO,9(Z9&6I7QLVW+4R%+(7WZ9A2J6DWZ3!VO31OT$K>&#XB%#I)
MG7Z;Z0TV1<>N^W/ED:8)DVU_OL?+!B)G'9+\A4M(Y\J5Y:OQXXU(@T#C>"Z4
MT:^=_(#1.R0=[406R,T1$7(H+DZ.Q\?+J3Y]Y&Q2DEQ(3I9'4E+DL7[]Y,D!
M ^3YP8,M-//=D2.MG:G#]Q,GRN_T7"&J/ILV0P:D[9*(Z=OUV9!L(8DI2]M)
MS-SI$I&V7Y:FKI??I*9EJ<>WVCZ)M6N[<5/7=$9(,5Y".+"(XT4 H:V,ESQ?
M(2"6*R ;W.]N"I3 >?+DD;SY\F4@?W[)!PH4,%(B?X&"]C??L9U7H>(#7EJ1
MU0SBBSKQW'?DFUM<!N/X3[^XZ^1'>D&6\GS&[PC%C$O*X26^2)Q!]E=\ DFT
M8?VC7*5*1A[YD4(Y@5-703Y!1%W]\AMY]%>?RZR-FZ1HZ7(2M_R*[_B0'9!\
MIT3E.I*Z<K5<_M5G(;++J^SRJU,XENP_$+HO4/P7*%'N^M^9T!LB]%E.@<HJ
M5:%__$.!4HKC:&?0/^^38A5K2N+:9[2=,L,7==PWTDKGSW[M>2OP_"E>J99T
M[]K?DA#UFC/;DA+YS:5!_,(A-O>>E3Q=_IXOOQ%<U!%/LJZ9];L)/E'T51 5
MX'TAX,:DH 0E*$$)2E"R7=P$R9%;O$%^5 &Y80^>R;I(@(SR$B1W"H@6B!>4
M12Y$\/N3)^630X?DS9T[9:LN=,J7+"7EZ[4Q?X#0@S:,W$*!P"(M?MD5J=HR
M.I0)IE#IBM)F^%+I.6.S]%G4W_<!?"LDIL=)SYGK)7+N">F[Y?4L#_I[@=:#
M%UJ8YY='C\J_:)OB ?8?VA8?G[DLDY8>U8G!7IT@##2U@+=>24MZ2/2<A68$
MGSAP4FA2,"8VUE1<J+?<OOY^]6H68HMCG9@_7Z;I(J][LV;2L'IU*5VL6(@L
M\\';"A0 >&V108[), ;<&&X3%L&;8A9I+-:<>LL17$$)RB^]T,^9=-/O';E%
MUL4?%) ;%J*'@?OMR"T'/Y*+;(6$^+&_S@]M]AU/;@?O&WKG4X@?2_3\TU*F
M5@L= W)9N&+G"=MTX3)7$M(3)7+F6B-XGI\VWT@?,CN^.G2HA326J=WR[@@W
M#UAXU8\>99Y@#\?$R*\]))-3=?FUE1^&-VX<&K_B:M8TX_RK_?I9"":$%FJM
MUX<-,\76^Z-&&;%%J"4AH1P7]1QMS_5R)!OX*'6VI*9NM@5;=-INV96V4G[G
M(;?8]K&^?:5UA0JAXRM0QNQ4H% @40&99P\H/E3\11%ZMGI1MF)%Z9&0**FK
M5LOF\Q?EX:>?DU.OOR6/?/RI/*6+=K\%^NU .->%#SZ2 \\\+ZN.'I>!$R9*
MN<I5PH]-?3]2C%5 Q#$7<&J*8$S_^12NE1N;O*27"V]TQ!<ACM@+D"P#THM$
M&]@.O*.P/C%B^@S?_I13./46Y--CGW]I?;E+;+Q4:-#!O*#\QH6<('G]"T9T
MC9D[3_?]*[GZQ5=90AC]ZA2.?4\^+:7*9A!;!8J6EI;]YTBG<1NE5/6&HI,<
M.:3 ;!US=YT8R^5,/**XH$#=M4FA$R-3?[DVC%>009'P1?W@OPQD,W1U(&D2
MOK+]M[XA W2\Y06'O9S(P4M<HB3:ZIRZZY3MTGO>E%N26UXPAV4.'IFZ4V:D
MS) _%RYN"C94;M0-S[?^#TV0M+7KI&7GKD;.NWHK&).^5A!N2[\-QJ2@!"4H
M00E*M@L/"C<1@MPBG2^+M(R'HRX\IB0ER8_GS_N257<#B!=41A!=^$3AS85W
MU*>'#IE1.J&0<W5A4KE,&2E>J;:T'##74B([WP",-4F!7.J!ZPL;ZCMD\ 0C
M@? '2,Z44-\)4I9VE>C9BZ7'C$/V)@R)?/B#_TY!R"($TZ_T7#GGEP^?D0?3
M#VN=-^F$(,6W/EXD+^DNT7,62.>)6Z1*BT@I5KBP#.S10R);MI3ZU:I)D>L9
M#V\&)@^$M7RJ>$*!6H]PF!@%$UU"9/#T0*W% HUP1++?$)((L<4;-A?R0M\)
M)AU!^6<IWC&3A2,JB?F*4"AWBTQO*R\!DQUX22Y43=],F&!$S&O#ADFM$B6D
M=(VF.A8]ZSNFW(#P%P(8#NL"![5K^U$KI5#)"G)_[CQ2N7F$=)FTP\:3Y"4]
MLHPSB>GQ$JGCZ(C4[?+$A!F66;%JBR@CR7R/>1=@?"]5H( 14]_I>3O"Z6:*
MKN=2%\C0M)V2EK9%/DZ=;9]!3M4M52HTSJWOWMW:[KU1HRP,D;#&+\>/EV]U
M_Y!:O\DDMO &,W)+CW6SXX'?I$Z7'U/3[#B$62[NU"E+MLE,8#(/N44(SJL*
MQMKKW]]_OU2L5EVZQL;)Y*7+9;\NKO$5\EMX_U?@TD>?R,@9,Z5LQ4K><\ [
M;JD"Y1E]/!CC?[Z%:^; N 5) -P+39[E7&<47@,4U@<@&\Z_]Z%OG\D)G(*+
M/O[8YU_)Q0\^ED&3IEC8,)Y/?F/!G:#[U%U27._]O=>>R"2Z/(JN;*BYCK_Z
MNM1ITB3CW L6M1#GF(5G+>-@S8[)<O]]]\L>_<YE#"3D[BT%&07Q,--&#-T_
MM10Z !B9@WJ)<#T T>6 7Y>#]W.W+;]ST)W>$0B=U!M7_WN?S9-CTR]:EL50
MZ")JKML07<Q[XY=?E>ZI^_59L%KGQ9VS/".R"\BNWO,FF0)L?NP$&9@G@\S*
MDS>?C%^P2$Z\]H;VC8^LC^ !]]"BQ39.NC95,*X2<@T![PUG#,:DH 0E*$$)
MR@W%37J8[!"J@$^#&9-6U,G"U56K?,FI>PFGZ'+^7)BQHQ9#E?3A@0/RQLZ=
MEB'P\35K9*4N]IK6JF4$CE;<^_"3<L6+R]&Y<[/L^^DC%Z7WS(,2-3L]VV^=
M0-]E'21Z]CSI,>.@)*Q^TO?!?[>HTJR']&C>7)[??4#ZSST@/6=LD>2E.2?D
M4I9UTKHNDF[3=DN-CLG_)U?NO"Q._JY *?!K!>&%J =8<.''0N:E2 49;2"R
M\ QJIX#,(GR!-[H8)/-VEU3E3'XAM9A8\!:8!4_XV[1@DA&47WJAC]/?&2^]
M/H7K%:%Q""7/!P\^Z$N09 >0*X!P/<+V")W[;.Q8>6?D2#,R;Z7[+U.KN2Y2
M;N);PX(ED]QB$9/AM_6!]-_QCF67;1P_P>I)$HY*3;MGAIS,U_&QD^_XXI"X
M.%['J*U&AO5>?$GW?^_#N%GP5FK21;I6J6)D%'YD$%#>T,4_*1Y/723Q:7NE
MY\P-DK0X1A(6)>EY[)*Q:=OEL]19%K;HKD>'RI7-1)_]09RACC/R3/<)H>4E
MM4"6:Z&?0WX1?DBFR7GMVYM!O=MW)E#L_;\*/(VV*1(4^&?IVC=CF_P%"DC*
MZ'%RZ-D7?!?7/R7@C]2@!<J^D+J79PGGX_41"Q:6OXSBQC*(+K*^\A+K*85=
M^\&3I_CVD9S PA2_^R$C1/'SKTS!M>?JXU*G<1/SU/(;!^X4*1M?E(*%"\N<
MS5N-G'OTT\_EVE??FD>7U>,V1->Y=S^0EEVZVKGGSEM 6O2?)?$KKTGRNN=L
M["Q3JYDTT>^>5Y!1\&E%!X5K+VU,::[X5N%(+$(',5S'>)X0/4>(12CP^=(;
M2>HHR.@X3T'&0C(2NJR._-Y+?N64\.)W.O'3_V:@8N,NDK3^!4NZX?7H,K++
MTY:,[SP[>J=?,#)2.X=LU#9Y*"E5(E)W6<(F/Y]"/Q#BG;@X5GI.WR9#1JV6
M'TJ6-T/_ 9EU(LQZXN(E64@N,F@Z<O+(BR]+N:P$/&'=1!0P'V4N2C\.QJ.@
M!"4H00E*EL*#@4DK"S;DZ\C5S1>$26YU75!MT44!Y).7/+J7<*%TCNC"1\K"
M%\^?EU^?/BU?'#DB'^S?;UD#G]VX46;VZR?%/:;(#:I5DU>V;3-?*;_]_\>U
MQ^6YHY<D>L;#$CEKA20MZ>G[( :\H8J>G2X]TO;) ^WZV +0^^"_5VC>=Z:%
M*NZ?.5,N;C\H?69IW6:ND>2EW7WK=2OT7=9>8N:F2K=I._Y/LWXS7BY0HL((
M;1?4>%XU%A,"S.%19!&&2A9$1V3AIT7( D:UD%GT Q8TD)[T"Q8V@3EQ4/Y9
MB^OKW@4A83Z'%"1?L(5*_WKUY%=CQF0A2>X4D"THA2!83,WUT$.F0GIS^'!Y
M8L  &49(WOVYI&&OT1:J'1I;,LDMI]RRD$3\MC:\*%5:1EK&+>H+N=5YXC;I
M-7>NCGE=?,>5FR%)%RN1L]9)S]G'I._6>QO&/7COQ]*DSR0SNO\PTQ\+4HIV
M^,.T:7(R=:DDI.W1XR\-F1P[L.!*2$^2B!G;I,_$35*S=E,[5[(\'HV+,Z+0
M2#,46Q[2#$!Z/3=HD*SIUDV2Z]:5)F7*2!4=GS&G9Q\^X 7"(XKI"D(0\3,B
M))'Q%B4LA)=M&Y&89(O[\ 7U3QDL+/<^\904S<S@FXF7%#POZ/_<!P'1]?,O
M;DR#B^9K)   I7])1$%4+.#9/U1!\@*I5/T!.?S\B[[]([MPQ))3<5WY] NY
M\/Z'LO;X2:E:M]$]5X/&+#HOA8L5D^4'#LG9=]XS-1#&]MDEN2Y_\JETCNEM
M_3U7[KS2/#E-$E8_8017WRVO2<^9AT0[OV6AA/1A.X>-"K(G0BI!3)%1$!-X
MPA=1=>7*E5MJ=QND8]=125SSM(4-<OZ02;RPZ+?U-3W64SKWW"\/M(TS_Z^&
MBI,*""^R$SK"*Z=D%[\9HG!U+52JDC2,&2,]4O=+PJHG+&P]9=-+IEAK.VR)
M5&K2U8BMPEIG'=PLV^;KBH\47RD^+51,ED4_:*';O>=-M#FH=RSVHL^BOCHF
M;Y:1(Y;)]R4KA.H-24A8)_4A/'O)WOUR\O4WLY!<7C^UQ[_^5D;/F1LZ!P7^
ML!,4J!"9IS(_#>:E00E*4((2E%!AH@K)Q<05<@./)0@0)N^0768V#U!/]=-%
MP(6E2^5?'[F>Y>]>PH4OXB=EX8L7+AC1]=[>O9*6DB)Y<N<./>0Z-&QHY);?
M?OSP/ZX]+L\>N22#YQ^V\!L\MWC#!)*61%M88MRL _+PIH/RYJ[=,C4Y60H4
M*2&=QV_TG5#="7A[5JM3BIGW;].%U0?[]IEB[3=GSLKC#Y^5OG,/FAR<$"&_
M"8,7*<LZ2LS<:=)ETE:IV;FOY,J3CVNU3\%"B_3A& GS9A8""\4)"W/>UG*=
MF1C@;\#DEFL/D>4ELP)"*RA!R>CW7G*+EP!D2M1U0P:Y-:)Q8_.J\B.K[@:0
M,*B,('C8_]?CQ\LGHT?+6R-&F*(+_Z>!]>M+D;SYI'S]=M+AP=7F;6-^6[OQ
MVWK;0E,J-NYLJBWJ6ZQ@$1DR;(XN3O;IXF3R+1<GMP(AC9&S5DG$S,.2O.'%
M>Z;J@N1J'#=!2N;/+^^.&B6?XY4U<:(<G;I8DM)VZQB]T,*T_>KD14:(Y6KI
M,&:=E'Z@B;2I5$GB:M4RE5V5(D5L_*4];@$64"0-('OA"46Z8I "!6PW!=Z$
M3OW*BP,\"@$$%_XQMI\ADZ?>L)#^.0%C\,B4OA9>F7E.]'V\&)U!/?=&\&SX
M>1:N&\]YE-FHM$F*<%5AB0T(7[U3_S<'(Y8RO;@>_S+#:!ZUU(;39Z5:[3K2
M9\4UWW'@3@"Q7Z-CDC1JW<:4/_>"Y&J6G&IU3%K[C/1:<-8RL_(=]P-C:F?]
M_RL*B!M';OW?BE\K1BC8ID'T@SHNO^Q;Y]N!* *2@134_<S6_?U9 7G&<5")
M<=R<D%VHT*S^"GS"QBF&*?HKABO('*D#G9Q2H%9[54%HYL<*R"T=$.5/BK\J
M.,^_Y"T@6[L/DEY3=ME<U(4Q$I88OV"()7!*[3=;OBU=*4L]=8 T]9JK2X(^
MTPX^^X*<?O,=>>2CZV&F7I++X<2K;X1\TQ0\AU<K(&B=)RQSUJ $)2A!"4I0
MLBSBW-L\E#T074S@R0A%J,*3"MY>Z[,JX\&D/Y1>;=J8;Q9DU,V45-E!%B77
M8X^%PA8_/WQ8IB8EA1Z&'#.Z52O+(NBWG^SBH[.79>#\P])S!BGBUTKRG(/R
M_.%S&>;WIT[))P</REN[=LG>M#0+VRQ2IJI$SSDN@S'J])F,W [XX'08O4;R
MYLTOD5K_%[=LD7?W[#&5&J&9?[QTR;(;_DW;\)V3C\C0A8=U(;K3%FOADG#"
MBGK-F26]9AZ0C1M/R*2D9-<^A"EN4!!N2)@AA!:*+!;G+$BXQDP"'(G%9,"!
M?@""$I2@9-P+W!?<)Y"_$,)S%':O%<V73]):MS8"RH^@NA=P*B/(+KRB4!L1
M-H<B"<-TS--1'V&J?CXQ4<8W;VZ>7=0M=QB)0V9'O*.<^3W9 )>DKI>>:0]+
MW(+1V2:["/G&E#YBYB%)7)=-7[ < -59N7IMI7O5JO+&R%&R?<)"Z96V5Z)F
M$6Y^ZW!*/Z",[3ECO71^:(L4KU+O_]/%*:%W_Z;XO8*7.!<59!8D64!O!>'Z
MJ+(@LGCV=5"0?8Z7!KI&M.<B) \9ZG@A1+8ZX%X.G558F\<,'&2*!.\"[><(
M"(HNL;'>_O2-@A<GW!/<&]PCP?/CYU6X5LS[G$T%GH*0N':-2Y<O+Y<^_,2W
M/^0$-R.YCK[XBD3W&R!E:C8SQ:G?6) 3H%YM.WR)E*Y8V?RXCKW\FAW'A2NZ
ML+?;D5R$.+;NUMW: -4K6;J[3=TMQ2O6LL\@K0CWZS)YF\[/]LK2W@_)GPL5
M-<+)*;<@A?+?GTMJ=>[K6]<[0;\MKTKEIMVDP'WWRP>9Q^%X'#<GJJZG%"C1
M.)?ZBN.*YQ00=81)4G<=%(W40FD%&?6#0@=+^5<%(8:06X11AA][=^=^$C-E
MET3/6B(]4_?)O(0I\M?\A4+'A@1DW^T4KI\5*%1(IBQ?:8;_QU]YS=K_RF=?
MF.K/$9-^UVFW7N-*#SS@]@/1-4516L%<EWFNF],&)2A!"4I0_LD+#P0F/"YL
M$6($U0]$"2%MO*EFHL^DGS?5$Q6/*4S-X%! %U</5*@@:;KH^G#__FR37H[@
M,@77E2N6&?!?SIZ5CHT;2^[,U.>\>4_JW-DR!_KMXT[ ,3\]=T7>/WU9_GHU
M0SWFLCS^^N1)^?3P87EW[UYY:<L6.3AKEK2J6U?RY"MH?CC=I^ZY[>0,4WRR
M\Q0N75GRY,DKPR(CY?+RY19V2?BERZH(F0>I!\%'G5SXYK<7'Y.'EARQMV&$
MX:!@B)JU5*)F') 3>\[)?VB=(<A:UZOGKL%_*#".1[T%P17N5^!%4((2E)L7
M[A'&12_YOT9A]UJUHD7E7%+2#<34O88CNE!TX4L%T47X'N&+GXX98V;JF*H_
M,W"@*;OFMFLGQ3R9J8KFS2N'8V.-)//;_P^ITV5YVGI=L.V6N 5C?(DB0$AC
M])SYNMU^:=6ICU32A1X9NOS&O;M!P]YCI4S!@G(X+D[>&#5:UDW2\2YMKT3/
M7G!')%?*LLX2.7.E=)RP\3^KMDM8=U_NW*2DQY/0J\8BC+NY B46+PCJ*5"U
M."(+%2PD &,JBA?('8@!^@7_9W$%T96JT'7??5*^2E4Y__Y'O@NTGR-8;$9I
M_^+<,O&\@@0D@:+KYU?<V.947$[!'PJQ7;+O8=]^D%,X8BD\7/'X*Z];.&R+
M3IVE8J,N=Y6E%057];:QTKA-6]EPZHP<? Y%T-M&TEG8FX?D\JNC%R=>>U/J
M-6V6T<=U[IDKTQ@]5][\4KMK?^DR>:?$S,W(*D@$0,*B?A(Y?8N,&KY,/B]6
M1H[HMMJXTBPY[8Y?B-X,S#?K=!\D.A!9AD?45([H@D#R([K^HT!AF9N4*J_H
MG)7O(:=0;'%.U'.: M+L<P4^8BBU\ W[HP)2B_!+"#6(K?!P23]R[?_1>>X;
MU1O;<=UG9)S4Q8/H@U3_S #SX<&3I\JFL^=EWY//6'\X_^X'IKQ#Q07!=;MK
MQF_=_A2\X&4\IR^[T,6 Z I*4((2E*"$"@\$1W;QAI9)/)-Z)OB\N67BS]MJ
MS,D)VR$LCC??O$4YK/B50I^#UQ]F/$BKER\O29TZR4)=C)U)3[=L@A!:7K()
M@@<ETY\N73+BI[,G#7SZ\.'R=_W>2U#=2SA2B7J0Y=%49%J/WYX]*]\</RZ?
M'#@@;^_9(R]OW2K/;-A@YO;3DI.E5^O64J]*%2E;O+@4RI_?B+ABA0J9\JM9
MK5K2KVM7F3]DB(5W/K=IDY%;A%U"GGUW\J3\>.Z<$7H0>UZ"*[Q^GYV[(FDK
MCDO*W$-R:?_U#)=DNVS?L&&HG127%5P?%ES.)#A8? 0E*#DOCOAG 0^1 >F/
M']$PA:X),L@,4$_O]P4=.IBY.:HK/S+I;F&*+@5$%^JQWTR>;";JA/.]I\==
MV+&C5/#X%#8L75H>[=O7=U]^^#)UIBF[(+MBYX^5E$QE%V&)D%NQJ7MEQX2%
MIJZZI&,?F2/)=HN?B]^"+*?HO^T-J=$A00KIXF=+SY[RNH[Y'XT>+5\_])!\
M/VFR[)NV7.+2=IN*+'E)MQO(K' D+HXV_\4.8]=+V=JM\"_[F[9+B@)_0A19
M9)%#L0Q1X[P((:MXWCD_0E0!D  NC-NK@@7N&0GYA=)+UYP9[;_MTJ.^"[.?
M,U#&-&W7WO4QGO-D7N2^H UHG^!9\_,H;I[G5%ST?^PI[-K6;-# ]_K?*8SH
M^NX'(RZN??&U$1F$$AY]Z179^_A3,F[A(JE8HZZT&;+0%.]^XX,?4C:](G6Z
M#9(*U6O*Q/0ELONQQ^7@<R_*R=??LNR-5S[[TGR=3!&4S;!+ZE/"DRDU?Y&2
M4KO[(.DR<:W$S!XAR8M;&[G5#V09;PB/7B.M!R^4:FUB?>M[KU"^?GL+-?Q.
MX26ZO*33UV6J2&J_61(Q?;O$+1@KT;.72._).^6Q1IWEL]QY;%[.^554?*&
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MU39/F^ZT<[K_E=>ZR^0Z0<)<S2,G_*SK>\0[2I0I7,=X-PKC*R)+N0\I6S#
MN#>Y1[DW*&.(+*6/U##!Z+,MCP+#!*-?TOTES#":61\K,0+MJ=*YTLU2J_2.
M1-]W_Y'&2[F9T9!6D<Z3ADA$1F$X83S1AQ;141A2F%L1O46$5'L&4EDL%V;7
MK^==))VTYTEIJY-O3CL<=WVZ8</=TV]FFB7]GGD245E$>M$T,O0SB>/!U"(2
M["\2QA;'1;-)(K<:,=[*PA0CDDP%K'[^5_1%=L6##Z>[GO].,6KK4V^_-TG'
M[T1Q36JZOYL>>/6-M-%VVZ<5MSVHZ(>KJGSIC%;9Z<BTV<X[ZUA>;#/;NL7D
M(C_R$9IG!,]%\K0QQA@SS1$O=Y5:ZXAK%UMHG_-Y6,8T8XSIC5 ^\4*?1V9@
M/!"%%,971'Q%Q32:;V,N$:$:T1F88)O-/-^B.ZUWT*4O;'[\7>-V/./HHH\7
M5#:WF+;]:6>DS8^_<]Q:!USP+:U+]!4#:F!<T1\AT1]YTVZBL3#?PL2BPDS%
M.9IT$QE$Q9H*-B83E6W.*?^0T)-E,MME7^R7"%W2[5*IJ$PMUJ]?41&LJG1U
M1+G)U1HFUX_>3O=\]Y6TY6Y[I$57WKA;F@?M=_M[:;7=CT_]5UT]W?GL"T4$
M6C<T5_P_B5&!;7)-G<3]A:)<"0,,\R B2KE'>4?B/@DCC/N82##N:?)'WF5$
M1(-1WE!.8'1C@A&]N;M$/V\,MD%?@W2&3Y-8\MG1$H88QBJF.7VAGB5=)1$%
M>I-$Y!@FV7,2T:J3F&,JC-)+4AA(HZ3<0$):L$/"=/K=_(NE'8Z[)6U]RK5%
M'UA1+NY\UN%%T\&S=OY:^LLLLQ416>R;?KQ"_&;ZQQ)F&Z86AEOYN.J96\Q#
M&&5[2ODYHUEFFRWM<^11Z9K'GDRW#FU-]WSGY>)>?NJ=]XLR(/K@*HRES.2*
M2"[*"Z(_%URB7]KQG"<KRYB.B#)MX-8'I*66[Y^N>N31PD1[_*UW)C7=&S2Y
MMMQM]_Q<R0>YR45>M<EEC#'&&&/,5$!5Y30JIIA&5$RIE%(AQ?RB0EHTVY;H
MN)V*PG(2S9166&"Y+ZRSP6%7W[G9B;>.WO'T$])>%T;'QNNG[4\_-6UQXLV?
M;7#855?,WV]E3#-,*RJV85P1^1'-N\M-NSD.*LH<5T3)AI$59E8HSJFGB72C
M@L2Q<=Q$IM#A?5&9HM^?J@I71U687-*DD1/OJ%+Y1KIY2',:N/H:J=_:VZ>]
MKW^SLK+8B+YXS2MIH?Y?2!MNNUVZ_LFGTWTOO9*^]8.WTM,1-:$*;J,F5ZGC
M^;]*],^4FUQ<N\EQC<R4(^[#N$]"<<]&68,B&BS,L+R_0<QLR@8,Y"AW8N -
MC# BPC#(PPS#?(\1:(D$9: ?^A]D$ XBQ!A0B @QC#%&HL44PPRC_[ 7I$F:
M:.L BBBG:R7ZJJIG(M72&\NMD?8_Y+*T[=<O2'N<M]U$<RL7'P!V.6??M/5)
MUZ=C]ST]_6*!)8JH+Z+&^)LK-[7"V"H?%\;<B])ITI;2,I(**LV:5*NNLVXZ
M\*13TL7?O#==]\33A;EU]PO?20^^\;W"2/_V!Q.:*$XTN=M,I3"Y*!<81?.I
M]SXH#+%[OO-2.NW:Z],"BRV1-CKL\LJRIA'11''!95<K1NN\\=M#TKW??;F(
MXF($1_;7FI5'C91)67F$N-YNKFB,,<888\PT0KEB2F4441$H&V"(+^$8451,
MB\KI$NOML.1&Q]Q\QZ;'WSI\ZY.O35L<?\?(C;YV_?ES]M\DOIR':1715XAM
MLP\4^RR;6'G%>4K#\7!L5- Y;XRZ&Z2B(K7!-MM45K8ZJZA83NQX_OV?%J.=
MW??R:\7P_@>>='):8/%^:?T#+TS[WO3#RHIC60SGO]/YSZ2EU]DA+;W"P'36
MC3>G6YM;5:%\94*%\MT/B@KE1(-+^Z\ZMK+8QLRSSAH5RE])-'G%S,2TX)IS
M;7O#-313GOR>1G&OQ[V/HEPHES^4.YAAF.*8890O:))^5"4,]8@2(S*5*%$B
M1C&EB22EN21YE/["Z)>0$6GI+^QYB::08Z3(STD'D/:0[I+H&XLHJ[+)A/DT
M=)5-TQ>/O#IM=^IY:8_SMZHTMZJT^[D[IZU/N2(=MO]YZ?W%EB],K3"R:%Y(
M'UQT-M\BW20=(>DDDA)EXC&61<?ZRZ^T<MIVK[W3B9==431U_L:CCZ<;GAZL
M^W58NNNY%XOFR1A5-#TD6G3B*(J_GM '5VXFY497'LWU\)O?+TRRF[X]).VP
M[Y?2PLNMDC8\[(JT]_7?JRR#<NU]W1MI(RT[SR+]TKI;;%GT!\:Q17GTE,JC
M&%FQT:;3Z%LZIRPM=&D*,Y0\D9ONY#ECC#'&&&/,-$A5A337?RNG2^X]&TVY
MVW[GR^3;"/4U. \JWE22J& 38<)(<D5EZLSK;ZRL<'5%5.@B>F+"B&8_+?KF
MNO^5U],=S[Z0;GQF<+K@SKO3@-573S/./$M:8HTMT^;'WY+VN/+%M,^-/TA[
M7OW=M/5)=Z?^F^R59IUSWC3/_ ND_8X[H:CLWO3MH45%]X%77T^/_>C'$SN9
M)F)B8O1& Q5*=,19Y^252J)CB+K!>, ,Q!0D/_3%:VYZ!WFY$65*E#MAD(<I
M%B+?88Y%M%@TSXY(L>@\/R+$B Z+?@F)"*.?0/H"HS_"D=)8:;R4Y_4TRPPS
MIK4WVC-M<>)=1=/L+UZX8:61U8CVO&"SM/7)UZ2-C[PFS;/$"I/L)Q/'P+%\
M*HV2Z+C_2>E,Z5:I6&[YE5=.US_U3+IY<'.ZK>79PHBZ[Z57BY$J&141@XI[
M?LB'/R^: F)LM=<<L"@3-)_EB@C3G_Z\:-J(47;O2Z^DVUN?U3Z_G2Z\X^ZT
MUB:;I%EGGSW-.,NL:9[%EDM+JFQ:=*6-TKSZ?R:55325W&2'G=)YM]^9KGOB
MJ73+D)9T%Q%EK[V9'O_1V^F9#W[:*<,=??WJ:_+T>E<BDACSD^N/:6J3RQAC
MC#'&&#/-0X6:RC.1:42/$!5")]A%9>JJA[]56>'JJB)Z@LI>RR]^E0;_Y,,B
M\N+AHF+Y:F%V49&][LFGT]6//);.O?7V=/IUUZ>3K[@JG7;-=>GLFVXI.I2^
M]O$G"U.,*# ZE[[_U=>+YHG1_TY1T8T*90<,+K3X,LODE4HZ"R>"!B.!M"+-
M2#MC>IK<#,N5&V,8'.1)S [,+XQ8(GQHFHT10I-L^@BCLWSZ)(R.\C&^B/BB
M4_SS)49^_;4T5KM(<R^V?%KOP O3-J=<EO8X?_M*$ZN6BJ:+9W\E;77R]6GU
M+YTV8I;Y%\%88_3)6Z1S)/H;HP\R.N?'?&/42IIGAFBB243:;5)Q'ZZ^_OI%
M!_)$1#&8!/<Y39%I^HR9'?<[AE682(W<\RQ#)_2%T:7U,:(PR^@[Z^$W?U 8
M:91)MPYM23<^/3A=^\13Z1N//E$8Z^@:_<\T1DZDZ?6=SSY?] 5&<TDB58OH
MK7)YU."QH9:?_RJMO>EF>7G$:)X8F7Q\L>ENC#'&&&.,,6WD)A<&#GV3/2H5
ME:F]CSBJLM+5587AE$=0$-5%9?6I=]\O(KL>?N/[1707E44,K#N?>T$5S><+
MW?G\B^F;+[Z4[GWYU?3@ZV^JTCNA>1+#\D<4Q\3^;CI0F0R=,FG4Q)\EFH41
MY19-@XBP<=2$Z6V$^<5]31Z-R"_N;R)^HD_",+YB0 Y&HR7JBV:/-(.+D2)I
M_KA-OPUV/7[#HZ_]Z=8G?R/M>LY>E:96B%%G=SKS\+3%\;>-V>"0RUOF768E
M.MBGCS%&EB6JC'[',-,QV]@O$6>,5HEIP_%$7V4<%\O1*?\_I+3HDDL5IG88
M6I0;5:961^]W5%DF:3\3RJ0/BDBL1[[W@_30Z]\KFD02Y443Q$(OO5J450^\
M]F81 48_8!AP-)<<^K-?3#"W.FB\Y;KRX6^E>>:?/\JCWTFD*65U-)V/\L@F
MES'&&&.,,6::AHH1%22B/Z@ 8^0PXMO$_GN...NLHM)75?GJ#D7%D@H@%<$P
MO(A\H)*(<46%\<FWW\WT7M'7%M$6Y2B.B17)3E0F$?V#S;?0PE&AI.^;0R1'
M39B^"'FTEO'%/1]]@7'OTQ27YH[T\X0!%F83!A3]?ZVRR,"-MMSP:]>^ML6)
MMXW?^:P#TEX7KC?1W-KKP@W2CF<,&K_)H-M&K7?HY?3KQ_I$/V+&4*ZP7<PU
M[B/VA:G.?C&.,>"XMU ,$H(9QW$P.N5]$LT9T_RZ-^\8]GQ1)H4Q574?=T6?
M*Y-4KE"^#/WP%VGP3W]6E#F4/2'*J6__Y,-BWB0&7,G8ZLRQ4J:ML_D641Y1
M+C.R)M>#:\6U(WK/Y9$QQAACC#'&""J_-'6BHD1%DTZNJ=C2?.A]J:A<S3[G
MG&G#;;8K^J>IJHAUAZ)B&95+*K&(2AZ5S+(B@@.Q/,V-NE*91$^_]T'::+OM
MHT))/T&/2$2<4$DOCV+F2J7I:^2F5QA?T?=7WM\7T4$Q$$>,$(GQA!989(W-
ME]GP:S?<M/D)-W^ZP^DGI>U..R=M?ORM'Z]_^)5'SK'LJIA3K,?Z; =QW[!=
MML]^$!&D[)?]HSB6*(_8!D881A>C3WY-&BX5]R?]7ZV\]CKIV/,O*B*MJN[G
MKBC*D8EE4ENYE)=-5:HJBSI;'CVK;:VZWOI1'B'ZXEI'(DTBBHMT='EDC#'&
M&&.,,2(JO%0VJ802&4"T!?WWT%3H<.EUB4ZJ\\I66F+99=-V>^V3CCG_PJ+?
MK&_]X$=%Y:ZJLM89Y17$]E2U?D=%/S\KK;5V?HZO232Q(B(E*NZ.XC)3*U4&
M6&X\A2@K"O5?;_^Y-SWA]@LW/.[6?9KZ[\"]$<O$NBBVAV(?H2J8SGIL#Z,,
M,X?.]&G62%]B]!\V5/J7E-^OA998=KFTQ:Z[I<//.#-=>-<WTS=?_&X1555U
MSW=&5>5/KJIU.BJV<\O0UK3,P!7S<V- $,KDB"K%?'04ES'&&&.,,<:4B HG
M%5<B+:@\T9R(:('H%R<ZJ3Y5>E7ZFS1"HCE?7A&;J#GGGCMML/4VZ=#33D_7
M/?%T,2S_$S]^IVC:0Z6SNRJ$G17[I\/[&YY^)@U<<\W\V#^3KI.J*I14X%VA
M-*9G":.+,HDH,,QW[D.:/F)V<6_2SQ=]ANTL72%]7Z+O+LJERE$C0_,OO'#:
M=,>=BA%4KWKXT:(_+?H!I DTS:0G=_E$Q!;EXEW/OYCV..B0--WTT^?'RXB3
M=-9/!!?E$=&V'E'1&&.F)I9==MD! P<.? ^ML,(*#[5--L888TS7B.@-FK\0
MU86Q0Q0%D5WTK4,_,#0;HN-H*IB;2]M)].%%OU5G2W1:_Z$T6LHK:I_3]*K(
M,1S_W//.EQ989)&TZ%+]4K_^*Z15UUDW;?/%+Z8#3SHYG7[=#>GBN^\I1BPC
M(N/1'[Q5]'E355&L$B.;T6G].;?<E@XZ^92TB2JV_588D.9?:*$T\RRSE(^)
MBO$=TK82_0 1P8791SI@_KE":<SD(\SWJC*)_J@PX6/$R.@T/\HE1F;<0SI
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ML9'6?(# W&$>^V#9*,>8%N+C5\![09Q3&(2 &173ZYGF3TDLP_,^#)I(1\J
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M&2\@A(+G\#(5T1.81U0LZC4SB8H/7QROD?+CRQ5&$5]?&X'P?+Z^LP[1*_7
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MN;AWHG\@3!W,:\JK,#2)$**9/L^8W%CF7(E083WN-?(B'XM8-R_/&C&Y($Q
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M8MEZ89:8>2SS]>+7?V$:JM4.F>@FYI?3M*O-%3'NN+ZUFBOF)M=7F%!!##2
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M1X[5$U\ 8CV8'"87Q#*8;4$C?7+%>KG)10AM3&]/#TEY'F_4Y.*\XDL"7Y&
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M8XPQQAACC#'&&&.,,<888XPQQAACC#'&&&.,Z:,T-?T_^1R$9BN[V X
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>figure1a04.jpg
<TEXT>
begin 644 figure1a04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -A!:0# 2(  A$! Q$!_\0
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MQ)^,WC[7X/"]OJ#66G:-HLZQ1I-M5V$22*\<4:*Z+PA9R22V02TEQXI\;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO/K%O^7DKKTM;4^0O^"W'_)%?A]_V,+_ /I-)7UU^QK_ ,FG_"+_ +%?3_\
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M)\^<,W"YR,_I'\7?V-?@O\=M4.J>-OA_INJZJQ!DU"!I;.YEP,#S)8'1WP
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MF^$_[*'PK^!OC'6?%/@;PN= UK6$=+Z:/4KN6.96D$A'DR2M&OS#(VJ,9(&
M2*[(SM4G-[25K=K.ZM\]_+N<KB_9*FNC3OU>U[_=I^A^;7_!/_\ Y2@?%/\
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MHUW9W>GS?9M3T?4XQ'=V,O. Z@D$'!PP)!P1P00(OA'^T5_PM3XV?%SX??\
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M/80RVL.H0[GM+C'FVLRL4E@DQQOCD5T;'&5.*ZBFURNS!.ZN@HHHI#"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX8S?";2==GM]3@T&ZU>XU*9XVO;1$N'><;HS(D:D1C( P<_,:_03X5_\DO\
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MU634/$>D W'A37KMCG5[#!8)N;EF"C<N23A9$)_=\\%IG[2'PZ_9Q_X*-?M
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M\T?,EO\ LV77Q[^*G[5VI^%I/[.^)OA'QC;ZQX9U*+"RB>,W#&#<>@DVKC/
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M?,[FB5@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\V^-#_:'[2L$+?,(!%@>F(-_\SFOI*OFO7O\ DZ*?_@/_ *1"M:>[
M./%? O4]6KF?B9<FU\!ZTX.,P>7_ -]$+_6NFKC?C%_R3G5_^V/_ *.2MD>>
M]C=_9ML5M?AC!*%P;FZFE)]<'9_[)7J=>>_ #_DD>@_]O'_I1)7H5<TOB9Z]
M+^''T"BBBI-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#1O&6CVNK:%JMGK.EW2[X+VPG2:&5?574D$?0UL YZ4 +1110 4444 %%%%
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M(7!';!XKKZ*.S[!W7<*X63X#_#2;Q1_PDDGP[\*/XB\WS_[7;1+8W?F9SO\
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M&\,:%IOAS2(F9X]/TFSCM;=&8Y8B.,!0222>.32>)/&GA[P;_9PU_7M,T/\
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M<,*[6N66[/9IZ0CZ!1114F@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5QWQ2^%6@_%[PS+HVNV^X<M;W48 FMI/[Z'^8Z$=:[&BJC)Q?
M-'<F45-.,E=,_*WXN_!W7_@WXF;2]8B\ZWE):RU")3Y5TF>H]&'&5/(SW!!/
MTE^S'^R3]F^R>+O'=F#-Q+8Z+,O^K[B2<'OW"'I_%SP/K/4]%T_6OLO]H6-O
M>_99EN8/M$2OY4J_==<CAADX(YI-4U:VTFSGNKJ>.VMH4:26:9PJ(H&2S$\
M #))K*G0P]"HZU&%IO[E_A72_7[E9'FT\#&,^:3NNB_S[EJ298UR3BOC_P#;
M#_X*+^"?V:8;G0]-,?BSQ[MPNCVTN([0D<-<R#.SUV#YSQPH.ZOF_P#:N_X*
M2>(OBAXDD^%O[.\-U?WETYMIO$MFN99>S"T_N*.<SMC R5P ','[-/["FB_#
M::#Q5X]>/Q5XUD;[1LF)EM;.0G.X;O\ 6R9Y+MP#T&1N/%B\;2P<;S>O1'TN
M#P-;&RM!675]#RC3?@Q\;?V[/$=OXR^+VO77A[PKGS+*Q\LQXC/:UMB<1J1Q
MYLF6(P?GK[#^$_[//@'X*V,<7A?P];6UVJ[7U.=1+>2^I:4C=@_W1A?0"O1M
MP]:AO+V#3[66YN9D@MXE+R22'"J!U)-?$8G'XC&2Y6]'T7]:GWN%R_#X*/,E
M=]W_ %H97C3PUX?\6>&[W3O$]A9ZEHLD9,\-\@:,* ?FY^Z1V88(Z@BOASX<
MZ+<_LL?%C4?&'PEU6]O=,^TA9="U!]L.H6/!:W+==X;<8Y3R/ER.6S[!\5/B
MQ/XWN&L+!GM]#C;A>C7!!^\WMZ+^)YZ>=U[.%K1R?W:BYYOXHWTBO_D_PCL[
MO;\US[.HXVJH87X8_:[_ /VOY_G^K'PM^).D?%+P7I7B319VFT[4(?,C\Q=L
MB')#QNO\+JP967LRD=J[*OS:_9P^/TWP;UIK&_5I_#%],'N%09>VD("^:@[\
M ;AW &.1S^BV@ZU9>(M)M=1TZYCO+*YC$L,\+;E=3T(-?71E"K35:B[Q?]6?
M9K_AM#@P^(C779K=&A1110=84444 %%%% !1110 4444 %%%% !1110 44E8
M7B_QIH_@?0+[6M=U*UTG2;&,S7-Y>2B.*)!U+,>!0!LRS+&,DU\A?M8_\%(O
MA[^S>;G1;%QXR\;)E3HVGS@1VS?]/,V"(_\ < 9^G !S7RC^T5_P4*\?_M->
M*I_AG^SU87]MID^Z*XU^-3%=W$><,ZL<?98?]MB'.1]S[IWOV<_V"_"_PK^S
M:]XO\GQ=XOR)=TR[K.U?K^[1OOL#_&X]" IKSL7CJ.#7ON[['I8/+ZV-?N*R
M[]#RG4+G]J;]NYI+W6]9D\"^ ;K[EDIDLK26(]EA7,EP,<[I#M/8CI6C=?\
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MM<*RR&11_JQRQ5>PK]!JTT<%+K=K\M?QV\K];*-5*W2R?Y_Y?C;H%>3?'?\
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M:2;CYT7R_?X^\..:^:O@?_RAC\2_]@?6?_2J6OLC]C7_ )-/^$7_ &*^G_\
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MEPWF2K$NU7=%/S.,Y8<9^E?.O[?4R6_Q:_98>1MJ_P#"P(%R?4F,#]2*V_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;_1[O'7_ &6]&'Z]1WQR5?17P7\>:?\ '[X-Z/K%_:1LNHVYCO;5AQ'.C%)
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MGOQ[915N3<I2>[M?Y;?UYLGE5E'M=_?N%<7\:/AS_P +>^$OB_P1_:']D_\
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M967DO7<\,^/G[+=A\9/"?PZ\.Z5JL7A#3/!>OV&LVL$%AY\;Q6JLJ6RKYB;
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MGD$'\C3J],]\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV.!CYR@+_P#CQ-=U7COP$OI?!<VL?"S6)-NK^')Y&L6DX-Y8.Q:.5<]<;MI
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MA;P9IH_T/0].AL4;&"Y1 &<^[-EC[DUUU1-*,FHNZ+@W**;5F%%%%06%%%%
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M7?U'\4OV=/"_Q&=9-:T:*YNHQ^ZO(RT4\?IB12&P.N"<>U>;_P##),.[RO\
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MJ6<ELUQ;NL.R:,.HW(V#AAD'!P:^LJ**?[N*BND7'[Y*7Z!/WVWW:?W1Y?\
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MB]DZ+V?_  7;Y.4FO7R*YFJD:JW7YZ*_W1BOEYL^)/A9^TS\4_@7X!TGX?\
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M']A?P'^UY\8/VA-0\8ZMXBTV;1/&=W!;KH=S;Q*ZR7%PS%_-@DR<J,8QWKZ
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M*]G_ +1: 6NP]F\W:?6O4;6ZAO;:*XMY8Y[>9!)'+$P9'4C(8$<$$=Q7Y[?
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MT'D:[X?TW6X1PJ7]HDP7Z;@<?A7A^O?\$X_A%JTS2R^"((7/_/I=7%NH_P"
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M745I$\VGV017D<(I8B[)QDC. :4?WD*2AK[L%\^5(=7]W5K.>BYI/\6>I_\
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M/$FD:Y>Z1-]FU&VTV^BN)+*7+#RYE1B8VRK#:V#\I]*WZX'X;_ GP-\(]?\
M%FM>$]#_ +)U/Q7>?VAK,_VN>;[5/N=M^V1V5.9'X0*.>G KOJCHOE]_7\=B
M^K[=/3H%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#R[XQ_M/_"OX >4OC[QMIOAZ
MYE021V3EY[IT)(#B")6D*Y!&[;C@\UC?"']L[X*_'C6AHW@CQ_I^K:NV?+T^
M>*:SN)L D^7'.B-)@ D[0< 9-?)GQ[U[]D/]G?\ : \9^*/B4VI?%GXBZTZ2
MW6@W]G;ZM%I:D?)''&R1PQ_($ 65V<*J]-Q+?.'Q;^+/PZ^(GQB^"/B7X4?
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M_P -Y+N?;'PA_;0^"OQW\0-H7@CQ]8ZMK0!*6$T$]G--@$GREGC0R8 ).S.
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M%</^VA\=?AS'^WJVD_&72-<\1?#?P+ID,.F^&]$CC:*:]ECCE+S(\L0V8?!
M//E1@@KN!NI'V<HT[ZO7R2M?YO9=-612?M(RJ+:-_5N]O^'WTU/OSX7?MS?
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M?\%0/C-X<F\!^&9?#VEZ%:W-AI,FCV[6EI+MLCYD4139&V68[E /S'UJL/\
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M8]NX\99<GFD_:$^T?\% /V8/"?Q5^#-EJ-OXG\(Z\=5TG3M6BBBN9G@;;)&
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M<8QYKH@#OCMN;<?QKMJ**VG)SDY/=F<8J$5%;(****@H**** "BBB@ HHHH
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M_C]^S?9/.W?OO]6^_;M^Y\N<_>%"U:CU;2^;=E^(=&^UW]VI[+1110 4444
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MD$'!IV;7,MA[/E>Y;HJCKFM6GAO1=0U;4'>*PL+>2ZN'CB>5EC12S$(@+,<
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M\N6?1=0AO(XV_NLT;, ?8T+78'IN='14=Q<1VL$DTTBQ0QJ7>1SA54#))/8
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M0<G(SU/ #$8T;M0>[<FGUO[S5O+W;:KI[S9K5M>2Z))]OLWO?KK?[K6/I_\
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M  _@/[4'_!2[Q7XOD#7'A'X0V0T;3VSF-]1?>KGT)#&XZ?\ /.,U]\U\P_\
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M/*HT@D9>QW;APV3]LUV5TU4=W=Z?BOS[^9A1:<-%W_,****P-@HHHH ****
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MK76:5I-CH6GP6&FV5OIUA;J$AM;6)8HHU'1550 !["K=%&RL@W=V<=I7P;\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOR/N?X'?M#^"?VAM#OM0\(:A-)/ITWV;4M+O[=K:^T^;G]W/"XRIX(R,J2I
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M^<0&&4R1$O0_,>_DO[8G[K]MK]DF5!LE.IZFA=>&*E(<C/IR>/>KOPQ98_\
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M5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /&O@#^SM_PHWQ5\5-9_X2#^V_\ A.?$<WB#R/L7V?[%
MO+'R=WF-YF-WWL+TZ5A?';]D2T^*7C[3?B-X2\8:M\,?B;I]O]CC\1:/&DR7
M,&<B*YMWPLRCL"1VSD!0/H*BE9>[_=M;RLK?EH5=WD_YKM^=W=_CJ?,7@S]C
M76+[XD:!XY^,GQ5U3XP:WX<D,VB6DVEV^E:;92GI-]EA)5Y00"')&,#@X&/#
M_C;\(?\ A<G_  4Z@TZW\2:KX0UG3?A[%JFE:YH[J)K2Z2\=58JPVR(5D=61
MN&5B.*_0VN,_X4]X0'Q9/Q,_LC_BMSI?]BG5/M,W_'GO\SRO*W^7][G=MW>^
M*I?%!O97>FFKBU?UNUKY$_9DNKM]R:=O2U]/,\7\$_L<:Q=?$C0O'7QB^*FI
M_&#6_#CF30K6;2X-*TZQE./WWV:$E7E&!AR>PX)"D=M=_L[?:OVL+'XU?\)!
MM^S>&6\._P!A_8L[LS&7SO/\SCKC;L]]W:O9:*+VM;I?\59_>F'=/K;\'=?<
MT>,_!W]G-/A3\4OB[XPDUU=93X@:A#?-I[6/E"R$:.IC+^8WFYW]=J].AKRH
M_L*^*/!,FM:1\)?CEKWPS\ ZU<2W-WX7CTFWOUMS+_K%L[B0J]J"#QMR0><F
MOKNBHY59+LE'Y*R2?=:+<=W=ON[_ #[KM\CPJ3]C/X=']F2;X&16UY#X1EAV
MM<B8&\:X\P2_:2^W!E\P!ON[>,8V\5P&D_L9?$K4-#3PCXW_ &D/$WB?X>+"
MMJVAZ?HUKIEW/;K@"&:_4O,Z%1M?H6!(R,U]:45;]YN3UOOV?RV$M$DNGWZ^
M>Y\]?L[_ +'^G_ GX*^,/A;<>('\1^%]>O+Z2)?L?V:6UM;F(1M 6,C^80H/
MSX7.?NU0^ /[(>J_"7X?ZY\./%GQ#;XD_#&ZL7T[3_#=]H<-H;&%W=I TZ.6
MF+!\9(&" 5V]*^E**3]Z_-K=)/S25E?T3WW!:6MI9M^C;N[>K^1\?Z+^Q'\2
M_AWI;>%_AU^TKXD\+?#\$K#H=[H=KJ5U:Q-UC@O'97B R=NU1MZ]>:]6\"_L
MB?#SP+\"]8^%4=E<ZMH&N+,VL7>HS>9>:C/+C?<2R@#]YD*0P V[5QTKVJBD
M_>BXO6^C[M=K[@M&I+2VJ]>]MCX_TO\ 8I^*WAWP\G@K1OVGO$EC\-XX?L<6
MD2>'[.748K3&WR4U$GS%PORJP4;1@   "OHSX-_"/PY\"?AOHG@?PI;R6^B:
M3$8XO.??+(S,6>1VP,LS,S'  R> !@5VE%7S/7SW[OU>_4GE6GE_6P4445)1
MD^+M!_X2KPIK6B^?]E_M*RFL_/V;_+\R-DW;<C.-V<9&<=:^;[[]A_[;^Q'!
M^SU_PFNSRT1/^$C_ +*SG;>?:?\ CV\[_@/^L]_:OJ:BIY4U)=[7_P"W;V^Z
M[*4FG&2Z7M\[7_)'-ZEX/_M#X<W7A7[7Y?GZ4VF?:_*SMW0F/?LS[YQGVS7&
M_LM_ K_AFOX&^'?AU_;?_"1_V.;@_P!I?9/LOF^;<23?ZO>^W'F;?O'.,\9Q
M7JU%:.3<I2ZRM?Y7M^;,^5*,8=([?=8****DH9+_ *M_H:_+_P#X)\_LY>,O
M$GP'D\9?#3XPZM\+M:U+5[RUU2#^R[?5K&[6*4B-Q;SD".4 [=ZGD #%?J$1
MN!!Z&N.^$_P?\(_ _P (KX8\$Z3_ &+H:W$ET+7[3-<?O)#N=MTKLW)[9P.U
M*"Y9RD^JM^-_R*E*]-07\R?R2DOONT<=^SS^S+HGP!M]>OAJVH^+O&/B29;G
M7O%&M.'NK^100JX'"1KD[4'0'&3@5Y=+^PYXB^'GB?6]2^!GQFU;X1:7KERU
MY?\ A]]&M]8TY9F^\]O%,5$.>^,]@"%"@?6E%/JGV5NVG;T\B5HFN[O\^_KY
MGB?[/?[+NE? O4O$/B2]U_5/'/Q \2,C:SXJUHKY\X4?+%&B\11#L@SC &2%
M4"Q^R[^SO_PS;X0\1:'_ ,)!_P )%_:_B"[UW[1]B^R^5Y^S]UM\Q]VW9][(
MSGH*]DHIWUOY6^5T[?>D*RZ][_.S5_N;/&O!'[.W_"&_M,?$7XN?\)!]L_X2
M^PLK+^Q_L6S[)]GC1-WG>8=^[9G&Q<9ZFC6/V=O[6_:MT#XT_P#"0>5_97AR
M3P__ &']BSYN^61_.\_S/EQYF-NP].M>RT4H^ZHI?9O;YWO^;*?O<U_M6O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME.#UE'IWU4=/.[2^>C9C2?ME"2VE^&C?W63_ ,D?HY17Q?X:_P"":GP_\0>
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M@QYHY!^7N?3*^,?%%O%9_P#!5+X>P01K%#%\-[A$C08"J+B<  >@%>5?#_\
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M@-2I_O%?U^5K[]KVTWW3[VJI^[T]/G>VW>W7;9H^WJ*** "BBB@ HK-\3?\
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MQS7YV?MC?!CP=\#OV!M'T7P3H_\ 8NF7GB+2-2G@^U37&^XDV!WW2NQ&=J\
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M-XET34?#NL07%\9=/U:TDM;B,-=RLI:.0!AD$$9'((-?45%./N\W]ZR^Z_\
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M)OTT37W(4_?L]FHM+YZK\3K****!A1110 4444 %%%% !1110 4444 %%%%
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M'VO_ &&_Z:#U_B^O7PRQ^'>N3:Y97^K:LMX;=U8L\LDKX4Y"@L.F?YUH^._
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MR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BOD6\_:7^,/QL^(GC+P_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*6X/22;'0>B]6]AS7YY>(O$6I^+=;NM8UB]EO]3NG\R6XE/S$]L>@'0 < #
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M*1F"C)H "<5Y]\:/C9X4^!?@>_\ %7B[58]+TJT7&6YDF<_=BC3J[MV4>Y.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM*,ZDI15DVSFI1<*<8O=)!11161J%%%% !1110 4444 %%%% !1110 4444
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M'[*_A'X\:6;7Q-I"W,T0/V;4(/W=U;$_W),=/]DY4]P:^JCS5*]L8ID.X T
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M(=:6?PZFL?\ $LU%(;5&,]Q!L_>7!W??R.53CBO9_P#@G[_R7+]K3_L?)/\
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M (<L/B='^QY\6_%'@CX2^'OA#XKUD22>&]"\+Z(-.U4V", LETJ'YKKRFE*
M*I!Q@9; BLXQC5<?AL[6VW5K/O:_GU>P4E*4J2E\3:O??9WNNU[>2V6Y./V:
M?'^M?#>'Q?\ %_\ :6\=^ /'UQ:FYN;72/$%MIFB:9(<E8FAC 214X#,) &P
M>>]4_P!FO]H[QI\8OV ?BMK^OZXUUXM\+VFMZ9'XAT]A#).T-GYL-PK1XPX\
MQ<.N#\H/7FO$O@[>?L@KX7TYE^'WB+XI?'%K-?[2\.ZKI6I:AJ-SJ)4>;YHE
M!M5'F9RV<!>3D\5N_L26]QHO[!?[4.@:G9II.NZ;>>($OM*4 &T8Z:B[,#C
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M%T235MMVG;RV_#J:T+>UP[ZN5G??9/5=]'^/0]H\+_LX_%7XK_ 30?'NO_M
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MQ@Y7[4OQZ?\ :4_X):VOCJXM8[+4[O4K&WU"W@_U:7,5V(Y"G)^5BNX#)P&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***BFF6)22<4 .DD$:DFOCW]M[_@H'X;_9ATN71-)\CQ#\0[B+-OI(?,
M=F&'RRW)'*CN$&&;C[H.X>;_ +>W_!2*U^$;7GP^^&D\6K>/I/W%U?Q@2PZ4
M3QM Y$D_/"\A3][)^6OSF\&_#N\O-6F\4>,+F;5M?O)3<N;R0ROYC')DD8D[
MG)]>GUZ>=CL=2P-/GJ/7HNK/LN%^%<PXKQGU;!1M%?%-_#%>?=]EN_2[27&G
M>+/CIXQNO'GQ-U2ZU2_O&WK%<'!*YRJ!1Q'&,\(H'X=^HAL]6\7>)(?!_@^"
M%+Y8P]U>2+^XTZ'@!B .6/9?IVK6U2]73[&>X?[D,;2-CT R:]:_99\)KHGP
MNMM9G4-JWB)VU*[FZDAB?*4'T"8X[%C7F\.8&7$V/=3%O]W#6W3T_P S]D\0
M,?A_"G(:>69"K8G$74JC^*RW=^F]HI:+6VNIYS\1_@!H'PW^&.O:U]GF\5>)
M8+8O]NU-C(%)(#.L6=@"@E@"#]WJ:\)^"/A?1-0D_M.XN8[K5(6)2S;CR<='
MQ_%['H/KT_0?7+ 7EL\;*'1E*LK#((]#7R1\3OV5_*OI-5\&W!TJ[5MXLV8K
M'G_IFXY3Z<CZ"OT?B'(IXC#^SP7N)*UDOZWZ]3^9N">+:&3YM',,UI?6&G?W
MF]_YNJNMU=->CLUU6DW$%K?))<1^8@_\=/KCO7H4$T<T2O&P9&&017R?:?$[
MQ'X$OETOQEI4^5X$^T+(0.X/W9![@_B:];\"?$_2M4P-/OX[F-N6MR=LJ>^T
M\_TK\@CAZV"I/ XV/+"]U-;)[>]W7JKQZ76A_1W&>!RKQ/I0S;A_$_[9"-O8
M3=G*.]H)NW-_A;C+K9ZGK-4=7O+:TLW-R R$8V'G=[5%>:_;6MBMP'#[Q\BK
MU:N(U#4)M2N#+*V?1>RCT%2Y+)VJU1WJ_9BG=?XI-?9?1?:_P[_FWA_X:8_B
MG%_6,:I4<-3E:3LXSE*+UC"^J:>DI?9>FLMN?UW2K?4DGC>!6MY,@Q/\PQZ5
ME>&=;\:_#5?(\+>(GCTT'(TK4H_M%NOLI/S(/9375LH;K5>2S5NU>+@<WQ6
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M?/#VBVNU\UHPE[L^1[V3^_8****8!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\C>*/
MA[\6OVF/C9X3@^('@33_  )\+/ NMMK4?_$[BU&?Q%<Q;EM'"1@>3&,[RD@S
M\V.>WUS10M)*?;\^C^73H#UBX]_RZKY_>%%%% !1110 4444 %%%% !1110
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ML/+RQC,FS;[*W0C_ &3^M?@&;YA1QV95W0ERS=HQE;M^5^Y_9?#?#N/R?AS
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M6V@,WV0F1=SA0RD-MW -GY20V#C%?)WQU_9>^$7PA^$&K^)-<_:&_P"$F_:
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M%?!OXA^(;"?QM:6L7V[4ITFEWW5Q):MYP1%24 C>I*94X(.0#6G^V5\#[_\
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M "BBB@ HHHH ***3I0!PWPY^$G@?X$Z/KJ>%M+B\/V&HWTVLZG-+=2R^9<.
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M@U>;X<^)?^$BCTEHTO6^P7-KY1D#%!^_C3=G8WW<XQS7SU=?\I<K/_LFA_\
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M(GBOQ)JT:ZA]FE.H6VFZ6H)N+B1H)5$;KE2 S=F^4\5Y3^T1\3+SQ=^V1?\
MPN\>_&'6/@7\-M/T*'4=-N]'U*/2)-:N'V[RU\XPJJ2Z["<'RC@9YKEUER1?
M>7E>T;V^73JWH]F;Z1YFGT3[[RMMW?W)>\;.L?%3XZ?LH_'KX6^&_B-\0=-^
M+G@KQ_J/]CK>G08-)O+"X+(BE4@.TKNE0Y8MD!A\O!/GO[4'P_\ B7JG_!2#
MX3VVD?%C^Q-0U>QU";P_??\ ".6UQ_8$*V\OF0[&;%UOVO\ -)@KYG'W17D'
MQHT[X/:/^TW\ !\-/$VM_$*]L_&&GQZ]XTU+6I]5MRS7$#0VXN6/DE\+*Y$?
M0#GT'T]^U3XDTCP#_P %$/V<O$OB;5+/P_X>BTK5HI=4U*X2WMHV,$J@-(Y"
MKS)&.3_$*NFDW1G+?FJ+MI[.Z_%Z/1M::IZD](55'^1.V^O-;\NFJZ[[>D:A
M\6?'&B?MX>!?A=+XB^V>%KKP+)J=_;?8H$^U7R2RH9]P0NF=@^17VCTKG]<^
M,'Q;_:.^.GC;X>?!SQ'IGPZ\+^!Y([/6O&5YI2:G=3WS;LP6\$A$>U=K!BW.
M5SGD Y_B'4+75O\ @J5\.+ZRN([NRNOAI--!<0N'26-KB=E96'!!!!!'K7-_
M 3Q]X?\ V2?VH/CEX)^)NJVWA&U\8:V?%/A[7-7E%O97T,I<R1^<V$5D+!?F
M(R0WMF(^\X*>]IOM=J;27RC=I>796"?N\_)T=-=[)TXMOYRLF_[S>^IW/@'X
MT?%;X)_M$>'/@_\ &;5]-\;Z;XNMYI/#/C;3[!=/FFGB7=);W-NA**<8P4]5
MY;<=G'VOQ>^/_P 3_P!L3XT?";P9XKTO0?#FB"QFAUO4M*ANFT6)K=&98(E5
M#/++(^?WSE56-L#D5#X^\>:+^UI^W)\&=.^&]Y'XHT#X:O=ZUK_B+37\RPA:
M5$$,*3J=LC%HE&%)!W'KM?;U'[,'_)_7[5_^]H?_ *2FKI+VCBY_RS\KI-<K
MT^?JEYDU?<C+D[P\[-WNONL_)NW0D^%/Q:^+OPG_ &L+#X(_%;Q7IWQ'L?$6
MCRZOHGB:VTJ+3;E&CW;XI88OD Q')TR?NG=R0/L>OB?XO_\ *4[X&_\ 8JZC
M_P"@75?;%*+YJ4)/=\WX3DE^"027+5G%;>Z_OBF_Q*NJ:E;Z/IMW?WD@AM+6
M%YYI&Z*BJ68_@ :^)/AMXR_:2_:Z\*WWQ.\#_$#1?A5X1EN;A/#?AZ;P_%J,
MFIPQ.R![N>4[HM[*5S&#@9P. 3]B_$+PVWC+P#XET!)/*?5=-N;%9/[IDB9
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M^+_^"KE]#H'[5?[/>LW[BVTVVDCEEN'X55COHG<D^RD$_6N]_P""T'C+1/\
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M,5Y=_-]7J[L_$,VXBRS#Y2N'N':#A0NG.I.WM*LEU=ME?I?:R7*KI^(>)O\
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M?";]HS[)I<E__P (5XPFPG]AZW*JB9SVMY^$EYZ+\KG^Y7U=0 4444 %%%%
M!1110!X'^TI^QCX)_:E\1>#]:\5ZIK^GW7A=I'LDT:X@B20N\;GS!)#(3S$O
MW2O4_A[U)&DT;1R*KHP*LK#((/4$4ZBC[/)TU?W[A]KGZZ+[MCYB^#7_  3Y
M^'?P#^-%[\2/!.M>*-(N[PW"S:&MW;G3##*=Q@\OR-_EJVTJ/,R"B\XX-7]H
M/_@FS\&OVC/%D_B?6+/5?#OB&Z(:\U#P[=) UV0,!I$DCD0MCJP4,>Y-?4]%
M*R:BOY=O(=W>3[[^9X!^S9^PW\*?V6+F?4/!^EW=WK\\)MY=<UBX^T79B)!*
M+A51 2!G8BDX&<XKS[XR?\$K_@;\9/%EYXCEM=;\)ZG?2M<7A\-WD<,5Q*QR
MSF.6*55)/)V!022<9-?8%%.7O--[H4?=32ZGAO[-?[&?PQ_95@O'\$Z7</JU
M[&(;K6M4G\^\FC!R$W *J+G!(15!P,YP,?GA\*?@OX0^/G_!2_X]^$/&^DIJ
M^BW$>J2!-Q22&5;J#;+&ZG*.,GD=B0<@D']@:Y;1_A3X)\/^+;[Q5I?@_0--
M\3WP<7>M6>F017MP'(+^9,JAWR5!.2<D"C>LJD]4HRC]]K?<._+2<(Z-RB_N
MN>"?L[_\$W_@]^S;XR'BO0K?5M>\00[OL=[XANHYS99!#&)8XXU#$'&Y@6 S
M@C)SZ=^T!^R_\.?VFM!M],\>Z"NHM:;C9ZA!(T-W:%ASY<J\X. 2IRI(&0<"
MO5J*)>^DI=!1]UMQZGQ[\'?^"5?P,^#_ (NMO$:6NM>+;^SE6>TC\2W<4T%O
M(IR&$<44:N0>F\, 0#C(KU?]J7]DOPA^UQX7T;0?&&HZWIMGI=X;Z%]#GABD
M9RA3#&6*0$88] #GO7M=%$O?2C+9!'W6Y+=GG/Q*^!>@_%+X(WOPNU6[U&W\
M/W=A#ISW-G)&MT(XBA4AF1EW?NQGY,<G@5S/PZ_9!^'GP^_9^D^#,MK=^*O!
M,S3--#KTB232>9(9#\\21[2K'*LH#*0"#D9KVRBA^\Y2>\M_/J$?=48QVCMY
M=#X4F_X(V? 637O[06]\816GF;_[*35(?LVW/W-Q@,NWM_K,^]?7/A/X.^"_
M _PTA^'VC>'+&U\&QVKV9TAH_,ADB<'S!)OR9"V3N+$EB2237944?9Y.@?:Y
MNI\-:[_P1S^ >L>(I-2MI_%FC6K/O_LFQU2(VJC^Z#+"\N/^VF?>OK#X0_!K
MP=\!_!5MX4\#Z+#H>B0.TODQLSO)(WWI)'8EG8X'+$\  < "NUHIIN,>5;":
M4GS/<****0PHHHH **** "BBB@ HHHH *KZA>?V?87-UY,USY$32^3;IODDV
M@G:J]V., >M6**3NU9#6^I^<7[&_[36I^)_VR/C4FH^"OB3<)XEU'3[6U6_T
MIF'AN&-;DK'?@R'[(A+G:HR"=U,_9O\ VD?#/P/^+?[2VG7NF^(/%7B;4OB%
M?3V/AGPGI<FHZE<1([!Y!&N J*2/F=E'IDBO2/V+_P#D\S]KS_L,Z9_Z#<TW
M]@#0K*/XY?M6ZR(%_M&7QY<69F(&X1+),X4'TW.3^ ]**6L:?_7I/_TWI_P1
MUM)5+Z_O%_Z3/].A[K\ ?VKO!7[1%YK>E:+!K.@>*-#*_P!I^&?$U@;+4;0,
M<*SQY88/^RQQD9QD9R/BU^VCX&^%GC63P79Z5XH^(GC6"-9KOP[X%TAM3N[2
M,@$/, RJG4?*6W893C!!/D>C@6O_  5MU\0*L?VGX<(TVT >8PN(@"WJ<*HS
MZ 5XI^Q))^T9JD/Q8UGX;I\*&NKSQI?#7)O&HU+^U#=*0=C&W^7RE#':#T)>
MB+Y^5[7C)O\ [=GR?<]^O;S$UR\W75)?./-^&WX^1]Q_ W]JCP1\?+[5-(T?
M^U="\5Z2JOJ/A;Q+8/8:G:*<89XFR".1RI8#<,XR,^P5\):=\-?C5>_MF?"S
MQM\3O%7P9T'6K.TO+%=(\+:C>P:EK-DT;ED6"Y4F<1L=_! 7YB>U?=M7HX1E
MU=_P?]>CNNA&JFX]-/Q_K[K!1114E!1110!X)\:OVT? 7P&^)%MX&\1V>O7.
MOWFD+JUA#I-B+HWQ:<P1VL**_F/<.ZG"[=N 26%7M,_:X\&1_!W4?B3XPT[Q
M!\,="L;MK&6T\::=]COVE !"I;JSLY;/ &2=K<8&:\5^(6CVNJ?\%8?AE+<Q
MB1['P#<W4&1]V3SKI,_D[5SO_!1B;Q9??M!?LSZ-X=7P_*]QJU[<6<'BT2G2
M9-0181!YXB^<D;CMQSN8>IJ8W<::ZS;7I[S7S=D_G;YW-)3G;:"3]?<3^2NU
MKT5SU&Q_X*+> 8KRR?Q1X,^(WP^\/7TJ0VOBGQ9X8DM-*F9_N8F#-@-U!90,
M<D@5S7_!2BXCNO"?P-FAD6:&3XE:.Z21L&5E(D(((Z@BJOQ:\+_M=>-OACXI
MT+QA-^SU:^%[_39X-2N9Y=9B2" H=\N]_E0H/F#'A2H/:O*_CEX>U'PE^R+^
MREHFJ>(]&\6W.G^.]'M5UGP_>&\L;F)&G6(Q3%5WJ(PBYQU4UI&SE'RG#\9?
MI;YWVT,W=1EYPJ?A'_@_*V^I]N_'+]HSP/\ L\Z387?BW4)A>ZG*;?3-'TZW
M:ZO]1E&/W<$*\L<E1DX4%E!(R,^?^ _V[/ WBSQII7A3Q#X:\;?"W7-8D\K2
M;?Q_H+Z8NHOQ\L+[G4GD !B,E@!DD"OGCXSR?%#5O^"GL=OX 7P7+X@TSP.L
MND)X]%T;..)I<326XM_F$Y+.N>FP/GM5O]JOX:_M.?%+X176E?$SQ%^S[X0\
M.PWEM=IK_P!OU2QDL;A) 8WCGG5D1B3LY&2'(')K.G*\8SDM&W]RDXZ>>E_P
M\RY1]YPB]DOO:OKY:^O7R/KSXX?M&>"OV?=/TN7Q3=W<NI:O,;;2M$TFT>\U
M#490!E(84&2>0,G"Y91G)&?,_!?[?W@7Q%\0M'\%^)/"GCOX7:[K3^5I4?CS
M03IR7TA( 2-@[\DD ;L D@9R0#QOQJ^)&A>%OC]\/(-"^%UU\9?VB+3PYYMM
M]@U@V=C86;!EEF:65O)7>S/AC'N((!9<J#X%^W9XK^-/B7_A3%_\1?!'ACP%
MI*>-[(V-G8ZRVHZJ)^22TBJL0BVCG;SNV5I!>_%/5.7+V7Q<NG=_KIYF4Y6I
MN2TM&_GM?7LOTU\C[J^.W[4?@WX 7>C:7J\&L^(/%&M;SIGACPSI[7^I7BI]
MYDB!  'JS#.#C.#C&^#G[9'@OXP>-W\%2:-XJ\!>-OL[7D7ASQMH[Z;>7$ Z
MR1C+*PZ\;LX!., D><_M+_!G7O%G[1WAKQU\'_B5X8T'XSZ%HCVTGA?Q!*DJ
MWNFM(QWM$NZ6-=SNN\(025PR$9/,Z)^T5XU\'?&[X>Z/^TC\#O#^E^(-4O6T
MGPW\0M!,5W#'<2X41QA]\L ?=@_O 3G[F,D31]YI2W;:M\VE;H^GXK<NK[J;
MCLDG^KNMUU_!^1[[\</VLO WP)UK3_#VHIK'B?QEJ,9FL_"?A73VU#5)XQG+
MB)2 J\'!=ESM;&<'%'X._MC>"/B]XQ;P:^F^)? ?C?R3<Q^&?&VDOIM]-",Y
MDC4EE<<$X#9P"<8!-?(WPRD^..L?MN?M)W_PU3X<2:_:ZA:V=S)X^%\;B*R"
ML+=;;[-TC*HI;/4B.NL^+_PU_:&\9?$KX/:Y\3?%7P)\(3>'_$]O<:7=:7J.
MHV=]>LS*);.$W"L)3(HQY:X+$+SC-%'WU3E+[=OES;6[VNK]]4K:!5]UU(QW
MC?YM?Y].VCUV/T"HHHH **** "N!^-7QT\%_L^^#F\2^-]772M.:5;>!%C:6
M>ZF8$K%%&H+.QP>@P "20 37?5\3_M%1IK'_  4>_9OTS7$670(=.U.]L(I_
M]4U^L;G(!X+KLA(]#BDKRJ0IK3F?Y)M_.RLO.P](PG4?V5?\4OS>OD=[X5_X
M*!> M6\6:3H'BCPMX[^%L^LRB#2KSQYX?;3K6_D.,+'+O89.1RVT<CG)%>%?
M\%:/BJT?A[P;\/9O"?BZ\TNZ\0:??7^H6FGDZ9J$.9@;!)@X+W!*AA%@=%.:
M]T_X*4:3HNJ?L7_$5]9BA86=O#<V<DH&Z*Z$\8B*'LQ+;>.H8CH37A/[:5]J
M>J?LG_LOWFM,S:O<>(_#DMVSDEC,UHQ<G/.<DTXI5))?RS@O7F>GS36OE;N$
MFZ<6^\)_+ECK]Z?RU\CZ]_9L'A*Y^&T6H^#_ (7WOPDT^\N)&E\/ZIH$6C7?
MF(?+\V6"/(RP488DDJ!7JM%%5)\SN1%65@HHHJ2@KQ+]L[6OAUX?_9T\47_Q
M6T'4/$W@6)K;[?IFER,EQ*3<1B/:1-$1B0H3\XX!Z]#[;7RA_P %2?\ DR'Q
M_P#[]A_Z6P5C6?+"_FOS1O07-42/0OBY^U)X!_9OT+X>R^)8]0L=%\331V%E
M=1I&T5BHC5@]PSR JBJ1DKO/'0UP3?\ !1SX<:?KVE6VO>%_B!X1\.:M<+;Z
M?XP\0^&Y+/1KMF&49)6;?M8<@E!@<G !->;_ +;.B6?B/4_V0=-U"%;BRN/%
MMBDT+@%9%\N$E2#U!Q@^QKT#_@J9#'+^Q#X\+QJYCEL&3<,[3]LA&1Z'!/YU
MO5E[.52<M4JCC\K0>_?WM/QN<U"/M53@M&X)_-N2^[3_ (8\N_X*Z?%B;3/A
M#8^ XO#?BF>TU:^L;RZURSL"VDR0B63_ $-[@,/W[-&KB/'(VG-<I\9_^$-N
MM-_9FU#P;\)]1^$%I-\5M.AFT?6/#T6C7D[1[ )GB0G>"#@.Q).#7:?\%&)7
MF_8=^',DC%W?5M"9F/4DPMDUUG_!0;_D;/V7O^REZ9_Z$*TI0]E4Y=_WT5]S
MI?\ #6^9,Y^UA">UZ3?WJ?\ 5_D>\_'#]I;P5\ 1I-MXAEU#4->UEFCTKP[H
M5D][J.H,H^810IZ9ZL0.V<UP/PZ_;S\"^-OB/IO@36_#/C?X9>*-5XTRQ\>:
M&=.-^W/RQ$.XSQ@;MN3@#)(%<A\<?B;X>\,_M8Z?%\/_ (07_P 6OCU::!MD
MDCUG[!::7IK.3AY)6,*.Q?\ YYAB'QO^8 _/O[8'B;XP^(OBU^S=?_$GP?X7
M\#V8\;6O]FV.FZLVH:FK^=!YGF2A5C\O&S[G?&>U94?>E"^TI6[;RY=.]NO2
M]UTN:U-%*VZ5^_2^O9?IKY'VE\9/VQOA]\!_B9I'@KQ>VI6=]JFF2:I;WD-L
MLMN55F00@*_FO,[+M5$C;)(YKCM%_P""BWPP;Q+<:'XSTKQ?\)KU;22^M_\
MA/M$;35O84#%FA^9RQPIP" 6. H+<5Q7QBT.SUS_ (*D?!#[9"LXL_"M_=Q*
MXR!(OVC:WU!.1Z$ TG[>7A_3M:_:+_9.%]9Q70/BZ2,B1<@KFW?:?4;D4_A4
MT[R5*_VY./I[\HI_@M.WJ%1J+J6VA%2_\D4FOGW\_+7OO#__  4"\ :G\0-$
M\+:UX8\=^!O[>G%MHNL^+/#SV%AJ<A(""&1F+?-N7!9%'S#.,UU_QO\ VO?
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M#?-\6+ZV89?;_P )5<+D^GR+C\.E.71_V^_AI_I.G^*+[Q#&G+#[?97^0/\
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M2?&&@^(-7U;2M+UO3=2U32'2+4;&TNXY9[)V&469%):,D D!@,@5L4 %%%%
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MS+_PM;5/@Y>?\))_9?\ PKO6(-5V?8/._M#RU1?+SYB^5G9][Y\9Z5M?M2?
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M]NR$'E[_ #%\O[GWL-UZ5[)10O=Y;?9=UZWYOS=_^ )^]S7^TK/TY>7\M/\
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MOOBK\%? _C'4X+>UU#7M'MM1GAM0PBC>6,.57<2< GN37>U^<FD7FB_L5_\
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M"<7QAM=/U3X_^&M$\5:AXQ^%W@Z:/4/#5SJ$DCRQ6A6<M&ID 8)B)0!@#()
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M]]-%M=\LE:+^*R?EKY_\"VOK;]?:*XCX(_$3_A;GP?\ !GC3R!:OKVDVVH/
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M_",>([_^V8)Y_P"W;'3_ #-+L?*7.RYGW#RV?H@P=Q]*Z^CI?^NP=;!1110
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M/[X&:AXMO/V"/&WP=U+X6^.O#WBSPWX/U&RW:GHKI;:G-)]HV1V3@DSM\R\
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MT\'^*?$FB_ OQYX:\):WXIA\&^*K+7-2T;2;,R:C]F&QSL@.&+@H%*XR"W.
M"1]F44[M))=)*7S5O_D4&[5^SC\G_P .SXK^.OA/Q[\1M9^$?[2GPO\ !>J+
MXL\,K<0WO@7Q1$--U&[T^4NCQE6)$<H!=@"3D2 C<0%:SXO_ &JOC%\7- /A
M;X2?!#Q]X)\:7K)%)XC\=Z1%8Z;I*%AYDR-(SK<%1G"[><YVMC:?LNBDK)<O
MV;MV[7=VK[V;U^;LU<-=)?:M:_IMIW7](S/"^GZAI/AO2K+5M4?6]5M[6.*[
MU*2%(FNIE4!Y2B *NYLG:H &<"M.BBG)\S;$ERI(****0PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BOS;^-?[0'Q"_X7QXM^+_AKQ#JJ?";X
M4>(=-\-:KHMK=2"RU)'WIJ,SPJ=KR1/-$H9@<84CI7Z.VM];WUE#>6\R36LT
M:RQS(<JR$9# ^A!S1'WJ:J?ULFG\TTU\^P2]VIR?UV:]4]&3T5X1I/[='P&U
MWXC1^!;#XEZ3<^))9_LL4*++]GEE)P$2YV>0S$\ !SD\#)KR;]JS]N;1O@1^
MTU\+_!UWXM31/#D9N;SQBG]F33ND+6_^AC<L3$JTA)(BRWRC=@<%75XZZ2T3
MZ;7*Y7[W>*NS[0HKPH_$+P!I/QV\2:K)\0_$T^LV?@]-5O/"7^DRZ5;:<'#B
M^BMUA(,Y^Z=K,Y!QLKUSPCXPT?QYX3TGQ-H-\FH:'JMK'>V=XJLHEA=0RMA@
M&7@]" 1T(!JK65W\_+5K]'\TUT9%TWI_6B?ZK[T^J-FBO-+;]I/X9W'PMD^)
M#>+[*T\$+-+ -9OEDMHI)(Y&C98Q(JM(=Z,!M!W8^7-<K\*OVY/@9\;/%<?A
MKP=\0;+4M=FSY-E<6MS9O.0,E8_/C02-@$[5). 3C I+WGRK<<O=5Y:'NM%?
M%%K^WMX=7]O#4_AO?>,4A\(PV,>A6=DNESYD\0M>+$\3.(BW RH8D1<DY[U[
MS\'=8\)7?Q$^+,>A^/?$7BG5+/58EUG2M;N)7M-"F\MB(+0/&BI&1EB$9QD#
MFB/O14ULTW]S2_5._9Q[H)>[)P>Z:7WJ_P"EK=T^QZ]17SVW_!0/]GA?&G_"
M+'XJ:-_:OF>5YFV;['N_Z^]GD8]_,Q7I/Q,^.7@7X.Q>'YO&7B*WT*WUZ\6P
MT^XG21H99BI8!I%4K&NT$[W*J!U-'12Z,-FXO='=T5XC\-?VU_@C\8/'#>$/
M"/Q!T_5O$66$=GY,\'GE<DB%Y8U24X!.(V;@$].:]NIV=D^C#JT%%>0?&?\
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M#-)8SL$)D( 4O!.N[(&=J]M] '[)T444 %%%% !1110 4444 %%%% !1110
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M_&L:DU3@YOIJ:0BZDE!=27PI\9-#\;?$?Q=X.T:"^O+CPLL*:GJBQI]ACN)
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MM.C\N&",<L>K.[=7=CDLQY)-.*NO:/9[>?GZ=N_IOFWM!?%I?R\O7\O7;/\
MA;\9-#^++^);;3H+[3=6\-ZI+I.JZ5JD2QW-M,G*L55F!CD0AT<$AE/8@@=W
M7R!\5M3/P._;[^&/B*U'DZ/\4=.G\,ZS&O"O=VV'M)B.[_O%CS_=S7U_2C[U
M.,_5/U6C^_1^C14O=FX_->C_ ,G>/FU<***^3/$'[2WQ9^+'Q:\8>!O@%X9\
M*7-KX-F6TUKQ5XVN+@6+7ASNM8([?YRRX(+$XR#D#Y2ROKRK?].X[:<SV/K.
MBOG_ /9F_:<O?BU'XY\/>.=#M_!OQ \!W0M=?L89S):E"I9+F%SSY3A6(!R0
M #DY%>=^&OVCOCY^TC'>>(O@;X.\%:3\/8;F2VL=<^(=Q=B76?+8JTL$-MS&
MFX$ OG/KD$!];+71/Y/9_/IU^YBZ.^FMOGV/L-FVJ2>PS7A7A+]L;P9XR_9S
MU_XT66F:]%X6T471N+2XMX1>M]G.'V()BASVRX]\5#^SO^TEJGQ0\1>+?A_X
M[\,+X*^)_A58WU#2X;D7%K=6\@_=W5M)WC;C(.2NY022>/D#X#_\HBOBI_NZ
MW_Z,K&I)QA5DND.9??;^O,UA%2<4]^=1?S4G^B^7DS]&OAYXVL?B7X"\.>+M
M,BN(--UW3K?4[:*[55F2.:-9%#A68!@&&0"1GN:Z&OCC_AI"3]G']B?X#76F
M:&OB/Q1XDTK0]!T73I;@6\#W4MHF&ED/W4 'XD@9 R1HR_%[]J/X4ZSH-Y\1
M?ASX1\:^%=3OH[*Y/PP74;C4-+5S_KY895;S$49SL&..HR,]U:"C7G3ALI./
MS[?BO+4Y82?LHSENU?Y=_P &?6U%)2USFH445\Z?'K]I;Q+X8^+/A[X0?"[P
MU8>*/B1K-C)JDDFLW3V^G:59J2HGG**7?+*0%7!Z<\@%7U26[_X?\A]&^B/H
MNO--<^/WA[P_\>O#?PDN+/4W\2:]ID^K6MU%%&;-(HM^Y78R!PQV' "$=.17
MSY)^U)\;O@7\7_ 7A3X[>%_!5QH'C:^&EZ=X@\"3W8CM;HE55)DN26;+.G3;
M@$D%MI%2_$S_ )2C_![_ +$S4OYSU45S3AV?,OG&$I6_+Y$S?+";ZKE^YSC'
M_/YGOO@/X_\ A[XA?%[XA?#K3K/4X=;\$&T&HW%U%&MM+]HC,B>2RR%FP!SN
M5>>F:],KXS_9CD6+]O;]K%W8(BG0RS,<  6K<U+X?_::^./[26H:WJ7P#\)^
M"[3P#I5[)80^)/'US=_\3B2,X=K:*V 9$!Z%\@Y'(.Y54=84VMW%2?\ G]Y4
ME:=1=%*R^Z_^9]CT5\D^#_VM_'GC?P7\5O#'_"&V'AGX^^ [$W3^';YGN[#4
M%V[TE@*.C,D@& -WREX_F;->H?"O]I#2?''[+.F?&346AM;+^PI-4U*. G9#
M+"C?:(UR2>)(W4 DGI2DU&$JE]$D[^3O9K[G^0).4E!+5MJWFK?YJW=:['LU
M>:_M"?'SP_\ LU_#.[\<>)[/4K[2;:XAMGATF*.2<M*X12!)(BXR>?F_.L']
ME_\ :"_X7E\![+QSKEG'X>U6V-S;ZYIY5D%A<0.PD4JY+*-H5L-R PKY[U_]
MN+XEZ;^Q?KGQTCT'PY UWXB^S>&[&ZM+C:VEFY$*27 $X+2G#G*E5X!V\U?*
MU45-[WC_ .3222O_ 'KZ/M=ZV"#4ES+K?\$V_NMKYV74^Z8I!-&CC@, PS[T
M^OE?]K_]K+Q9^SKXT^#FE^'?#%IXJ3QG>7-I<Z=M87<LBB 0QV\GF*D99YL%
MG5P!SCCGC_B=^T[^T1^S7_97C+XK^"O 5U\,KS4(K.]7PG>W<FI:2LK85I6E
M CE*\CY$PQ&,KD&E'WVK=7R_/16_'_,G503WNN;Y:ZV^3_2Y]L45X)^T]^TU
M=?!>+PCX>\(>'O\ A-?B-XTN6M- T7SO*B8*H,EQ,_\ #$@92>F<]0 6'@7[
M0O[6G[3/[*?PUN==\>^!? &K27LD<.FZSX8EO9;&RG+J3#>02NDAW1B3;(CA
M0RJ#G-1S)*[VO;Y]OQ^_3?0M1YFDNJO\N_I_P^Q]\45G>'-1DUCP]I=_,JK-
M=6L4[K&"%#,@8@9/3)K1K247"3B]T9QDIQ4ELPHHHJ2@HHHH **** "BBB@
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M?VN>#9)""(VWQNK' )X)(/?-<\%[BA4U]Z#]8Q>S\[:>=M6=$I>_S1T]V?\
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MY_G9SYM5T5VW?MYH=/\ <M3E_*K]M(M:=]DN7OZGZH>!_P#D2O#_ /V#[?\
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MI !/R%N!GI27O/E6XWHN9['MU%?&_P 9O^4F/P _[%S5_P#T7+7T-KWQ_P#
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MBDE=P5^7 *G.*_1Z'P7X>MO$&HZ]#H.F1:YJ4*VU[J:6<8N;J)1A8Y90NYU
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M(RE)1AN]CJ_V2=<N-0^#>D6-W,T]SH\USH[2,<EEMYWA0_\ ?")7N(Z5XO\
MLT^#[WP7\,='T_4@!JL@DO+X#H+B:1I9%_!G*_\  :]H7[HK_*#B25"IF^*J
M87^&YS<?1R=C^S,N52.$I1J_$HJ_K86O)/VM+/[=^S;\0H\9VZ5)+_WP0_\
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MZI=/R?R.U\#_  E^&?PW_:4\9:_H'B5-/\<^+=.BN=4\'QZA;+')'&V%O5M
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M "8SQ!X;\%_LL_ G]H]_A'XL-QK<,%YKEWH$6HV\_P#PCUW+"VWRX8E#VZX
M8+)GB,8. :\C_8[\6?&'X9_L^^%[7P3^R;:Z_I>J6*7MQXB_X3S3;>76GE&X
MW$J21EP6SPCDE1A>U?3O[/W[*-G\+_ GC6Q\9ZJOCKQ/X^N)KOQ7JDT BCO#
M*A0P(@^[$JLP _VB<*"%'F'@G]G?]I/]F_2Y/"'PD\=>!?$OP_CE=],M_B!:
MWBWNE1LQ;RHWMN)0,YR^!GHJCBFERMIO>,%Y:)W7>VJMT=M>@/WDFNDI/SUM
M9^N]UNKZ=3,_9'^&OQ2^'_Q"^-FH^(OA:GPG^'_B:T74M/\ #UOKEGJ-O:7R
MQ[)O*\AAM$@)8_(H&U5["K/_  25\#Z-I?['>CZI'I]NU]K>I7=U>3-$I>1H
MIVCBR3UVB,$>A)(ZUZM^S[^R[>_"6U\<^(O$_B;_ (33XG>-SYFLZ\\'D0@*
MA6*"&,9V1)G'J<#@  "]^Q3\"]>_9O\ V=?#O@+Q+=Z=?:QITMU)+/I,DDEN
MPEN'D7:TB(QX89RHYSUK6G[O,G_+!?<VVK];:*_9&=3WN5_WI/\ \E2O;I??
MU>NI[I7Q)_P3WT^V\<?$;]H;XCZW:QW7C"X\;WFB_;+A0TMO9P!1' A(RJ@$
M @8SL7/05]MU\F>(/V:?BQ\)OBUXO\<? 'Q+X4MK7QE,+O6O"OC>WN6L5O.=
MUU!);_.K-DY4C&2<DC:%RB^6IS/K%KYMQ?Y)KY]C1KFAR^:?W)_YI_+O8LZC
MX2\"_LT:-^T;KOPT\3*?&%SI-QXCO_!\=_;R1Z5<I;.Z3QVJ*)(1(65CO)#?
M+C Q7S[^Q'XP^,'P]^ >AW/@O]EJ'Q?#KB/?WGBZ3QWIUM<:U([L6EE21#(O
M.5",3C'N:^JOV=_V7;CX<KX\\1?$#6;?QMX^\?R!_$-Y%;F*T$(0HEI AY\I
M59ER<%AC(&!7F?@[]FO]H3]F>*]\-?!+QKX)UOX>2W$EQ8:/\0K>[\_2 [%F
MCAEMLF1<G/SX&?X<DDD5R.SZQBM-M+WCWMJK/9\NOV0D^=72VDWKN[VU[;IZ
M;VEZE/\ 9!^'/Q7\(?M'?$KQ%KGPCC^$7P]\5:='=?V);:_9:C;QZG$44O&L
M# H9$:5F_=@9')Z5X]\!_P#E$5\5/]W6_P#T97UW^SA^S/J?PM\2>+O'_CKQ
M,GC7XH^+?+74=4AM_(MK6!  EK;)DD1K@<G!;:N0,<^=?#/]CGQIX-_86\:?
M!>]U/09?%.M#41;W=O<3&R7[0V4WN80XQWPA]LUE5B_95():^SY?GS7M?K9:
M=%966B-*<ES*3_Y^1?R49*_EK\];O5LY/QU^SYXO^.W[$W[.=UX(;2[S7_"-
MAHFO0Z'KF?L6J>79I^YD[?@V 06!*YR,'XD?M*Z/J5SX9LOVK/V<O$7@:'1=
M2M[G3?%6EW$EWI]E= _+)]IMFC9%R ?+1Y<X!(.!CVCQQ^QOJGC;]GSX0^'+
M?Q/#X7^)?PVMK"32?$5E$;FWCNX($CD4JX4O"Y0=0#\JDJ1E3R_CK]GG]I/]
MI#PW_P ()\7/&'P[T+P#/-#)J+^"+.]DU'4$BD5Q$3<X2+)4'<N<$#@C(/;5
MES8BI*.SGS:[=/>36J>FVNR:W.>$4J4%+^6VF_71K9[_ (M,^RK6ZAOK6&XM
MY%F@F021R(<JZD9!![@BI:\:^+_@GXL37WPVM?A)XFT?PMX>TF_C7Q%::E$K
MO>:>AC'DPEK>7#;%D&08^H^;T]EK)VU<=KM>?K_79E*]ES;V_I?UY!1114C"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***CN+B*U@DGGD2&&-2[R2,%55 R22
M>@ [T 97C'QAHWP_\*ZIXD\0ZA#I6B:9;M<W=Y<'"11J,D^Y[ #DD@#)-?D=
M(WC3_@K=^TSM3[9X>^"OA67KT,,!/7NINYPON(U'?;\^G^TU\;/%O_!2/X]6
M/P1^$<SI\/-.N/-OM5 8077EL ][,1_RP0G$:?QL0>K*%_33X"_ OPO^SI\,
MM*\$^$[7R=/LUW37$@'G7DY \R>4CJ[$?0 !1@   '4^"_!NB_#OPII7AKPY
MIT.DZ'I=NMM:6=N,)'&HX'J2>I)Y))))))K:HHH *^:?V]OV3;7]JSX+7.GV
M44:>-=%WWV@W38&9<?/;LQZ)* %] P1C]W!^EJ* /Y\?V4_V:=2^-VM:UHWA
M#QE/X!^-?AJ5[JTT_47>U6[C0[9!%-&/,@GB8$,I#9#@_*%8U]6^$O\ @H1\
M?OV0=>MO"/[1?@:^U_3E;RXM8*K%>,@ZM'.O[BZ 'N&S]Y\U]CZK^P;X,NOV
MM-)^/.FZG?:)K-L[7%[I-FJ"WO;@Q-'YI;JA96^<#.\C/!+$_07BWP=H7CW0
M;K1/$FCV.O:/=+MFL=1MUGA?ZJP(R.Q[4 ><_ ;]K'X7?M):>LW@?Q3;7U^J
M>9-H]S^XOX/7="WS$#IN7<OHQKUZOSD^//\ P2"T2[U#_A)_@=XEN/ 7B*W?
MSX--N[B5K42#D&&=<S0'W^<>FVO,_#?[=7[1_P"Q7K5KX6_: \&WGBO0@WE0
M:Q.0MRZCO%>)F*XP.=K_ #]-S+0!^L]%>*_L_P#[8WPI_:6M$_X0SQ/"^K[-
M\N@ZABWU"+C)S$Q^<#NT991ZU[50 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%4]8UBR\/Z7=:EJ5U%96%K&99KB9MJ(HZDFGOHA;:LB\17&EVN@W
M\FMR6L6C^0XNVO2HA\HC#!]W&T@X.?6OSS_9=_X)HP?"W]K[Q-XUU*..]\ :
M#,M[X.W.)!<23#?&S<G/V<$J"?O/L<=*7]I']I&]^,FJ-I>F-+9>$+63,,!^
M5[MATED'I_=7MU//3J/V7/VI)/ ,UMX3\67+2^&I&V6E](26L"3]UO6+_P!!
M^G1*I0E6>%C/]ZNG3T3_ )EV^6^AYBQ\'4Y;>[W_ *Z'WI14<=Q'/"DL<BR1
M.H9'0Y5@>00>XH\Y?6@]0\]_:(^*TOP/^"OB[QO;Z3=:W=Z18M-;V-K \IDE
M.%3<$!(C#,"[?PJ&/:OA'_@D5\#-4UR^\7_M">, ]UJ_B"XN+72[BX'SR[Y2
M]Y=?\"D'E@C^[*.AK],MZMWJ#3].M-)LX[6QM8;.UCSL@MXQ&BY))PH&!R2?
MQH LT444 %%%% !1110 4444 %%%?F'\0/VPOVW;?Q5KEII/P.32M+M;B589
M6T"ZN%6)20&-P9?+?@9+J O4]* /T\HK\*-8_P""M'[1OVF> :WH=A)&[(PM
M=(@< @\X+;@1[Y-?J'^P'XG^*WQ"^ MCXV^+.O'5M4\12&\TVU%A;VJVMCC$
M9Q%&NXR<R98GY63&.<@'OVO+NLY/I7XW^-!_PAO_  5A:60>5;W]S'L)Z/Y^
MF"/_ -&$_B*_9C5H_,MG'M7X\?\ !3O1[OX6_M*?#GXGV<+%<1;MHX::TG$F
M"?\ :211SU"'WKR\UPKQV7XC"K>I"4?OBT=.&J>QKPJO[+3^YGW+45Q&)$(-
M5]%UBS\0Z/8ZII\ZW5A?0)<V\R?=DC=0RL/8@@U=K_/AJ4)-25FC]STDKH\S
M^(GP\T[QAI%WINIV,5_87*E)8)ERK#^A[@CD'D5X-)\,_'_P_;R?"?B.WU;2
M5.(]+\3H\AA7^ZERAWX'0!@V!WKZ_FMUE4@BLJZ\/PS$DJ*^_P"'>,LTX<ES
M8&LXI[K=/U3T/!S+)<)FD>7$TU+\_O/E/^TOB]=*(HO#?A>SE[W$^ISRH/?8
ML0)_.M_P+\$-0OO$MKXD\::NWB76K8[K.%8O)LK$D<F&')R_;S&);ITKZ"7P
MK"K9VBM.STF.WQA:^JSSQ0S[.L,\+6K6@]U%)7];:GD9?PIEN7U56I4_>75Z
MV^\BT73Q:0J,8K7I%4**=7XQ.;G*[/M4N56"OD3_ (*6?$"+P]\%[#PO'*!>
M^(;]-T6>3;P$2.W_ '\\G\Z^H_%WB[2/ GAN_P!>UZ_BTW2;&,RSW,QP%'H.
MY).  .22 .37Y\^"=/U3_@H%^UI#JTUK-!X \/O&QBF7A;5'W)"V./,F;);G
MA=W)V"OU3PYR&MFF;PQLH_NJ#YF^CDOA2\[V;\EYH^:S_'1P^%E13]Z>GRZO
M]#])/V!_AS)\-?V<? NCSQ-%=?8%O+A'&&66=C.ZGW4R%?\ @-?5$?"BN6\'
M:9]CLXQC'%=4*_L4_*!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***:S!>M #J:T@7J:\X^-'[0/@;X!^%WU[QOX@MM$LN5B20EIKAQ_
M!%$N6D;IPH..IP.:_.+XF?\ !4#XI?'S7IO"/[/7@J\LS(=O]K7$"W-[L/&_
M8<PVZ_[4A<>ZFFDWH@/U-\0>+M'\*Z=)?ZSJEGI-A']^ZOITAB7ZLQ %>&^)
M?^"@W[/OA6=HKSXI:'.X[Z:[WR_]]0*X_6OS^TC_ ()S_$WXR:DGB#XU_$ZY
MFOG^8VT<SZC<*IZIYDC!(L>B!U]*]C\/_P#!,?X):/"JWEEK6NN ,R7VILA/
MX0B,5V1P=672Q/,CZ5T'_@HM^SQXBN%AMOBAI4+LP4&^BGM%Y]6FC48]\XKW
MSP_XLTCQ5IL.HZ-J=GJVGSC=%=V,ZS12#U5U)!_ U^>NO?\ !,_X':O:O%9Z
M3JNARLN!/8ZI*[*?7$QD'Z5X-KW['?QO_9(U6;QA\#/&=]K-I&/,N-/MU"7+
MH.=KVYW1W(QVQN]%I3PE6"O:_H',C]F@P;I2U\'_ +%O_!2_1/CI>VG@KQY;
MP^$_B'GR8P24M-1D'!6/<<QRYS^Z8G)^Z23M'W7#,LR@@YKC*):*** "OR__
M ."A?[6VO_&3QS%^S3\%?-U74]1N?L&NWE@W,TG.ZR1QPL: $S/G "E20%?/
MIO\ P4D_;DN/A#IP^%'PXGDN_B;KR+!/-8@O+I<,N H0+S]HD# (!RH.[@E,
M]3_P3M_8;M_V9/!I\4^*H([KXG:Y"#=R-A_[,@;#?9D;NQ.#(PZL !D+E@#T
MS]C3]DG0/V2?A=%HEGY6H>)[\)/KFLA>;J<#A$SR(DR0J^Y8\L:]^HHH ***
M* "BBB@ HHHH *S/$?AG2/&&BW6CZ]I=GK6DW2;)['4(%GAE7T9&!!'U%:=%
M 'YX?M ?\$@?"GB*[?Q%\&]<F^'OB.)_/AT^>622P,@.08Y!F6W.><@N!P H
MKR+1?VR_VG?V%]6M?#GQS\*77C7PMO$-OJUU)NE=1_SQOU#+*<?-LE!DZ E*
M_6RJ.M:'IWB72;K2]7T^UU33;I#'/9WL*S0RJ>JNC AA[$4 >+?L\_MM?"3]
MI>&&'PGXDCM]>9-S^'M6 MK].,D!"<2@=S&S@=R*]WK\_/VA?^"0O@7QM/-K
MWPIU27X<^)%?SH[(L\NFM(#D;1GS(#GG*%E'9*\1TO\ :H_:J_8%O[;1/C%X
M;G\>>"E<10:I>2F4E>PAU!0<G'.R<%N.BB@#]<:*^>OV=?V[_A#^TLMO:>'O
M$*Z7XDD W>'=:Q;7F[TC!)6;_MFS''4"OH6@ HHHH **** "BBB@ HHHH **
M*^>OVE/VI+3X6V\WA_P[)%?>+9$P[<-'8 C[S]B^.B=N"W& U1C>[;LENWLE
MW9E5JQHQYIGT+7Q'^W7XA\:KKMEI%W ;/P2X5[62W8E+N8#+>:<<,ISA.F.>
M>WJO[-7[4UI\4(8?#WB.2*Q\6QKA'X2._ 'WD["3U3OU'&0/:?&W@_1O'GAN
M\T/7;1+W3KI<.C<%3V93_"P/((K2/N]=)+22\^L?Z^YG+4MC*/[M_P!=F?DE
M17H?QP^#=_\ !CQ9_9\TOVW2KG=)87V,>:@/*L.SKD9'N#WKR#Q%KPT^$Q0L
M/M+#COM'K7P=3+*N%JMUI<M..O/TMTMWD^BWOZ-F.49-C\]QT,MP%)SJRZ=N
M[;V45U>Q[/\ #3]O*[^!\T'@G4+:;Q1;M \EI:QDB2RZ%=\O(6(X8 %2<D8P
M!@^'>"?CU\6/!GQT\3^/XO%]W?6FJ?:8K;2=6O)KZ*U@EF258D60X4)L"@K@
MX'N:Y.1C+,\K_-(_WF/4TE>=C^(<1B:C=#W8VMTN_-NRU?6Q_=O#'A#D^3X6
M$<S_ -HK1E>^JC:WP\MVG%.[U5WUVL?3?['G[87Q(F^.GB:/XM>,K.V\%ZF9
M;BQM[B)3!;SLX*)',2&AB5 1B0E>G0DFOT:^'7Q*\.?%3PM9^(O"NL6NNZ+=
M[O)O+-]R,58JP]B"""#SQ7X@:MI=OK6FW%C=*7M[A"CJ#@X/H:^COV&_VGOA
MA^RSHMC\-]::^LM4US6(W^WY9X7,V(Q-,68)"JE%4E1TVD@X9J]S*,W>+?L:
MWQ=++I8_)?$3P[AP[368Y9_ 7Q<TE=2<M$E9:6:6EWIKW?ZM45\Z_M&?M46G
MPRLY=!\.O%?>+)4PS?>CL 1]Y^Q?'1/Q;C 9_P"S5^U-:?%"&'P]XCDBL?%L
M:X1^$COP!]Y.PD]4[]1QD#Z_D^S=<UKVZV[V[?UL?SM]:I>T]E?7\+]O4^AZ
M***S.L**** "BH+Z^M]-LY[N\N(K6T@1I99YW")&@&2S,>  .237YT_M1?\
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MSCD_-_#7Z@_LY?L\^'_@OX/L= \/V/V:SA^9Y'P9;B0@;I9&Q\S''7H,
M >D^'/ $-B%)09'M7=6=@EK& HQ7[1A,)A\#1CA\+!0A'9)61\E5JSK3=2H[
MM]Q]G;BWC"@8Q5FBBNLR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[QBX0X1K+ Y1A77=**I\\>574;Z<]KR5]>VK>^C\0HKTSQA\!I6EOK_PO?\
MEWUY=0L;74I2;2WA VR")47()'/)ZYKRFQU!;Y92(YHC'*\++/$T;;D8J>&
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MFKIMN+-SD @\;ERK+DA2"I!4<9ZSQA>>'OV>/!NL^(/#?PWOM3>\O1<7>D^
M]$B>^OKB1L-.\:E [=V=CG []*^9?V*-:L_B=^U)\:_B3JZ+X.\9ZG#:Z?\
M\*^OH9;?5+&SB6,"YN4D1-S2;8SE-RKNP6R111]YN$M=&V^STV7;6WDM6PJZ
M+FCIJK+NKVU\[:]%?3J?<M%%% $%]?0:;8W%Y=2K!:V\;2RRR'"HB@EF)[
M&OE7]D_]ONP_:=^(NK>%9?!MQX0/V!M6T*ZN;_[1_:]DEP\#2A?*3RR&4?+E
M_P"+GY<FS_P4@^)U]X)_9UN?#&@%G\6>/KV'PMI<,9P[&X.V4CT_=[ESV+K7
MC'[4?PQ7]CG0_P!G/XI^'(V:#X;26_AO7GB4YN=/G7;*[8]7,V/]J<&E3:<[
MS^&ZC\VGK\FX?)O?HZB?):/Q6<ODGM_V\E+YI=S]#Z*\T^/7CJ]\,_L[>._&
M'AC4$AO[+PY=ZGIM_&B2JKK;M)%(%8%6&<'!!!]*^7?@E<_M6?M+? GPSXYM
M/BSHGPZEN+'-I:+X:M[^75V7*FXNI' 6 2.K$+#'A4(ZFC6\E;X;7^=_\MM_
MQ#1J,K_%>WRM_GOM^%_N+5M4M=#TJ]U*^E\BRLX7N)Y=I;9&BEF; !)P >@S
M7FOA']H+2_B=\ ]0^*7@32=0\1V*VFH7&FZ:8FBN=1>V>5!&B@.P,KQ87Y2V
M&7*Y^6OGWX??&;Q_^UA^Q-XWNQKUKX!\?:%/?Z1K%_8Z;'>P3&VCWRHD4K84
M2Q.%+9^4DE>PKSS]A&+XA?#W_@GWX@\=0_$'[5H\/AK6;KP_X>_L6W3^QKJ"
M6Z8S?:#EKC<Z%MLB[1G'(%3)VC5;>D5%IKM)2=_G9<OSO96-(1YI4DEK*3BT
M_+1KY=7VVNS[K^$7C35?B-\-?#WB76_#-YX,U;4[59[G0=0+F>Q<DCRWWHC9
M&.Z+UZ5U]?&3?M@^)O ?["OPY^(-]%'XN^)OBZ.UTS2[>:-(4O=2G=@I=8@J
MA0%+$+MS@#(SD9OQ(A_:V^!OPGU[XC7WQ-\.^.Y[/3I;O4O":>'8;1--3RR7
MDL[I<M,T/W@)DPRH<@G .E9JG*HVK*+:^>]N^UM=E?5F%%.I"G9W<DGY^O;_
M (9V/M^BOC+P[^V-K_@G]@OP%\3O$,?_  F7Q"\2>7INGVFR.V&H:A+/(D2D
M1JJJH5,G:!D+C@G-:4WPX_;!L]$?Q4OQD\*7?B%8OM)\!-X5B72RV,FW%Z&^
MT>P;N<9..:*B]G*<9;1=F^E_S?W=4%.2J0A*/VE=+R_)??T?8^NZ*^)/BK^V
M?KWBG_@GGJ_QE\#2MX0\7VLD%G<0M#%<FPNUO(X;B/;*C*P(8D;ESM=3P:-7
MA_:Q\1?"%?BM9?$[P[X4N8](&LQ> (_#D-S!+"L?FB.>]D/F"5D'S;%50QP-
MHY$R?(IREM&UWTU5[^:MV+BG+E2WE>RZW3LUY:L^VZ*\I_98^-3_ +0_P!\'
M^/YK..PN]6M6-U;0Y\M)XY&BEV9).W?&Q&23@C->J2$K&Q'4"JK)T7)2^S?\
M"(251*2ZCJ*_.C]DSXE_M1_M>?#B]NK;XD:;X!T_2=2N+5O%4OAVUO[W4Y@0
MPA2W*QPQQ1HR@O@L6/4\@>[_ +,/QZ\=ZC\4O&_P6^+:Z=<>/O"UO%J%KK>E
M1&&#6+"3 $_E]$<%D#!<#+$ #:<EGL][72[JU_RUMVUV*G[C:[.S];V_/2_R
M>I]045^>G[,/CS]IO]K#PGK6JV/Q8TSP1IWAW7+K3!=MX:M;VYUAUDWE'!58
MX8XXWC1612Q.XMFO3M;^+7Q<_:(^,WC'X>_![Q#I?@#PSX(E2QUOQO?::FI7
M4]^1DP6ULY$>%PP8MW'!' *5VHV6K5[>5D[OIU77?U0Y+E<D^CM?SNU9=>C^
M7HSZ]HKY%\/_ !9^+7[.WQL\%?#[XP^(]+^(GACQO))9:+XRLM,73+J"^0!A
M!<P(3'M?(52G.3SWQSGB#XV?%'X[_M2>/OA-X&^)VB?!>S\&K;HDMUH\&J:G
MK,LB;G:.&=@OE+Q]WD;D)SNX%[S2AK>_X;[]KK[TUH+X4W+2UOQV^_7[G<^W
M:*\*_9_OOC?H&N>+/#OQABTS7='TL1RZ-X\TU8+4:I&1F19K19"T3KQR%"\-
MR< MX]X#^(/QX_;.75_%OPZ\=Z7\&OAC;WTUEHEX=!BUC4=86)BCSR+.P2)"
MP. N".0<XW$W=HZZ7]%YWV]-_(.C<M-;>KWTMOI_P3[6HKY@^!'QP\?Z+\=-
M7^!OQ@ETK5?%,.EKKFA^)M'@-M%J]EO*-YL)XCF5@<A?EX;'W0S>.? GXF?M
M)_M+>*/B[X=T;XA:7X,T3PQXMOK"'Q1<Z#;W]XL:R%8;*&WQ'$514+/+*6<^
M8@'0T;M<NMTW\DTGOYO\/2YM?FTLTOO5UMY?UO;] J\]^'OQV\*_%#QYXY\)
M^'Y[FZU'P;<0VFJRR0&.)9Y/,_=H6P6*^6<G&WD8)YQX+^SC\8OBI=?&+XG_
M  %^)/B#3M9\6^']-34=(\9:?IZ0&XAF "O+;#$>]#+&=H '# D\,?$_V"_A
M_P#$J']JSXZ2S_%?[3;Z+XDC3Q+;_P#".6R_\))(5N LFX-FTVMEML60<XIP
M]Z:7V7'F3_[>4?735/2][6OJ*?NP;ZJ25O5-^FJM;6UKWMH?;GP9^*GB'XF7
MWCB#7O .I^!X] UR;2K";43(1J]NGW;R+?%'\C=MN\?[1KTROE#]F+XX>-OB
M'IO[14OB#6O[0D\)^*]4TW13]E@C^RV\,9,:?(@WX/=]Q/<FO*?V5_%7[4O[
M6GP'TCQ0GQ8TGX?1127$$>JCPS:ZC>:U(LSY>1&"0P1I\L:A$+$QLQZBHB^9
M:=(Q;])+?_-+OI=;7-<K=_YI+[GMZ=G]Y^@M%?)G[+O[6.NZY\,?BS)\6_L,
M?B/X4ZA=V.MZAI*;8;R.!';SE3C#'RY!@  X! 7.!R_PMU#]JC]HSP;;?%72
MOB'X=^&VDZF&N]!\#S>'H[^&ZM<GR3=W;$2QEP!DQ]B" N=HKKIJK)W\I:KS
MU[)7)Z:Z.[5O-:/[N^VQ]MT5\@?L!_M _$GXYZ_\9H/B.T=K>^'==BT^#1X8
M8E332!*)85=$5I%#IPSEC@=3U/U_5-6L^Z3^]7_4E2O?R;7W-K] HKX^\1?%
MCXM_M$?'[QO\-_A%XJT[X;>&O HA@UGQ;<Z0FJ75Q?2 GR(892(]BA6#$\@K
MG/(%=K^SG\1/BSI_BGQWX$^,FG->R>&%CNM.\?6>E/9Z?K5HRY8DX\I9DXW*
MAXR1CY"QB+4H\ST35U?JN_W:Z[K5:%R7*^7>SL_)OI^FFST9]&45\4?#WQU\
M?OVS;&_\;> ?'NE_!;X:_;9[707_ + AUG4-6CB<QM/,)V"1*64X"X(P0<X#
M-WG[/_QR\>6?QK\0_ _XO-I=]XQT[34UK2/$6C0M!!K&GE_++O$>(YE;J%^7
M[V!A=S5&+;L]&U>SWVO]]M;/7R%+W;O=)V?WV_/2ZT+_ ,,_VOO^%C?!SXO^
M//\ A$_[/_X5]J.K6']G_P!I>;]O^PP"7?YGE+Y6_.,;7V]<MTKTWX!_%7_A
M>'P;\)^//[+_ +%_MZR6\_L_[1]H\C)(V^9M7=TZ[1]*^)_V9?\ DSG]K_\
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M@K_P(TXJ[L1.7)%R9Y)X1GF\;>.]8\472G!D8QAOX2W"K_P%!C\JT/BIHO\
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MQ3<RWNN7L;/IV@6(#7-UCC<2>(XP>"[>^ Q&*_.RVTC]H_\ X*K:^EUJ$I\
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MS;N9<JBHQCM%RMZ/ELOE:Q\'?\$_;6:^_9E_:&MK>-I9YO%WB"..->K,;2(
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MVIG.T[B&&?H;QE\/O"WQ&TU-/\6>&M(\3V"/YBVNLV$5W$K?W@DBL ??%7]
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M  .@ [5F>*O".A>.M#N-%\2:+IWB'1[@J9M/U6TCN;>3:P9=T;@J<, 1D<$
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M103W.*]#\/\ Q6\$^+/$E_X>T/QCH&L^(+ ,UWI6GZG!/=6P5@K&2)&+( Q
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MM/M%C(,=JZ.J&K0^9;./:@#\=/AY&?@'_P %0-=T-?W&E>*)+A!V4K=1BZ0
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M\7FQ-$ R[T967/JI!K1\:?\ !-O]E_PEX5U/6'\/2>!19P/,/$4/B2^C?3R
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M/ACX1_:=_9L^'NEZ/\.#X"_:#^$<*,VEK#<BTOY;-RSD))O$+*2S<[ILYX[
M?27PF_9?LOASXI^,VI:EJ\?B73OB5J;7USIDUCY*6T3)(CP,WF-YH(D(SA?I
M7F.@_L2?$GX8V$GAOX7_ +1VO>#?A_YCM;Z!?>'[35)K1')+1PW4C!HUR3C
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MOVT_\)-:Z/\ 8MNW9_KU/F;\M]WILYZBJ/C3]G?_ (2[]ICP!\7/^$@^R?\
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M.\[VR/YC;U+LO(5/N=,DT4O=J>]\-U+_ +>CM][Y6_*'F.I[U/3XK./REO\
M<KV\Y'(?M7*L?[;G[)2JH55O=8 4#  ^SQU6\(Z3;7G_  5B\<WLT8>>S\ 6
MQA)'W"\L*DCWQD?0FO;_ (L?L[?\+0^.'PE^(?\ PD']F?\ "!3WDW]F_8O-
M^W?:(U3'F>8OE[=N?NMG/:ET/]G?^QOVJ?$?QF_X2#SO[8\/PZ%_8GV+;Y7E
MNC>;Y_F'=G9C;L'7K2H^[[/FZ2J-_P#;T))?>V*M[U^7^6"^Z=W^!YO^UUX]
M\%>%OBU\*H1\-M0^*WQECDN;KPEHMGJ#6D=L,#SIYF+>4JX3AG1\%"1MQFOF
M'_@H_P",OCIXP_9N2X\?_#?PK\//#*:S:$6[:]_:>J&X^?9Y31((@,;]W).,
MX[U]G?M%_LJ_\+J\6>%O''AOQIJ/PY^(WAE9(M-\0V%M'=+Y4GWXIH'($B\M
M@;@/F;.0<5Y1\5?^"=_B#X_>"+FP^*'QSU[QAXFBVG2=0_LFWLM-TY@ZEI!I
M\#*LLC('3<TG <XY%1%/EC?=2OY:23T\[+6_7Y&RDE._1JWGL]_+72W3S(OV
MOG:3XW?L=LQ+,WBC)8G))\N#FO5/B5\:?CUX8\;ZII?A+]G#_A-?#MNZBTU[
M_A.;"P^UJ44LWD2(73#%EP3SMSWK0^)W[,]Q\3O%'P4UR[\4K:W7PYOUU"58
M]-W+JCA(U8#]Z/(!,9/_ "TQNQSC)]TK;2TDG]N3^34;/\'^O0Y(IKDNMH17
MS3FVOQ1S_@'6==\0^#=)U+Q-X=_X1+7[F 27FB?;H[W[')DYC\^,!9,<?,HQ
MS70444GJ[FB5E:]PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "H+I=T1
M^E3TV1=RD4 ?F'_P6&\!MJ7PM\.>)8H]SZ-JWE2''W89T()_[[CB'XU]!_L\
M^/(_B9\#_!'B5)%EDOM*@-PRG($ZJ$F7\)%<?A7HG[3GPCL_C!\+_$?A2^PL
M&J6CPB7;N\J3[T<@'<HX5O\ @-?F1^R;^TI<?L>^*==^#WQ:AGT[2H+UI+6_
MCC:5;.1L;B0.6@D&'#*"023CYCM[L)55.=I;,F2NC]-J*\NC_:D^#TEFMR/B
M?X3$;#(5M8@5^F?N%MP_*N+\2_M^? KPRK!_'$6HS#I%IMG/<%OHRIL_-J]M
MU(+>2,K,^A:3:#7PAXT_X*R^$;/=%X2\$ZQKD^=J2:E-'9H3Z@)YK$>V 3[5
MP%U^T[^UE\<CY7@SP@?"FGS<)<VVG"+*GOY]V2I/N@!]*YY8NE'K<?*S]'M<
MU[2O"^G2:AK.I6>DV$?W[J^G2&)?JS$ ?G7S+\5O^"D/PB^'<<L&C7MQXWU1
M<A8-'3$ ;MNG?"X]TW_2OG[0O^"=_P 3?BUJ46K?%;X@W-S.W)A2:2_G /\
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MZ, 58'N""#5BG9Q;3)34DF@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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M#KG[4GP'O_&HTZS\.:E<WU]96%M%(TJ0",[8B[L/G.>2=H!_NU-_BLK\JO\
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MM=E_9%_/Y?F1)*GSQ0,ARDB'ACC.#R"*_('_ ()<?\GV?#+_ +B?_IKNZ/\
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M^W,TO[$__)2/VFO^RBW/_HF.N2GJH1?6FI?/W/\ Y)^O4Z6])272HX_+W_\
MY'3LC*T?]M+Q3JW[(/Q/^(<_AS2](^(G@"[N](U+2I6DGL3>V[1AF7:ZN8R)
M!QOSD'YCU/.^,OVNOC[X$^&.C?&K5_A]X0@^$DD5G/>Z3]MN3XA6WG9$6X'_
M "PC#%T81DNP# ,<Y(\DL_\ DT/]N'_L>-8_]#@KW;]MQ0O_  33UD 8 T/1
M0 /^OBTHYFWS+>U%^5Y*7-]YM&FG6C0Z.517ZV4HI?=?^M2E\1OVKOCM\*=%
MT;XI>)/ 'A&Q^#M]>6L4^F+?W#^(K&WN'"1SS-@6X/S*3&N[!8*6ZL/8OCE\
M5/BGIOC+0_!/PE\!VVMZOJ5G)?W'BCQ,+B'0=-C4X5))(D)DE<YQ&C!@,-@@
MDCRG_@IA_P F$ZW_ +^C_P#I5!7%_MC?$B?P_P#'[P[HOQ-\>^-_A=\#V\/+
M<6NL>"_.A^W:IYA#0W$\$;R!1'_RS ]#QG-:R27N_P!^4=^B@GJ_6_J[(YX-
MM1F^L+_/FMHOGUVM?U]2^&'[0WQ>T/\ : L/A!\9/#GA&+6=<TF?5=%USP;<
M7)LI/)SOBDCGS(#@$[N.@ !SD>/_ +$-U\7K']IKX^W/B23P)%HL.N+)XODL
M?MGFK<"VD,1L=_R^4,?/YOS8SBO._A+I/@K2_P#@H!\&]?\  NA^++/PEK%A
MJ=O;^*?&$UTTOB"Y6UD9I(A<GS!&JR( Q5 Q+8!QFO7?@WXGT+P[^UE^TK\*
M/$M[/HOB?X@Z@L^@PRV<Q2\MS8REY$D"; %4G[Q&2"!DC%1[\??BKR=.>G=J
M:LK?X5?Y7:0.S?+)^[SQ=^R<'=W_ ,6GSL=1X7_:,_:(_:"TV[\;?!SP1X&M
M?AQ'<30Z:WC.\NEU+6XXG*F6 0X2$,590)>A[D5/XM_;MOO^&.?%'Q:T/P[!
MI/B[PSJ<>C:SX;UG=.MC>+=113Q$HT9?Y9-RMD=1D<$5P?[-_P"UQX1_9)^#
M^E_"#XPVFM>$_'GA5I[&WL$T>YN5UJ/SG:*6SDC0HZN& !8J,]\5YG\3O _B
M31?^">/QZ\9^*M%N?#6H?$#QBOB:'1;U2MQ9VTU];")94/W7(4DCK@C..E4T
MDVJ;O'2TN[YHK\4VW'I;H:TES2BJBM)NS7E:7Y-)*76_4^C?$WQP_:/\'?!_
MQ/\ %/6?"O@2VT"SMK76+#P_:F\N=32P,BM<I<OYB1B9("6!0%=RG(.*]-_:
M*_:"NOAQ\%M'\3>"8;'6_$7BF]T_3?#-M>AVM[J>[==A8(RL5$9=SAA]WK7J
M=OH]IXA\#1:5J$"7-A?:<+:XAD&5DC>+:RD>A!(KX*_9CT+7_&7Q^\(_"SQ#
M'<2:7^S['J'F3S*-EY/-(T6E.?\ =M"7'H15<J]LZ/2]_P#MU?&F_2R7FW\L
M(R?L57>]K?\ ;S2Y=.U[W\K'Z'6PF6WB%PR//L'F-&I52V.2 22!GMDU+114
M[EK16"BBBD,*9-#'<0O%*BR1.I5T<95@>"".XI]% 'PK^U!^RK)X->[\7>#K
M9I=!8F2]TV)<M9=RZ#O%ZC^'_=^[\O9&,]J_8IE#J58!E(P0>AKP%OV,_!1^
M* \3A"-'_P!>?#^P?9S<9SNSG_5]_+QC/?;\M<>+R_#YA)5*CY9+=I?$O_DO
M/[SQ:^"ES7H[/IV_X'D>(?LO_LJR>-GM?%GC"V:+P\,26>GR95K[T=QVB]OX
MOIU^ZX88[>%(HD6.)%"HB#"J!P !V%*B+&BHBA548"J, #TIU=JY805.FK16
MR_K=OJST:%"-"-EOU84444CI"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#\V/VL/C;J_P\_:?UOXH_ _3KKQGK7A'P[)HGCQ9+%I='LX1)OB#3JZL9HW
M8,Z1YPJ')&U\?1W['=KX%^&?P^T94^(6E^)?%/Q0O;OQ6;PLEHVK7,@5I_LU
MN3N"QJ%!3J-K$@<@>4?#/Q%XU_8NO/'_ (%\2?!OQE\2?#FM^(+W6M'\0>"-
M+34Q>17)RT5ZF]3&RX"DMG.3@$ $^;_LO_L\_$SX*?M+Z)\1;_X/7%OX(\13
M7MCI7AVVUE;JX\%1SN)#,Z,5C5'4/D*<@,0?GVH[PVJC![-;]F_></G.WI9W
MZ6*^\I+=/;NEHI?*-_6_<_3BOC[]GFW_ .%!_MC?%GX3L&@\/>,$7QWX=4C"
M"1SY=]$I]0^TA1T5*^P:^6?VY_!_BG3;7P'\8/A]H-YXD\<> -4\Q-)T^!YI
M[^PN5\FY@5$!9NJ-P#@*QQ6?-[.:F]MGZ/\ RDHOT3*Y74BX+?=>J_S5X_,R
M?",:_M!?M[^(_$SXN/"WPAT_^PM./6-]8N1NNI%/3=''^[(['::\'N/$WPI_
M:>^)G[26M^//B'X3\/07-B? ?A6WUS6K6UEBB@/FO=HDD@)1KE8W5L<[2,U[
M3H/@_P :?LS_ + ^L'2-"U;Q%\7/$%O-J-[#IMC)<W;ZOJ##?(Z(I/[D.,D\
M 0UWOP-_8=^%'@#X0^$] \1?#7P?XB\06>GQ+J6J:GH5K=3W%T1NE8R21EF&
M]F R>% ':JE2:3IM_"N7_MZ5W)KTU2\I(%4U52/VG=?X86Y4_71^J?30D_8%
M^-W_  O/]FGPU?W=U'=:_HJG0M6:.42;KBW 42;APWF1^7)D<'?7S[XF\>?"
M[X[?MC?%%/B1XX\-:#X1\'^'IO!>EVNN:Q;6AGN[M6%_<1+(ZG*#,1('8<Y%
M:^J:#XG_ &+/V@_B;<_#OX=:SK/P_P#&GAIM4TS3?"VAS7%II^N6Z,B0>7;Q
ME85DZ] /G&.%X]'_ &5_V*_ OASX&>&O^%C_  \\-^)_'NHQ-JNMW_B'1;:[
MN_M5PQE>-GD0M\FX)C.,J?6JG_M$G5>S3NO[TKQ?Y3^3BR(_N8^R6]U;_"K2
M7YQ7RD1?\$V?BU'XY^ \O@ZXU:TUG6?A]?R^')KRRG6:&ZMHV(M;B-U)#1M&
M-H8'GRR:^LZ^-HOA%=?LU?MO>'->^'W@N:V^&GC_ $EM(UVS\-Z419:5>P'=
M!<R)"FR)&R%W$ 9:0DU]DU<I>T2J/=[^JT?W_%Z,E1]G)P6VZ]'JE\OA^044
M45F6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 444E 'PC\1O@[\/O$'Q1\::M^
MUG\3_#5W9W-WN\*^"QXNGL+73]/7(21H T+M.W\1&X9!Y.0!Q/["WCSPOX;_
M &T_'7PT^$GB^\\1_!J;0?[2L;&XN)IX+"[22%76!I>=O[QQD?>!7);:#5'X
M6^%I?@!\0/B!#\7?V:?%7Q>\8ZOXBN-2T_QMHWAV'78;BW<_NAYDK 6V,$X!
M!&[! VBNP^!7A'XI+_P40NO'GC;X;77@W0M>\(26NG0Z?&;NTTU$DC$=O<W,
M2^2DS"%W*YQ^\4#THP^CIM;.+OZ\C=GWDG\[J]ULRM]N^Z:M_P"!)779-?*S
ML>/Z]J7PFNOV@OB58_MFVWB=-:?6YCX5GO9=031XM+!Q#]E^R,,'&"S$%>F2
M&WU]A?LV^%9_!OP3\>1?##XN0?%S29/M,OA%)YEN6T>3R6,5E)<><^]0WE\,
MJ;>>.>.+OOBY\4_A/KGC+P?\:_A+XJ^.7A*\U&6?P_KOA'P[:ZFDEBP&VWNK
M5 BH4'&YQEB6Z@ G*_9/_9_\8:?XX^-?Q!\/>%9/@+HOC#38['PQX>GBB::T
MF2,[;V:T^:.(ASD1$<;W&,8+905Z#AJER;KT6C7\U]+[WN]KFD]*O,[7YMGM
MO;1K[-G>VUM-[(^9_@_%^S1XNT5M+_:"U;Q;X2_:(,DR:AX@\4WVHVUQ;7)9
MC'+"ZMY,:HI3 E5>G<8K[!^*WQ5\1?LM?L W'B"R^(5O\5/$-K:QV.E>,5B7
M;=&>81Q3-B659&C1OO%SO,8)ZFN0C^.'B^3P+!X%_:"_9B\9?$[QC8AH'U31
MO#5KJND:BP)V3B4%4@+#&=J_+UPOW11^%O["OBC6OV&?'_PT\210^$M9\4:Q
M/KVCZ(;K[3%H>'B>WMFD!.1F+#%<\.3RV:TJ>]3FEMI\.SU5U%=&TWMKI9VT
M)IV52#EO=[[K1ZM]5>WEK='7>&O^":GP_P#$'@.PU;Q9K'B?6/BQ=V:7,_CT
MZ]=_;H+QE#;X1YGEA48X4,I.T#)SS7F6B_MD>//!?[!GQ2OM7U3^T_B1X$UZ
M;P5'KC@,\\GFI%'=-G(+JKL<G.XQ@G))SZ=X;_:Z^+?A+P/9>$==_9Q^(&I_
M%"RM%LA<:;91RZ!=SJNU9FO@^V-&P&(P=N2,]ZQ/#W[!_B76/V(_'G@/Q-J%
MI%\2O&VIR^*KR1'W6]MJ+2)+'#N&?E_=A689Y=L;@!EUM?:<O\/R_P 2^%=^
M3F^]7UL31WI^T^.^M_1[OMS<OXVTN27'_!-W2V^%-IX@\+>*-;M/V@/LD5['
M\0+[7;PR3WI =EE 9E$+'*\(6"XSNYR[_@H;'K\/[/?P4C\5/92^)4\<Z$NI
MR::S&V>Y$4PE:(LJML+9(RH.#TJ/6/VC/CGXF^#[_"_3?@9X\T'XP76G#1Y/
M$7E)!H-HY7RWO(M163 (7+J%Y#8 8XR;7[7WP;\9P?LT_!+PG:C7_B+XAT/Q
M=HLNJZE%%/J%S-Y<<WGW4I^9PFYOO,< %036TK>T3C\//"W;XM;=E:U^FW5,
MRC?V;4_B]G._?X>O=MWM\^YZ%^UYX"U3QWX@\')XG^)&E_#OX&V;22^)U?7'
MTJ\U64J1%;>;A5\D_P 0\P$[FXRJD?$?QVU;X _LU^//AQXA_9D\;)9^+/[?
M@M]7TG0M;N=0L[^Q8_O/.>1Y$/(5=N[G>3MR 1]%_MC?#?6XOVI_ _Q)\2?"
MW5OC9\*-.T233W\.:-:+J$UA?,[$W!LF.)@RE!SQ\O)!5<^2_M9Z3X]^-7PS
M\*R?#C]G/7/ 7P^\/:]:ZG<6,VC16NLWLH+)^ZTVVW.L<:LQ9FY.\8&%8UCA
M])TWM[ZOZ<UM7VMTVMHNYKB+N$XK7W';UY;Z+O?KO?7;0ZO_ (*"?L_^ ?%/
M[6_[/=QJF@_:IO&^LR:=X@;[9<)]MMX1;)$F%D'EX5V&8]I.>2:/VP_BOX-^
M&/Q4^&_[/FJ>,]3^%'P9TS0%O=7FT;[5-=7L(+16U@)8UDF"$1'<QSN!.3D"
MO4OV\?"OBF3QY\ /B?X>\(Z[XRTSP3KTEYJFE^'[,W&H>3+Y)#)!D,Q'E$$=
MB1D@<U1^,7A?X@3?%'X;_M1?#/P/JNIW\>BMI7B'P'K"+8ZJ]B[,XPC$[9D+
M'*9)RJ8##-13M&G&#T2G*_;X?=NNU_5+6^ERYMRES1W<%;O\;O;SY;+OLEK8
M^5_B3\6OV6_@GX?7QC^S#\1-5\,?$32[B*<:,BZS)8Z['YBB2"Z6ZC*$;"Q!
MW+R/7!'TO\:_'6I_M4_'#X/?!_3M9U/PUX'\1>%_^$S\2#2IS!<7EJZGRK3S
M5Y"$C# <$/Z@5T'BS]I3XT?'2SM/"GP?^$WCGX9:U=7$0O\ QA\0-&AL[;2X
M P,CPQ2F07+$ KC'0YQW%_\ :6^$_CSP9\9/AU\>? &D2^/M;\-:=)H?B'0T
M:.&[U.P<,3+#@!?-5G=MBCDE0!@8K16M'VGP\W7_  OI_+S<N^FCTM<S=]?9
M_%R]/\2Z_P W+S6ZZZM>Z?,__!1C]C/PM^S_ / %-=^%TVJ^&_#S:K:P:UX;
M;4[BZL;K<Q\JXVS.Y657"C(/(<CCO^I=E_QYP?\ 7-?Y5^:O[='Q(^*_[57P
M/71?!/P+^(.A:!:ZG;7&IMXBT=H=1NG4D)%;V<9D=XP3O:4X4; .]?I79J5M
M( 1@A%!!^E5"_L6I?SO[N6']+RVT"I;GA;^5W];_ -?\/<S_ !8NM-X7U<>&
MS9CQ";24:<=19EMA<;#Y9E*JS;-V,X!.,\5^>$_P+_9FT[PM--^TE\6]'\;_
M !=4RMJ^JKXRN))K*8LQ\JVMHY%*JG&%:'J/N@84?<'[17A3Q+XZ^!7CKP_X
M.O/L'B?4M(N+;3Y_,\LB5D("A_X"PRN[MNSVKXI_9VU2#X3^ =!\(Z5^QGXH
M;XM:99+:3ZS>Z!:0Z?=W:C#3OJ\K9V,V6XR!G:N0!6"7-*2ZV7KUO;M;2_JC
M1NT8^K_3?]/F:W[ ?Q.U;QY^R+\9=*OO$5[XKTOPW=:IIVC:KJ+,T\EC]EWQ
M!BWS8Y) ;D!MO   Y[]AG]BGP5\?/V3_  ?KGQ4?6/%:S+<IHVFMJUQ;6FD0
M+<2J##%"Z*9'8,[.^XG*CM74_L0_#/X@> ?A9^TGX<\;^&=0L/$]]JM_>))'
M8S+::BTULZ[K-V4"92ZG&W)&Y<\FO=/^"?/A?6O!?['_ ,/-&\0Z1?Z%K%K!
M<BXT_4[9[>XA)NIF >-P&7((/(Z$5K%<SG*6K<:7WVE=^OGOJ^YC)M*$5TE4
M^ZZLO3R\D>(?L<>&H/BS\%_CI\$_B#=7WC;PCX2\4W.BV7]IWDHN&M(7#PQM
M+&ROA7A##! &=OW<"N4_X)C?!3P9IG[+OB/XF6VC>7XWO+;6-(GU3[5,=]JI
M#"/RB_ECF-/F"[N.O6O8?V%_ 'B3PSXL_:2.O:#JFA0ZSXXO+G3YM2LI(%NX
M&,F)8BX D0Y'S+D'/6N(_853Q?\ "WX2>+/@=XI^&?C+2=<L5U>\37I=*)T:
M[#X"1PW()#R-N.% ((!YSQ7/4<G3JO[4J2^;LN;YVWZLZ8V4HQ7PQJO[KRM\
MM%^!YW\-OC-X@^"__!)KP#/X2G-GXK\0ZI/X>TR\49-M+<:C=9D'^T$1]I[,
M0>U>SZY_P3D\)^"OAKJ.N>$?$'B73_C':6$EU_PG)UFYDN+^Z5"S+/$SF)XI
M&&UDV?=/)/.>'^&W[*GBOXJ?\$P?"G@*XTZ[\*?$#2+JXU?3+36[9[66&[BO
M[AXUD20!D#QN0"1P) W(KN/$7[5_Q<\6_"W6?"=E\ /&^@?$M]+FM[O5=5MH
MX/#UF_EE9;E+TN?-51EU15)8@ $]:Z,>US8AQ^*[L_*VEGVOS7]5?2QCA_BI
M7^'6_KS/?U5N7T=M3Q'X2_'K5OV=_P#@D?HOB3P_.EIX@N]0NM+L+R1-ZVLD
MU],&FVX.2B*[ $$;@.#TKG-/U+]A&YT.&\\1?%WQ3K?Q*:$-/X^=M?34A=8Y
MFC_=>6N#]T%6P  2>M>@_L\?L]7G[2'_  2FT#PCIUU'IVN_;+O4M(N9^(Q<
MPW\Q0,1DA6^9">V[.#C%>PZ#^V;\4M"\,V_A_P 3_LU?$>[^)4$(MG;2+".;
M0[FX P)/MP?;&C'D\,%R1DXS6M?^-53^*ZMWM9;/UO=*SVWTM%/X(6V]Z_:_
M,]UVM:U]-_GXKX?^/VJ?'3_@F3\;(]:UIO$^H>%S<Z*GB"2-D?5+96B>"X=6
M 8,R. =PW';EN2:[GX5_L ^!/BU^S3X/\0_$.]U_Q!XYO/#=M<VFMOK%Q&='
M4VZM#%:PHXA5(AM&"C9().<UU_Q(\%_&C7OV ?B18?$::7Q9\2M<LYKB/1=$
ML8W-DCR(8[*%;=,S%%!);YR22-S  GW_ ."6E7ND_L[^!=-OK.XL]1M_#%E;
MS6=Q$R312K:HK(R$9# @@@C((KFJWM7E]KEIZ^=JEWIUOO;Y:%T]Z2Z7G]UX
M6^5MK_/4^0?@O\4OB]\2O^"76LZKX9O]0USXEV$5UIEK?QLTE_-#%<!69#]Y
MIA 6"GEBR@C+=?&?ASHW[(WQ \*6MKIWQ \0?!WX\) GVGQ7XDU*_M[^WOUP
M)7E:29;9MSA@5#(Q!_A->Z_LA_#3XQ>&?^"?>JZ%X42_^'GQ1CU.]NM-CUW3
M%B=B)E<(T5U&0%E4,H<K@;@<\55^)WQ8O_CE\/;CPCXV_8_\:Z]\39;%[%+J
M\T& Z5#=E"GFQ:H7'EIN^8,N,=,]ZTJRM.4XJ[:B^SO:_NOUW7>W2PX)<JA>
MR4I^:MS65UZ+1]KGW1X-MKZS\(Z+;ZGK$7B'48K.%+C5X8!"E[($ :81AF"A
MS\V Q SUK8)P":\>_9"^%&N_ _\ 9O\  W@GQ->B^US2[-EN663S%B9Y'D$*
MMW6,.$!Z83CBO8:TK?')1=]7J8TM81NK'QQ_P3:FE\8:+\9/B)?9DU/Q1X[O
MBTK8+""$(L,>?10[ "OISXN?\DI\:?\ 8%O?_1#U\Q_\$];=_AWKWQW^%%\Q
M2_\ #?C.?4((VX+65XBM X'H1&3Q_>KZA^*%G/J'PS\6VMK!)<W,^D7<44,*
M%WD=H7"JJCDDD@ "N#%*^"LO^?<?_2$=E#3%._\ /+_TM_H>%?\ !-/_ ),D
M^&7_ %[W7_I7-7SW^VW^T%X ;]MKX4^#O'WB)=&\"^ S_P ))JS_ &:>Y$NH
MLNZUA,<*.V5 C;.,;96!KZ._8+T76/AO^Q=X&LO$6A:KI.K:;97<EQI-U92Q
MWBXN9G"^2RA]Q!&%QDY&.M>5?L7_ +,=I\2+'Q_\5_CC\-K&]\7>-M?FN[?2
M?&.BI+/IMG&2L2"*X0F,G+#H,HD9Z8KTL1>6,E*.T6Y?.]H__)+_  G#1M'"
MI2WE[OZO\%;_ +>/&?%W[8WPBMOV_OAS\3?ASXP75]*\1V7_  C/BV/[!=6@
MC4LJV\[&>) P#&,DC.!!VS7W7^UU\:(_@#^SKXU\9K*L=_:V30:<#_%=R_NX
M?KAV#'V4UYC^U=^PS\.?'W[/_C#3/ _PW\+>'_%Z6AN]*O-$T2VM+EIXB)%B
M#QH&Q)M*8S_'7@NJ6?Q-_;$@_9H^'WC3X?\ BK1-%TT_VQXYNM=T2YM;:66T
MW11QN\B*I,RH[;?^GA3V-<G*JM+ZLM'>U_[LKMO_ +=][[UY'5S>SJ>WEJK;
M><4DE_V]HOD>:>#_ (V?LT0?\$];WX/:K\18U\8ZMI\NIWC2:+J+;=8=O/3=
M(MN5.QUCC+ D$)G)S7V]_P $[_CJ/CQ^RWX6U"ZN3<:[HJ?V)JFYMSF:  ([
M>[Q&-\^K'TKT+_AD[X(?]$;^'_\ X2]C_P#&J^4/!OA/Q=^QK^U-\8K+PCX!
MUS5/AEXLT&7Q#H\?A_1II[.TU*&*1UM%\I"D99A*BH,<-" .E:RJI2J.2^)7
MTVO!-I?.-TO1(R5-N,.5_"^N]I-)MO\ Q6;^;/7_ -F3'Q*_:1^/?Q/<^=:V
MVI0^"=)D8?<AL4#7.T_W6GD)^JUP\-K_ ,,W_P#!29BH-OX3^-&E$],1KJ]J
M,D>Q9<GW:XKW#]C#X9WOPG_9I\$Z-J\$UOK]Q:G5-62Y4K,+RY<SS"0'G<K2
M;3GGY:Y3]OSX3:W\0O@O:^(?!UC-?>/? VJ6_B30XK2-I)Y9(7!DB15!9BR9
M(4<LR**))8>I33VA[LO1Z3?WWGYM=QQ_?QGR_;U7RUA^"47Y7U.!^-D(_:._
M;T^'/PU7-QX6^&MK_P )?KJCF-KUBHM(F[9'[ML'JLCUP'_!1[XW>"V_: ^#
M/PQ\:ZZNC>"=-OT\4^)IOL\UP&5-PMH"D2LQWE9 0 <"13QBO:_V#?A]XDT_
MPUXZ^*OC[1;S0_'7Q$UN;5+K3;^W>.ZL;.,M';6S(P##:NX@$ X9>*X#]E7]
MGF/XV?$;XO?&/XT_#>&>[\2:S]CT+1/&NAJTMII\"[8Y!!<(2A9?+7.!GRR1
MPU3&,H2IPZQ]^7^*ZLODW%>D.V@Y2C*-2?27N+TL[OYKF?\ V\CQ/X^?MJ_!
ML?M;?!WXP?#?QF-7FM2^@>*;9=.O+0MILC?+(3-"BL$\R1L YRJ>F1^B7QZ^
M+MA\%?@EXM\?7$D<D&DZ;)=6XW?+/,1M@0'_ &Y&1?\ @5>7_'K]AOX5?$+X
M.^+?#_AOX;>#_#OB*\L)!INIZ9H5K:SP7*C=$1)'&& +JH;!Y4D=Z^2[JT^+
MO[3'P+_9_P#@EXD\ >,="5=7$'C+5-4T6ZMH%L+''DEYG0+F2,Y!SS)&,=:G
ME]I3>'AI*^C\IMW?_;KO+YE74)JO-7C;5><5=?\ @2]WY(YG]G_]H#]G'3_V
M+_%?P_\ '_Q'6/QKX\^W:CK\CZ+J$S17TY/E,72W96,>R)LJ2-P)%?5O_!+?
MXY+\7_V7]+TF[N_M.N>#Y/[$NB3\SPJ,VTG/.#$0F3U,;5[2O[)GP/154?!O
MP 0!CGPQ9$_F8J^<?!/PEUK]F#_@H)=/X,\&7L?PC^(VD(MW_86EM_9VCWT(
M.S?Y2;(5)4XS@?Z2?[IK:,DZCC:W,DEV3BGR_A>*^1C)2]FI7^%MON^9I2_&
MSVZ'W+17BWP\_:$U3QG^T3\0/A?J/@:\\.P>&;2"]LM<NKARNK0R-M\R.-H5
M 0,'7<KN"4(Z@U[36:]Z,9K9ZHTVDX]5H_S_ %/P!_X)<?\ )]GPR_[B?_IK
MNZ/^"H__ "?9\3?^X9_Z:[2C_@EQ_P GV?#+_N)_^FN[H_X*C_\ )]GQ-_[A
MG_IKM* /W^KY[_X* >%;;Q=^QW\4;:X S9Z2VIQ-W22V99U(]\QX_&OH2OG'
M_@H9XP3PC^R)X_C53-?ZY;)H5E;(-SSS73K$$4=SM9S_ ,!-85[NE)1WZ=[]
M+>=[6\S>CI4BWMU].ORMN>B_LV>-KGXC?L^_#GQ->OYM]JF@65S<R?WI3"OF
M'\6S7I-<-\"_ ;_"[X+^!O",I!GT71;2QE9>ADCB57/XL#7<UWXAIUIN.UW^
M9PT-*4$^R_(****YS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO/?CG\;M _9_\
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M?0D\8;5-@?$JS-8;MZ[A+Y)$F-F[!7H<=17!?LT_!+6/A+H_B35_&&K6>O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1M*P7J0H)./?BIE)13D]D-)R=D3T5\ ?\/J_@A_T*WQ _P#!=8__ "92Q_\
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M<J\],UZ90M8J2V8/1N+W7_#A1110 45'<7$5K!)--(L,,:EWDD8*JJ!DDD]
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M_P""<OQE^/'[47C7QUX4LM'FT#5?L7V9[K4EBD/E64$+Y4CCYXV_#%?J_10
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MB;R"[\$ZKJ\=U;7UE,61X/M<0V;RH#H> #(0Q^7FC>^ ?C=^U7\1/ %U\3?
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MCFNU^.WPK\4^,OVF/V>_%>CZ7]LT#PK=:Q)K%Y]HB3[*L]JD<1V,P9]S CY
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M/)(J?\$_X;I?^">/[3<KAA9O;7RQ$]"XT[Y\?@4_2NY_8%_Y1??&K_KGK_\
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MKE=/5W(B[K0****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#D %2WH$_P"TQ!>?M467P7T+1$UV2'1Y-7UW6H;\!=' )$<3Q",[G<F/@NI
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M_P //$GA:>VBU >$_#MY?R:^;>0*P57VM#)(%8$A%;.. :\I_9.\3>#O"/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\%&O'O[6'C;P=X!_9MTSQ+X:OGO5N)+Z8QQW5PV"NV1(VD1+= Q=R[$' )
MV\]A_P %;/@GXKNOA3\)_&=XTWC$>$(WL?$=TL0C,QE6$FX=8P B,\+ E0 O
MF+TJ91M!7]V#DK]+^>G2^C]=.I46G4LO>DHNWEY?JO2S/,?'GC3XE_LR^%;'
MXD^'/VSM"^+6OQ3P'5/!;:['J$3*[ .L,37,GFH&."4CB8+E@5Q7IW_!3CXI
M6GQL_8+^%/CJRA^S0:[K-I>&WW;O)<VER)(\]]KAES[5P'_"5?\ !-U/#^C7
MS>"]9EU"^,:W.E6\^M&:P++EC(S7"QL%/!\MW)R, UZ!_P %//"?A+P3^PG\
M,=)\"Z9<Z-X2CU^";3K&\%P)HHY+:ZDPXN"95.7)P_(SCBJKZ49)K[<;=EKJ
MK_BM^HL/K633^S*_=Z;_ .?R,_\ X*+?\HX?@/\ [VC_ /ILEK]!/V;?^3=_
MAA_V+&F_^DL=?GW_ ,%%O^4</P'_ -[1_P#TV2U^@G[-O_)N_P ,/^Q8TW_T
MECKOJ?'B_P#KXO\ TEG''X,+_P!>W_Z4CY/_ ."S_P#R:IH?_8UVO_I-=5]0
M?LF?\FN?"+_L4M+_ /22.OE__@L__P FJ:'_ -C7:_\ I-=5P'P/_P""NGP>
M^&GP9\"^$=3\-^.)]2T+0[+3+F6TL;-H7DA@2-BA:[4E25."0#CL*XJ$E[.M
M'KSQ_P#2?^"=M=.]%_W7_P"E,]8_X*N?\)_X5^">B_$#P#XO\0^%Y_#NI*FI
M1Z+J<]K'/;3D(&E6-@'VRB,#<#Q(WK5_]IC]KO\ LW_@GG!\3="U!].U[Q;I
M=K9:?-:3&.6WO)UQ-Y;J<J\06<@CD&.NF^&?[0WP\_X*-_"/XF>$_#^E:]IE
M@+'^SKMM=MX(F#7"2>6\?E329*-'NYQ@@=:_*;X66WC/XW>*/A=^RUK-N\.F
M^'?%M\]X@8[DC+ W*D8X\H1W1!SR9B.W,QIRG*6$>CDXR3\GI)?=9W\^@G4C
M%1Q.ZAS)^N\?772Q]P:Y\7/BO^R[_P $R?#_ (REU_6=?^(7B:YAFDUG7KJ3
M4)=,BNMSQL//+8VQ)&H4_*'DS@\Y\<\!Z+\5OB)X.T?Q;\,_VTIO%OQ)NO)G
M;P%J6K/9E9&(\V-8KFX*R",D\& (P4XZ@']#OVPOB-X=^"_[/^J7_B#X<W7Q
M#\)JJ6=WHUK#$\$4./D>;>?EC5E4;E5BI*G ZC\FOC9IW[&'BGX0W/BCX?ZM
MXG\&_$1[-)(/!:I<75JER2-T<DLT1!4<_,LPX .TGY:)5$ZE6HMKJUMTK;6Z
M^;6OH3"#5.G![V=[[-WU=^GIH?I'^UUXJ^)G@G_@GKXDUG7]53P]\2[.QLA>
M:CX4O98528WL",\,JA'7<IY X&YE!(Y/B.C_ +47Q$^&/_!*'P]\1++5[[7?
M&UY=3V!U[6)6OIK</J%P@F=I2V\JJA%W9 )3@@8K,UM?&Z_\$9=8;Q[)?2:J
M\$#VAU)F:X^Q'4H#;[RW.-F-N?X-M=+^SO\ $W1OA/\ \$I_#&M^)/ -Y\1O
M#N+^#4-(M88I(Q$U_<_O)Q(>(@P7+!6*D@XP"1I6CRPQ&MO>A^MUY=GV*HOF
MI4':^LOPBM?/NN_S/"OA_IOQ3^)W@?2_&'P]_;3G\1?$VZ$5P?A]J.K/8D3$
MKYL*I<7&Q]F3_P L C;3C@C/ZL?!W_A.%^&F@+\2%TP>-DMPFIMH\A>VDD!(
M#KE5P6&"5 P"2 2,&OQ9^,-G^Q;XQ^#]WXI\$ZEXF\"_$9K'S(/!4*W%W;+=
MGK&\LT14IG/S+,OR\[<_+7Z8_P#!,Y?&_P#PR)X4?QU)>RWDDDSZ:=19FG_L
M\M^XW%N<8W%<_P !3'&*U7O1J*UK6\UVLG_P]TO(YI:2@[WO?U[W:_X;7U/J
M>BBBL#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME\M]M>U[GV#\9OVO/@_^S[JEOIGC[QS8Z'J<ZB1;%(IKJX"'HSQ0([(IYPS
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MK:?'&T9^(&D^7?JT8W2S*T1WM)G+;LD[N:[K_@GS\-OB5\*M(^(NC^-?!#>
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M2+0;"31K_P *PRW]N]LFV\EEM0\LD@Q\S,S$Y//3T%?+7[.FH7%]_P $<_&
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MB1VY(ZXQ7RY^TM<--^V)^QY-,^7DFU1F9N,L;6+^9-3?\%<O^30+K_L.Z?\
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MD="?T1HJH/EFZCU=K+R3237X?UH*?O04%HKIOS:>@UT6161U#*PP589!'I7
M6G[//PKT_7EURU^&?@^VUI9/.&I0Z#:+<A\YW"01[MWOG->@T4MG=;ATL97B
M;PKHOC;0[G1?$6CV&O:-=!1/I^IVJ7-O*%8,N^-P5;#*",C@@&F^&/".A>"=
M!@T/P[HNG:#HMON$.FZ7:1VUM'N8LVV- %&69B<#DDGO6O10!Y]#^SQ\*K?7
MAKD7PS\'1ZT)/.&I)H%H+GS,YW^9Y>[=GOG->@=.!2T4=+!UN%%%% !1110
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MQQX#\/> )I(VU-? -K>'4-5B1@WDN]QA8E; )*?]\L.*^RJ*A=GJKWL]5?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !17YS?!7PA\2OVG/C1^T%H&J_&7QWX
M3\%>%O&-Y'I\?AO56@NS,\DBI$)W#%+>)(AB! %)ESQ@5K_$SXU3^,?CS?\
MP1N/CM%\'O G@72[2#6O$EUK%O9ZYK]X\2G9#<SM\NT8+NO.[.<AAA1?,H]Y
M)-+R:O=^FGK==="I1Y9372+:;\T[67K^%G?8_0*BOSEN/CA8?LK?$7P)/X2_
M:1_X7CX!\0:O%HVM>']>\26FM:I8&;(2]AGB/F!$(P5*[><<E@5V/VE?C!<Z
MU^V)/\+O'WQ<U_X%_#>VT2&]TS4= NAILNKW3D;BU\R,(T7]XN#A28_4T]^7
MEZMKMJE=_AM;>_K:=N:_1)_)OE7X[]K7V/T"HKYL_9I\ ^/_  3XRU"2T^+T
M7Q?^"E]8+)I=]K6IB_UFVNPPR/M,<>R>)AGDOD?+A1@EOG_P!I?Q;^/W[6?[
M07@F+XJ^)O"7PYT?5X6N9M)O6^WQ[D<16ME))N6U0X=W:-<G8@Z&C>:IK>S?
MI9I._P!_SZ;BVBYO:Z7WI[?D?HG17Q3X.U[QW^RA^U5X-^%GB'Q[K7Q(^'/Q
M M;G^Q;[Q1,+C5--O8%WM&]Q@&5&!4<CJZX VG=5TG4O'?[;WQL^)>EV'Q&\
M1?#3X4^!-2_L&)/!MPEIJ6J7R9\Z1KHJS(BD<* 00R\9!-'Q6<-;W^5G9W^=
MO6Z>VHW[M^;2UOG?56^2?I9GW!17Q9X+\3>/_P!E?]J;P?\ ";Q/XXU7XD_#
MSQY:W)T'4_$;K-JNG7D"[WBEG !F5@0,G^\N NT[N,T*S^*7QL_;C^/O@*S^
M*OB;PCX TP:=+<_V5=%KJ#=;+L@LFDW):!V9W=T3<?+4=S3C[[2AK=2?_@+L
MT_Z]-T$O<3<NC7_DVS7];GZ#45\._#6_\;_LU_MM:%\';[XC>(_B1X&\8:#/
MJ=FWB^Z^V:A87$6\G_2, LI$3<<#YQQE<GS_ ,3_ !53XM_M3?%#P5\6/CUX
MH^!&F>'+R.V\-Z/H&K)H2WL!4YN9+MT(D+C8P5B.'^7@5/Q./+]I-_\ @+Y7
M\[]NFNP_AYN;I;_R977RM^.F]C](J*\!_9Y\/_$3X5Z/XP/CCXB6/Q)^'UN!
M>^&O$$DYEU1;0(S2)=LL823& 5D#L3\Q. 0J_*/P]^+6G_M:V-_XY^)/[4[?
M!K2[F]GCT+P3X3\6V>AW=E:HY17O'<F21WV[L,,8^8$!@JO[7+'M=^5^GKY>
M3Z"^SS/O;U_X'_ ZGZ645\5?LG_M"7UK^T)X@^"5_P#$_3OC-HBZ4-;\.>+[
M.ZM[FX$0<))9W4D#%7E7.[<?F(!)X8*OVK5-:*2V?_#?FFORTU%?5Q>Z_P K
M_DPHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image3a01.jpg
<TEXT>
begin 644 image3a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  24DJ  @    $ !H!!0 !
M    /@   !L!!0 !    1@   "@! P !     @   #$! @ 0    3@
M  !@     0   &     !    4&%I;G0N3D54('8U+C P /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( "@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MI4VNMK_Q \=^&[JY\&?#KP?X=A$]SXR\32W,\UK;1B5K5DMIUM/SO_X(>?\
M!6O_ (*?_P#!2O\ ;0_:&\/_ !F^'W[-GA[]D[X0^'TM/%&L_#*TU[4_^$1\
M?^(C<2^ O!/@;XD1^+O&/A+X@>)UC_ML^.E:!X1%HGG0RVXDM+>X /ZW:Y'2
MO%OA?Q'>:]8^'O$>@ZYJ?A+4/[$\3V>C:UH^HZIH.K%"[:)X@A@,KZ%<<#_1
MYUBG;:S*BE26\G_:?^/'@;]E_P#9]^-G[07Q%GM8/!WP6^&/BOXFZWE8G:_T
M[PUH[W,6CHC13G[1XJFC3PS9EHV5IYHBH4D,GXB?\&VTW@&?]@V\^/FL_%GX
M9>+_ (]?MP?M&?%[]HGXW_V)XST;6-8L?B/\1=?D&B> ==(E%U!XG\*>&]$C
MD_X1 PQM;RZY<,T*I+&P /Z'+CQ#X?T_6M,T&\U?38=>UVVU.[T?19[M1JFI
MIH2J=:?1=&D)EECMXW62=X&<J)=SHZ*Q/E'QD_:1_9[_ &:]$TSQ%^T1\<OA
M%\"M#U74$TW1M>^+GQ#\%?#W1]4U)E"C2M!G\5^(K:)YP$Q);V[R,@([8V_A
M-\&OBSX%_:[_ .#B3]I+7KKXB^%7\)_\$Q/V6])_9_\ AQX4O?%&C6FHWWQE
M^-&OCQ5^T!\0_#FBL1*5\$^'O#C?!_X@NT<*6[)"4D4D"+ _X.>_BIH?@/\
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4+^NE%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>logo1.jpg
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[2Q64&AO=&]S:&]P(#,N,  X0DE-!"4
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M=#PO<W1R:6YG/@H\+V1I8W0^"CPO<&QI<W0^"CA"24T#Z0      >  #
M2 !(      +> D#_[O_N P8"4@-G!2@#_  "    2 !(      +8 B@  0
M &0    !  ,# P    %__P !  $               !H"  9 9       "
M                                 #A"24T#[0      $ $L     0 !
M 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24T$"@       0  .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-!         (  #A"24T$ @       @
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      T4    &              #A   #P     @ 3P!. $, ( !,
M &\ 9P!O     0                         !              /
MX0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MX0    !29VAT;&]N9P   \     &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   .$     4F=H=&QO;F<
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M '0 ;P!S &@ ;P!P    $@!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P    $ .$))300&       '  @    ! 0#_X0E@17AI9@  24DJ
M  @    ' !(! P !     0"+>1H!!0 !    8@   !L!!0 !    :@   "@!
M P !     @"]#S$! @ =    <@   #(! @ 4    D    &F'!  !    I
M ,X    L 0   0   "P!   !    061O8F4@4&AO=&]S:&]P($-3($UA8VEN
M=&]S: " ,C P.#HP-3HR,B Q-3HR.3HS.  #  &@ P !     0#__P*@!  !
M    P ,   .@!  !    X0         &  ,! P !    !@#F_QH!!0 !
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M^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_HG>S^VMKZL_\
M-3T[/^;_ *.^?T\3Z_\ Z$?:/UO_ +=7SBDHX[CY?I_W*?M?JI)?*J2E0_52
M2^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_522^54
MDE/_V?_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:
M( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M  #VU@ !     -,M2% @(
M                        $6-P<G0   %0    ,V1E<V,   &$    ;'=T
M<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M%&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
M    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@
M  0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E
M>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M$G-21T(@245#-C$Y-C8M,BXQ
M                              !865H@        \U$  0    $6S%A9
M6B                      6%E:(        &^B   X]0   Y!865H@
M    8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6
M245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W
M=W<N:65C+F-H
M             &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M              !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X
M   !6%E:(       3 E6 %    !7'^=M96%S          $
M           "CP    )S:6<@     $-25"!C=7)V        !      %  H
M#P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\
M ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L
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MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Z*-/DCYDMW"BBBMA!1110 4444 %%%% !1110 4444 %%%% !2$ C!Z4M%
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M117>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/C^V%SX*U
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M # %90I2J+FFP;ML>0V_PFU>0 W%]9Q9[+N<C]!4DOPCU%5_<ZG:NWHZLO\
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M=17)?$>[2V\&72,1NG9(U![G.?Y U%3X&-;GAE>L_"*8G3=1A.<+*K#\1_\
M6KR:O8/A-:-%H-W<L,":?"GU"C_$FN##?Q$7+8] HHHKTC,RO$__ "*VJ_\
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MJ[885VCU/J3[D\U)9V5MI]LEM:0)#"GW408 J>MJ5%4UYB;N%%%%;",KQ/\
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M7@?0[OP_X>^R7NP3-*TA"-D ' Z_A7'AZ<HSNT7)Z'2T445W$!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5QWQ!\+G7=)%U:IF^M02@'61.Z_P!1_P#7KL:*F45)68'S 1@X->K_  Y\
M8BXBCT/4)<3(,6TC'[X_N'W':L[XB^#3:RR:WIT7[ASFYC4?</\ >'L>_I7G
M2,T;AT8JRG((."#7G)RHS--T?3U%<!X'\>QZHD>FZK*$OA\L<K<";V/^U_.N
M_KT834U=&;5@HHHJ@"BBB@ HHHH **** "BBB@ HHHH *\Y^(WC$6L+Z)I\O
M^D2#%S(I_P!6O]T>Y[^@^M6?''CR/28Y--TN17OR,22+R(?\6_E7CSNTCL[L
M6=CEF8Y)/K7)7KV]V)20VO;/AYX7.B:5]MNDQ?78!(/6-.R_7N?P]*Y?X=^#
M#>S1ZUJ,7^C1G-O&P_UC#^(^P_4UZY2PU*WOL)/H%%%%=A(4444 %%%>#7,E
MQJ'CJ6SFO[B**:^,;.)"-JE\<=JRJ5.2VFXTKGO-%<6/AWIL>2-:U=?4_:E'
M_LM<CXGM_P#A&ECFTGQ;<3S;]IMS<;F7WX./S%*5245=K\0L>Q45R?@'5=9U
M;16GU:,%0V()R-K2KW)'MZ]ZZRM(RYE=""BBBJ ***S?$,CQ>'-2>-BKK;.0
MRG!!VFDW97 TJ*\C^%5W<S>(+N.6XE=/LQ.UG)&=R_XUZY44Y\\>8;5@HHHK
M004444 %%>>^.?'L^CW;:7I847*J#+,PSY>>0 /7'K3=(\%ZAK5E%?Z_K=^S
MS*'$$4F-H/3)/\@*R]K>7+%7'8]#WK_>'YTM<@?AOHI7"SZ@I[,+@Y'Z5S?B
M'1]>\&0#4=)UNZFLU8!XYFW%,],@\$?@*)3E%7:"QZG17(^"/&/_  DT$L%S
M&L=]  6"?==?[P';GJ*ZZKC)25T(****H HHKF=7\$V6L:C)>S:AJ43N "D,
MX"C QP"#BE)M;(#IJ*\F\;^%8O#>C17MEJ>HN[3B)EFFR,%6/8#TI/!'A:/Q
M)I,UY>ZGJ*,LQC589L#  /.0?6L?:RYN2VOJ.QZU17*:?X"L-.U"&\34=4E:
M%@ZI)<#:3[X KJZUBV]T(****H HHKGO',\MOX,U*6"1XY B@,AP1EU!Y^AI
M2=DV!T-%>+>!M.;Q+>745]K%_$L*!E$5Q@MD^^>/\:[;_A -/_Z#NL_^!8_^
M)K*%24U=(;1V=%<[H_A"UTB_6]BU+4KEE4@+/<;DYXS@ 9KHJUBVUJ(****8
M!1110 4=*\N\3?$BZ>^?3= 50 _E_:2-Q=LX^4=,>]:MGX!O+V-9M?UV^FF8
M9:*&4A5]LG.?P K'VO,[05QV[G=[E)P&'YTM<<_PWT9E_=W.HQ-V9;CG]16I
MH'AH:$7(U._N]PP%GERJ_0>M6G*^J W:***L04444 %%%<I\1IY8/!MR\,KQ
ML7C!*-@XW#BIE+EBV!U=%>;_  HOI)K74HI[IG*NC*LCY(R#DC->C>8G]]?S
MI0GSQYAM6'45Y[\5;YX=(L8X+HH[SDE4?!( ]NV:TOAI/+/X01II7D83. 7;
M) XXI*I>?(%M+G84445H(**** "BBB@ HHHH **** "BBN,^)T\T'A0&&5XR
M;A 2C$9&#4SERQ;!'9T5P/PIN)I]"O?.FDDVW.!O8G'RCUKOJ(2YHJ0,****
MH HHHH **\,\77%[/X\O;6.\E3=.L:?O" N0 /H.:W-"\::EX8U!M&\2I*\:
M' E;YGC]\_Q+7.L0N:S17*>KT5%;W$-W;I<6\J2PR#<CH<@BO%A?W@^)P47<
M^/[1V8WG&W?C&/3'%:5*G);S$E<]NHHHK004444 %%9/B'7[7PYI3WMSEN=L
M<:]7;TKSS3-5\4>/=2FA@O\ ^SK*( R>2"-H/09ZD\'N.AK.=51?+NQV/6"P
M'4@4 @]"#7'1?#?3=N;K4-2N9>[M/C^E-?X<622![35M4MN>0L^?Z4<T^WXA
MH=I14%I;BTM([<2RR[!C?*^YF]R:GK004444 %%%% !1110 4444 (RJZ,CJ
M&5A@@C((KQ[QOX"DTII-2TJ,O8D[I(AR8??W7^5>Q4A (((R#6=2FIJS&G8^
M802""#@BO0_"GQ*ELE2RUO=- .%N1RZ#_:_O#]?K6IXM^&J71DOM#58Y3\SV
MO16_W?0^W3Z5Y9<6\UI.\%Q$\4J'#(ZX(/TK@:G1D7HSZ4L[RVU"V2YM)TFA
M<?*Z'(-3U\X:1KNI:'<>=I]T\1/WEZJWU'0UZ/HOQ7MI0L6L6K0O_P ]H/F4
M_5>H_#-=4,3&7Q:$N)Z116?I^N:7JJAK&^@FS_"KC=^76M"NA-/8D****8!1
M110 45GZAK>F:4I-]?008_A9QN_+K7#ZU\5[:(-%H]JTS]/.F^51]%ZG\<5$
MJD8;L:5ST&[O+:PMGN+N>.&%!EG=L 5Y9XK^)<MV)++1"T,)RKW)X=O]W^Z/
M?K]*XO5]=U+7;CSM0NGE(^ZG15^@Z"J,$$US.D,$3RRN<*B#))^E<=3$.6D2
ME$82222<D]2:[KP1X#DU=X]1U.-H]/!RD9X,W^"^_>MKPE\-5@,=]KJJ\@^9
M+3J%_P!\]_I7I0 4    < "JHX?[4P<NPD<:11K'&H1% "JHP /04ZBBNT@*
M*** "BBB@ KP"6SBU#Q])9SL5BFU HY4X(!>O?ZXV]^&NB7M]-=O)=(\SEV"
MR# ).>.*PKTW.UAIV'-\-?#S##+=D>AG-<_XE\$:%X?TU]0@U&6UG3)A64B0
M2-_= QG_  K<_P"%9Z3_ ,_FH?\ ?[_ZU*GPQ\/AMTINYCG^.;_ 5+IW6D4.
MYB_#[QCJVI:J-*O1]IB,999@N#'@=\<8[?E7IM4-,T;3M&A,6GVD<"G[Q4<M
M]3U-7ZUIQE&-I.XF%%%%:""LOQ)_R+.I_P#7M)_Z":U*AN[6.]LYK68$Q3(4
M;!P<$8I-75@/(_A-_P C)=?]>I_]"6O8JYWP_P"#-,\-W<MS9M.TLB;"9'!P
M,Y[#V%=%6=&#A"S&W<****U$%%%% 'B/Q'T6ZL/$L]\T;-:W9#I)C(!P 5/O
MQ^5>I>%=;L]:T.VDMY5,L<:I+%GYD8#!R/3WK7N+>"[@:"XB26)QAD=0P/X&
MN5N?AOH,LQFMEN;.3L;>4C'TSFL%3E"3E'J.]SKZXKXEZQ;V?AJ6Q\R,W-TR
MJ(\@D+G);';I^M2?\( I&T^(=:,?]S[3Q_*I+/X<^'[:;SI89KN3J3<2%@3]
M!C-.7/)62L&ARGPFTRY_M&[U1HRMMY)A5B.&8L"<?3;^M>L4R**.")8HHUCC
M485$& !["GU5.')'E!NX4445H(**** .%^*__(J0?]?B?^@/3?A/_P BQ<?]
M?3?^@K74:]H-GXBT\65[Y@C#B0&-L$,,C^1-)H.@6?AVP:SLC(8V<R,9&R23
M@?TK'D?M>?H.^EC5HHHK804444 %<UX__P"1'U/_ '4_]#6NEJGJNF6^L:9/
M876[R9@ VTX/!!&/Q%3-7BT"/'/A_P"&].\17MY'J!D(AC5D1'VYR>M=[_PK
M'PW_ ,\KG_O\:B3X6Z)&<I<7RGU$H']*?_PK/2?^?S4/^_W_ -:N>%)Q5G%,
MILZ71](M-#T];&R#B%26 =RQR:OURFG^ -,TZ_AO(KJ_:2%MRAIN"?? KJZZ
M(7MJK$A1115 %-D3S(V0DC<",CM3J* / &LY_"/B^W.I6Y9+><2=.)$!^\/6
MO<]-U6PU:V$]A=1SH1GY6Y'U'4?C3K_3;+5+<P7UK%<1^DBYQ]/3\*YB;X::
M$TADMFN[1_6&8\?GFN>%.5-OEU0V[G8TT.C,RJREE^\ >1]:Y ?#VU/$NL:O
M(G=6N>#^E:NB^$M)T"=Y[&*03.NUG>4L2/Y5JG)O5!H;E%%%6(**** "N0^)
MG_(E7'_76/\ ]"%=?6?K6CVNNZ9)87>_RG(.4.""#D5$US1:0T>5_#SPMI?B
M&&^DU&.20Q,BH%<J!G.>E=M_PK3PS_SZ3?\ ?]O\:U/#WAFP\-0S1V1E/G,&
M=I&R>.E;59TZ,5%*2U!L\@^(7A/2O#^GV=QIT<D;R2E'#2%@1C/>NL^%_P#R
M)R_]?$G]*W/$'ARR\26D=O>F4+&^]3&V"#C%2Z)HMKH&FK8V>\Q!BV7.22:(
MTN6IS+8+Z&E1116X@HHHH **** "BBB@ HHHH *XCXJ?\BDO_7RG\C7;UF:[
MH=IX@TXV5YY@CW!P8VP0145(N46D-;G(?"/_ ) 5_P#]?/\ [**]"K(\/^';
M+PW9R6UD9"LC[V,C9).,?TK7HI1<8),'N%%%%6(**** /"/%+;?B-=-Z7:'_
M -!KUSQ'X7T_Q+:>5=+LF0?NIU'S)_B/:J&H^ -'U+67U.9K@3.X=E23"DC\
M/:NJ P,5A3I-.7-LQMGC5M=Z]\-]4%O=(9]-D;H#\CCU4_PM[?\ ZZS(KN"_
M^),%Y;,6AGU!)$)&#@L#R*]OO]/M=4LWM+V!9H''*L/U'H:YFR^&^AV&I0WL
M)N2\,@D1&DRH(Z=LUG*A*Z2>@[G7T445UDA1110!Q7Q+T6[U;08I;-&E>UD,
MC1J,EE(P2!WQ7.?#'Q!IVFI=:=>R);S32!TED. W&-I/;']37K%86J^#M"UB
M1I;JP03-R98SL8_7'7\:PG3?/SQW&GI8W%974,I!4\@@Y!H9U12SL%4=23@"
MN-3X;Z? <6NIZG;I_=CGP/Y5(/ASI,F/MEUJ%WC_ )[7!(J^:?;\0T.N!! (
M.0:6J]C90:=916=JA2"(812Q.!]35BM$(**** "BBB@ HHHH **** "BBB@
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>optiontable.jpg
<TEXT>
begin 644 optiontable.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &.!$H# 2(  A$! Q$!_\0
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M]K;2W$V@Z4L42%W;[%&< #)/"UYA=ZSXLOM0U/5K66YB6ROFA0MJD,%K$%;
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M ,*/^$3\-_\ 0OZ5_P" 4?\ A6NJA5"C. ,<G)_.EI 8_P#PB?AO_H7]*_\
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M'@^[UF32M)C^P1>'+)HW*D.UQ\@(V G(VD8&2<]>O?H=9T'2_$%DMIJEHMQ
MKAU4L5*D=P5((H7Q#HCO"B:QI[-.=L2BY0F0YQA>>>>..]:5&Z#J9%KX7T6S
M%XL-BFV\C2*X61V<2*B[5!#$C@5#I/@SP[H?VC^S]+AC^T)Y<N\M)N0]5^<G
M@]QT-;M% &!I/@GPYH5^;[3M,2&Y(($A=WV@]<!B0/PJ_K.AZ=X@L?L6J6_G
MVX</LWLO(Z'*D'O6A11N!S.G?#[PMI-_%>V>DHEQ$<HSRR2;3Z@,Q&?>KP\+
M:(-/O; Z?&UK>S-//&[,VZ1NK DY4\=L8[5L44 9&B^%]%\.QS1Z581VXF_U
MAW,Y;V)8DX]NE5(? OAJ"PN[&/2T%K=L'FC,CD$C.",GY2,G[N*Z*BC<#(T[
MPOHFE:9-IMGIT*6<^?-C;+^9G^\6))_&JVG>"/#FDPW<5EIB1+=Q&&8F1V9D
M/!4,22 ?8CMZ5T%% &2WAK2'L].M&M,P:=(LMJOF/^[9?NG.<G'OFK6J:59:
MUI\EAJ$/G6LF-Z;F7.#D<@@]15RB@%IL9\&AZ=;:A=WT-OMN;N-8YWWL=ZJ,
M 8S@<>E4I/!OA^;0H=%DTU'T^%BT<3.Y*$DDD-G<.2>_M6[10!A#P;X?71%T
M==-1;!9!+Y2NP)<=&+ [B?J:W>@HHH *S-:\/Z7XAMXH-5M!<1Q/YB NRX;&
M.JD?E6G10!2U/2+#6-.>PU"U2>U;&8VR,8Z8(Y!]Q5*S\):#8://I-OID*V-
MP<RQ-E]_U+$GCMSQVK:HH Q-%\(Z#X=>9]+TY('F7:[%V<D>F6)P/85-HOAO
M2/#WVC^RK,6PN&#2 2,P)&<<$G'4]*U:* ,C7/#&B^)%B75K!+GRCE&W,C+[
M;E(./;I2+X6T--";1%TV$:<W6'GD^N>N[_:SGWK8HH\@.?M_!'ARUTBZTJ#3
M$2SNB#.@D?<^#D9?.[ (Z9]?4UH2:)ITVH6-]);YN;!62V?>WR!A@\9P>/7-
M:%%%P,&V\%>'+/63J]OI427Q8OY@9L!CU(7.T'Z"H[_P+X9U34);^\TF*6YF
M4K(^]EW9&,X!QGWQGWKHJ*+ <_?^"?#FJ064-YIB2I91B*#]XX*H,84D'+#C
MOG]:=#X,\/V\444.G+''%=_;8T61P%F_O 9Z<=.GM6]11<#!N?!7AR[UH:O/
MI43WP8/YA9L%AT)7.TGZBMJX@BNK:6WF7=%*A1UR1D$8(XJ2BCI8.MS-/A_2
MSH']AM:*VF^7Y?D,S'Y<YZYSU[YS5&]\#^'-1L;.SO--$L-FFR#=-)N1?[N[
M=N(]B:Z"BC<-CD->\%0ZK?>'XXK>T72M.\U9K9\C<C*  H Z\>H]:V--\+Z'
MI.FS:?9:;"EK/_K8V!?S/]XMDG\:UZ*.E@[>1AZ+X.\/^'KF2XTO34@F==ID
M+LYQZ L3C\*O:9H]AH]DUG86XBMV=G*%BV2W7[Q-7J* ,K1?#>D>'OM']E68
MMA<,&D D9@2,XX)..IZ5JT44 17-M!>6TEO<Q)-#(I5XW7*L/0BL71O!7AWP
M_=F[TS3$AN"NWS#([D#VW$X_"M^B@#%@\(Z#;7U]>1:;$)KY2MR&+,D@)R<H
M3MZ^U-T7P=X?\/7,EQI>FI!,Z[3(79R!Z L3C\*W**%IL!SZ>"/#<>M?VPFD
MPB^W^8'RVT-_>"9V@]\XZ\]:F;PGH;65_9M8*T&H2F>Y0R.=[YSNSG*G/IBM
MJBCI8/,9%&L,*1)G:BA5RQ)P/<\G\:?110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .-4?\+)OO\ H VW_@P;_P"-4 >AT5YY_P +)OO^@#;?^#!O_C5'_"R;[_H
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MJC_A9-]_T ;;_P &#?\ QJ@#T.BO//\ A9-]_P! &V_\&#?_ !JC_A9-]_T
M;;_P8-_\:H ]#HKSB3XG7L;Q*=!@S*VT8OSUP3_SR]C4G_"R;[_H VW_ (,&
M_P#C5 'H=%>>?\+)OO\ H VW_@P;_P"-4?\ "R;[_H VW_@P;_XU0!Z'17GG
M_"R;[_H VW_@P;_XU1_PLF^_Z -M_P"#!O\ XU0!Z'17GG_"R;[_ * -M_X,
M&_\ C5'_  LF^_Z -M_X,&_^-4 >AT5YY_PLF^_Z -M_X,&_^-4?\+)OO^@#
M;?\ @P;_ .-4 >AT5YY_PLF^_P"@#;?^#!O_ (U1_P +)OO^@#;?^#!O_C5
M'H=%>>?\+)OO^@#;?^#!O_C51GXG7HN$A_L&#<ZLP/V\XP" ?^67^T* /1Z*
M\\_X63??] &V_P#!@W_QJC_A9-]_T ;;_P &#?\ QJ@#T.BO//\ A9-]_P!
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MJD_X63??] &V_P#!@W_QJ@#T.BO//^%DWW_0!MO_  8-_P#&J/\ A9-]_P!
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M\O=NV[F+8SQG&: .WTW_ )!=I_UQ3_T$5:JKIO\ R"[3_KBG_H(JU0 4444
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MIO\ R"[3_KBG_H(JU573?^07:?\ 7%/_ $$5:H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** +VB_\AW3_P#KYC_]"%6?$*[_ !=J
M:#'S7T@^;I]\]:RD=XY%DC9D=2"K*<$$=Q6A/XBUNZ@>"XUG4)87&'CDNG96
M'H03S1V\O^ '<]"?#76O:1+-?77V6PF,D 3R;*W"H"FR,EB3N&0V5/?G)K+C
MNIM7M/[,MKN_TN=--R^GW$ >U=44-O7NA8#?N*DY/#=*X]M>UAX4A?5;YHD7
M:J&X<JHQMP!G@8)'TIAUC5#8?8#J5X;/&W[/Y[>7CKC;G%#_ *_'_,%_7X?Y
M&YXVO;JZFTA;BYFF TRWD DD+?,R_,>>YP,GO5Z.^AM?#7AVWO"WV"\CNH+D
M 9(4R##CW4@-^&.]<?->W=Q;PP37,TL, (BC>0E8P>NT'@?A3'N)I(8H7FD:
M*+/EHS$JF>3@=LT=7ZAT1Z3=:=<:?>P[YU@DT_0%+SQ1&:1/G(W1 ,HS@_>)
MX!S5JUE2670-25;R1GAU 1S:BXEEEC6/*[CCIDG .<9/)KS2/5=1BN(IX]0N
MDFAC\J*19F#(G]U3G('L*=)K6JRR>9)J=X[Y8[FG8GYAM/.>X !]J'U^?XW_
M ,P73^NAV$&O:K_PCV@W7V^<W4FHO$\Y<F1HP4(0MU*Y8_*>*NZA]ETBQU.X
ML[R\TUSK,\4TUA '<*.40GS$VKU.._X5YT+JX$4<0GE$<3EXTWG",<9('8\#
MGVJ>#5]3M;F:YM]1NX9YCF66.=E9^<_,0<GGUI_U^7^0+^OQ_P S1\8K&OB.
M8I;26[M'&TL<B(AWE06.U68+GKC.1FL&G22/+(TDCL\CDLS,<EB>I)]:;4H
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MV^G7$3SLZF.1@GS@*!E<'I\QSCM7!47#H%>95Z;7F5 'H>F_\@NT_P"N*?\
MH(JU7N@T3P5I>C:=)J?A*TDFEMD>1XO#S3D':-Q?R[<;3D_Q(G?Y1T%>!_A=
M<:?_ &@GAJQ%CL$@NI/#<B1,I( (=H0#DD=#1N#T/$Z*^DO^$$\'_P#0J:'_
M ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XF
MC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__
M $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
M@NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H
M^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^
M$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0
MJ:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z
M'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!
M/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*F
MA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_
M^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*
M^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'
M_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_
M ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XF
MC_A!/!__ $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__
M $*FA_\ @NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
M@NA_^)H ^;:*^DO^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H
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M 'A-57_Y"EO_ -<9?_0DKWG4E^&FCK.^H>%+:WB@;9),_AB7RP<X^_Y.T@G
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MKW*&'X:SZK::9_PBUG#>7A86\=SX;D@\S:,M@O"!P.O-=!_P@G@__H5-#_\
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M6KY%G,MWYKJVTNJRKL4(64'[K.,C&>AJ&+QW,]I;:Q)I*)X=N;H6\5[]KS,
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M%N]/O+>[MG)"S6\JR(V#@X8$CK7DZQA;*/5I+H7FACQ,EW<S06A@M=HC*F5
M9'+1"7:Q8G&0QZ<UW&EW%IJAUBY\*20PO-<HTFH2Q-<6MRX0!C&%E7=@ *6!
M R.Y!I]/Z\O\_P !?U^?^1<U[Q!-IE_IVF:?8"^U*_9S%$\WE1HB %W=]K$
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MT6-Q&$*3*)D^7*@[E#'!(QP!5JPT+5/"6IV=Y9:2NH0'28K":VL)54PR1LS
MJ9Y!F,[V'+%A@=<G'71Z==)LW:S?2;=N=R0?/CR\YQ&.NQLXQ_K7QC";"/3K
MI-F[6;Z3;MSN2#Y\>7G.(QUV-G&/]:^,838+3^O)K\F']?K^A2&B2ZOI]G)K
MLL\>H)'^]73-0N;:($\X 1QNQTR?TSBN<U:TU?4/$K1ZEX=U2_T"QV?8[:WG
MMFCN7 R9)O,F5FP>BD8R-QR>G81Z==)LW:S?2;=N=R0?/CR\YQ&.NQLXQ_K7
MQC";"/3KI-F[6;Z3;MSN2#Y\>7G.(QUV-G&/]:^,838=;ATLSG[BWU2Q\5IX
MEM=&NKJ.]T]+6YLTE@6>!T8LI^9PC#YF!PYP<8R.D_A_0KW3_"6H0W4<:ZCJ
M,MS=RQ1L"$DE)(3=P#@$#/3BMF/3KI-F[6;Z3;MSN2#Y\>7G.(QUV-G&/]:^
M,8381Z==)LW:S?2;=N=R0?/CR\YQ&.NQLXQ_K7QC";$TFG'^M=1IV=_ZTT.3
M/AO5(O!/A$1VH;5="^S3/:&109"L122,-]W=AC@YQD#D#FM31;"_N_%VH>([
M^P?3U>TBLK:WF='EVJS.S-Y;,HRS  !C]W)QG%;$>G72;-VLWTFW;G<D'SX\
MO.<1CKL;.,?ZU\8PFPCTZZ39NUF^DV[<[D@^?'EYSB,==C9QC_6OC&$V4W=N
M7?7[]";:6_K34-"C\KP]ID?E^7LM(EV;-FW"#C;L3;]-B8_NKT&A6'HNGSKH
MVF[;^[@1;>'%NL,2*@"Q?)@PH0/D88VH1YK\+A ER/3KI-F[6;Z3;MSN2#Y\
M>7G.(QUV-G&/]:^,838AFA16?'IUTFS=K-])MVYW)!\^/+SG$8Z[&SC'^M?&
M,)L(].NDV;M9OI-NW.Y(/GQY><XC'78V<8_UKXQA-@!H45GQZ==)LW:S?2;=
MN=R0?/CR\YQ&.NQLXQ_K7QC";"/3KI-F[6;Z3;MSN2#Y\>7G.(QUV-G&/]:^
M,838 :%%9\>G72;-VLWTFW;G<D'SX\O.<1CKL;.,?ZU\8PFPCTZZ39NUF^DV
M[<[D@^?'EYSB,==C9QC_ %KXQA-@!H5YGXVM=7GUJTLK_2(M=TNYO]]C$?)
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M1:7WVTP"W25K*X7$;M&V""N!S(F21D8?.-C[:WASQ8/%5EJUSIEBZ?8[EK>
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ML^.;6#L\RQL5SMW[;USC_5[L?NAG&9<=,[$Z;SL(YM8.SS+&Q7.W?MO7./\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW"C"Y*$#L,@U#J/@Y]2\1:59R?V@-!TY)+KS6U*5I9;IOE0"0N90%7<>H'S
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ML;LQ9RK% 26. &/ ZY.!VNHZ':ZJ8FN9=0C:-< 6NH3VP_$1.H/XYH%U.?\
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M=N=R0?/CR\YQ&.NQLXQ_K7QC";"/3KI-F[6;Z3;MSN2#Y\>7G.(QUV-G&/\
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M$D^4CD(,DY. 0OX5RCZ=;:QX.\6^);N%6UJWN;UK2]9?WUJ+=F$2QMU0#9G
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MG6/RU=]H4!5R=JA5  ))]22:C@M/#(TN/4[>UTH6"1+,ERD4?EJBB,A@P&
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MOZW?Z-+_ (9!U_KLOU39QFDP7\VB^!+F37M9:?6)##?.;^0B6/RG?:!G"'Y
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MS;%?#?MQNL)U^]Y>,Y3C_6KG/3#YQL?:1ZS:R;-L5\-^W&ZPG7[WEXSE./\
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M=2,DTB B.VQ&T@#-C!<A>%SG')QQGI:Y+Q3_ ,CEX+_Z_KC_ -)I*VC!KO\
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M.SS+&Q7.W?MO7./]7NQ^Z&<9EQTSL3IO.S0HH SXYM8.SS+&Q7.W?MO7./\
M5[L?NAG&9<=,[$Z;SL(YM8.SS+&Q7.W?MO7./]7NQ^Z&<9EQTSL3IO.S0HH
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M4)+:1YY&7:"WERL>,\# 4 8&*ZR/3KI-F[6;Z3;MSN2#Y\>7G.(QUV-G&/\
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M0<AFPF Q'<XZTND1:G?> M8TRUU>XL8]-O[RT6=4WS&WC9MJ([$[2!A=Q!(
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M\^N[2[U/PMXUN["2*#19+VY>ZLY?]?,8L"4I+TA#;#@,DF/49&WT2T>*[O\
M2+R&%EB?3I60O'RBL82%+;#@\=-ZYQ]U\925K&_I^*_K_@#>CMZ_@68]"T>+
M9Y>E6*>7MV;;=!MV^7MQQQCR8L>GEI_=&,.WU+P7_:45A!;6:RB<6T,@T]E@
M,J;,1I-L\LN/(C 4-D&)1U08ZBXW_9I?+^_L.WZXKRC!/P"T818^U%[/R\DY
M\[[2F??.[-"U=O3\0>QW\UOX9TV^TZQDL].@NKI]EG$+==S&-4;Y0!P%$$7/
M0>7'Z+5R/0M'BV>7I5BGE[=FVW0;=OE[<<<8\F+'IY:?W1CE/$6D6%O\1_"F
MJ1VX^W7-Y,DL[,68JMM)A1D_*O? P,\]:Z@ZI>?VK]D_L#43!NV_;?,M_*QZ
MX\W?C_@&?:@'H_Z\SFX/$7@86_VF#3R+6!MOVE-"G\F/RR@SY@BV@*8(^<X'
ME+_=&.DMM'T-H8)K73=.,6U&A>*!,8'EE"I Z#RH<8_YYIC[HQSOPPV?\*^A
M\S&S[3>;MW3'VB3.:XO0-1U%M%\):+';ZI-I]S%>W(BTZX6WFEC27$2B1I(R
MJ!7!PK D!>V:%V!Z7]6>LQZ%H\6SR]*L4\O;LVVZ#;M\O;CCC'DQ8]/+3^Z,
M$>A:/%L\O2K%/+V[-MN@V[?+VXXXQY,6/3RT_NC'G8U/6A;PZ'<7%Y9V]QKR
M62R37D<EW';M$9?*>2.1BKDC:&+;]K ]>:[&Q$F@QZE;VMS=ZYY4R-'8K.DE
MS;*RCY6DFE!8$@L-Q!P<#( HZ7_KH_U#K;^NJ_0=J8\+>'8;:2\L;.'?(D5M
M'#9>9([CR]H1$4L2/)BZ#CRD_NC%>WOO!8T/^V8(=/2QMW$6X6>UXY$,:K'Y
M>W>'!BA 3&[,<>!PM-U;5=.M%L-=U31KV+5HVDMM/LF9)+B1G RJ+&[)R%ZD
M\ '.!7,3Z-J&EW/A^[U9HA=:GXE%Y=Q0DF*%C"RQH#WQM3D]30M7;T_%K]-0
M>U_7\$_^&.QT8>%]5$@T[3[59+-D1X9+ P2P$",IF-U5EXBA*G'_ "S3'W1B
M33H?"]VURNGVFFO_ &=,+>8QVZ@0R((CMSC&5$</3IY:CJ@QD?9EO/BIJUN=
MWV>7088[CRY&1LF63;RI!!V[N0<BL?18M+\/>&OB!&MB%TRTO)P;6W^7,8MH
MLJ/0GGGWS2;]UOR;^YV&E[UO-+[U<Z'2=1\&:C>6]II]I:"1EWVI;3FB298_
M+YA=D"R!?*A(*$X$:'HHQMQZ%H\6SR]*L4\O;LVVZ#;M\O;CCC'DQ8]/+3^Z
M,>?VUC?Z8W@2?5KB&ZLHI5M[2&W&R2%Y(6"&1N1-A002HBZ[L'H/4*MJQ*=_
MS.?T+1='%B6CTVQ/EW<ZH5B1MFR;"@'<^-ODQ #(V^4@VIL"+H1Z%H\6SR]*
ML4\O;LVVZ#;M\O;CCC'DQ8]/+3^Z,&C2>98R-YGF8N[E<[]_29QC.]^F,8R,
M8QM3&Q="I&9\>A:/%L\O2K%/+V[-MN@V[?+VXXXQY,6/3RT_NC!'H6CQ;/+T
MJQ3R]NS;;H-NWR]N..,>3%CT\M/[HQH44 9\>A:/%L\O2K%/+V[-MN@V[?+V
MXXXQY,6/3RT_NC!'H6CQ;/+TJQ3R]NS;;H-NWR]N..,>3%CT\M/[HQH44 9\
M>A:/%L\O2K%/+V[-MN@V[?+VXXXQY,6/3RT_NC!'H6CQ;/+TJQ3R]NS;;H-N
MWR]N..,>3%CT\M/[HQH44 9\>A:/%L\O2K%/+V[-MN@V[?+VXXXQY,6/3RT_
MNC!'H6CQ;/+TJQ3R]NS;;H-NWR]N..,>3%CT\M/[HQH44 9\>A:/%L\O2K%/
M+V[-MN@V[?+VXXXQY,6/3RT_NC!'H6CQ;/+TJQ3R]NS;;H-NWR]N..,>3%CT
M\M/[HQH44 9\>A:/%L\O2K%/+V[-MN@V[?+VXXXQY,6/3RT_NC!'H6CQ;/+T
MJQ3R]NS;;H-NWR]N..,>3%CT\M/[HQH44 8=_HNFVUK UII=I&Z7%LJF*U7*
MJ)81QB-\ +%'V&!&OS)M#K<CT+1XMGEZ58IY>W9MMT&W;Y>W''&/)BQZ>6G]
MT8-9C\RQC7R_,Q=VS8V;^DR'.-C],9S@8QG<F-ZZ% &?'H6CQ;/+TJQ3R]NS
M;;H-NWR]N..,>3%CT\M/[HP1Z%H\6SR]*L4\O;LVVZ#;M\O;CCC'DQ8]/+3^
MZ,:%% &?'H6CQ;/+TJQ3R]NS;;H-NWR]N..,>3%CT\M/[HQE:C-X4T">WMY]
M/MUN"GF10VFFM/(J)Y8#[8D8JJF*$!B !Y:?W1CI:R;^))KBZCTJZTZUUQH$
M#32P":18MQQN4,K%<[L9.,YZ\BD[]!HH33^$-.TVRU 6VGM;3E%LS:6@F:4@
M(4$:QJ6; AB/R@X$2GC8,6-'@\-:I9I=:986+1Q/Y>/L@C>%XS&-I5E#(R^3
M%P0"/+3^Z*X'PA,DFM>"X1"T4=K;ZG;$-(7#3HZJ[!L '=AR.!P2.U6KC4KS
M3]?\8Q:?%>;;S4;:#[1:6LMP;4FV4RR%45CD# ''WB,\4_3Y??82\_F=GI,7
MA?4A,=+L].E6QN/LSF*V4".2/R_E!Q_#Y4/3@>6G]T8BU%_"V@RVL,^G6ZSO
MS;P6NG-/+A/+^8)$C,%7RH><8'EQ^BU@_"LZ?!!X@T_3;>Y@MH-4?RDFM98L
M)L0#.]1\W!R#SSDCD5I6V[_A;VH>9_T!8/)SGIYTF_'X[?TH_E2ZK]+BOHWV
M?ZV)VO/!MII-CJ<=O8-:W!1;,VMEYCR$;-HC1%+$KY$? &5\E>FP8(KSP;'H
MIU>.WL([.VD$1/V+9)'(AC58_+V[PX,4("8W9CCP.%KB/"@<>/=/WX^QF_UO
M[+R<9\U.G;/^L_6B]#_\+)F(Q]A/B:TW<G'F_8CU[?>V?CBA:V\[?BTOU&]+
M^5_PN=]HP\+ZJ)!IVGVJR6;(CPR6!@E@($93,;JK+Q%"5./^6:8^Z,?$-?:%
ML&_X6]J!CQY8T2#SL$_?\Z3;^FZOB^CHG_6]@V;7];7/M'3/$NF6VA6=A-8Z
MROE6R0ND>A7FT84 @;;=!CZ*H]%'05_MOA3_ (1R/P__ &5KG]EQHL:P?V-J
M'"J00-WE[NH'>NFT*/RO#VF1^7Y>RTB79LV;<(.-NQ-OTV)C^ZO0:% ')2ZW
MX<GU+^T)=,UJ2Z-NUJ6;0[X@Q,<E2OE8()'I5#3V\'Z7<I<6NE>(/,B1HX?-
MTK4I5@1NJQ*\9$8/3" <#'2N\HH XJ"]\*V]MI5O%I6N+%I3;K)?[&U ^4=I
M7_GG\WRL1SGK6+XBAT'5FM%MK#68XVU=-2OMVD:BK2$1E"4(BRK?<Q@KC&<@
MUZ?11UO_ %_6@?U_7WG"(_@]--N;'^R=>>*YD$LTDFDZB\SNN-KF5HS)N7 P
M=V1@8Q2P2^$(+:]@;2=>N5O5"7+7ND:C<O*HZ*7DC9MH[#. 22.:[JB@#A+6
M3PC9QW2IIGB*5KN#[--+<Z7J<\ABY^0/(A95Y/ (&>:M#5O#0?3'&F:YNTQ2
MMF?[%O\ ]T"FP_\ ++GY>.<UV-% 6.?_ .$RTO\ Y]=<_P#!#>__ !FC_A,M
M+_Y]=<_\$-[_ /&:Z"B@#G_^$RTO_GUUS_P0WO\ \9H_X3+2_P#GUUS_ ,$-
M[_\ &:Z"B@#G_P#A,M+_ .?77/\ P0WO_P 9H_X3+2_^?77/_!#>_P#QFN@H
MH Y__A,M+_Y]=<_\$-[_ /&:/^$RTO\ Y]=<_P#!#>__ !FN@HH Y_\ X3+2
M_P#GUUS_ ,$-[_\ &:/^$RTO_GUUS_P0WO\ \9KH** .?_X3+2_^?77/_!#>
M_P#QFC_A,M+_ .?77/\ P0WO_P 9KH** .?_ .$RTO\ Y]=<_P#!#>__ !FC
M_A,M+_Y]=<_\$-[_ /&:Z"B@#G_^$RTO_GUUS_P0WO\ \9H_X3+2_P#GUUS_
M ,$-[_\ &:Z"B@#G_P#A,M+_ .?77/\ P0WO_P 9H_X3+2_^?77/_!#>_P#Q
MFN@HH Y__A,M+_Y]=<_\$-[_ /&:/^$RTO\ Y]=<_P#!#>__ !FN@HH Y_\
MX3+2_P#GUUS_ ,$-[_\ &:/^$RTO_GUUS_P0WO\ \9KH** .?_X3+2_^?77/
M_!#>_P#QFC_A,M+_ .?77/\ P0WO_P 9KH** .?_ .$RTO\ Y]=<_P#!#>__
M !FC_A,M+_Y]=<_\$-[_ /&:Z"B@#G_^$RTO_GUUS_P0WO\ \9H_X3+2_P#G
MUUS_ ,$-[_\ &:Z"B@#G_P#A,M+_ .?77/\ P0WO_P 9H_X3+2_^?77/_!#>
M_P#QFN@HH Y__A,M+_Y]=<_\$-[_ /&:/^$RTO\ Y]=<_P#!#>__ !FN@HH
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MM(K6UT_68;>% D<<>@7H5%'0 >3TK%F'A*;4;O4!:^+8;F[</.UM;:O )"
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M8SN3&]>FJFFG9DIW5T<__P )EI?_ #ZZY_X(;W_XS1_PF6E_\^NN?^"&]_\
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MT4 #L *L?\--?]2C_P"5+_[52&>_T5X!_P --?\ 4H_^5+_[51_PTU_U*/\
MY4O_ +50![_17@'_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 'O]%> ?\
M#37_ %*/_E2_^U4?\--?]2C_ .5+_P"U4 >_T5X!_P --?\ 4H_^5+_[51_P
MTU_U*/\ Y4O_ +50![_17@'_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 '
MO]%> ?\ #37_ %*/_E2_^U4?\--?]2C_ .5+_P"U4 >_T5X!_P --?\ 4H_^
M5+_[51_PTU_U*/\ Y4O_ +50![_17@'_  TU_P!2C_Y4O_M5'_#37_4H_P#E
M2_\ M5 'O]%> ?\ #37_ %*/_E2_^U4?\--?]2C_ .5+_P"U4 >_T5X!_P -
M-?\ 4H_^5+_[51_PTU_U*/\ Y4O_ +50![_17@'_  TU_P!2C_Y4O_M5'_#3
M7_4H_P#E2_\ M5 'O]%> ?\ #37_ %*/_E2_^U4?\--?]2C_ .5+_P"U4 >_
MT5X!_P --?\ 4H_^5+_[51_PTU_U*/\ Y4O_ +50![_17@'_  TU_P!2C_Y4
MO_M5'_#37_4H_P#E2_\ M5 'O]%> ?\ #37_ %*/_E2_^U4?\--?]2C_ .5+
M_P"U4 >_T5X!_P --?\ 4H_^5+_[51_PTU_U*/\ Y4O_ +50![_17@'_  TU
M_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 'O]%> ?\ #37_ %*/_E2_^U4?\--?
M]2C_ .5+_P"U4 >_T5X!_P --?\ 4H_^5+_[51_PTU_U*/\ Y4O_ +50![_1
M7@'_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 'O]%> ?\ #37_ %*/_E2_
M^U4?\--?]2C_ .5+_P"U4 >_T5X!_P --?\ 4H_^5+_[51_PTU_U*/\ Y4O_
M +50![_17@'_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 'O]%> ?\ #37_
M %*/_E2_^U4?\--?]2C_ .5+_P"U4 >_T5X!_P --?\ 4H_^5+_[51_PTU_U
M*/\ Y4O_ +50![_17@'_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 'O]9^
MC2>98R-YGF8N[E<[]_29QC.]^F,8R,8QM3&Q?$/^&FO^I1_\J7_VJJ]G^TE)
M;0-')X5\QC+)(&_M-N SLP'S(QX! ZXXX"C"@ ^AZ*\ _P"&FO\ J4?_ "I?
M_:J/^&FO^I1_\J7_ -JH ]_HKP#_ (::_P"I1_\ *E_]JH_X::_ZE'_RI?\
MVJ@#W^BO /\ AIK_ *E'_P J7_VJC_AIK_J4?_*E_P#:J /?Z*\ _P"&FO\
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M*\ _X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /;]1DV7VDKYFW?=LN-^W?\
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MUM\2[?5?%L=Q_P (]>:4UL)(?,"^>C%E5MG/H0#QD9Z U1_X::_ZE'_RI?\
MVJC_ (::_P"I1_\ *E_]JI-7_KRL-.PEA-J/AW3_ (:^*/$RW:65@+J&YGDC
M9W@CD!$)<#)QMQCCH *H74%W+\.M2U9[2YCTC6/$_P!LDN1"3+;6F[(G0=5/
M&,XZ?6M#_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JJF[N_P#6Z?YH2_K[FOU-
MGX8:SIVCKXRU47=S=>&8IXYDUN]B=KB=MN'#';N<*<=N-Q]:D\1>(=/\-_$V
MW\7WS2C0]4\/F"VNEA<JTF[>JX R"1CJ!U]C7+ZE^T8-2TVXL6\,30)<1F-I
M(-4"N >#@F$X.._Y5-;?M)16EK#;0>#@D,*".-!J?W5 P!_JO2D]?NM^#3_X
M +3Y_P"::_X(S1[.X\$Z=\.O$6N07%OI]J]Y]K8Q,QMA/GR]P R <^E1"SNQ
MX77QD;6Y_LW_ (2\:OCRSN%IG_6XZX__ %]*N_\ #37_ %*/_E2_^U4?\--?
M]2C_ .5+_P"U4^9WNOE]Z?Z!OO\ /\5^IV'PWF37O'/C#Q78B5M(OG@AM)G1
FD$WEKAF 8 \'^=?)]?0'_#37_4H_^5+_ .U5\_TNB2Z!U;?4_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
